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Foreword 
 
The following work represents the experiments I completed during my time in the 
Nutrition Graduate Program at the University of Minnesota.  Throughout my time in the 
program, I was fortunate to gain experience in several laboratories and under the 
guidance of multiple mentors.  My dissertation projects share the common thrust of 
furthering the knowledge of how nutrition relates to cancer prevention, development, and 
progression. The projects described herein incorporate my coursework in nutrition, 
epidemiology, immunology, and cancer biology to advance the understanding of 
polyunsaturated fatty acids, dietary bioactives, and antioxidants in relation to cancer 
development and progression while simultaneously establishing methods and data from 
which to structure future human research. 
In the first section, I will review the scientific literature regarding consumption of 
polyunsaturated fatty acids—specifically omega-3 fatty acids—in regards to breast 
cancer prevention and treatment.  The experiment I conducted to measure the effects of 
omega-3 fatty acids on in vivo lipid peroxidation was part of a crossover feeding study 
specifically addressing breast cancer risk biomarkers.  Although I did not include any of 
these biomarkers in my analyses, my results are informative and pertain to future research 
exploring lipid peroxidation and breast cancer risk. 
In the subsequent section, I will detail the development of a highly sensitive 
technique to quantify the exposure of individuals to indole-3-carbinol, a chemopreventive 
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bioactive compound produced following the consumption of cruciferous vegetables such 
as Brussels sprouts.  This work represents a majority of my experience as a trainee under 
the Division of Epidemiology’s Nutrition and Cancer training grant.  The series of 
validation experiments improved my knowledge of analytical chemistry and biomarker 
development and measurement immensely, and the resulting technique will prove useful 
for epidemiological and experimental research of cancer chemoprevention by indole-3-
carbinol and its metabolite, 3,3!-diindolylmethane. 
The final section of my dissertation addresses statistical analyses to explore the 
relationships between dietary fish, fat, and antioxidants and the risk of gastric cancer in 
the prospective cohort of the Singapore Chinese Health Study.  This experience allowed 
me to directly apply the proficiency in epidemiological methods gleaned during my 
required coursework for the Nutrition and Cancer training grant.  Additionally, the work 
augmented the collaborative skills necessary for population-based research into nutrition 
and cancer while offering additional information about dietary prevention of this deadly 
cancer. 
These three sections share several commonalities in addition to their broad 
exploration of nutrition and cancer.  Lipid peroxidation metabolites and 3,3!-
diindolylmethane function similarly to prevent carcinogenesis, including by up-regulating 
cancer cell death.  Due to their corresponding chemical properties, they follow 
overlapping metabolic pathways within the body.  Another common theme is 
inflammation, which is associated directly with consumption of polyunsaturated fatty 
acids as well as cancer development in breast and gastric tissues.  Infection of the 
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stomach with Helicobacter pylori, a strong risk factor for non-cardia gastric cancer, 
increases inflammation while triggering an immune response that may be enhanced or 
attenuated by dietary constituents including salt, antioxidant vitamins, and omega-3 fatty 
acids. 
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Part I: The effect of omega-3 (n-3) fatty acids on in vivo 
lipid peroxidation 
 
Introduction 
 Consumption of omega-3 fatty acids (n-3) is recommended to promote 
cardiovascular health, and there is some evidence that n-3 may reduce the risk of cancers, 
including breast cancer.  However, polyunsaturated fatty acids (PUFA) such as n-3 are 
highly unsaturated and therefore susceptible to lipid peroxidation, an autocatalytic 
process triggered by the presence of free radicals that produces several reactive 
metabolites that have been shown to bind DNA and modify proteins.  Nevertheless, cell 
culture and animal studies largely support a protective effect of dietary n-3 on breast 
cancer risk, at least partially due to lipid peroxidation.  Human research has shown lipid 
peroxidation is increased in breast cancer patients compared to healthy controls but does 
not support a causative role of lipid peroxidation of n-3 in the development of breast 
cancer.  More research will be needed to characterize the interaction between n-3 and 
lipid peroxidation in breast carcinogenesis. 
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Chapter I: Literature Review 
 
Health benefits of n-3 fatty acids 
 Omega-3 fatty acids (n-3) are polyunsaturated fatty acids (PUFA) classified by the 
position of their first double-bond at the third carbon from the methyl end of the 
hydrocarbon chain (Figure 1)[1].  N-3 include the essential fatty acid "-linolenic acid 
(ALA, 18:3) as well as long-chain n-3, such as eicosapentaenoic acid (EPA, 20:5) and 
docosahexaenoic acid (DHA, 22:6)[2].  Some food sources of n-3 include canola oil, 
soybean oil, flax seeds, and walnuts, providing ALA, and salmon or cod liver oil, 
providing EPA and DHA[1]. 
 
Figure 1.  "-Linolenic acid (ALA, 18:3) with double bond denoting omega-3 (n-3) fatty acid classification 
indicated (adapted from [3]). 
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 Over the past several decades, evidence has accumulated that suggests that 
increased intakes of n-3, particularly EPA and DHA, are associated with a decreased risk 
of cardiovascular disease, including sudden cardiac death, cardiac arrhythmia, 
atherosclerosis, hypertriglyceridemia, and cerebrovascular accident[2, 4].  Although the 
Institute of Medicine has yet to establish Dietary Reference Intakes for EPA and DHA, 
the American Heart Association recommends consumption of fatty fish at least twice per 
week for all adults and consumption of one gram per day of EPA and DHA from fish 
and/or supplements in individuals with coronary heart disease[5]. 
 
Chemopreventive effects of n-3 fatty acids 
 More recently, there has been increasing interest in the role of n-3 in the prevention 
of several human cancers.  In a seminal review, Terry et al.[6] concluded that while there 
was some evidence that high intakes of fatty fish or n-3 reduce the risk of breast cancer, 
particularly among Japanese and Norwegian women, many epidemiological studies 
yielded null results, indicating no significant effect of such dietary exposures on breast 
cancer risk.  A subsequent review by MacLean et al.[7] reached similar conclusions.  The 
benefit of both reviews is the inclusion of results from large data sets among free-living 
populations, which provide more generalizable results.  However, such studies are subject 
to the limitations of all epidemiological studies including measurement error, dietary 
variability during the years of follow-up, and variability in the fatty acid content of fish 
consumed within and across populations.  In contrast to human epidemiological studies, 
controlled animal studies, typically conducted in mouse models of human breast cancer, 
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have demonstrated that a diet supplemented with fish, flaxseed, or canola oil or EPA 
and/or DHA reduces mammary tumor size, incidence, and multiplicity and decreases the 
rate of metastasis when compared to a control diet typically containing corn oil, which is 
high in n-6 PUFA[8-22]. 
Several independent but interrelated mechanisms are postulated to account for the 
possible beneficial effects of n-3 in reducing breast cancer risk.  Increased intake of n-3 
displaces n-6, such as arachidonic acid (AA, 20:4), in cellular membranes.  This 
displacement, in addition to competition for the enzymes cyclooxygenase and 
lipoxygenase, can shift the production of pro-inflammatory eicosanoids from n-6 to anti-
inflammatory eicosanoids from n-3, and this is the primary justification for the use of n-3 
in cardiovascular disease prevention[23].  Decreased inflammation may reduce 
carcinogenesis, cancer progression, and metastases, all processes that are associated with 
inflammation.  Rose et al.[10] measured decreased pro-inflammatory eicosanoids in mice 
fed either 8% or 4% DHA or EPA versus an equal amount of linoleic acid (LA, 18:2 n-6), 
and a dietary crossover study showed a significant decrease in plasma F2-isoprostanes (a 
marker of AA oxidation) in women consuming 15 g fish oil versus 15 g sunflower oil, 
providing mostly oleic acid (18:1 n-9), for five weeks[24]. 
A second potential mechanism for chemoprevention by n-3 is the modulation of 
signal transduction.  Several studies have shown an effect of n-3 supplementation on 
genes involved in cell cycle progression, apoptosis, lipid metabolism, eicosanoid 
synthesis, and antioxidant activity[14, 20-22, 25].  It is likely that n-3 affect gene 
expression through several pathways, but the principle mechanisms appear to be the 
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alteration of signal transduction by incorporation into cellular membranes and acting as 
ligands for signal transduction factors, particularly for peroxisome proliferator-activated 
receptors (PPARs).  Displacement of cholesterol and proteins by n-3 in lipid rafts and 
calveolae within cellular membranes can disrupt receptor-mediated signal transduction, 
including via the T cell receptor[26].  PUFA and their oxidative metabolites, including 9- 
and 13-hydroxy-octadecadienoic acid (9- and 13-HODE) have been shown to specifically 
bind to multiple isoforms of PPARs but especially PPAR![27, 28].  There is a large body 
of evidence indicating that PPAR!, which can be over-expressed in tumors including 
breast cancer, promotes cell differentiation and inhibits inflammation and tumor 
growth[28-31].  In addition to up-regulation of apoptosis, or programmed cell death, via 
signal transduction, n-3 consumption may enhance apoptosis from lipid peroxidation.  
This potential chemopreventive mechanism will be discussed in the following section, 
Polyunsaturated fatty acids and lipid peroxidation. 
 Lastly, the role of restricting dietary fat to reduce the risk or severity of breast 
cancer has been closely examined and must be addressed, although such research does 
not specifically measure the effects of n-3.  In a review commissioned by the World 
Health Organization and Food and Agriculture Organization, Gerber[32] concluded that 
there was a probable positive association between total fat intake and risk of breast 
cancer, likely due to increased estrogen synthesis in the adipose tissue of postmenopausal 
women.  In a large, randomized controlled dietary intervention trial of postmenopausal 
women diagnosed with early-stage breast cancer entitled the Women’s Intervention 
Nutrition Study (WINS), subjects in the intervention group with a mean daily fat intake 
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of 33.3 g showed a significant 24% decreased hazard rate for breast cancer relapse 
compared to subjects in the control group averaging 51.3 g of fat per day after a median 
follow-up of 60 months[33].  A corollary to WINS was the Women’s Healthy Eating 
Living (WHEL) randomized controlled trial of postmenopausal women diagnosed with 
operable breast cancer following a low-fat (15-20% of energy), high fiber (30 g), and 
high fruit and vegetable (eight servings total) diet daily for a mean of 7.3 years[34].  The 
results of this study showed a modest but non-significant reduction in the hazard rate of 
breast cancer relapse or overall mortality in the intervention group; the mean energy from 
fat ranged from 21.2-28.9% during the first 72 months of follow-up in the intervention 
group.  However, the mean energy from fat ranged from 27.8-32.4% in the control group 
over the same time period, reducing the likelihood of a significant effect of dietary fat 
given the relatively similar patterns of intake between the two groups.  Nevertheless, a 
decrease in total fat intake may lower the risk of breast cancer by reducing adiposity or 
through independent mechanisms, suggesting that a low-fat diet (approximately 20% or 
fewer calories from fat) supplemented with n-3 may be more beneficial than a higher fat 
diet supplemented with n-3 for breast cancer risk reduction. 
 
Polyunsaturated fatty acids and lipid peroxidation 
Chemistry of process and formation of metabolites 
 Lipid peroxidation refers to the free radical-initiated autocatalytic degradation of 
unsaturated fatty acids in the presence of molecular oxygen[35].  The rate of lipid 
peroxidation increases exponentially with an increasing number of double-bonds, and 
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highly unsaturated fatty acids such as DHA and EPA are exceedingly susceptible to lipid 
peroxidation[36, 37].  Following the removal of a hydrogen from a methylene group 
("CH2") between the double bonds of the fatty acid by a free radical, such as the 
hydroxyl radical (#OH) (Figure 2), the resulting lipid radical undergoes conformational 
changes and reacts with molecular oxygen to yield a peroxyl radical (LOO#) followed by 
a lipid hydroperoxide (LOOH) (Figure 3 and Figure 4)[38].  This unstable lipid peroxyl 
radical is converted to a lipid alkoxy radical coupled to the production of an additional 
hydroxyl radical (Figure 5), which readily degrades via $-scission into several reactive 
metabolites (Figure 6)[35]. 
 Several reactive electrophilic compounds are formed following the $-scission of 
lipid peroxyl radicals, including malondialdehyde (MDA), 4-hydroxyalkenals, 2-alkenals, 
and 2,4-alkadienals[35, 36].  Of these metabolites, the 4-hydroxyalkenals, 4-hydroxy-2-
trans-nonenal (HNE) and—to a lesser extent—4-hydroxy-2-trans-hexenal (HHE), in 
addition to MDA, are the most extensively studied (Figure 7)[35, 38-40].  It has been 
shown that HNE is produced from the lipid peroxidation of both n-6 and n-3, whereas 
HHE is generated almost exclusively from n-3[36, 41, 42]. 
 Because they contain multiple double bonds, EPA and DHA are considered highly 
susceptible to oxidative stress.  Indeed, Guillen et al.[43] measured a number of lipid 
peroxidation products in the head space of cod liver oil, including ketones, 
monounsaturated aldehydes, diunsaturated aldehydes, and oxygenated aldehydes.  A 
lipidomic analysis of DHA methyl ester by Kawai et al.[44] established that 
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Figure 2.  Initiation of lipid peroxidation by free radical attack on methylene hydrogen of the n-3 docosahexaenoic acid (DHA, 22:6, A) and conversion to DHA 
radical (B) (adapted from [3]). 
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Figure 3.  Formation of conformational structures (C1 and C2) from DHA radical (B) (adapted from [3]). 
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Figure 4.  Reaction of DHA radical (C2) with molecular oxygen to form DHA lipid peroxyl radical (D) (adapted from [3]). 
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Figure 5.  Degradation of DHA lipid peroxide (E) into DHA alkoxy radical (F) coupled to production of additional hydroxyl radicals (adapted from [3]). 
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Figure 6.  Degradation of DHA alkoxy radical (F) via !-scission into aldehyde (G), acid (H), hydrocarbon (I), and/or oxoacid (J) (adapted from [3]).
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Figure 7.  Common reactive metabolites formed from lipid peroxidation of polyunsaturated fatty acids 
(PUFA). 
 
4-oxo-butanoate, 2-pentenal, 2-octenal, 2,4-heptadienal, 8-oxo-4,6-octadienoate, 2-
hydroxybutanal, 5-oxo-4-hydroxypentanoate, HHE, 4-hydroxy-2,6-nonadienal, 7-oxo-4-
hydroxy-5-heptenoate, 4-hydroxy-2,6,9-dodecatrienal, 10-oxo-7-hydroxy-4,8-
decadienoate, 13-oxo-10-hydroxy-4,7,11-tridecatrienoate, glyoxal, and MDA were 
detected with gas chromatography-mass spectrometry following the induction of 
oxidation.  
 Research examining the production of specific lipid peroxidation metabolites 
following fish or long-chain PUFA consumption by humans is presently lacking.  
However, the measurement of thiobarbituric acid reactive substances (TBARS) in plasma 
or urine is commonly employed as a non-specific measurement of lipid peroxidation[45].  
Table 1 summarizes relevant studies examining the response of in vivo lipid peroxidation 
to dietary supplementation with fish oil and/or n-3.  In general, fish oil or n-3 
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Table 1.  Summary of human intervention studies of fish oil and/or n-3 PUFA and in vivo lipid peroxidation. 
Reference Subjects Intervention 
Peroxidation Outcome 
Measurement(s) Results Notes 
Meydani et 
al.[46] 
Human female, 
22-35 or 55-71 y 
n=25 
Daily supplement for 3 
months: 
• 1680 mg EPA 
• 720 mg DHA 
• 600 mg other 
fatty acids 
6 IU vitamin E 
Plasma fatty acids 
Plasma vitamin E 
Plasma TBARS 
Older women had sig. higher increase in 
plasma EPA and DHA than younger 
women. 
Sig. increase in ratio of PUFA:saturated 
fatty acids in both age groups with 
supplementation. 
Sig. decrease in plasma triglycerides in 
both age groups with supplementation. 
Sig. decrease in plasma vitamin E in young 
women at 3 month compared to 1 month of 
supplementation. 
Sig. decrease of vitamin E relative to EPA 
and DHA in both age groups with 
supplementation. 
Plasma MDA equivalents sig. higher at 
month 2 compared to baseline in both age 
groups, but no significant difference 
relative to baseline at 3 months. 
Decreased MDA at 
3 months possibly 
due to increased 
activity of GSTs. 
Female hormones 
reported to have 
antioxidant activity. 
Nair et 
al.[47] 
Human men, 24-
57 y 
n=40 
Controlled diet with: 
• 15 g/d of 
placebo oil for 
10 weeks 
• 15 g/d fish oil 
concentrate 
with 15 mg 
vitamin E for 
10 weeks 
• 15 g/d fish oil 
concentrate 
with 200 mg 
vitamin E for 8 
weeks 
Plasma TBARS 
Plasma !-tocopherol, 
retinol, and "-carotene 
Plasma TBARS sig. increased with fish oil 
diet but sig. decreased with fish oil + 
vitamin E compared to the placebo diet. 
Sig. decrease of plasma !-tocopherol with 
fish oil diet, restored to placebo level with 
200 mg vitamin E. 
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Reference Subjects Intervention 
Peroxidation Outcome 
Measurement(s) Results Notes 
Suzukawa et 
al.[48] 
Human, 
hypertensive men 
(n=6) and women 
(n=14) (mean age 
60 y) 
6 wk. crossover: 
• 3.4 g/d n-3 fatty 
acids + 2 
mg/mL vitamin 
E 
• 3.4 g/d corn oil 
+ 2.2 mg/mL 
vitamin E 
Plasma TBARS 
Plasma lipid peroxides 
LDL TBARS 
Copper-induced LDL 
oxidation 
 
No sig. difference in plasma lipid 
peroxides between 2 supplement periods or 
baseline. 
Sig. reduction in lag time with fish oil 
supplementation for copper-induced LDL 
oxidation, particularly among subjects 
taking both a diuretic and beta-blocker. 
Fish oil treatment sig. increased LDL 
TBARS compared to baseline or corn oil 
treatment with 90 or 180 minutes 
oxidation.  TBARS also increased with 
fish oil treatment during macrophage 
culture experiment. 
Authors conclude 
there is a need for 
increased !-
tocopherol intake 
with large doses of 
fish oil. 
Palozza et 
al.[49] 
Human male 
(n=22) and female 
(n=18) (25-46 y) 
Double-blind 
randomized controlled 
dietary trial for 6 mos. 
of: 
• 2.5 g/d PUFA + 
2.7 mg vitamin 
E 
• 5.1 g/d PUFA + 
2.7 mg vitamin 
E 
• 7.7 g/d PUFA + 
2.7 mg vitamin 
E 
Placebo with mixed fatty 
acids and no added 
vitamin E 
2,2’-azobis-(2-
amidinopropane) 
hydrochloride (AAPH)-
induced lipid 
peroxidation of plasma 
membranes followed by 
TBARS 
Dose-dependent increase in TBARS, sig. 
in highest dose of PUFA for 6 months. 
 
Wander et 
al.[45] 
Human female, 
postmenopausal 
n=48 
Double-blind crossover 
trial for 5 wks: 
• 15 g/d fish oil + 
0 mg vitamin E 
Urinary TBARS 
Urinary and plasma 
MDA by HPLC 
Sig. increase in urinary TBARS with fish 
oil vs. baseline, which decreased with 
increasing amounts of vitamin E. 
Sig. increase of urinary MDA with fish oil 
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Reference Subjects Intervention 
Peroxidation Outcome 
Measurement(s) Results Notes 
• 15 g/d fish oil + 
100 mg vitamin 
E 
• 15 g/d fish oil + 
200 mg vitamin 
E 
• 15 g/d fish oil + 
400 mg vitamin 
E 
not ameliorated by vitamin E. 
Sig. increase of plasma MDA with fish oil 
supplement, not sig. decreased with 
vitamin E. 
Turley et 
al.[50] 
Human female 
(18-28 y) 
n=30 
Double-blinded, parallel-
arm, 28 d supplement 
with: 
• 2.4 g fish oil  
2.4 g fish oil + 
3 mg/g vitamin 
E 
Plasma ascorbate 
Plasma MDA and HNE 
Borderline sig. decrease in plasma 
ascorbate in fish oil group, and borderline 
sig. increase in fish oil + vitamin E group. 
No sig. differences in plasma MDA and 
HNE from baseline or between groups. 
 
Saito et 
al.[51] 
Hyperlipidemic 
female (48-58 y) 
n=5 
2-wk. controlled diet 
with: 
• 2.43 g/d EPA 
Plasma TBARS 
Water-soluble 
fluorescent substances 
No sig. changes in plasma TBARS and sig. 
decrease in water-soluble fluorescent 
substances following EPA 
supplementation. 
Authors 
recommend double 
the equation 0.3 x 
double-bond index 
x oil supplement 
intake (g) to ensure 
adequate vitamin E. 
Higdon et 
al.[24] 
Human female, 
postmenopausal 
(50-75 y) 
n=15 
3-treatment crossover 
trial (5 wks. each): 
• 15 g sunflower 
oil (12.3 g 
oleate) 
• 15 g safflower 
oil (10.5 g 
linoleate) 
• 15 g fish oil 
(2.0 g EPA and 
Plasma F2-isoprostanes 
Plasma MDA 
Plasma TBARS 
After fish oil treatment, plasma MDA 17% 
lower (sig.) than sunflower oil and 13% 
lower (NS) than safflower oil. 
After fish oil treatment, plasma TBARS 
were more than 21% higher than sunflower 
oil and 23% higher than safflower oil 
treatment (both sig.). 
No difference in MDA or TBARS between 
sunflower and safflower supplementation 
periods. 
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Reference Subjects Intervention 
Peroxidation Outcome 
Measurement(s) Results Notes 
1.4 g DHA) Normalization of MDA to plasma PUFA 
eliminated sig. differences between diets, 
but normalization of TBARS to PUFA 
maintained sig. higher concentration with 
fish oil supplementation. 
F2-isoprostanes sig. lower following fish 
oil treatment than sunflower oil. 
Grundt et 
al.[52] 
Human male 
(n=238) and 
female (n=62) 
with recent 
myocardial 
infarction 
28-87 y 
Double-blinded, 
placebo-controlled, 
randomized trial for 1 y: 
• 3.464 g/d n-3 
• 4 g/d corn oil 
Serum MDA via HPLC Sig. increase in TBARS in fish oil group 
vs. baseline or corn oil group. 
 
Wu et al.[53] Human female 
vegetarian, 
postmenopausal 
n=27 
Single-blind, 
randomized, placebo-
controlled trial for 6 
wks. of: 
• 6 g/d DHA-rich 
algae oil (2.14 
g/d DHA, 1 IU 
vit. E/g) 
• 6 g/d corn oil 
LDL TBARS following 
copper-induced 
oxidation 
Urinary 8-iso-
prostaglandin F2 
Sig. increase in LDL TBARS with DHA 
supplementation. 
No difference in urinary F2 isoprostane 
between groups. 
 
Calzada et 
al.[54] 
Human male, 53-
65 y 
n=12 
Increasing doses of DHA 
for 2 weeks each: 
• 200 mg + 0.125 
mg vitamin E 
• 400 mg + 0.25 
mg vitamin E 
• 800 mg + 0.375 
mg vitamin E 
• 1600 mg + 0.5 
mg vitamin E 
LDL vitamin E 
LDL MDA via HPLC 
LDL and cholesteryl 
ester fatty acids 
Copper-induced LDL 
oxidation 
Plasma hydroxy-alkenals 
Sig. increase in LDL vitamin E with all 
supplementation except 1600 mg DHA, 
highest increase with 200 mg. 
Sig. decrease in LDL MDA with all 
supplementation except 1600 mg. 
Sig. increase in lag time for copper-
induced LDL oxidation in 200-800 mg 
DHA, highest time with 400 mg. 
Sig. increase in plasma HHE with 800 and 
1600 mg DHA. 
HHE represented 
0.01% of plasma n-
3 PUFA. 
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Reference Subjects Intervention 
Peroxidation Outcome 
Measurement(s) Results Notes 
Kimura et 
al.[55] 
Human male 
(n=290) and 
female (n=205) 
Cross-sectional Serum fatty acid 
composition 
Urinary 8-oxoGua 
Sig. positive correlation for serum n-3 
PUFA, EPA, and DHA with urinary 8-
oxoGua. 
Sig. positive correlation between double 
bond index and urinary 8-oxoGua. 
8-oxoGua is a 
marker of oxidative 
DNA damage. 
Abbreviation:  
8-oxoGua = 8-oxo-7,8-dihydroguanine 
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supplementation increases plasma, low-density lipoprotein (LDL), or urinary TBARS 
relative to baseline or control groups[24, 45-49, 52, 53].  It is notable that increased 
vitamin E supplementation was shown to ameliorate the increase in TBARS from high n-
3 intake in two of the studies[45, 47].  In contrast to the TBARS results, a more specific 
measurement of plasma or LDL cholesterol MDA via high-performance liquid 
chromatography (HPLC) indicated no differences or decreased concentrations following 
fish oil supplementation[24, 50, 54] with the exception of Wander et al.[45].  
Additionally, in a study of men only, Calzada et al.[54] showed a significant increase in 
plasma HHE following DHA supplementation at 800 or 1600 mg per day, which 
comprised 0.01% of total plasma n-3 PUFA.  However, Turley et al.[50] did not detect a 
significant increase of plasma HNE with daily fish oil supplementation in young women 
compared to baseline or women consuming vitamin E in addition to fish oil. 
 
Biological effects of metabolites 
 In contrast to free radicals, aldehydic degradation products of lipid peroxidation are 
relatively stable and believed to diffuse from the site of production to distal tissues within 
the body[39].  4-Hydroxyalkenals possess an !,"-unsaturated structure that renders the 
compounds electrophiles and are readily bound via Michael addition by nucleophiles 
such as DNA, proteins, and phospholipids[56].  Such binding can cause a number of 
deleterious effects including mutagenesis, enzyme inhibition, and cell death. 
 In 1984, Chung et al.[57] demonstrated that acrolein, an !,"-unsaturated aldehyde 
found in both foods and cigarette smoke, can form adducts with deoxyguanosine in vitro.  
   23 
These researchers further detected DNA adducts from additional lipid peroxidation 
metabolites, such as HNE, in the liver and colon tissues of rats and humans[58, 59].  
However, in a mouse model of tumor induction, HNE or its epoxide (at 50, 100, or 200 
nmol injected intraperitoneally) failed to induce lung or liver tumors at statistically higher 
rates than vehicle controls; the epoxide—but not HNE—did induce skin papilloma 
development at significantly higher incidences than acetone control when applied to the 
skin of mice at 128 µmol[60].  The inability of HNE to promote tumorigenesis was 
attributed to the well-documented repair of DNA adducts by DNA glycosylase[58, 61].  
Nevertheless, DNA adducts with the oxidized product of HHE, 4-oxo-2-trans-hexenal (4-
OHE), have been detected recently in noncancerous lung tissues from lung cancer 
patients, independent of age and smoking status[62].  More recently, serum n-3 PUFA, 
EPA, and DHA were significantly positively correlated to urinary 8-oxo-7,8-
dihydroguanine (8-oxoGua) in a Japanese population, suggesting an association between 
dietary n-3 intake and oxidative DNA damage[55]. 
 Similar to their reaction with DNA, 4-hydroxyalkenals can modify proteins through 
Michael addition by binding to the sulfhydryl group of cysteine[35, 63] and imidazole 
nitrogens of histidine and lysine[40, 64, 65].  It has also been established that HNE can 
bind to a terminal lysine via Schiff base formation[40, 65, 66].  Protein binding by high 
concentrations (25 µM to 1 mM) of HNE has been shown to substantially reduce the 
enzymatic activity of glucose-6-phosphate dehydrogenase[67], cytochrome P450 (CYP) 
2E1, 3A6, and 2B4[68, 69], and glyceraldehyde-3-phosphate dehydrogenase, potentially 
impairing the biological pathways of glycolysis and detoxification[70, 71].  Additionally, 
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HNE and other aldehydes produced during lipid peroxidation were shown to bind via 
Michael addition to bovine serum albumin, and HNE bound carnosine, a peptide found in 
cardiac and skeletal muscle tissue[72, 73].  Binding of the latter peptide is considered a 
detoxification mechanism, but binding to serum albumin may explain how HNE and 
other lipid peroxidation metabolites are able to travel through the bloodstream. 
 Finally, HNE has been shown to result in the death of cells via necrosis or 
apoptosis[39].  Conditions of oxidative stress, as would lead to lipid peroxidation, are 
known to activate the tumor suppressor protein p53, resulting in the mitochondrial 
process of apoptosis[74].  Pillon et al.[75] showed that HHE, HNE, and other lipid 
peroxidation metabolites at high concentrations (100 µM) result in more necrosis than 
apoptosis of muscle cells, which the authors attributed to lethal binding to proteins within 
plasma membranes or organelles; however, apoptosis was also detected in the treated 
cells from a significant increase in caspase-3 activity.  The cytotoxic activity of HNE has 
also been attributed to its alteration of cell signaling pathways[76, 77]. 
 
Role of antioxidants 
 Oxidative stress and lipid peroxidation can be quelled by exogenous or endogenous 
antioxidants[78].  Of the exogenous dietary antioxidants, the lipid-soluble vitamin E is 
the most important for suppressing lipid peroxidation[1].  Several studies have shown 
that an increase in dietary PUFA must be accompanied by an increase in dietary vitamin 
E to decrease lipid peroxidation[45, 79, 80].  It has been established that vitamin C can 
quench free radicals, and there is some evidence that it may inhibit lipid peroxidation, 
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either directly or via regeneration of vitamin E from the vitamin E radical[1, 81, 82].  
Non-essential dietary antioxidants, such as soy isoflavones, may also reduce lipid 
peroxidation[83]. 
 Endogenous antioxidant systems are directly involved in the quenching of free 
radicals as well as lipid hydroperoxides.  Although there are no inherent antioxidant 
enzymes that consume the hydroxyl radical, superoxide dismutase (SOD) converts two 
superoxide molecules (O2-) to hydrogen peroxide (H2O2) and molecular oxygen (Figure 
8), which prevents the formation of the hydroxyl radical via the Haber-Weiss reaction 
(Figure 9)[84, 85].  Hydrogen peroxide can be converted into water by catalase, 
peroxiredoxins, or glutathione peroxidase (GPx)[84].  GPx, which contains the essential 
nutrient selenium, can also detoxify lipid hydroperoxides into hydroxy fatty acids[86]. 
 
 
Figure 8.  Conversion of two superoxide molecules (O2-) to hydrogen peroxide (H2O2) and molecular 
oxygen (O2) via the enzyme superoxide dismutase (SOD). 
 
 
Figure 9.  Haber-Weiss reaction cycle. 
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Detoxification and excretion of metabolites 
 In addition to the aforementioned endogenous antioxidant enzymes, several 
metabolic pathways serve to detoxify and excrete lipid peroxidation metabolites from the 
body.  Aldehyde dehydrogenases (ALDH) are ubiquitously expressed in human tissues 
and function to oxidize aldehydes, such as those produced during lipid peroxidation, into 
carboxylic acids[87].  It has been proven in humans and rats that HNE is readily oxidized 
to 4-hydroxy-2-trans-nonenoic acid (HNA) by ALDHs[69].  However, the primary 
detoxification mechanism in mammals appears to be reduction of HNE by alcohol 
dehydrogenases (ADHs) or aldo-keto reductases (AKRs) to 1,4-dihydroxy-2-trans-
nonene (DHN) (Figure 10)[88-90]. 
 Reactive electrophiles, such as HNE and HNA, can be bound to the tripeptide 
glutathione (GSH), with or without catalysis by glutathione-S-transferases (GSTs)[89].  
DHN, which no longer possesses an !,"-unsaturated structure, cannot form adducts with 
GSH; however, HNE adducted to GSH can be reduced to form DHN-GSH.  Binding with 
GSH can occur in all cell types, but the liver is the site of the greatest frequency[91].   
Upon formation, GSH adducts are readily transported to the kidneys, where they are 
catabolized to cysteine S-conjugates and N-acetylated to form mercapturic acids excreted 
in the urine.  Mercapturic acids may also be formed in the liver and excreted into the bile 
or circulation, but urinary mercapturic acids offer an opportunity for non-invasive 
measurement of the excretion of electrophilic compounds formed endogenously, present 
in the diet, or from exposure to environmental toxins.  Mercapturic acid conjugates of 
DHN and HNA have been detected in the urine of rats and humans, and this pathway 
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represents the accepted mechanism for 4-hydroxyalkenal detoxification and excretion in 
mammals[82, 88-90]. 
 
 
 
Figure 10.  Metabolic conversion of the !,"-unsaturated hydroxyaldehyde, 4-hydroxy-2-trans-nonenal 
(HNE, A), via aldehyde dehydrogenase (ALDH) into 4-hydroxy-2-trans-nonenoic acid (HNE, B) or via 
aldo-keto reductase (AKR) into 1,4-dihydroxy-2-trans-nonene (DHN, C) in the liver.  A and B can form 
glutathione (GSH)-conjugates (A1 and B1), typically catalyzed by GSH–S-transferase (GST); alternatively 
A may bind to GSH followed by reduction via AKR to form the GSH-conjugate of DHN (C1).  The GSH-
conjugates are catabolized to mercapturic acids (A2, B2, and C2) via AKR or carbonyl reductase (CR) in the 
kidney for urinary excretion (adapted from [89]). 
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Free radicals, lipid peroxidation, and cancer 
 As mentioned previously, free radicals and electrophilic lipid peroxidation 
metabolites may bind to DNA, leading to genetic instability or mutations.  Such 
modifications are implicated in cancers, which are characterized by DNA mutations 
resulting in cellular immortality, sustained proliferation, evasion of apoptosis and 
immune detection, the promotion of new blood vessel formation, and the ability to spread 
to and invade distal sites with the organism[61, 92].  Conditions of elevated oxidative 
stress have been detected in case-control studies of cancer patients, but it has been 
difficult to ascertain the role of oxidative stress in carcinogenesis[61].  The subsequent 
section includes an extensive review of primary literature regarding lipid peroxidation 
and breast cancer. 
 It has been estimated that oxidative lesions to DNA are present under steady-state 
conditions at 0.4-0.8 clusters per million base pairs, and HNE is present within cells 
under steady-state conditions at 5-10 µM[61, 73].  Consequently, endogenous DNA 
repair activity and antioxidants have important functions to maintain homeostasis and 
prevent the formation of tumors.  In addition to the aforementioned antioxidant and 
detoxification pathways to eliminate free radicals and reactive electrophiles, base 
excision repair and nucleotide excision repair serve to repair DNA damage resulting from 
oxidative modifications and prevent genetic mutations that may lead to cancer[73].  
Nevertheless, the disruption of DNA repair or antioxidant activity with or without an 
increase in cellular exposure to free radicals would promote mutagenesis in a typical cell. 
 Cellular oxidative stress also plays an important role in the function of a key tumor 
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suppressor protein, p53.  The gene p53, also called TP53, is frequently mutated in human 
cancers[93].  When intact, p53 can induce the mitochondrial pathway of apoptosis in 
response to oxidative stress[74].  At low levels of oxidative stress, p53 serves as a 
transcription factor to increase the expression of the antioxidant enzymes SOD and GPx.  
The protein itself senses the redox status of cells via ten cysteine residues located in its 
DNA-binding domain; oxidation of these residues leads to the formation of disulfide 
bonds within the protein, resulting in a conformational change that may allow p53 to bind 
to its response elements on DNA.  When functional, p53 acts to protect the cell against 
oxidative stress by up-regulation of antioxidant enzymes or the stimulation of apoptosis.  
However, if p53 is mutated in cancer, it no longer protects the cell and cannot stave off 
the increased oxidative stress and replicative potential present in cancer. 
 In the event of an oncogenic transformation of a cell that is not repaired or 
eliminated via apoptosis, there is evidence that oxidative stress enhances the promotion 
and progression of cancer.  If they do not trigger apoptosis or necrosis, free radicals can 
serve to promote the development of cancers by acting as second messengers[94].  Cell 
culture work has demonstrated that reactive oxygen species (ROS) are involved in cell 
cycle progression through the Ras/ERK/MAPK pathway, which can be mutated in human 
cancers[94, 95].  Oxidative stress is also known to activate NF-!B, a transcription factor 
that promotes cell proliferation[94, 96].  In the later stages of cancer, ROS participate 
directly in angiogenesis, invasion, and metastasis by disrupting structural proteins or by 
increasing the expression of and activating matrix metalloproteases (MMPs), enzymes 
that remodel extracellular matrices allowing for the formation of new blood vessels and 
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distal transport of tumor cells[94]. 
 Recently, Cortes et al.[97] used RNA microarray to assess changes in breast cancer 
cells and normal breast cells following the induction of oxidative stress; the transformed 
cells were relatively unaffected compared to the normal cells.  Notably, genes involved in 
the metabolism of antioxidants were up-regulated in the normal cells but not the cancer 
cells.  Additionally, genes regulating DNA repair were up-regulated by oxidative stress.  
The authors were surprised that oxidative stress tended to down-regulate the expression 
of cancer progression genes in all three cell lines tested but were able to differentiate and 
correlate those genes responding to the oxidative stress versus those responding to cancer 
progression.  SOD and GPx were up-regulated by both oxidative stress and cancer 
progression, while GSTs and genes encoding for peroxiredoxins were up-regulated by 
oxidative stress but down-regulated by cancer progression.  Therefore, it is evident that 
an important part of cancer progression is the change in antioxidant enzyme expression 
patterns, allowing for either the promotion or suppression of malignancies in response to 
pro-oxidative conditions. 
 
Lipid peroxidation and breast cancer 
Cell culture and in vitro studies 
 As summarized in Table 2, several primary research articles have examined n-3 
and lipid peroxidation in human breast cancer cell lines.  There is general agreement that 
treating such cells with PUFA including n-3 increases lipid peroxidation measured via 
TBARS and decreases cell viability.  Begin et al.[98] tested DHA and EPA in addition to 
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Table 2.  Summary of cell culture studies examining lipid peroxidation and breast cancer. 
Reference System/Controls Intervention Outcome Measurement(s) Results Notes 
Begin et 
al.[98] 
Human breast 
cancer cells ZR-75-
1 
Untreated cancer 
cells as controls 
20 µg/mL 
gamma 
linolenic acid 
(GLA), 
arachidonic 
acid, DHA, 
EPA 
Cell viability 
TBARS 
Phospholipid composition 
GLA-induced cytotoxicity suppressed 
by SOD. 
DHA was least effective and EPA 
intermediate in increasing TBARS.  
GLA and AA generated highest levels of 
TBARS. 
The addition of iron or copper increased 
GLA cytotoxicity, whereas vitamin E, 
BHT, and BHA suppressed cell death. 
Increase in TBARS correlated with 
increase in cell death. 
 
Menendez 
et al.[99] 
Human breast 
cancer cells SK-Br3 
and MDA-MB-231 
(negative control 
because constitutive 
expression of fatty 
acid synthase) 
Untreated cancer 
cells as controls 
0, 6.25, 12,5, 
25, or 50 
µg/mL LA, 
GLA, AA, 
ALA, EPA, 
and DHA 
Cell viability 
In situ immunofluorescent 
staining of fatty acid synthase 
(FAS) 
ALA sig. decreased cell viability. 
FAS over-expression and activity in 
breast cancer cells sig. suppressed by 
ALA and GLA (strongest effect), and 
FAS activity sig. reduced by LA, DHA, 
and EPA.   
FAS over-expression suppression by 
ALA and GLA inhibited by vitamin E. 
FAS expression reduced with MAPK 
and PI-3’K inhibitors in SK-Br3 cells. 
GLA is n-6. 
Authors conclude 
effect of PUFA on 
cell growth due to 
functions in 
addition to lipid 
peroxidation (gene 
expression). 
Maheo et 
al.[100] 
Human breast 
cancer cells MDA-
MB-231, MCF-7, 
and MCF-7dox 
(doxorubicin-
resistant) 
Untreated cancer 
cells as controls 
30 µM DHA  Cellular phospholipid 
composition 
Cell viability 
MDA, GSH, GSSG, and 
vitamin E concentrations via 
HPLC-UV 
DHA incorporated sig. more in MDA-
MB-231 than MCF-7 membranes. 
DHA sig. increased cytotoxicity of 
doxorubicin in MDA-MB-231 and 
MCF-7dox cells. 
DHA increased MDA concentration by 
approx. 4-fold in each cell line.  GSH 
and GSSG sig. increased by DHA in 
MDA-MB-231 cells. 
Vitamin E levels were undetectable. 
 
Menendez 
et al.[101] 
Human breast 
cancer cells BT-474 
and SKBr-3 
0, 2.5, 5, 10, 
20, or 40 µM 
ALA 
HER2 quantification via 
ELISA, immunoblotting, and 
in situ immunofluorescent 
ALA treatment sig. reduced HER2 
protein levels and HER2 gene 
expression in both cell lines.   
HER2 
overexpression 
associated with 
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Reference System/Controls Intervention Outcome Measurement(s) Results Notes 
Untreated cancer 
cells as controls 
staining 
Cell cycle distribution via 
flow cytometry 
HER2 gene concentration via 
RT-PCR 
HER2 promoter activity 
Cell viability 
ALA treatment sig. enhanced reduction 
in cell viability with trastuzumab 
treatment. 
aggressive breast 
cancers, decreased 
survival times, and 
increased relapse 
rates.  LA shown 
to increase HER2 
expression.  
Grossman 
et al.[102] 
Human breast 
cancer cells MDA-
MB-231 (ER-
negative) and 
MDA-ER!7 (ER-
positive) 
Untreated cancer 
cells as controls 
0, 2.5, 5, 10, 
20, 40, or 80 
µM eleostearic 
acid (ESA) 
(conjugated 
LA), CLA, or 
ALA 
Cell proliferation 
Immunoblotting and Western 
blots of poly ADP ribose 
polymerase (PARP) 
Cell cycle distribution via 
flow cytometry 
Apoptosis via flow cytometry 
kit 
Mitochondrial membrane 
potential via kit 
20-80 µM ESA sig. decreased 
proliferation of both cell lines and sig. 
increased apoptosis.  These effects were 
eliminated by the addition of vitamin E. 
Similar results seen for mitochondrial 
membrane potential, indicating ESA 
enhanced intrinsic apoptotic pathway. 
No effect of ESA on cleaved PARP 
concentrations. 
ESA treatment sig. increased proportion 
of cells in G2-M phase.   
Inhibition of AMPK blocked the effect 
of ESA on cell proliferation. 
ESA found in 
bitter melon seed. 
Cipak et 
al.[103] 
Human breast 
cancer cells 
SUM159 
Untreated cancer 
cells as controls 
Treatment with 
hydroxyl 
radical 
Treatment with 
10, 35, or 50 
µM HNE 
Differential scanning 
calorimetry 
Cellular dichroism 
Immunoblotting for HNE-
collagen and protein adducts 
Cell viability 
Treatment of collagen with hydroxyl 
radical produced two denaturation 
transitions, causing significant structural 
changes. 
Treatment of cells with native collagen 
decreased cytotoxicity of HNE, whereas 
oxidized collagen + HNE sig. decreased 
viability. 
Cells with oxidized-collagen had greater 
amounts of HNE-protein adducts than 
those with native collagen. 
HNE above 10 µM 
supraphysiological. 
Oxidative 
treatment 
decreased amino N 
content due to 
modification of 
lysines.  HNE has 
high affinity for 
histidine, lysine, 
cysteine, and 
arginine. 
HNE binds in 
particular to 
membrane-
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Reference System/Controls Intervention Outcome Measurement(s) Results Notes 
associated 
proteins. 
Rysman et 
al.[104] 
Human cancer cells, 
including breast 
cancer cells BT474 
Untreated cancer 
cells as controls 
Human prostate 
cancer tissues with 
matching normal 
tissues 
siRNA 
targeting FAS 
and acetyl-
CoA 
carboxylase 
(ACC) 
Cellular phospholipid 
composition 
Lipid peroxidation product kit 
(MDA and/or HNE) 
Immunoblotting for FAS and 
ACC concentrations 
Lateral membrane dynamics 
via fluorescence recovery and 
diffusion 
Membrane flip-flop via 
fluorimeter 
Cell death 
Inhibition of ACC sig. increased 
membrane PUFA and decreased 
saturated fatty acids and MUFA, 
particularly in phosphatidylcholine. 
Prostate cancer tissues with increased 
FAS expression also had increased 
saturated and MUFA and decreased 
PUFA compared to control tissues. 
Inhibition of ACC sig. increased lipid 
peroxidation products, which was 
reversed with supplemental palmitic 
acid.  Inhibition of ACC also enhanced 
cell death due to hydrogen peroxide, 
which was also suppressed by palmitic 
acid.  Addition of PUFA increased lipid 
peroxidation-induced cell death with 
ACC inhibition. 
FAS inhibition shown to increase lateral 
and flip-flop membrane mobility. 
ACC inhibition enhanced cell death 
from doxorubicin. 
Increased 
membrane 
saturated fatty 
acids decreased 
lipid peroxidation-
induced cell death 
and entry of 
chemotherapeutics 
into cancer cells. 
Slade et 
al.[105] 
Human breast 
cancer cells MCF-7 
Untreated cancer 
cells as controls 
In vitro cytochrome 
c binding 
64 µM 13-
HPODE (LA 
hydroperoxide) 
and ascorbic 
acid or 13-
HPODE-biotin 
and ascorbic 
acid 
Immunostaining 
Neutravidin affinity 
chromatography 
2D-SDS-PAGE and Western 
blot to identify modified 
proteins 
Mass spectrophotometry to 
identify modified proteins 
Treatment with 13-HPODE results in 
DODE binding to cytochrome c. 
98 proteins identified as modified by 
DODE; 31 identified by all 3 techniques. 
Most proteins were cytoplasmic, but 
17% were nuclear.  Main protein groups 
were molecular chaperones, glycolysis, 
regulatory, nucleotide binding, and 
structural. 
Biotin 
modification 
allows for better 
uptake by cells. 
Extraction used not 
optimal for 
preserving 
membrane 
proteins. 
Cortes et 
al.[97] 
Human breast 
cancer cells 
HMLER-1 and 
0, 0.2 units of 
glucose 
oxidase 
GSH and GSSG 
concentrations via kit 
RNA microarray 
11,895 genes differentially expressed in 
response to oxidative stress between the 
3 cell lines. 
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Reference System/Controls Intervention Outcome Measurement(s) Results Notes 
HMLER-5 
Normal human 
mammary epithelial 
cells HMECs as 
controls 
Genes involved in cancer progression 
were down-regulated. 
Tumorigenic cells relatively unaffected 
by oxidative stress versus non-
transformed cells. 
Genes involved in DNA repair up-
regulated by oxidative stress. 
GSTs and peroxiredoxin up-regulated by 
oxidative stress but down-regulated 
during cancer progression.  SOD and 
GPx were up-regulated by oxidative 
stress and cancer progression. 
Kang et 
al.[106] 
Human breast 
cancer cells MCF-7, 
MDA-MB-231, and 
MDA-MB-435s 
Untreated cancer 
cells as controls 
0, 15, or 25 
µM EPA or 
DHA 
Cell viability 
DNA synthesis 
Cell death via flow cytometry 
Apoptosis via TUNEL 
staining 
Intracellular ROS 
concentrations 
Caspase 8 activity 
IC50 of DHA and EPA 20.2 and 57.4 
µM, respectively, in MCF-7 cells.  
MDA-MB-231 and MDA-MB-435s less 
sensitive to EPA and DHA. 
DHA treatment for 72 h resulted in 
decreased DNA synthesis, decreased cell 
viability of MCF-7 cells and increased 
apoptosis. 
Knockdown of caspase 8 eliminated 
effect of DHA on cell death. 
Vitamins E and C and N-acetyl cysteine 
protected MCF-7 cells from cell death 
due to DHA.  DHA treatment increased 
ROS production in cells. 
 
Abbreviations:  
13-HPODE = linoleic acid hydroperoxide 
DODE = 9,12-dioxo-10(E)-dodecenoic acid 
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gamma linolenic acid (GLA) and AA, both of which are n-6, and concluded that GLA 
and AA treatment resulted in the highest concentration of TBARS, whereas DHA yielded 
the lowest increase in TBARS.  In contrast, Maheo et al.[100], using different cell lines, 
were able to increase TBARS four-fold with DHA supplementation.  These differences 
are likely due to the use of different cell lines and concentrations of DHA.  DHA 
treatment was also shown to decrease cell viability and DNA synthesis and enhance 
apoptosis[106].  However, Maheo et al.[100] also demonstrated a significant increase in 
GSH with DHA treatment, which would increase the capacity for GSH-mediated 
detoxification of lipid peroxidation metabolites.  Additionally, n-3 treatment reduced the 
levels of vitamin E present within the cells, and treatment with vitamin E negated the 
cytotoxic and oxidative effects of n-3 in a number of the studies[98, 102, 106].  In a study 
specifically addressing the effects of HNE on breast cancer cells, Cipak et al.[103] 
showed that exposure of cells to supraphysiological levels of HNE (35 or 50 µM) 
resulted in enhanced cytotoxicity and decreased viability.  Cells treated with HNE under 
conditions of elevated oxidative stress had increased levels of HNE-protein adducts 
compared to cells treated with HNE under basal conditions.  Slade et al.[105] measured 
the changes in the proteome of breast cancer cells treated with a LA hydroperoxide, 
which affected a total of 98 proteins, including many found in the nucleus.  However, this 
work was primarily for method development, and it was not possible to draw meaningful 
conclusions regarding lipid peroxidation and breast cancer risk. 
 Cell culture studies are advantageous for exploring the specific mechanisms by 
which n-3 and lipid peroxidation may affect cancer promotion.  In addition to promoting 
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apoptosis and protein binding, n-3 and lipid peroxidation metabolites can alter membrane 
fluidity and signal transduction.  Menendez et al.[99] showed that the activity of fatty 
acid synthase (FAS), a protein frequently over-expressed in cancers, was significantly 
reduced by treatment of breast cancer cells with ALA, EPA, DHA, GLA, and AA, and 
this effect was blocked by the addition of vitamin E.  In a follow-up study, the same 
authors showed that ALA significantly reduced HER2 transcription and expression; 
HER2 over-expression is associated with more aggressive breast cancers with poorer 
prognoses and decreased survival times[101].  In a study that did not address the effects 
of supplemental n-3, Rysman et al.[104] showed that the inhibition of enzymes involved 
in saturated fatty acid synthesis, FAS and acetyl CoA-carboxylase (ACC), increased lipid 
peroxidation as well as protein motility within the cellular membranes and ultimately 
promoted cancer cell death.  These studies offer important information about the 
association between dietary n-3, lipid peroxidation, and breast cancer but cannot be 
directly applied to the association within human beings. 
 
Animal model studies 
 Table 3 includes a summary of animal studies measuring dietary n-3, lipid 
peroxidation, and breast cancer risk.  In a seminal study, Gonzalez et al.[107] measured 
the effects of various ratios of corn oil and fish oil in the diets (20% energy from fat) of 
mice xenografted with human breast cancer cells.  The mammary tumor TBARS 
significantly increased with increasing amounts of fish oil in the diets while mean tumor 
volume significantly decreased.  Supplementation with vitamin E and TBHQ, a synthetic 
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Table 3.  Summary of animal model studies examining lipid peroxidation and breast cancer. 
Reference System/Controls Intervention 
Outcome 
Measurement(s) Results Notes 
Gonzalez 
et al.[107] 
Female athymic 
nude mice 
implanted with 
human breast 
cancer cells 
MDA-MB-231 
Corn oil diet fed 
mice served as 
controls 
Corn and/or fish oil diet 
beginning 7-10 d following 
xenograft: 
! 20% corn oil 
! 15% corn oil, 5% 
fish oil 
! 10% corn oil, 10% 
fish oil 
! 5% corn oil, 15% 
fish oil 
! 1% corn oil, 19% 
fish oil 
! 1% corn oil, 19% 
fish oil + 2000 
IU/kg vitamin E 
and 2% total fat 
TBHQ 
Tumor incidence 
Mean tumor volume 
Breast carcinoma 
TBARS 
TBARS sig. increased with increasing 
proportion of fish oil, while mean tumor 
volume decreased. 
Increase in TBARS was prevented by 
supplemental antioxidants, but mean tumor 
volume was not sig. lower than high corn 
oil diets in this group. 
Increased time that fish oil diet remained in 
food jar also sig. increased tumor TBARS. 
 
Hardman 
et al.[86] 
Female athymic 
nude mice 
implanted with 
human breast 
cancer cells 
MDA-MB-231 
Corn and/or fish oil diet 
beginning 3 wks following 
xenograft: 
! 5% corn oil 
! 5% corn oil + 2000 
IU/kg vitamin E 
! 3% fish oil, 2% 
corn oil 
! 3% fish oil, 2% 
corn oil + 2000 
IU/kg vitamin E 
5 mg/kg body weight every 
4 days doxorubicin in 5 
mice per group for 5 weeks 
Mean tumor volume 
Tumor, liver, and colon 
TBARS 
Fatty acid composition 
in mitochondria and 
microsomes of colon, 
liver, and tumor tissues 
Catalase, SOD, and 
GPx activity in tissues 
GPx activity sig. decreased in tumor tissue 
of mice consuming the fish oil diet + 
vitamin E.  There were no other sig. 
differences in antioxidant enzyme activities 
between diets or tissues. 
Vitamin E with fish oil diet sig. decreased 
tumor TBARS, although tumor TBARS of 
fish oil diet were not sig. different than corn 
oil.  Vitamin E with corn oil diet prevented 
increased tumor TBARS with doxorubicin 
but not in fish oil diet. 
Fish oil diet sig. increased liver TBARS, 
which was suppressed with vitamin E with 
or without doxorubicin. 
Fish oil diets with doxorubicin sig. halted 
tumor growth compared to corn oil diets. 
GPx reported to 
be more 
important than 
catalase in 
neutralizing 
lipid 
hydroperoxides. 
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Reference System/Controls Intervention 
Outcome 
Measurement(s) Results Notes 
GPx activity accounted for 78% of 
increased TBARS following doxorubicin 
for 19% of variation in tumor growth. 
Hilakivi-
Clarke et 
al.[108] 
Rat model of 
mammary cancer 
induction with 
DMBA 
Low-fat 17:1 diet 
as control 
Rat pups fed low-fat (16% 
energy) or high-fat (39% 
energy) diets between 
postnatal days 2 and 5: 
• 2:1 n-6:n-3 
• 17:1 n-6:n-3 
Tumor incidence 
Tumor latency 
Mammary gland 
morphology 
Apoptosis via TUNEL 
Cell proliferation 
COX-2 expression 
PPAR! activity 
Cyclin D1 expression 
Lipid hydroperoxide 
concentration 
BRCA1 and Caveolin-1 
expression 
8-OHdG 
Low-fat 2:1 diet reduced the incidence and 
multiplicity of mammary tumors, whereas 
high-fat 2:1 diet increased the incidence and 
multiplicity of tumors. 
No differences in tumor incidence and 
multiplicity between low- and high-fat 17:1 
diets. 
Increased mammary gland differentiation in 
both 2:1 diets. 
High-fat 2:1 diet had highest level of lipid 
hydroperoxides, while low-fat 17:1 diet had 
lowest.  Low-fat 2:1 diet showed modest 
increase in lipid hydroperoxides. 
Both n-3 diets showed decreased Cox-2 
expression. 
Low-fat n-3 diet showed increased and 
decreased proliferation. 
PPAR! activity lowest and cyclin D1 
expression highest in high-fat 2:1 diet.  
PPAR! activity sig. increased in low-fat 2:1 
diet. 
BRCA1 expression highest in n-3 groups. 
Caveolin-1 expression highest in n-3 
groups. 
8-OHdG increased in high-fat 2:1 diet but 
decreased in low-fat 2:1 diet. 
Supplement 
article 
El-Mesery 
et al.[109] 
Female Swiss 
albino mice for 
tumor 
experiments via 
injection with 
0, 125, or 250 mg/kg DHA 
for 20 d 
0, 125, or 250 mg/kg DHA 
following cisplatin injection 
Mean tumor size 
TBARS 
Serum C-reactive 
protein concentration 
Leukocyte count 
High-dose DHA sig. reduced mammary 
tumor size and serum TBARS in mouse 
model.  There was no correlation between 
TBARS and tumor size. 
High-dose DHA + cisplatin for 10 d sig. 
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Reference System/Controls Intervention 
Outcome 
Measurement(s) Results Notes 
Ehrlich ascites 
carcinoma cells 
(mammary origin) 
No injection for 
control mice 
Male Sprague-
Dawley rats for 
nephrotoxicity 
experiments with 
cisplatin injection 
No injection for 
control rats 
Kidney glomerular 
function 
TNF-! and GSH 
concentrations 
 
decreased kidney TBARS and TNF-! and 
increased kidney GSH in rat model. 
Kang et 
al.[106] 
Female athymic 
nude mice 
implanted with 
human breast 
cancer cells MCF-
7 or MDA-MB-
435s 
Control diet (5% 
corn oil) mice 
served as controls 
Control diet + 5% fish oil Mean tumor size 
Plasma and breast, 
uterus, skin, and tumor 
fatty acid 
concentrations 
Morphological 
characteristics 
Cell proliferation and 
apoptosis via 
immunohistochemistry 
Fish oil diet sig. decreased tumor volume 
and cell proliferation and increased 
apoptosis in MCF-7-implanted mice. 
 
Schubert 
et al.[110] 
ATM-deficient 
mice (at high risk 
for multiple 
cancers, including 
mammary) 
Control diet fed 
mice served as 
controls 
Wild-type mouse 
splenocytes used 
as controls in in 
vitro analyses 
EPA-enriched fat blend diet 
AA-enriched fat blend diet 
Plasma and erythrocyte 
membrane EPA 
8-OHdG concentration 
No differences between diets in latency to 
tumor development. 
EPA treatment sig. increased 8-OHdG 
compared to control and AA treated 
animals. 
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Reference System/Controls Intervention 
Outcome 
Measurement(s) Results Notes 
Kansal et 
al.[111] 
Female Wistar 
rats fed DMBA to 
induce mammary 
tumor formation 
1.0 mL olive oil 
fed animals with 
or without DMBA 
treatment as 
controls 
• 0.5 mL fish oil 
• 0.25 mL fish oil 
• 20 mg/kg body 
weight celecoxib 
• 30 mg/kg body 
weight celecoxib 
• 0.5 mL fish oil + 
20 mg/kg celecoxib 
• 0.25 mL fish oil + 
30 mg/kg celecoxib 
DNA fragmentation 
Mammary tissue and 
liver mitochondria 
TBARS 
SOD and catalase 
activities 
GSH concentration 
Fish oil with or without celecoxib sig. 
increased DNA fragmentation. 
Carcinogen treatment sig. increased 
TBARS. 
Fish oil treatment sig. increased liver 
TBARS but decreased or did not change 
mammary TBARS.  Celecoxib + fish oil 
sig. decrease liver TBARS to control levels. 
Sig. decrease in SOD and catalase activities 
and GSH concentrations in carcinogen-
treated animals.  Fish oil + celecoxib sig. 
increased liver and mammary SOD and 
catalase activity (30 mg/kg celecoxib group) 
compared to carcinogen controls. 
Fish oil + celecoxib sig. increased 
mammary and liver GSH compared to 
carcinogen controls.  0.5 ml fish oil group 
also had sig. increased mammary GSH. 
 
Manni et 
al.[112] 
Female Sprague 
Dawley rats 
injected with N-
methyl-N-
nitrosourea 
(MNU) to induce 
mammary cancer 
Saline-injected 
rats or 20% corn 
oil diet as control 
• 20% corn oil 
• 20% corn oil + 100 
µg/kg tamoxifen 
• 17% fish oil + 3% 
corn oil 
• 17% fish oil + 3% 
corn oil + 100 
µg/kg tamoxifen 
• 10% fish oil + 10% 
corn oil 
• 10% fish oil + 10% 
corn oil + 100 
µg/kg tamoxifen 
Cell proliferation and 
apoptosis via 
immunohistochemistry 
Mammary tissue 
TBARS, GPx activity, 
GSH levels, and 8-OH-
dG 
Plasma protein 
carbonyls via DNPH 
Mammary tissue 8-
isoprostane via ELISA 
Plasma free and 
protein-bound GSH 
Plasma and mammary 
tissue fatty acid 
distribution 
No effect of fish oil or tamoxifen on 
preneoplastic lesions. 
17% fish oil diet sig. decreased cell 
proliferation but no effect on apoptosis. 
No sig. effects of interventions on 
mammary TBARS or plasma protein 
carbonyls.  Both fish oil diets sig. decreased 
8-isoprostane levels in the mammary tissue. 
10% fish oil diets sig. increased GPx 
activity, while 17% fish oil GPx activity did 
not differ from controls. 
GSH levels sig. lower in 10% fish oil group 
and borderline sig. lower in 17% fish oil 
group. 
Authors suggest 
that fish oil and 
tamoxifen block 
progression of 
hyperplasia to 
carcinoma. 
Reduction of 8-
isoprostane 
likely due to 
lower amounts 
of arachidonic 
acid. 
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Abbreviations: 
DMBA = 7,12-dimethylbenz[a]anthracene 
TNF-! = tumor necrosis factor-! 
8-OHdG = 8-hydroxy-2’-deoxyguanosine  
13-HODE = 13-hydroxyoctadecadienoic acid 
ATM = gene product mutated in ataxia telangiectasia 
MNU = N-methyl-N-nitrosourea
   42 
antioxidant, reduced the concentration of TBARS but also increased the size of mammary 
tumors to the levels seen in the high corn oil diet, demonstrating that the 
chemopreventive effect of fish oil was due to lipid peroxidation.  A subsequent study 
conducted in the same system by Hardman et al.[86] explored corn and fish oils as part of 
a low-fat (5% energy from fat) diet.  The authors were unable to demonstrate a significant 
difference in mammary tumor TBARS between the corn and fish oil groups, although the 
supplementation of the fish oil diet with vitamin E significantly reduced tumor TBARS.  
The fish oil diet significantly increased liver TBARS compared to the corn oil diets; 
again, this effect was suppressed by vitamin E.  Treatment with doxorubicin, an anti-
cancer drug, in addition to the fish oil diet significantly decreased tumor growth 
compared to the corn oil diet.  The authors also measured the activity of the antioxidant 
enzymes SOD, catalase, and GPx in the colon, liver, and tumor tissues, which did not 
significantly differ between treatments with the exception of a significant decrease in 
GPx activity in the tumors of mice consuming the fish oil diet with vitamin E.  Using 
linear regression modeling, the authors concluded that the activity of GPx accounted for 
78% of the variation in tumor size, while increased TBARS following drug treatment 
accounted for a further 19%. 
 The differences in a low- versus high-fat diet with or without supplemental levels 
of n-3 was further explored by Hilakivi-Clarke et al.[108].  In this study, rats were fed a 
low-fat (16% energy from fat) or high-fat (39% energy from fat) diet with a ratio of n-
6:n-3 of either 2:1 or 17:1 beginning between two and five days following birth; 
mammary tumors were induced via 7,12-dimethylbenz[a]anthracene (DMBA).  There 
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were no differences in mammary tumor incidence and multiplicity between the two 17:1 
diets, but the low-fat 2:1 diet decreased and high-fat 2:1 diet increased the development 
of mammary tumors.  The concentration of lipid hydroperoxides was highest in the high-
fat 2:1 diet and modestly increased in the low-fat 2:1 diet; the lowest concentrations of 
lipid hydroperoxides were evident in the low-fat 17:1 diet.  The concentrations of 8-
hydroxy-2'-deoxyguanosine (8-OHdG) followed similar patterns to the lipid 
hydroperoxides, with increased levels in the high-fat 2:1 diet and decreased levels in the 
low-fat 2:1 diet.  This study also measured the effects of the diets on gene transcription 
and expression; the tumor suppressors BRCA1 and caveolin-1 were highest while Cox-2 
was lowest in the n-3 groups.  These results appear to implicate the importance of both 
absolute and relative amounts of fatty acids in the development of breast cancer.  
Although the gene expression profile did not favor cancer progression in both n-3 groups, 
the high-fat 2:1 group exhibited increased oxidative DNA damage, lipid hydroperoxides, 
and tumor incidence, suggesting that the detrimental effects of lipid peroxidation may 
outweigh the beneficial effects of n-3 on gene transcription when breast cancer is 
induced. 
 El-Mesery et al.[109] evaluated the effects of DHA in a mouse model of 
mammary cancer induced by Ehrlich ascites carcinoma cells.  In contrast to the 
previously mentioned studies, 250 mg/kg body weight of DHA significantly decreased 
serum TBARS as well as mammary tumor volume.  The effects of DHA and the cancer 
drug cisplatin were also addressed in a rat model; when 250 mg/kg body weight of DHA 
in addition to cisplatin were given to the animals for ten days, there was a significant 
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decrease in kidney TBARS and increase in kidney GSH.  This suggests that treatment 
with DHA at this concentration for ten days is not toxic to the kidney. 
Kansal et al.[111] addressed the effects of fish oil with or without celecoxib, a 
cyclooxygenase-2 (COX-2) inhibitor, in a rat model of mammary carcinoma induced by 
DMBA.  Although fish oil treatment significantly increased DNA fragmentation, it did 
not increase mammary TBARS.  However, fish oil treatment did significantly increase 
liver TBARS, which were repressed to control levels with the addition of celecoxib.  The 
fish oil and celecoxib treatment also significantly increased liver and mammary tissue 
SOD and catalase activity and GSH concentration.  These results suggest that the use of a 
COX-2 inhibitor in addition to fish oil can enhance antioxidant defense and detoxification 
by GSH and suppress liver TBARS but still results in DNA damage. 
Recently, Manni et al.[112] measured the effects of a 10% or 17% fish oil diet 
with or without tamoxifen, an anti-estrogen drug, in a rat model of breast cancer.  The 
study did not address frank mammary tumor development but rather the formation of 
precancerous lesions, such as mammary hyperplasia.  There were no significant 
differences in the development of such lesions between the treatments tested.  However, 
the fish oil diets significantly decreased a marker of cell proliferation, suggesting a lower 
risk of cancer.  The authors also measured markers of lipid peroxidation including 
mammary tissue TBARS and protein carbonyl levels in the plasma but found no 
significant effects of fish oil.  The 10%—but not 17%—fish oil diet significantly 
increased the activity of GPx within the mammary tissue, indicating such a diet may up-
regulate detoxification of lipid hydroperoxides. 
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In a mouse model implanted with MCF-7 human breast cancer cells, Kang et 
al.[106] demonstrated that a 5% fish oil diet significantly decreased mammary tumor 
volume and cell proliferation while increasing apoptosis; lipid peroxidation was not 
measured.  Schubert et al.[110] assessed an EPA- or AA-rich diet on the development of 
several cancers, including mammary cancer, in a mouse model deficient for gene product 
mutated in ataxia telangiectasia (ATM).  There were no differences in tumor latency, but 
EPA supplementation significantly increased 8-OHdG compared to AA supplementation.  
Although these two studies did not directly measure lipid peroxidation, each showed no 
effect or a reduced risk for breast cancer with n-3 supplementation.  Again, n-3 
supplementation increased the levels of oxidative DNA damage within the latter animal 
model. 
 Together, these animal research studies show that while diets supplemented with 
fish oil or long-chain PUFA including DHA increase markers of lipid peroxidation 
(usually TBARS), such diets are associated with a reduction in the incidence and size of 
mammary tumors.  Although the oxidative stress induced by a diet high in PUFA 
increases the amount of oxidative DNA damage, an up-regulation of apoptosis and 
decrease in cell proliferation may limit the development and spread of tumors.  
Additionally, the up-regulation of certain antioxidant defense systems may also serve to 
reduce the risk of breast cancer. 
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Human studies 
Table 4 summarizes notable work in observational (cross-sectional and case-
control) human studies exploring the relationship between lipid peroxidation and breast 
cancer risk in women.  Although a chief limitation of such studies is the inclusion of 
subjects with established disease processes that precludes the assignation of cause and 
effect, the studies offer information involving the potential role of lipid peroxidation in 
breast carcinogenesis and cancer progression in the general population. 
Several studies examined the extent of oxidative stress in breast cancer cases 
compared to controls.  Ray et al.[113] detected significantly higher levels of superoxide 
and hydrogen peroxide in the serum of breast cancer cases compared to non-cancer 
surgical patients as controls.  Similar results were seen in a study conducted by Yeh et 
al.[114], wherein breast cancer patients had significantly higher superoxide levels than 
healthy controls.  Chandramathi et al.[115] measured increased advanced oxidative end 
product in the urine of breast cancer cases compared to healthy controls, but the authors 
did not detect a significant difference in urinary hydrogen peroxide in cases versus 
controls. 
Most studies that measured lipid peroxidation via TBARS in breast cancer cases 
and healthy, typically age-matched controls indeed demonstrated increased lipid 
peroxidation in cases over the controls[113, 114, 116-123].  One study conducted by 
Gerber et al.[124] reported lower plasma TBARS among breast cancer cases compared to 
controls; however, in contrast to the other studies included in Table 4, this study used 
non-cancer hospital patients as controls rather than healthy members of the general  
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Table 4.  Summary of observational human studies examining lipid peroxidation and breast cancer in women. 
Reference Study Design Outcome Measurement(s) Results Notes 
Karihtala et 
al.[125] 
Cross-
sectional 
breast cancer 
patients 
n=80 
8-OHdG, HNE, 
nitrotyrosine, DNA 
topoisomerase II binding 
protein I, and mismatch 
repair proteins 2 and 6 
expression via 
immunohistochemistry of 
tumor tissues 
HNE present in 86.8% of stage I tissues and 
usually co-expressed with nitrotyrosine. 
8-OHdG expressed in 58.9% of tissues, and DNA 
repair proteins expressed in 55.9-65% of tissues. 
Stage I tumors had increased nitrotyrosine 
expression compared to hyperplastic tissues. 
Topoisomerase binding protein I expression was 
sig. associated with 8-OHdG expression in stage I 
tissues. 
11 of 12 tissues negative for 8-OHdG in 
hyperplasia. 
Nitrotyrosine is a marker of 
nitrogen stress. 
Stage I breast tumors 2 cm 
or less in greatest dimension 
and no spread to lymph 
nodes. 
Carneiro et 
al.[116] 
Cross-
sectional 
breast cancer 
patients, 
n=59 
Healthy 
female blood 
donors, n=76 
CXCR4 expression in 
peripheral blood cells via 
PCR 
Plasma MDA via HPLC 
Plasma MDA sig. higher in cancer patients versus 
controls.  Stages II and III had sig. higher plasma 
MDA versus controls. 
No sig. differences in CXCR4 expression. 
Numbers of samples in 
stages I and IV were low. 
Vinothini and 
Nagini[126] 
Cross-
sectional 
breast cancer 
patients 
n=60 
Adjacent 
normal 
tissues used 
as controls 
Tissue cytochrome p450 
and b5 content and 
ethoxyresorufin O-
decarboxylase (EROD), 
methoxyresorufin O-
decarboxylase (MROD), 
pentoxyresorufin O-
decarboxylase (PROD), 
GST, and quinone reductase 
activity via 
spectrophotometry 
CYP1B1, CYP1A1, HNE, 
8-OHdG, and anti-hexanoyl 
Activities of phase I enzymes sig. increased in all 
cancer tissues compared to control tissues; the 
highest levels of activity were among grade III 
cancer tissues. 
The expression of CYP1A1 and 1B1 were sig. 
higher in breast cancer tissues and the highest in 
grade III tissues. 
GST and quinone reductase activities were sig. 
increased in all breast cancer tissues and were 
highest among grade I tissues. 
HNE, 8-OHdG, and HEL levels were sig. highest 
among breast cancer tissues compared to controls, 
with the highest levels among grade III tumors. 
CYP1B1 catalyzes the 
formation of 4-OH-E2 in 
mammary tissues, 
promoting carcinogenesis 
and oxidative stress. 
Increased markers of 
oxidative stress and phase I 
and II enzymatic activity in 
higher grades implicates 
role of lipid peroxidation in 
cancer promotion and 
progression. 
NF-!B expression can be 
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Reference Study Design Outcome Measurement(s) Results Notes 
lysine (HEL) expression via 
immunohistochemistry 
NF-!B, I!B, p-I!B, and 
IKK" expression via 
immunohistochemistry and 
Western blotting 
NF-!B, p-I!B, and IKK" expression sig. up-
regulated while I!B (inhibitor of NF-!B) sig. 
down-regulated in cancer tissues, particularly in 
grade III tissues. 
Overall changes were more pronounced in 
premenopausal tissues compared to 
postmenopausal. 
up-regulated by oxidative 
stress and promote 
proliferation. 
Karihtala et 
al.[127] 
Cross-
sectional 
breast cancer 
patients 
n=219 
8-OHdG and HNE 
expression via 
immunohistochemistry of 
tumor tissues 
8-OHdG expression in invasive carcinoma sig. 
lower than in hyperplasia (usual or abnormal) and 
ductal carcinoma in situ. 
There was a trend for increased HNE content in 
higher-grade ductal carcinoma in situ lesions.  
HNE expression was sig. highest in invasive 
carcinomas. 
Negative 8-OHdG and positive HNE sig. reflected 
different patient cohorts (aggressive vs. less 
aggressive). 
8-OHdG staining sig. or borderline sig. correlated 
with estrogen receptor presence, low cell 
proliferation, and small tumors. 
No associations between 
HNE and prognostic factors, 
and authors conclude this 
indicates a role in 
carcinogenesis.  The authors 
also note it is impossible to 
determine if HNE levels are 
causes or consequences in 
breast carcinogenesis due to 
the study design. 
Authors conclude that low 
8-OHdG levels in invasive 
cancers due to up-regulation 
of DNA repair during 
oxidative stress. 
Gerber et 
al.[124] 
Case-control 
Breast cancer 
cases, n=120 
Hospital-
based non-
cancer 
controls, 
n=109 
Questionnaire including diet 
history  
Plasma vitamin E 
Plasma lipids 
Plasma TBARS (in 95 cases 
and 70 controls) 
Plasma vitamin E sig. higher in cases vs. controls.  
Significance remained after adjustment for total 
cholesterol in premenopausal patients only. 
Plasma total cholesterol sig. higher in cases 
compared to controls. 
Plasma TBARS sig. lower in patients compared to 
controls with adjustment for menopausal status. 
 
Kumar et 
al.[117] 
Case-control 
Breast cancer 
cases, n=43 
Age-matched 
GPx, SOD, GST, and 
catalase activities 
Serum vitamins C and E, 
ceruloplasmin, and Se 
Serum lipid peroxides and ceruloplasmin sig. 
increased in cases vs. controls.  Cerulosplasmin 
was sig. higher in malignant vs. benign cancer 
cases. 
Authors did not include 
their definitions of benign 
and malignant cancers. 
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Reference Study Design Outcome Measurement(s) Results Notes 
controls, 
n=20 
Erythrocyte and serum lipid 
peroxide levels, likely via 
TBARS (no method 
described) 
Serum vitamins C and E and Se were sig. 
decreased in cancer vs. controls.  Vitamin C levels 
were sig. lower in malignant vs. benign cancer 
cases. 
Erythrocyte lipid peroxides were sig. higher in 
cancer cases vs. controls.  Lipid peroxides were 
sig. higher in malignant vs. benign cancer cases. 
Catalase, GPx, SOD, and GST activities were sig. 
lower in cases vs. controls.  Catalase and GPx 
activities were sig. lower in malignant vs. benign 
cancers. 
Huang et 
al.[118] 
Case-control 
Breast cancer 
cases, n=35 
Healthy 
controls, 
n=35 
Serum MDA via HPLC 
Serum mineral content (Cu, 
Zn, Fe, and Se) 
Breast cancer cases had sig. higher serum MDA, 
Cu, and Cu/Zn ratio compared to controls. 
Serum Se was sig. lower among stage III cases vs. 
controls. 
MDA and Cu levels highest among stages I and II. 
 
Ray et al.[113] Case-control 
Breast cancer 
cases, n=54 
Surgical, non-
cancer 
controls, 
n=42 
Serum superoxide and 
hydrogen peroxide 
productive via 
spectrophotometry 
Serum TBARS 
SOD, GPx, and catalase 
activities 
Cases had sig. increased superoxide and hydrogen 
peroxide production and SOD and GPx activities 
compared to controls.  The highest superoxide 
value was in stage II cases, and the highest 
hydrogen peroxide value was in stage III cases.  
SOD activity was highest in stage II, while GPx 
was highest in stage III. 
Cases had sig. decreased catalase activity 
compared to controls.  The largest decrease was 
among stage II cases. 
Breast cancer cases, except stage IV, had sig. 
higher TBARS than controls.  The highest TBARS 
values were in stage II cancer patients. 
There were differences in the results with respect 
to menopausal status.  Postmenopausal patients 
had higher hydrogen peroxide, TBARS, and GPx 
increases and a greater decrease in catalase 
activity, while premenopausal patients had 
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Reference Study Design Outcome Measurement(s) Results Notes 
increased superoxide and SOD activity. 
Gönenç et 
al.[128] 
Case-control 
Breast cancer 
cases, n=26 
Healthy 
controls, 
n=41 
Plasma MDA via HPLC Plasma MDA sig. higher in breast cancer cases 
compared to controls. 
Study found similar results 
with lung cancer cases. 
Yeh et al.[114] Case-control 
Breast cancer 
cases, n=117 
Healthy 
controls, 
n=117 
Whole blood GPx, SOD, 
and GSH reductase 
activities 
Plasma TBARS 
Plasma vitamins A, C, and 
E 
Superoxide generation via 
lucigenin-based 
chemiluminescence 
Plasma GSH concentration 
Plasma MDA and superoxide levels were sig. 
higher in cases compared to controls. 
SOD, GPx, and GSH reductase activities were sig. 
higher in cases vs. controls. 
Cases had sig. lower plasma GSH compared to 
controls. 
Plasma vitamin C was sig. lower in cases 
compared to controls. 
Superoxide radical levels were highest among 
estrogen receptor-negative, progesterone receptor-
positive cases compared to double-positive cases.  
SOD activity was sig. lower among HER-2/neu-
negative cases compared to positive cases. 
 
!ener et 
al.[119] 
Case-control 
Breast cancer 
cases, n=56 
Healthy 
controls, 
n=18 
Serum total antioxidant 
capacity via ABTS radical 
cation decolorization assay 
Serum TBARS and lipid 
hydroperoxides via 
spectrophotometry 
Serum lipids 
Serum total antioxidant capacity was sig. lower 
and serum TBARS were sig. higher in cases 
compared to controls. 
There were no sig differences in lipid 
hydroperoxides between cases and controls or 
within stages. 
TBARS were sig. highest among stage II cases, 
and total antioxidant capacity was sig. lowest 
among stages II and III. 
 
Kasapovic et 
al.[129] 
Case-controls 
Breast cancer 
cases, n=53 
Healthy 
controls, 
n=67 
SOD, GPx, and GSH 
reductase activities. 
Plasma GSH concentration 
Plasma lipid hydroperoxides 
via spectrophotometry 
 
CuZnSOD activity sig. lower in breast cancer 
cases of all ages compared to controls.  GSH 
reductase and catalase activities sig. lower in ages 
45->58. GSH concentration sig. lower among 
cases >58 vs. controls. 
Lipid hydroperoxides sig. higher among cases ages 
Tumor cells may produce 
increased levels of hydrogen 
peroxide. 
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Reference Study Design Outcome Measurement(s) Results Notes 
45->58 vs. controls. 
CuZnSOD and catalase activities decreased with 
age among controls and cases. 
Suzana et 
al.[120] 
Case-control 
Breast cancer 
cases, n=57 
Healthy 
controls, 
n=139 
Questionnaire including 
dietary history 
Plasma TBARS 
Plasma vitamins A and E 
via HPLC 
Toenail and hair Se content 
via ICP-MS 
Controls had sig. lower plasma TBARS compared 
to cases. 
Controls reported sig. higher vitamin A and E 
intakes and had sig. higher plasma vitamin A vs. 
cases.  Controls also had sig. higher toenail (but 
not hair) Se compared to cases. 
With binary logistic regression, 75th% quartile 
TBARS sig. increased OR for breast cancer.  
25th% quartile or higher for biochemical marker of 
vitamins A and E also increased OR for breast 
cancer. 
Authors used independent 
sample t-tests to compare 
cases vs. controls. 
Rajneesh et 
al.[121] 
Case-control 
Breast cancer 
cases, n=40 
Healthy 
controls 
Plasma lipid hydroperoxides 
and conjugated dienes 
Plasma TBARS 
Plasma GSH concentrations 
and GST, SOD, catalase, 
and GPx activities 
Plasma TBARS sig. higher in cases vs. controls.  
Plasma conjugated dienes and lipid 
hydroperoxides also sig. higher in cases vs. 
controls. 
Plasma GSH concentrations and SOD, catalase, 
GST, and GPx activities sig. higher in cases vs. 
controls. 
Stage I and II cancer 
patients only. 
No indication of number of 
controls included. 
Chandramathi 
et al.[115] 
Case-control 
Breast cancer 
cases, n=101 
Healthy 
controls, 
n=95 
First morning urinary 
advanced oxidative end 
product, hydrogen peroxide, 
MDA (via 1,1,3,3,-
tetraethoxypropane), and 
ferric-reducing antioxidant 
power 
There were no sig. differences in urinary MDA or 
hydrogen peroxide in breast cancer cases vs. 
controls (colorectal cancer cases were sig. higher 
in both than controls). 
Urinary advance oxidative end product was sig. 
increased, and ferric-reducing antioxidant power 
was sig. decreased in breast cancer cases vs. 
controls. 
There were no sig. differences between stages of 
breast cancer for the outcome measurements. 
Study also evaluated 
colorectal cancer cases, 
n=49. 
Spot urine samples collected 
prior to any heavy meal. 
Goswami et 
al.[122] 
Case-control 
Breast cancer 
cases, n=60 
Healthy 
Whole blood GPx and SOD 
levels 
Plasma TBARS and 
conjugated dienes 
TBARS, conjugated dienes, ferritin, and IL-6 sig. 
higher in cases vs. controls. 
GSH, GPx, and SOD levels and catalase activity 
sig. lower in cases vs. controls. 
IL-6 and ferritin both 
considered inflammatory 
markers. 
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Reference Study Design Outcome Measurement(s) Results Notes 
controls, 
n=60 
Plasma catalase activity 
Plasma IL-6 and ferritin 
concentrations via ELISA 
Sig. positive correlation between conjugated 
dienes and IL-6 and stage of breast cancer.  Sig. 
neg. correlation between SOD levels and stage of 
breast cancer and conjugated dienes. 
Kasapovic et 
al.[130] 
Case-control 
Breast cancer 
cases, n=58 
Healthy 
controls, 
n=60 
Plasma lipid hydroperoxides 
Plasma catalase, GPx, and 
GSH reductase activities 
and GSH levels 
Plasma CuZnSOD activity 
Plasma lipid hydroperoxides sig. increased in 
cases vs. controls and sig. increased in cases 
following chemotherapy in all age groups. 
CuZnSOD activity sig. decreased following 
chemotherapy in both age groups and in cases vs. 
controls among >58 y. 
GSH and GSH reductase sig. decreased among 
cases following chemotherapy, while GSH was 
sig. higher among cases vs. controls 45-58 y. 
Following radiation treatment, CuZnSOD levels 
sig. increased in both age groups compared to 
cases before treatment. 
Stage II and III breast 
cancer cases only, 
undergoing chemotherapy 
or radiation treatment.  
Fasting blood samples taken 
before and after treatment. 
Authors used independent 
(cases vs. controls) and 
paired t-tests (before and 
after treatment). 
Kedzierska et 
al.[123] 
Case-control 
Invasive 
breast cancer 
cases, n=35 
Benign breast 
disease cases, 
n=24 
Health 
controls, 
n=40 
Urinary 8-isoPGF2! 
Plasma TBARS 
 
Invasive breast cancer cases had sig. higher 
urinary 8-isoPGF2! compared to controls and 
women with benign breast disease. 
Plasma TBARS were also sig. higher in women 
with invasive breast cancer compared to controls 
and women with benign breast disease. 
 
 
Abbreviations: 
CXCR4 = chemokine (C-X-C motif) receptor 4 
EROD = ethoxyresorufin O-decarboxylase 
MROD = methoxyresorufin O-decarboxylase  
PROD = pentoxyresorufin O-decarboxylase  
HEL = hexanoyl lysine 
ABTS = 2,2’-azino-bis(3-ethylbenz-thazoline-6-sulphonic acid) diammonium salt 
8-isoPGF2! = 8-isoprostaglandin F2 
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population.  Because the controls were also undergoing treatment for disease, it is 
possible that the controls’ levels of lipid peroxidation were elevated due to underlying 
disease or illness. 
Many studies also utilized more specific measurements of lipid peroxidation than 
TBARS.  In a cross-sectional study of 80 breast cancer patients, Karihtala et al.[125] used 
immunohistochemical staining of tumor tissues to measure the expression of HNE, 8-
OHdG, nitrotyrosine, and several markers of DNA repair.  The authors detected the 
presence of HNE in 86.5% of stage I breast tumors, defined as less than two cm at 
greatest dimension and without lymph node involvement, and HNE was usually co-
expressed with nitrotyrosine, a marker of nitrosative damage to proteins.  8-OHdG was 
expressed at lower levels in stage I tumor tissues (58.9%) and shared similar expression 
patterns with DNA repair proteins (55.9-65%).  In a subsequent study, the authors again 
demonstrated lower 8-OHdG formation in invasive breast cancer tissues than in 
hyperplasia or ductal carcinoma in situ[127].  HNE formation was greatest in the invasive 
cancer tissues, and individuals with HNE but not 8-OHdG expression comprised those 
subjects with the most aggressive breast cancers.  The results from these two studies 
suggest that the expression of 8-OHdG and DNA repair proteins are closely related, 
which would account for repair of DNA damaged due to oxidative stress.  On the other 
hand, HNE is associated with frank tumor development and cancer progression. 
In another immunohistochemical study, Vinothini and Nagini[126] detected 
significantly increased levels of HNE, 8-OHdG, and anti-hexanoyl lysine in breast tumor 
tissues compared to adjacent normal tissues.  The highest levels of these markers of 
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oxidative stress were seen among grade III breast cancer tissues, which are defined 
histologically to have a high risk of recurrence[131].  The authors also measured 
increased activities and expression of phase I enzymes (such as CYP) in breast cancer 
tissues, particularly grade III tissues.  A similar trend was seen with expression of the 
NF-!B family of transcription factors and regulatory proteins, which are involved in 
controlling cell proliferation.  The activity of GST was significantly up-regulated in 
breast cancer tissues, with the highest activity in grade I tissues.  The results of this study 
indicate that markers of lipid peroxidation are increased with the increasing grade of 
breast cancer, suggesting the participation of lipid peroxidation in cancer progression and 
risk of recurrence.  Additionally, the up-regulation of antioxidant enzymes in grade I (low 
risk of recurrence) and phase I detoxification enzymes in grade III demonstrate an 
attempt at homeostasis due to elevated oxidative stress within the tumor tissues.  The 
increased expression of NF-!B family members demonstrate that transcriptional 
regulation is also involved in cancer progression. 
Huang et al.[118] specifically measured serum MDA via HPLC in breast cancer 
patients and healthy controls.  The cancer cases had significantly higher serum MDA 
relative to controls, and the highest levels of MDA were present among stages I and II, 
which include tumors that are less than five cm at the widest dimension and may or may 
not have spread to an axillary lymph node[132].  Gönenç et al.[128] also measured MDA 
in the plasma of breast cancer cases and healthy controls with HPLC and demonstrated 
significantly higher MDA in cases compared to controls.  Lastly, Chandramathi et 
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al.[115] specifically measured urinary MDA in breast cancer cases and healthy controls, 
but there were no significant differences between cases and controls. 
Several researchers measured circulating lipid hydroperoxides via the oxidation of 
ferrous ions and subsequent binding of ferric ions to xylenol orange, which can be 
measured spectrophometrically, in breast cancer patients and healthy controls.  !ener et 
al.[119] did not detect any differences in serum lipid hydroperoxides between breast 
cancer cases and controls.  However, Kasapovic et al.[62] demonstrated increased plasma 
lipid hydroperoxides in breast cancer patients between the ages of 45 and 58 years old 
compared to age-matched controls.  Rajneesh et al.[121] measured plasma conjugated 
dienes in addition to lipid hydroperoxides and found both markers significantly elevated 
in stage I and II breast cancer cases compared to controls.  In an additional study 
conducted by Kasapovic et al.[130], plasma lipid hydroperoxides were significantly 
higher in stage II and III breast cancer cases than controls and were further increased 
following chemotherapy.  Goswami et al.[122] also measured plasma conjugated dienes, 
the first step of free radical-induced peroxidation of PUFA, which were found to be 
significantly higher in breast cancer cases compared to controls.  Additionally, the level 
of conjugated dienes significantly and positively correlated with the stage of breast 
cancer within this population.  Kedzierska et al.[123] measured urinary 8-
isoprostaglandin F2 as a marker of lipid peroxidation (of n-6) and detected significantly 
higher levels in invasive breast cancer cases compared to healthy controls or women with 
benign breast disease.  Altogether, the results of these specific measurements of lipid 
peroxidation in observational human studies indicate that lipid peroxidation is present at 
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higher levels in individuals with breast cancer than in healthy individuals and that 
increased lipid peroxidation is positively associated with breast cancer progression and 
severity. 
 A number of the studies described in Table 4 also include measurements of 
antioxidant enzyme activity and dietary antioxidant status in breast cancer cases and 
healthy controls.  Several studies demonstrate increased activity of SOD, GPx, GSH 
reductase, catalase, and GST in the blood of women with breast cancer compared to 
controls[113, 114, 121].  However, Kumar et al.[117] concluded that the activities of 
catalase, GPx, SOD, and GST were significantly lower in cases compared to controls.  
Kasapovic et al.[129] also demonstrated decreased SOD activity among breast cancer 
cases and lower GSH reductase and catalase activities among breast cancer cases between 
the ages of 45 and 58; additionally the authors measured significantly decreased SOD 
activity following chemotherapy but increased activity following radiation treatment 
among breast cancer patients[130].  Although some studies indicate increased antioxidant 
enzyme activity among breast cancer patients, it is not possible to draw conclusions given 
the body of evidence showing an opposite association.  It is likely that the measurement 
of enzyme activities varies with regards to the methods employed as well as 
characteristics of the study subjects, including genetic variations, dietary intake, and 
medication use. 
With regards to dietary antioxidant status, Gerber et al.[124] noted significantly 
higher plasma vitamin E in breast cancer cases compared to controls; again, this study 
used individuals currently under the care of a physician as controls, which may have 
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biased the results.  Kumar et al.[117] measured significantly lower levels of vitamins C 
and E and selenium in breast cancer cases compared to age-matched controls.  
Significantly lower selenium status among breast cancer cases relative to controls was 
also demonstrated by Huang et al.[118].  Yeh et al.[114] detected decreased plasma 
vitamin C in breast cancer cases relative to controls, and Suzana et al.[120] measured 
significantly higher plasma vitamin A and toenail selenium in healthy controls compared 
to breast cancer patients.  A decrease in antioxidant status among breast cancer patients is 
expected due to an increase in oxidative stress in addition to the presence of disease, and 
the results from these studies corroborate such an association, particularly with vitamin C 
and selenium.  However, the diet consumed by each subject will also influence the 
circulating levels of antioxidant nutrients, and few studies included a subjective 
assessment of the typical diet consumed by subjects. 
In addition to dietary antioxidants, several studies also measured the 
concentration of GSH within the blood of breast cancer patients and controls.  Yeh et 
al.[114] measured significantly lower concentrations of plasma GSH in breast cancer 
cases compared to controls, while Kasapovic et al.[129] detected this difference only in 
breast cancer patients greater than 58 years old.  On the other hand, a subsequent study by 
Kasapovic et al.[130] showed increased plasma GSH levels in cases between the ages of 
45 and 58.  Rajneesh et al.[121] concluded there was a significant increase in plasma 
GSH in breast cancer cases compared to controls.  As with antioxidant enzyme activity, it 
is likely that GSH concentrations vary due to genetics, diet, and other factors, which may 
explain the conflicting results. 
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 Table 5 summarizes two prospective cohort studies that measured the associations 
between lipid peroxidation and breast cancer risk among women from the general 
population.  Prospective cohort studies and nested case-control analyses conducted within 
them are not affected by the same limitations as traditional case-control studies, which 
recruit subjects after the diagnosis of disease.  The latter studies may be influenced by 
recall bias, a type of information bias whereby subjects with the disease recall their 
exposures prior to diagnosis differently than the control subjects.  A distinct advantage of 
prospective cohort studies is the collection of exposure data, such as dietary and other 
environmental exposures, at the baseline of the study; subjects are then followed for 
several years until an adequate number have been diagnosed with the disease of interest 
to conduct statistical analyses.  In addition to reducing recall bias, the collection of 
baseline variables allows for inference of cause and effect that is not possible with 
retrospective studies, such as traditional case-control studies.  However, randomized 
controlled trials remain the gold standard for proving cause and effect. 
 In a nested case-control analysis within the Singapore Chinese Health Study, a 
large, population-based prospective cohort, Gago-Dominguez et al.[133] evaluated 
polymorphisms of the GST isoforms and marine n-3 intake assessed via food-frequency 
questionnaire in relationship to breast cancer risk.  No results for marine n-3 were 
reported independently, but among postmenopausal women possessing two null alleles 
for GSTT1 (conferring reduced activity), marine n-3 intake in the highest three quartiles 
significantly reduced the odds for breast cancer by 46% compared to those women in the 
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Table 5.  Summary of prospective cohort studies examining lipid peroxidation and breast cancer risk. 
Reference Study Design Outcome Measurement(s) Results Notes 
Gago-
Dominguez 
et al.[133] 
Population-
based 
prospective 
cohort, nested 
case-control 
analysis 
Breast cancer 
cases, n=258 
Healthy 
controls, n=670 
Baseline diet via food-
frequency questionnaire 
Breast cancer diagnosis via 
national registry 
GSTM1, T1, and P1 
genotyping 
No sig. associations between M1 and P1 genotype 
and breast cancer risk.  T1 null genotype sig. 
associated with reduced risk for breast cancer. 
Borderline sig. reduced risk for breast cancer among 
GSTT1 null/null post-menopausal subjects with 
marine n-3 intake in the highest 3 quartiles.  Sig. 
decrease risk in GSTP1 heterozygous post-
menopausal subjects in highest 3 quartiles of marine 
n-3 intake. 
Post-menopausal subjects with GSTM1 or GSTT1 
null/null and GSTP1 heterozygous had sig. decreased 
risk for developing breast cancer. 
Authors interpret results 
as suggesting anti-
carcinogenic effect of 
lipid peroxidation. 
Lee et 
al.[134] 
Population-
based 
prospective 
cohort, nested 
case-control 
analysis 
Breast cancer 
cases, n=327 
Healthy 
controls, n=654 
Baseline questionnaire 
including dietary intake 
Breast cancer diagnosis via 
national registry 
Baseline urinary 1-
hydroxypyrene, 2-naphthol, 
MDA, and 8-OHdG 
No sig. differences between cases and controls for 
any of the outcome measurements. 
Authors note that 
estrogen may inhibit 
lipid peroxidation. 
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lowest quartile of marine n-3 intake.  GSTP1 heterozygous postmenopausal women in the 
highest three quartiles of marine n-3 intake had 51% lower breast cancer odds compared 
to women in the lowest intake quartile.  When these genotype characteristics were 
evaluated together, postmenopausal women with both of these beneficial genotypes and 
in the highest three quartiles of marine n-3 intake had 64% lower odds of developing 
breast cancer.  Because the breast cancer risk reducing effects of high marine n-3 intake 
were seen only among postmenopausal women with lower GST activity, the authors 
concluded that the beneficial effects of n-3 on breast cancer risk may be largely due to 
increased lipid peroxidation, which would be suppressed in women with more active 
GST isoforms. 
 Lee et al.[134] conducted a nested case-control analysis of lipid peroxidation and 
breast cancer risk within the Shanghai Women’s Health Study, another large population-
based prospective cohort.  Baseline urinary MDA and 8-OHdG were measured in 
addition to markers of polycyclic aromatic hydrocarbons, likely breast carcinogens to 
which humans may be exposed through cigarette smoke and air pollution.  The authors 
found no associations between these baseline markers and breast cancer development in 
the cohort.  Although subjective dietary data were not included in this experiment, the 
results suggest that lipid peroxidation and oxidative DNA damage are not causally 
associated with breast cancer among Chinese women in Shanghai. 
 Finally, human intervention studies addressing dietary n-3, lipid peroxidation, and 
breast cancer risk are summarized in Table 6.  Unfortunately, no single intervention study 
has addressed these three areas simultaneously to date.  Thangaraju et al.[135] examined 
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Table 6.  Summary of human intervention studies examining lipid peroxidation and breast cancer. 
Reference Subjects Intervention 
Outcome 
Measurement(s) Results Notes 
Thangaraju et 
al.[135] 
Postmenopausal 
female breast 
cancer patients, 
n=64 
10 mg tamoxifen 
twice daily for 6 
months 
Serum TBARS at 0, 3, 
and 6 months 
Serum retinol, ascorbic 
acid, vitamin E, GSH, 
ceruloplasmin, uric acid, 
and Se at 0, 3, and 6 
months 
Plasma catalase, SOD, 
GPx, and GST activities 
at 0, 3, and 6 months 
Tamoxifen treatment sig. 
decreased TBARS and 3 and 
6 months. 
Treatment sig. increased 
serum antioxidants and 
increased activity for all 
enzymes measured. 
No control group 
Tamoxifen activated by 
phase I enzymes contains 
phenolic hydroxyl group, 
which may account for 
antioxidant effects. 
Tamoxifen functions to 
suppress cell proliferation, 
not cause cell death. 
Wu et al.[53] Postmenopausal 
healthy female 
vegans and lacto-
ovovegetarians, 
n=27 
Single-blinded, 
placebo controlled 
study of: 
• 6 g corn oil/d 
• 6 g DHA-rich 
algae oil/d 
(2.14 g 
DHA/d) 
Fasting plasma lipids 
Plasma copper-induced 
LDL oxidation and 
TBARS 
Plasma lipids and 
vitamin E concentrations 
Spot urine estrogen 
metabolites, F2-
isoprostane, and 8-iso-
prostaglandin F2 
TBARS from oxidized LDL 
increased sig. in DHA 
supplemented group vs. corn 
oil supplemented. 
Total cholesterol sig. 
decreased with DHA 
supplementation. 
No sig. differences in vitamin 
E status, estrogen 
metabolites, or urinary 
prostaglandins between 
groups. 
 
Muralikrishnan 
et al.[81] 
Postmenopausal 
female breast 
cancer patients, 
n=60 
Healthy controls, 
n=15 
5 treatment 
groups: 
• No treatment 
• Breast cancer 
patients not 
treated with 
tamoxifen 
• Breast cancer 
patients 
treated with 
Plamsa TBARS 
Erythrocyte catalase, 
SOD, GPx, and GST 
activities 
TBARS sig. increased in 
untreated breast cancer 
patients and patients 
receiving tamoxifen without 
vitamin C compared to 
controls.  TBARS reverted to 
control levels in both groups 
treated with vitamin C. 
The same trend was seen 
with antioxidant enzyme 
activity, which sig. decreased 
Authors do not report how 
much vitamin C was 
supplemented to patients. 
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Reference Subjects Intervention 
Outcome 
Measurement(s) Results Notes 
tamoxifen 
• Breast cancer 
patients 
treated with 
vitamin C 
after 45 d of 
tamoxifen 
treatment 
• Breast cancer 
patients 
treated with 
vitamin C 
after 90 d of 
tamoxifen 
treatment 
in breast cancer patients 
receiving no treatment or 
tamoxifen alone.  Vitamin C 
supplementation restored 
enzyme activity to control 
levels. 
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the effects of treatment with tamoxifen, an anti-estrogen drug commonly used to treat 
breast cancer, on serum markers of lipid peroxidation and antioxidant function.  Although 
no control group was utilized, 10 mg tamoxifen twice daily significantly decreased 
fasting serum TBARS at three and six months compared to the values at baseline.  The 
treatment significantly increased the serum concentrations of vitamin E, retinol, ascorbic 
acid, selenium, and GSH and significantly enhanced the activity of plasma catalase, SOD, 
GPx, and GST at three and six months.  These results were not surprising given that 
tamoxifen can function as an antioxidant following activation by phase I enzymes in the 
body, and they suggest that suppression of lipid peroxidation may be one pathway by 
which tamoxifen effectively treats breast cancer. 
 Muralikrishnan et al.[81] evaluated tamoxifen treatment with or without 
supplemental vitamin C in postmenopausal breast cancer patients and a group of 
untreated controls.  In contrast to the work of Thangaraju et al., these authors showed that 
tamoxifen treatment significantly increased plasma TBARS.  The addition of vitamin C 
beginning at either day 45 or 90 of tamoxifen treatment reduced plasma TBARS to the 
levels of healthy controls without breast cancer.  This study also showed that tamoxifen 
treatment significantly suppressed the activities of catalase, SOD, GPx, and GST, and this 
down-regulation was eliminated with the vitamin C supplementation.  The authors do not 
report the quantity of vitamin C that was given to patients, but the results suggest that 
tamoxifen may increase lipid peroxidation and that the consumption of additional dietary 
antioxidants during tamoxifen treatment may be warranted in breast cancer patients.  The 
authors also do not report the duration of the treatment and at what point blood samples 
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were collected, rendering it impossible to evaluate a potential timing effect.  It is possible 
that the patients were not fasting prior to blood collection, and the contents of the most 
recent meal may have increased the levels of TBARS detected.  Blood samples in 
Thangaraju et al.[135] were collected following a 12-24-hour fast; therefore, the effect of 
tamoxifen to decrease serum TBARS is not influenced by recent dietary intake in that 
study.  More research is needed to clarify the effect of tamoxifen on lipid peroxidation as 
well as its interaction with dietary n-3 and antioxidants in so doing. 
 In a study of healthy vegetarian postmenopausal women, Wu et al.[53] randomly 
assigned subjects to consume a 6 g corn oil or 6 g DHA-rich algae supplement daily for 
six weeks.  In blood samples collected following a 12-hour fast, women consuming the 
DHA supplement showed significantly increased LDL TBARS following induction of 
oxidation with copper versus women consuming the corn oil supplement.  However, total 
plasma cholesterol was significantly reduced in the DHA group compared to the corn oil 
group, and there were no significant differences in plasma vitamin E, urinary estrogen 
metabolites, or urinary prostaglandins between the two groups.  These results suggest that 
LDL from women consuming about 2.14 g DHA per day are more susceptible to lipid 
peroxidation because of the higher membrane content of DHA, but women consuming 
this level of DHA do not exhibit depletion of vitamin E and may lower their overall 
cholesterol.  The results of the urinary estrogen metabolites suggest neither a protective 
nor enhancing effect of such a DHA supplement on breast cancer risk. 
 Although retrospective human data suggest increased lipid peroxidation in women 
with breast cancer compared to healthy controls, prospective cohort studies do not 
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support a causative role of lipid peroxidation of dietary n-3 in breast cancer development.  
In fact, some prospective data indicate a protective role of marine n-3 due to lipid 
peroxidation.  More randomized controlled trials will be needed to parse out this 
association. 
 
Conclusions  
 Public health recommendations to increase dietary consumption of n-3 and/or fatty 
fish for cardiovascular disease prevention are likely to expand due to the documented 
beneficial effects of these dietary components on plasma lipid profiles and cardiac events.  
However, the effects of such recommendations on in vivo lipid peroxidation and the 
resulting biological consequences remain poorly characterized.  Of particular interest is 
the role of dietary n-3 and lipid peroxidation in reducing the risk or slowing the 
progression of human cancers, including breast cancer. 
 Lipid peroxidation of n-3 produces several reactive polar aldehydes that have been 
shown to bind DNA, alter enzyme functions, and trigger cell death.  Antioxidants from 
the diet or present within the organism can slow or prevent the process of lipid 
peroxidation as well as detoxify the reactive products.  In studies of cancer cells, n-3 
and/or lipid peroxidation metabolites significantly altered signal transduction and gene 
expression and ultimately reduced cancer cell viability.  However, it is not likely that 
such results are directly applicable to humans. 
 The results from animal studies addressing dietary n-3 and the risk of mammary 
cancer have been less conclusive.  Although some demonstrated that n-3 decrease the size 
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and number of mammary tumors due to enhanced lipid peroxidation, differences in 
absolute and relative amounts of fatty acids consumed across the studies limit the 
consistency and generalizability of the results from these studies.  In contrast, human 
case-control studies fairly consistently showed that women with breast cancer have 
increased lipid peroxidation relative to non-cancer controls.  However, the observational 
studies were also inconclusive regarding alterations in antioxidant status associated with 
breast cancer, with studies indicating either increases or decreases in antioxidant 
concentrations or functions in women with breast cancer versus non-cancer controls. 
 Human cross-sectional studies that have utilized immunohistochemical staining of 
cancer and surrounding non-cancer tissues have suggested that lipid peroxidation is 
associated with breast cancer progression rather than carcinogenesis.  This association is 
also evident from the few prospective cohort studies that have not demonstrated 
significantly increased risks for breast cancer with increased n-3 intake or in vivo lipid 
peroxidation. 
 To fully characterize the relationships between dietary n-3, in vivo lipid 
peroxidation, and breast cancer risk, additional prospective and intervention data will be 
needed.  There are presently no intervention studies that directly assess these 
associations, and the limited data regarding the function of tamoxifen to increase or 
decrease lipid peroxidation in treating breast cancer are conflicting.  With increasing 
access to highly sensitive techniques to ascertain antioxidant status and quantify in vivo 
lipid peroxidation, controlled studies of dietary n-3 supplementation will provide 
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valuable information regarding this intriguing and controversial topic of whether n-3 and 
lipid peroxidation are beneficial or detrimental to human health.
   68 
Chapter II: Moderate consumption of omega-3 (n-3) fatty acids 
significantly increases in vivo lipid peroxidation in healthy post-
menopausal women 
   69 
Introduction 
 Lipid peroxidation is an autocatalytic, free radical-induced process by which 
polyunsaturated fatty acids (PUFA) are degraded into lipid hydroperoxides and reactive 
lipophilic aldehydes and ketones.  This process can occur in food products as well as in 
biological membranes, where the production of lipophilic aldehydes such as 4-hydroxy-
2-trans-hexenal (HHE) and 4-hydroxy-2-trans-nonenal (HNE) may result in cellular 
damage or death[35, 136].  In addition to vitamin E deficiency and impaired endogenous 
antioxidant systems, a diet high in PUFA would be expected to increase total lipid 
peroxidation within an organism[98, 137, 138]. 
 Fish oil is a rich source of the long chain omega-3 (n-3) PUFA eicosapentaenoic 
acid (EPA, 20:5 n-3) and docosahexaenoic acid (DHA, 22:6 n-3), and many studies have 
linked fish oil consumption to reduced risk of cardiovascular disease, cognitive decline, 
and cancer[6, 139, 140].  The American Heart Association currently recommends that 
adults consume two servings of fatty fish per week (about 500 mg EPA + DHA per day) 
to reduce the risk of coronary heart disease[140].  However, increasing intake of fish oil 
would likely increase lipid peroxidation within the body, and as atherosclerosis is highly 
influenced by lipid peroxidation, the concomitant increase of PUFA due to fish 
consumption may increase the risk of atherosclerotic cardiovascular disease[39].  
Increased consumption of the essential n-3 !-linolenic acid (ALA, 18:3 n-3), found in 
plant sources such as canola oil, flaxseeds, and soybeans, would also be associated with 
an increase in in vivo lipid peroxidation. 
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 Studies examining fish oil consumption and cancer risk have been largely 
inconclusive[141].  With respect to cancer, lipid peroxidation products such as HNE have 
been shown to bind to amino acids and DNA, resulting in protein dysfunction and genetic 
mutations[35].  The process of lipid peroxidation and its reactive products have also been 
shown to result in cancer cell death and augment chemotherapy during cancer 
treatments[98, 142].  These disparate functions of lipid peroxidation suggest that it may 
initiate cancer development yet also eliminate cancer cells from the body. 
 Recently, this laboratory developed a method to identify and quantify polar and 
nonpolar aldehydic products of lipid peroxidation and validated this method in 
humans[143].  However, no research has been conducted on the response of such 
compounds to a well-controlled feeding study including fish oil and ALA.  As a 
supplement to a crossover feeding study examining the influence of dietary fats on the 
risk of breast cancer, the following study was completed to compare the effects of a low-
fat diet with or without n-3 PUFA on whole body lipid peroxidation in post-menopausal 
women.  The results from this study suggest that a moderate increase in n-3 consumption 
increases in vivo lipid peroxidation, as measured by urinary lipophilic aldehydes and 
ketones measured as DNP-hydrazones. 
   
Materials and Methods 
Chemicals and supplies 
Trichloroacetic acid, 2,4-dinitrophenylhydrazine (DNPH), hexanal (98%), pentan-
2-one (97%), hept-2-enal (97%), hepta-2,4-dienal (90%), decanal, deca-2,4-dienal, 
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methanol, water, ethyl acetate, 1-chloro-2,4-dinitrobenzene, acetonitrile, N-acetyl-L-
cysteine, and diethyl ether were purchased from Sigma-Aldrich (St. Louis, MO).  
Thiobarbituric acid, hydrochloric acid, methylene chloride, and dibasic phosphate were 
obtained from J.T. Baker (Philipsburg, NJ).  Acetone, monobasic phosphate, and 
dimethyl sulfoxide were purchased from Fisher Scientific (Fair Lawn, NJ); hexane from 
EMD Chemicals (Gibbstown, NJ); malondialdehyde tetramethyl acetal from Kodak 
(Rochester, NY); DNPH-derivative of butyraldehyde from Supelco Analytical 
(Bellefonte, PA).  DNPH-derivatives of butanone, octanal, non-2-enal, 4-hydroxyoct-2-
enal, and 4-hydroxydec-2-enal were generously provided by Dr. Esterbauer, University 
of Graz (Graz, Austria).  4-hydroxy-2-trans-hexenal and 4-hydroxy-2-trans-nonenal were 
purchased from Cayman Chemicals (Ann Arbor, MI).  L-ascorbic acid was procured from 
Eastman (Rochester, NY), and ammonium formate was purchased from Fluka (Buchs, 
Switzerland).  All chemicals and solvents were HPLC-grade and filtered and degassed 
prior to use.  Silica gel thin layer chromatography (TLC) plates (20 cm x 20 cm, 250 µm 
layer, AL SIL G) and #1 filter paper were purchased from Whatman Ltd. (Kent, 
England). 
 
Instrumentation 
The HPLC system included a Varian 9010 solvent delivery system (Varian, 
Walnut Creek, CA), a Waters WISP 710B sample injector (Waters, Milford, MA), an 
Ultrasphere ODS C18 reversed-phase column (25 cm x 4.6 mm i.d., 5 µm particle size) 
(Beckman, Fullerton, CA) equipped with a 7.5 x 4.6 mm guard column (Alltech 
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Associates, Deerfield, IL), and a Varian 9050 variable wavelength UV-VIS detector 
(Varian, Walnut Creek, CA).  The integration of peaks was completed with Varian Star 
Chromatography Workstation (Varian, Walnut Creek, CA) software installed on a 
computer connected to the detector.  A Spectronic 20 spectrophotometer (Bausch & 
Lomb, Rochester, NY) was used for the urinary thiobarbituric acid-reactive substances 
measurements. 
 
Study population and diets 
Complete inclusion and exclusion criteria have been provided by Young et 
al.[144].  Healthy postmenopausal women with a body mass index between 19 and 32 
kg/m2 were eligible to participate in the original study.  Each woman was assigned to 
complete three study diets in a random order: a high-fat diet (45% energy from fat), a 
low-fat diet (20% energy from fat), and a low-fat, high n-3 diet (low-fat diet + 3% energy 
from n-3 fatty acids).  The subjects consumed the assigned diet every day for 8 weeks 
and consumed each of the other study diets for the same period of time following two six- 
to eight-week washout periods.  Study diets were prepared in the metabolic kitchen of the 
General Clinical Research at the University of Minnesota and distributed to each subject 
in person.  Compliance to the study diets was assessed via daily questionnaires.  The 
study was approved by the University of Minnesota Committee for the Use of Human 
Subject in Research and the US Army Medical Research and Material Command’s 
Human Subjects Research Review Board. 
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Twenty-four hour urine collection protocol 
As part of the original study, each subject completed two consecutive 24-hour 
urine collections during the final week of each diet[144].  The samples were kept in an 
opaque, 3.5 L jug with 1 g ascorbic acid at refrigerator temperature throughout the 
collection.  The collections were pooled, and aliquots were stored at -80°C prior to 
analyses.  The present study includes urine samples from the low-fat (– n-3) and low-fat, 
high n-3 (+ n-3) diets only.  Urinary creatinine was measured for each sample by rate 
reflectance spectrophotometry using an Ortho Clinical Diagnostics Vitros analyzer at the 
University of Minnesota Medical Center, Fairview, Diagnostic Laboratories. 
 
Urinary thiobarbituric acid-reactive substances (TBARS) 
Urinary TBARS were conducted in duplicate for each sample following the 
method by Lee et al.[145].  Three mL of 5% (w/v) trichloroacetic acid and 1 mL of 0.6% 
(w/v) thiobarbituric acid were reacted with 1 mL serial dilutions of urine samples, 
malondialdehyde (MDA) standard, or water (as reagent blank).  The mixtures were 
incubated at 80°C for 90 minutes.  The absorbance of the clear supernatant was measured 
at 535 nm against the reagent blank, and results are computed as MDA equivalents. 
 
Preparation of DNPH reagent 
The DNPH reagent was prepared daily following the method in Kim et al.[143].  
12.5 mg of DNPH, recrystallized three times, was mixed the 25 mL of 1 N hydrochloric 
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acid at 50°C for approximately one hour.  Following cooling, the reagent was rinsed four 
times with hexane to remove any impurities. 
 
Preparation of DNP-hydrazone standards 
Four mL of pure standard were combined with 800 mg DNPH, 80 mL methanol, 
and 2 mL 6 N hydrochloric acid and mixed for 10 minutes at 60°C.  After overnight 
cooling, the solution was filtered and recrystallized three times to purify.  The final DNP-
hydrazone was dried for two to three days prior to use. 
 
Synthesis and isolation of DNP-hydrazones of urinary aldehydes and related compounds 
Three mL of urine were reacted with an equal volume of DNPH reagent overnight 
at room temperature.  A reagent blank and acetone-DNPH standard were prepared by 
reacting an equal amount of DNPH reagent or 1% acetone/water (v/v), respectively, and 
DNPH reagent.  The following day, the reaction mixtures were extracted three times with 
10 mL methylene chloride, and the organic phases were separated via centrifugation for 
10 minutes at 1360 x g.  The sample extracts were pooled and evaporated to 500 µL 
under N2 gas.  Each sample was applied to two thin-layer chromatography (TLC) plates, 
and the plates were developed with methylene chloride at room temperature for 
approximately one hour for primary separation. 
Nonpolar and polar compounds were isolated by comparison to the Rf values of 
acetone-DNPH (0.55) and DNPH reagent (0.23).  The nonpolar carbonyl compounds 
(alkanals, alkenals, ketones, dienals) were found between Rf 0.55 and the solvent front, 
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while the polar compounds (containing hydroxyl groups) were found between the solvent 
origin and Rf 0.23.  Osazones were isolated between the acetone-DNPH and DNPH 
reference bands and were discarded from the following analyses.  The polar and nonpolar 
carbonyls were cut from the TLC plates and eluted three times with 10 mL 100% 
methanol.  The pooled extracts were evaporated to approximately 5 mL under N2 gas and 
centrifuged for 20 minutes at 1360 x g to remove any silica.  The clear supernatants were 
evaporated to less than 1 mL and made up to exactly 1 mL with 100% methanol. 
 
Identification of DNP-hydrazones 
Prior to injection into the HPLC system, the methanol extracts were filtered 
through a 0.45 µm filter.  Aliquots of the nonpolar and polar DNP-hydrazones were 
analyzed separately via HPLC with two different solvent systems[36].  100 µL aliquots 
of nonpolar carbonyls were injected into the HPLC system, using isocratic elution for 10 
minutes with 75% methanol (v/v), followed by a linear gradient of 75% methanol (v/v) 
for 20 minutes and 100% methanol (v/v) for 10 minutes.  The analysis of polar carbonyls 
was identical, but the initial isocratic gradient was 55% methanol (v/v).  The absorbance 
of polar and nonpolar carbonyls and related compounds was monitored at 378 nm, and 
the rejection of peaks was set to 2000 area counts.  The detection limit of the system was 
1 ng hexanal-DNPH per 50 µL injection.  Peaks were identified by comparison of 
retention times to known standards and previous results from this technique.  Each 
sample was injected at least twice, and paired samples were run in the same series, 
whenever possible. 
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Quantification of total urinary mercapturic acids 
Following the method of Kress and Pentz[146] as detailed by Kubo et al.[147], 3 
mL of urine was acidified with HCl to a pH of 1-2, and the organic components were 
extracted with ethyl acetate.  The extracts were evaporated to dryness under N2 gas and 
reconstituted to exactly 3 mL with water.  The samples were hydrolyzed with the addition 
of 900 µL 13.3 N NaOH and one hour incubation at 96°C.  Eight hundred µL 0.1 M 
phosphate buffer (pH 8), 200 µL freshly prepared ascorbic acid solution (2 mg/mL), and 
100 µL 1-chloro-2,4-dinitrobenzene (CDNB) solution (0.1 M in DMSO) were added to 1 
mL of hydrolyzed urine, and the samples were incubated for 30 minutes at 56°C.  Once 
cooled to room temperature, 150 µL HCl were added to each sample, followed by 
extraction with diethyl ether. 
 To quantify total urinary mercapturic acids as N-acetyl cysteine, 100 µL of the 
aqueous phase were injected in to the HPLC system and eluted with an isocratic gradient 
of 23 mM ammonium formate buffer/acetonitrile (80/20, w/v) at a flow rate of 0.8 
mL/min.  N-acetyl cysteine-CDNB was detected at 340 nm, and the limit of detection was 
74 ng N-acetyl cysteine-CDNB per 100 µL injection. 
 
Liquid chromatography-mass spectrometry (LC/MS) analysis of 4-hydroxy-2-trans-
decenal (HDE)-DNPH adduct 
Representative subjects’ following the + n-3 diet (n=8) DNP-hydrazones were 
pooled in duplicate, and two samples were collected between 32 and 35 minutes of the 
polar HPLC method described above.  LC/MS analysis was completed by Chi Chen 
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following his previously published technique[148].  A 5-!L aliquot of the pooled samples 
was injected into a Waters Acquity ultra-performance liquid chromatography system 
(Milford, MA) and separated by a gradient of mobile phase ranging from water to 95% 
aqueous acetonitrile containing 0.1% formic acid over a ten minute run.  LC eluate was 
introduced into a Waters SYNAPT QTOF mass spectrometer (Milford, MA) for accurate 
mass measurement and tandem MS (MS/MS) analysis.  Capillary voltage and cone 
voltage for electrospray ionization was maintained at !3 kV and !35 V for negative 
mode detection, respectively.  Source temperature and desolvation temperature were set 
at 120 and 350°C, respectively. Nitrogen was used as both cone gas (50 L/h) and 
desolvation gas (600 L/h) and argon as collision gas.  For accurate mass measurement, 
the mass spectrometer was calibrated with sodium formate solution (range m/z 50–1000) 
and monitored by the intermittent injection of the lock mass leucine enkephalin ([M ! 
H]! = 554.2615 m/z) in real time.  Mass chromatograms and mass spectral data were 
acquired and processed by MassLynx software (Waters) in centroid format.  The 
presence of HDE-DNPH in the samples was confirmed by a comparison with the 
authentic standard and MS/MS fragmentation.  
 
Statistical analysis 
Data were log-transformed and analyzed in SAS v9.2 (SAS Institute Inc., Cary, 
NC) via paired Student’s t-test.  The cutoff for significance was set at p = 0.05. 
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Results 
Subject characteristics 
A summary of baseline characteristics for the subjects is shown in Table 7.  The 
average age of the subjects was 56.21 ± 5.72 years, and the average BMI was 27.70 ± 
3.38 kg/m2.  Baseline diet information was collected via food frequency questionnaire for 
14 of the 15 subjects, and daily diet data are included in Table 7.  Compliance during the 
study was monitored via daily questionnaires and was determined to be less than 1% 
deviation in energy and less than 0.5% deviation in n-3 fatty acids[144]. 
 
Table 7.  Baseline demographic and dietary characteristics of healthy women participating in n-3 crossover 
feeding study. 
Baseline characteristic (n=15) Mean ±  SD 
Race/ethnicity, n (%)  
      African-American 1 (6.67%) 
      Hispanic-White 1 (6.67%) 
      White 13 (86.67%) 
Age, y 56.21 ± 5.72 
Body mass index, kg/m2 27.70 ± 3.38 
Systolic blood pressure, mmHg 119.07 ± 15.59 
Diastolic blood pressure, mmHg 72.07 ± 7.49 
Follicle stimulating hormone, IU/L 72.77 ± 21.89 
  
Baseline diet (n=14) Mean ±  SD 
Total energy, kcal 1785.11 ± 668.08 
Protein, g (% energy) 72.23 ± 30.24 (15.94 ± 1.83%) 
Carbohydrate, g (% energy) 229.38 ± 86.52 (51.67 ± 5.56%) 
Total fat, g (% energy) 66.06 ± 26.18 (33.41 ± 4.16%) 
Saturated fat, g (% energy) 22.10 ± 9.34 (11.18 ± 2.24%) 
Monounsaturated fat, g (% energy) 24.65 ± 10.16 (12.43 ± 1.85%) 
Polyunsaturated fat, g (% energy) 14.35 ± 10.16 (7.28 ± 0.69%) 
     18:2n-6, g 12.87 ± 4.69 
     18:3n-3, g 1.19 ± 0.46 
     20:4n-6, g 0.086 ± 0.048 
     20:5n-3, g 0.021 ± 0.037 
     22:6n-3, g 0.055 ± 0.037 
Dietary fiber, g 18.77 ± 7.22 
Cholesterol, mg 174.61 ± 85.90 
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Urinary TBARS 
There were no significant differences in urinary TBARS between the diets (Table 
8).  Urinary MDA equivalents were marginally increased with the n-3 supplemented diet, 
but this increase was not statistically significant (p = 0.55).  The inability to reach 
statistical significance may be due to the relatively small sample size (n=15) and limited 
sensitivity and specificity of the TBARS method. 
 
Table 8.  Urinary thiobarbituric acid reactive substances (TBARS) following each 8-week diet. 
Diet + n-3 – n-3 
p for 
difference* 
 
MDA Equivalents (µg/mg 
creatinine) (geometric 
mean ±  SE) 9.07 x 10-12 ± 1.12 x 10-12 8.49 x 10-12 ± 1.07 x 10-12 0.55 
Abbreviation: 
MDA = malondialdehyde 
*p-value determined via paired t-test for lognormal distribution 
 
Total polar and nonpolar DNP-hydrazones 
The total area under the peaks measured from the polar and nonpolar HPLC 
systems are shown in Figure 11.  Following the n-3-supplemented diet, urinary total polar 
DNP-hydrazones were significantly increased more than two-fold compared to the diet 
without n-3 supplementation (p <0.05).  In contrast, there were no significant differences 
in urinary nonpolar DNP-hydrazones between the two diets (p = 0.78).  Although the 
total concentrations of nonpolar DNP-hydrazones was slightly higher, the significant and 
substantial increase in polar DNP-hydrazones confirms the hypothesis that moderate n-3 
consumption increases total in vivo lipid peroxidation, as these polar aldehydes and 
ketones represent the reactive products of n-3 peroxidation in vivo. 
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. 
 
Figure 11. Total urinary polar and nonpolar lipophilic aldehydes following each 8-week diet. 
*p <0.05 for paired t-test for lognormal distribution 
 
 
Total mercapturic acids 
Despite the significant increase in polar DNP-hydrazones, there was no 
significant effect of n-3 supplementation on total urinary N-acetyl cysteine (Figure 12). 
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Figure 12. Total urinary N-acetyl cysteine (NAC) following each 8-week diet. 
 
 
Individual polar and nonpolar DNP-hydrazones 
Representative chromatograms are shown in Figure 13 and Figure 14.  The mean 
values for individual polar and nonpolar DNP-hydrazones are shown in Figure 15 and 
Figure 16, respectively.  The urinary concentrations of HHE, HDE, and unidentified 
compounds E and G were significantly higher following the + n-3 diet compared to the – 
n-3 diet (p <0.05).  Additionally, 4-hydroxyoct-2-trans-enal (HOE) concentrations were 
borderline increased with the + n-3 diet (p <0.10).  Although all nonpolar compounds 
quantified in the urine were slightly increased in the + n-3 versus  
– n-3 diet, none of the differences in concentrations reached statistical significance. 
 
   82 
 
Figure 13.  Representative HPLC chromatogram showing polar DNP-hydrazones isolated from human 
urine. 
 
 
Figure 14.  Representative HPLC chromatogram showing nonpolar DNP-hydrazones isolated from human 
urine. 
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Figure 15.  Individual polar urinary DNP-hydrazones following each 8-week diet. 
*p <0.05 for paired t-test for lognormal distribution 
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Figure 16. Individual nonpolar urinary DNP-hydrazones following each 8-week diet. 
 
 
Identification of HDE 
Figure 17 shows LC/MS traces confirming the presence of HDE in the urine 
samples of women consuming n-3.  As stated above, the concentrations of HDE were 
significantly increased following the + n-3 diet (p <0.05).  This result marks the first 
published demonstration of HDE produced from in vivo lipid peroxidation of dietary 
PUFA in human beings. 
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Figure 17.  LC/MS trace of 4-hydroxy-2-trans-decenal-2,4-dinitrophenylhydrazone (HDE-DNPH) standard (A, with HDE structure), and pooled + n-3 urine 
samples (B and C) (chromatograms generously provided by Chi Chen). 
A 
B 
C 
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Discussion 
 This is the first study to measure a significant increase in total urinary polar DNP-
hydrazones and HHE in individuals following a low-fat diet supplemented with 3% of 
energy from n-3.  These results confirm the hypothesis that a moderate increase in dietary 
n-3 increases in vivo lipid peroxidation.  Because n-3 PUFA are highly unsaturated, they 
are susceptible to lipid peroxidation, as shown in previous work by our lab[36].  
Although the findings were statistically significant, more research is needed to ascertain 
the clinical significance of this increase. 
 Previous human studies have generally shown a significant increase in plasma, low-
density lipoprotein (LDL), or urinary TBARS with fish oil or n-3 supplementation[24, 
45-49, 52, 53], but our results may not have achieved statistical significance due to the 
relatively small concentration of n-3 provided to the study subjects as well as the small 
number of subjects (n=15).  In addition, the TBARS method has relatively poor 
sensitivity and specificity compared to HPLC methods and can result in false positives 
due to the reaction of thiobarbituric acid with urinary components such as amino acids, 
sugars, and albumin in addition to MDA[149].  Meydani et al.[46] detected a significant 
increase in plasma TBARS of women supplemented with more than 2 g of EPA and 
DHA daily after two months, but this difference was no longer significant at the third 
month.  In a study of men only, Nair et al.[47] documented a significant increase in 
plasma TBARS following a 10-week treatment with 15 g fish oil per day versus 15 g of 
placebo oil.  Wander et al.[45] supplemented post-menopausal women with the same 
level of fish oil with or without various concentrations of vitamin E and measured a 
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significant increase in urinary TBARS after five weeks.  In the latter two studies, 
increased vitamin E intake attenuated the increase in TBARS from high n-3 intake.  
However, with supplementation of 2.43 g EPA for two weeks, Saito et al.[51] did not 
detect a significant increase in plasma TBARS among hyperlipidemic women.  In the 
present study, subjects consumed approximately 6.82 g n-3 daily, of which only 0.46 and 
0.99 g were EPA and DHA, respectively.  This relatively low amount of long-chain n-3 
likely explains the contrast of our TBARS results to the studies providing much higher 
concentrations of n-3 (up to 15 g/d fish oil). 
 This study is the first to quantify total urinary lipophilic polar and nonpolar 
aldehydes and ketones produced from the in vivo lipid peroxidation of n-3 and among the 
first to report the concentrations of specific polar lipophilic aldehydes.  We documented 
significant increases in HHE, HDE, and two unidentified compounds in women 
consuming 3% of energy from n-3 for 8 weeks.  This increase in HHE was expected due 
to its formation from lipid peroxidation of n-3 and confirmed the results of Calzada et 
al.[54] showing a significant increase in plasma HHE following DHA supplementation at 
800 or 1600 mg per day in men.  Similar to Turley et al.[50], we did not detect a 
significant increase of HNE with n-3 supplementation.  This is not surprising given that 
thermal oxidation of ALA did not produce quantifiable levels of HNE, in contrast to 
linoleic acid (n-6)[36].  As discussed below, this is the first study to document an 
increase in HDE excretion from in vivo lipid peroxidation of dietary n-3, and additional 
human studies are required to confirm this result.  In addition, further research is needed 
to identify unknown compounds E, and G, but it is plausible that they are long chain (at 
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least ten carbons) polar lipophilic aldehydes produced from lipid peroxidation of n-3.  We 
failed to quantify any significant changes in total or individual nonpolar lipophilic 
aldehydes following the n-3 diet treatment.  Although not significant, there were 
increased concentrations of these compounds following the n-3 diet, suggesting an 
overall increase in their production, likely due to increased substrate availability. 
 We did not measure significant differences in urinary N-acetyl cysteine 
concentrations following the two diets, indicating the low-fat diet supplemented with n-3 
did not change total mercapturic acid excretion.  However, this method did not quantify 
specific mercapturic acid conjugates, which may be influenced by other environmental 
exposures.  Nevertheless, our results are supported by those of Kubo et al.[147], who did 
not detect a statistically significant difference in total urinary mercapturic acid excretion 
between rats fed a standard diet or a diet supplemented with 8.4% of energy from DHA.  
These results suggest that either intracellular glutathione has been saturated or higher 
concentrations of n-3 are required to enhance this method of detoxification.  The work of 
Kuiper et al.[89] suggests that substantially enhanced lipid peroxidation is required to 
increase urinary mercapturic acid excretion, as these researchers documented significant 
increases in mercapturic acid conjugates of lipid peroxidation metabolites in rats treated 
with CCl4, a potent inducer of oxidative stress. 
 Through highly sensitive LC/MS analysis, we were able to confirm significantly 
increased concentrations of HDE following the + n-3 diet.  This is the first study to 
document urinary excretion of HDE from dietary fat intake as well as its significantly 
increased concentration following a diet containing 3% of calories from n-3.  These 
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results suggest that HDE is produced from lipid peroxidation of n-3.  Although research 
examining HDE is limited, it is plausible that this compound shares the abilities of HHE 
and HNE to bind proteins and DNA, potentially resulting in cellular mutations and death.  
More research is needed to confirm this finding in humans as well as establish its clinical 
relevance. 
 In conclusion, we demonstrated that a low-fat diet supplemented with 3% of 
energy from n-3 significantly increased total polar lipophilic aldehydes from in vivo lipid 
peroxidation.  At present, it is not known whether this increase is clinically significant.  
The absence of an increase in mercapturic acid excretion may indicate that the increase of 
in vivo lipid peroxidation falls well below toxic levels, but slight increases in the 
production of reactive aldehydes such as HHE may cause cellular damage leading to 
neurodegenerative diseases, atherosclerosis, or cancer[35, 39, 40, 58-60, 75, 150-153].  
Future research utilizing highly sensitive techniques to characterize urinary lipid 
peroxidation metabolites from diets with a range of n-3 concentrations will help establish 
at what doses n-3 are no longer beneficial and may become detrimental to human health. 
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Part II: Validation of an assay for the measurement of 
3,3'-diindolylmethane as a marker for indole-3-carbinol 
exposure in free-living subjects 
 
 
Introduction 
 There is ample evidence that consuming cruciferous vegetables, such as broccoli, 
cauliflower, or Brussels sprouts, reduces the risk of several human cancers.  In addition to 
macronutrients, vitamins, and minerals present in these vegetables, crucifers are rich 
sources of glucosinolates, which generate bioactive compounds during metabolism.  
Indole-3-carbinol is a metabolite of the glucosinolate glucobrassicin and has 
demonstrated substantial chemoprevention in cell culture and animal model studies of 
cancers.  However, the lack of a reliable biomarker of indole-3-carbinol exposure in 
humans has limited epidemiological research in this area.  The development and 
validation of a urinary assay for 3,3'-diindolylmethane, the principle metabolite of indole-
3-carbinol in humans, would prove valuable for human research of indole-3-carbinol 
exposure and cancer risk. 
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Chapter III: Literature Review 
 
Cruciferous vegetables and cancer risk 
 Cruciferous vegetables largely consist of the Brassica genus of vegetables, such as 
cabbage, Brussels sprouts, broccoli, cauliflower, turnips, and bok choy, but also include 
non-Brassica vegetables such as radishes, watercress, horseradish, and arugula[154].  
These vegetables are characterized by bitter, pungent flavors and aromas due to their high 
concentrations of sulfur-containing compounds called glucosinolates[155].  Upon 
damage to the plant cells by processing or mastication, the enzyme myrosinase is 
released, resulting in the hydrolysis of glucosinolates (Figure 18)[156].  The hydrolysis 
products, which include isothiocyanates and indoles, are the putative bioactive 
constituents of cruciferous vegetables that exert health effects in vivo[157-159]. 
 
 
Figure 18.  Conversion of parent glucosinolate, glucobrassicin, to indole-3-carbinol (I3C), catalyzed by 
myrosinase. 
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 There has been extensive epidemiological research into cruciferous vegetables and 
decreased risk of several human cancers, particularly lung cancer (reviewed in [154, 156, 
158, 160, 161]).  Although they are also a source of dietary fiber and several vitamins and 
minerals including the antioxidant selenium, the chemopreventive effects of cruciferous 
vegetables are credited primarily to the modulation of phase I and II xenobiotic 
metabolism enzymes by isothiocyanates and indoles[154].  Phase I metabolism is 
generally considered an activating step for pro-carcinogens, while phase II metabolism is 
responsible for the conjugation of carcinogens and other xenobiotic compounds to 
increase water solubility and excretion via urine or feces (Figure 19)[154, 162].  
Therefore, a dietary bioactive that increases the activity of these enzymes would decrease 
the exposure of an organism to a carcinogen, thereby reducing cancer risk.  Additional 
chemopreventive mechanisms specific to indoles, including the up-regulation of 
apoptosis, will be discussed in the next section. 
 Much nutrition and cancer research has focused on total and specific 
isothiocyanates generated from hydrolysis of glucosinolates because of the existence of 
sensitive and specific urinary biomarkers[163].  Specifically, phenethyl isothiocyanate 
(PEITC, generated from watercress glucosinolates) and sulforaphane (SFN, generated 
from broccoli glucosinolates, among others) have been extensively studied with respect 
to human cancers[164].  Their effects on chemoprevention have been largely attributed to 
the up-regulation of phase II metabolizing enzymes, but there is some evidence that SFN 
may decrease the activity of phase I metabolizing enzymes, reducing the activation of 
pro-carcinogens[164].  Intriguingly, SFN may also enhance formation of the lipid 
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Figure 19.  Example of Phase I and II metabolism of the tobacco-specific carcinogen 4-(methyl-nitrosamino)-1-(3-pyridyl)-1-butanone (NNK) into 4-
(methylnitrosamino)-1-(3-pyridyl-1-butanol) (NNAL), catalyzed by cytochrome P450 (CYP) isoforms 1A1, 1A2, or 2B1, and NNAL-N-glucuronide (NNAL-N-
Gluc), catalyzed by UDP-glucuronosyltransferase (UGT).  Both enzymes have been shown to be up-regulated by indole-3-carbinol (I3C) (adapted from [157, 
161, 165, 166]). 
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peroxidation-derived !,"-unsaturated aldehyde HNE to increase cancer cell 
apoptosis[167].  However, the chemopreventive effects of indoles are more appealing 
from a therapeutic and public health standpoint because they have been shown to 
modulate both phase I and phase II metabolism with greater potency and less toxicity 
than isothiocyanates[154, 158, 162, 168, 169]. 
 
Metabolism of indole-3-carbinol  
 As previously mentioned, processing of cruciferous vegetables through chewing or 
chopping releases myrosinase, which cleaves the glucose moiety from the 
glucosinolate[158].  Indole-3-carbinol (I3C) is formed following the degradation of 
glucobrassicin by myrosinase.  Following ingestion, the low pH of the gastric cavity 
promotes the dehydration and oligomerization of I3C into several metabolites (Figure 
20)[154, 170, 171].  Of these metabolites, 3,3'-diindolylmethane (DIM) is the most 
prevalent and stable in body tissues; therefore, it is a promising candidate for a biomarker 
of I3C exposure[170, 171].  Relatively little is known about the metabolic fate and 
excretion of DIM.  It is plausible that the compound is excreted in the urine as an N-
glucuronide following conjugation via UDP-glucuronosyltransferases (UGTs)[172].  
Additionally, DIM may be excreted as a sulfonated conjugate, produced by the phase II 
sulfotransferase enzymes (SULTs)[173, 174].   The pharmacokinetics of I3C metabolism 
and DIM formation in animals and humans will be reviewed below. 
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Figure 20.  Acid condensation of indole-3-carbinol (I3C) into 3,3'-diindolylmethane (DIM) as well as [2-(indol-3-yl-methyl)-indol-3-yl]indol-3-ylmethane 
(linear trimer, LTr1), indolo[3,2b]carbazole (ICZ), indole-3-carboxylic acid (I3CA), indole-3-carboxaldehyde (I3A), and 1-(3-hydroxymethyl)-indolyl-3-
indolylmethane (HI-IM) (adapted from [171]).
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Indole-3-carbinol, 3,3'-diindolylmethane, xenobiotic metabolism, and cancer risk 
In vitro studies 
 A majority of primary research into I3C, DIM, and human cancers has occurred in 
cell culture systems, and a selection of relevant studies are summarized in Table 9.  To 
explore the apoptotic mechanism in the single cell fungal organism Candida albicans, 
Hwang et al.[175] supplemented cells with 1% I3C with or without inhibitors of 
oxidative stress and measured the generation of ROS and hydroxyl radicals and markers 
of apoptosis and necrosis.  The authors concluded that I3C indeed acts through an 
oxidative stress mechanism, chiefly an increase in the production of the hydroxyl radical, 
to stimulate apoptosis and possibly necrosis of C. albicans.  Such effects of I3C may be 
similar to the effects of lipid hydroperoxides to prevent cancer progression (see Chapter 
1), but more research is needed to demonstrate this. 
 Many studies examining I3C and human cancers have focused on the 
transcriptional effects of the dietary bioactive.  Marconett et al.[176] treated estrogen 
receptor-positive human breast cancer cells with varying concentrations of I3C and 
concluded that I3C decreased cell proliferation by down-regulating the transcription of 
multiple growth-inducing genes.  I3C treatment was shown to interfere with the 
interaction between estrogen receptor-! and the transcription factor Sp1 via 
phosphorylation of a key amino acid on the molecule, providing a possible explanation 
for the transcriptional effects of I3C. 
 In a study of human prostate cancer cells, Wang et al.[177] showed that treatment 
of cells with either I3C or DIM significantly decreased proliferation of androgen-
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Table 9.  Summary of in vitro studies examining indole-3-carbinol, 3,3!-diindolylmethane, and cancer. 
Reference System/Controls Intervention Outcome Measurement(s) Results Notes 
Hwang et 
al.[175] 
Candida albicans   
Untreated cells as 
controls 
1% I3C (with or 
without thiourea or 
trehalose as 
inhibitors of 
oxidative stress), 
amphotericin B, or 
hydrogen peroxide 
Minimum inhibitory 
concentration 
ROS and hydroxyl radical 
concentration via fluorescent 
dye 
Apoptosis and necrosis via 
Annexin V staining and 
TUNEL staining 
Cytochrome C via 
spectrophotometry and SDS-
PAGE 
Mitochondrial membrane 
potential via flow cytometry 
Metacaspase activation via 
kit 
I3C was as efficient as amphotericin B or 
hydrogen peroxide in anti-candidal activity. 
I3C did not increase cellular ROS as much 
as amphotericin B or hydrogen peroxide but 
did increase hydroxyl radical production. 
I3C stimulates apoptosis or discrete necrosis 
and DNA condensation and fragmentation 
via an oxidative stress mechanism. 
I3C increases cytochrome C release from 
mitochondria, which was not inhibited with 
protection against oxidative stress.  I3C also 
increases metacaspase activation, 
stimulating apoptosis. 
 
Jin[178] MCF-7 and 
MDA-MB-468 
human breast 
cancer cells with 
transfected 
Cdc25A, a 
phosphatase 
involved in cell 
cycle progression 
Untreated cells as 
controls 
BALB/C female 
nude mice (n=40) 
with or without 
human breast 
cancer cell 
xenograft 
30, 45, or 60 µM 
DIM for 24-96 h 
For mouse study, 5 
mg/kg/d DIM or 
sesame oil as 
control 5 d each 
week for 7 weeks 
Cell proliferation via cell 
counting 
Colony formation via 
staining 
miRNA target prediction via 
computer programs 
Growth inhibition via anti-
miR-21 or miRNA negative 
control treatment and cell 
counting 
Protein expression via 
Western blot 
Cell cycle progression via 
flow cytometry 
 
DIM inhibited the growth and proliferation 
of breast cancer cells in a time- and dose-
dependent manner. 
DIM treatment significantly decreased 
tumor formation by 60% in xenograft study 
(p <0.05). 
DIM treatment increased the proportion of 
MCF-7 cells in G1 and G2/M phases of the 
cell cycle; MDA-MB-468 cells treated with 
DIM were arrested in the G2/M phase. 
DIM decreased the expression (but not 
transcription) or CDK4 and CDK2 in MCF-
7 cells and increased p21Waf1/Cip1 in both cell 
lines.  DIM treatment was also shown to 
down-regulate Cdc25A, Cyclin B1, and 
CDK1 expression in both cell lines. 
The Ser124 residue on Cdc25A is likely 
responsible for effect of DIM, shown via 
miRNA target prediction. 
MCF-7: 
estrogen 
receptor-
positive, wild-
type p53 
MDA-MB-
468: estrogen 
receptor-
negative, p53 
mutant 
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Reference System/Controls Intervention Outcome Measurement(s) Results Notes 
Cells treated with anti-miR-21 and DIM had 
increased proliferation over cells treated 
with DIM alone, indicating the miR-21 is 
involved in the effect of DIM on breast 
cancer cell proliferation. 
Marconett et 
al.[176] 
MCF-7 human 
breast cancer 
cells, with or 
without 
transfection of 
hTERT, which is 
involved in 
telomerase 
activity 
Untreated cells as 
controls 
50, 100, 150, 200, 
or 250 µM I3C for 
48 h 
200 µM I3C for 72 
h 
Gene expression via RT-PCR 
Cell cycle progression via 
flow cytometry 
Telomerase activity via kit 
Cell senescence via 
fluorescent microscopy 
Binding of hTERT to ER! 
and Sp1 via chromatin 
immunoprecipitation 
I3C decreases hTERT, ER!, CDK6, and 
progesterone receptor in dose-dependent 
manner.  Down-regulation of hTERT 
correlated with the proportion of cells in the 
G1 phase of the cell cycle.  Cells transfected 
with hTERT were resistant to this effect of 
I3C. 
I3C treatment decreased telomerase 
activity; again, this effect was ablated in the 
transfected cells. 
Treatment with I3C significantly increased 
cellular senescence (p = 0.0225), and this 
result was absent in transfected cells. 
Decrease in ER! and CDK6 were detected 
prior to decrease in hTERT, suggesting that 
hTERT expression may decrease as a 
response to the down-regulation of ER! and 
CDK6 by I3C. 
I3C treatment disrupted the interactions 
between ER! and Sp1 on their response 
elements located on the hTERT promoter.  
I3C was shown to increase phosphorylation 
of Sp1 at Thr579. 
 
Saati and 
Archer[179] 
MCF-7, MDA-
MB-231, and 
SKBr-3 human 
breast cancer 
cells 
MCF-10A 
nontumorigenic 
50 µM DIM Cell proliferation via MTT 
assay 
Fatty acid synthase and Sp1 
protein expression via 
Western blot 
Treatment with DIM significantly decreased 
the proliferation of all cancer cells at all 
time points (p <0.01).  DIM had no effect 
on proliferation of the nonmalignant cells. 
DIM treatment for at least 24 h significantly 
decreased the levels of fatty acid synthase 
and Sp1 in MCF-7 cells (p <0.01).  There 
Cancers 
frequently 
overexpress 
fatty acid 
synthase. 
Plasma DIM of 
24 µM and 
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Reference System/Controls Intervention Outcome Measurement(s) Results Notes 
human breast 
epithelial cells 
Also untreated 
breast cancer 
cells as controls 
were significant reductions in expression of 
these proteins in MDA-MB-231 and SKBr-
3 cells after 48 h of DIM treatment (p 
<0.01).  There were no changes in the 
expression of these proteins in 
nonmalignant breast cells treated with DIM. 
tissue DIM of 
32-200 µM 
reported 
following oral 
supplementatio
n of 250 mg/kg 
DIM by mice. 
Lerner et 
al.[180] 
HCT-116 and 
Colo-320 human 
colon cancer cells 
Untreated cells as 
controls 
10-100 µM DIM 
for 24, 48, or 72 h 
Cell viability and 
cytotoxicity 
Toxicity via lactate 
dehydrogenase leakage 
DNA damage via DAPI 
staining 
N-myc downstream regulated 
1 gene (NDRG1) expression 
via PCR 
Cell differentiation via 
alkaline phosphatase activity 
DIM treatment up to 80 µM significantly 
reduced viability of both cell lines in a 
dose-dependent fashion (p <0.001). 
There were no toxic effects of DIM 
treatment as indicated by leaking of lactate 
dehydrogenase. 
Cells treated with 60 µM exhibited signs of 
apoptosis via DAPI staining after 48 h. 
Treatment with 60 µM DIM significantly 
increased NDRG1 expression in Colo-320 
(p <0.001 for all time points) but not HGT-
116 cells. 
DIM treatment had no significant effects on 
differentiation of either cell lines. 
HCT-116 have 
wild-type p53; 
Colo-320 have 
mutant p53. 
Wang et 
al.[177] 
LNCaP and PC-3 
human prostate 
cancer cells 
Untreated cells as 
controls 
0-25 µM DIM for 
0-72 h 
0-100 µM I3C for 
0-72 h 
1 nM 
dihydrotestosterone 
or 17!-estradiol for 
gene expression 
experiments 
Cell growth via 
sulforhodamine B assay 
Cell cycle distribution via 
flow cytometry 
Gene expression via RT-PCR 
Protein expression via 
Western blot 
Androgen receptor binding 
affinity via kit 
Aryl hydrocarbon receptor 
binding via siRNA 
knockdown 
Both DIM and I3C significantly inhibit the 
proliferation of LNCaP cells (p <0.05) in a 
dose-dependent manner.  DIM is more 
potent than I3C (EC50 10 µM and 100 µM, 
respectively).  Only I3C significantly 
decreased PC-3 proliferation at 100 µM (p 
<0.05). 
Both DIM and I3C stimulated G0/G1 arrest 
in a dose-dependent fashion; again DIM 
was more potent than I3C. 
At 25 µM, DIM significantly increased 
CDKN1A and CDKN1B (p <0.05).  I3C 
exerted the same effects at 100 µM.  Only 
I3C significantly increased the CDKN1A 
LNCaP are 
androgen-
dependent 
whereas as PC-
3 are androgen 
non-responsive 
cells. 
This study also 
compared the 
effects of DIM 
and I3C on 
gene 
expression to 
genistein, 
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Reference System/Controls Intervention Outcome Measurement(s) Results Notes 
protein levels (p <0.05), while both DIM 
and I3C significantly increased CDKN1B (p 
<0.05) in LNCaP cells. 
All concentrations of DIM tested 
significantly decreased the transcription of 
androgen-dependent proteins (PSA, 
NKX3.1, and IGF-1R) and expression of 
PSA (p <0.05) in LNCaP cells.  I3C showed 
similar effects at higher concentrations. 
Both DIM and I3C significantly increased 
transcription of AHR, CYP1A1, and NQO1 
(DIM only) (p <0.05).  DIM significantly 
increased CYP1A1 and NQO1 expression 
in both cell lines (p <0.05).  These effects 
were blocked with AHR siRNA. 
In PC-3 cells, DIM and I3C significantly 
increased CDKN1A transcription (p <0.05).  
CYP1A1 and NQO1 were significantly 
increased in PC-3 cells treated with DIM or 
I3C (p <0.05). 
DIM was the only phytochemical tested that 
bound to the androgen receptor. 
Both DIM and I3C inhibited the 
dihydrotestosterone or 17!-estradiol 
induction of PSA (p <0.05). 
SFN, and 
resveratrol.  
The effects 
were similar, 
but SFN 
inhibited 
CYP1A1 
expression. 
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dependent cells in a dose-dependent manner (p <0.05) and that DIM was more potent 
than I3C, with a 50% median effective concentration of 10 µM compared to 100 µM, 
respectively.  Further experiments demonstrated that DIM was also more effective than 
I3C at up-regulating gene expression involved in stimulating cell cycle arrest (CDKN1A, 
CDKN1B) and phase I metabolism (CYP1A1, AhR, NQO1); the blockage of these effects 
through the addition of small interfering RNA for AhR suggested that they are due to the 
binding of DIM to this transcription factor and subsequent up-regulation of gene 
expression.  This study also compared the effects of I3C and DIM to several other 
phytochemicals including SFN, which were similar with the exception of SFN inhibiting 
CYP1A1 expression. 
 Although numerous cell culture studies have utilized pure I3C, it is important to 
note that I3C can spontaneously form DIM at rates in excess of 50% during such 
experiments even in the absence of low pH[181].  Therefore, it is plausible that DIM 
accounts for the majority of biological effects of I3C documented in the aforementioned 
studies.  Focusing on treatment with DIM alone, Jin[178] treated human breast cancer 
cells and a human breast cancer mouse model and detected a dose- and time-dependent 
suppression of breast cancer growth and proliferation.  Both cell lines used showed 
enhanced cell cycle arrest through decreased expression of cell cycle progression 
molecules (Cdc25A, Cyclin B1, and CDK1) and increased expression of a cyclin 
inhibitor, p21Wad1/Cip1.  Further treatment with a small interfering RNA demonstrated that 
the effects of DIM on the cell cycle might be due primarily to its up-regulation of a 
micro-RNA, miR-21.  These experiments provide some evidence that DIM is effective at 
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suppressing breast cancer proliferation irrespective of hormonal dependence and may 
exert its effects through the activation of a micro-RNA, a burgeoning field of interest in 
cancer research. 
 Subsequently, Saati and Archer[179] tested the effects of DIM in several human 
breast cancer cell lines in addition to a non-tumorigenic human breast cell line and 
concluded that DIM significantly decreased proliferation of all cancer cell lines (p <0.01) 
but had no effect on non-tumorigenic cell proliferation.  Similar results were seen 
regarding the decreased expression of FAS and Sp-1 in the cancer but not non-cancer 
breast cells.  The results suggest that the ability of DIM to decrease cell proliferation may 
be confined to cancer rather than non-tumorigenic tissues, but it is noteworthy that the 
experiments used a relatively high concentration of DIM (50 µM) for at least 24 hours, 
and these levels are not achievable through dietary intake of cruciferous vegetables alone. 
 Lerner et al.[180] tested the effects of various concentrations of DIM on two human 
colon cancer cell lines with regard to viability, toxicity, DNA damage, differentiation, 
and gene expression.  These researchers concluded that DIM treatment up to 80 µM 
significantly decreased cell viability in a dose-dependent manner (p <0.001), and 60 µM 
of DIM resulted in apoptosis after 48 hours.  Additionally, the absence of lactate 
dehydrogenase in the surrounding media suggested that DIM treatment at the median 
inhibitory concentrations (~54 µM) was not toxic to the cells.  Although 60 µM of DIM 
was shown to increase the transcription of a gene involved in cell differentiation 
(NDRG1) in one of the cell lines, DIM treatment did not show any significant effects on 
cell differentiation in either cell line. 
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 While each of these cell culture experiments demonstrates the capacity of DIM and 
I3C to enhance apoptosis, decrease cancer cell proliferation, and cause cell cycle arrest, it 
is difficult to extrapolate the results to humans or even animal models for several reasons.  
As mentioned previously, the concentrations of DIM and I3C used are not achievable 
through dietary consumption of cruciferous vegetables and likely represent 
pharmacological rather than physiological doses.  Consequently, it is impossible to 
achieve the level of exposure to cells within a whole organism without the use of a high 
amount of oral supplementation, which is limited by the bioavailability of the supplement 
as well as possible adverse events, such as gastrointestinal discomfort.  Additionally, cell 
culture systems utilize continuous exposure to the compound of interest, typically over 
the course of multiple days.  Given the continuous metabolic flux within cells and the 
documented short half-lives of DIM and I3C (see below), the exposure of cells within an 
organism to these compounds for such a long duration is not plausible.  In contrast to 
lipid hydroperoxides, which are continually present in cells at basal levels (see Chapter 
1), dietary bioactives such as DIM and I3C are not endogenously generated and are 
subject to xenobiotic metabolism and excretion by the very systems they up-regulate.  It 
remains to be seen what effects—if any—a physiological dose of DIM or I3C achieved 
through the diet has on human cancers, whether in the whole organism or isolated cell 
culture systems. 
 
Animal model studies of DIM and I3C pharmacokinetics 
 Because of their potential for therapeutic use, the pharmacokinetic profiles of DIM 
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and I3C have been evaluated in mice and rats, as summarized in Table 10.  Seminal work 
in this field was conducted by Stresser et al.[170], who administered radio-labeled I3C to 
rats over a one-week period and measured the presence of I3C and its metabolites in 
blood and numerous tissues.  Once steady-state was achieved, 75% of the I3C dose was 
excreted in total.  Seventy seven percent of the total excreted I3C was detected in feces 
and 23% was detected in urine.  The highest concentrations of I3C were measured in liver 
tissues, followed by lung and blood.  Additionally, the authors identified and quantified 
several acid condensation products of I3C, including DIM, which was present in high 
concentrations in the liver relative to other metabolites. 
 Anderton et al.[182] compared the bioavailability and pharmacokinetics of 
crystallized and microencapsulated DIM in female mice.  Although the 
microencapsulated formulation of DIM resulted in increased absorption and higher tissue 
concentrations, both formulations elicited a peak DIM concentration in all tissues 
between 30 minutes and one hour following administration.  This is indicative of the 
short half-life of DIM.  Additionally, the researchers did not detect downstream DIM 
metabolites in the plasma or tissues, which suggests that DIM likely exerts its biological 
effects in its native form. 
 As a corollary study, these researchers performed similar experiments with the 
administration of the same amount of I3C to female mice[171].  Plasma concentrations of 
I3C peaked at 15 minutes following gavage, and concentrations fell below the limit of 
detection within one hour, establishing a very short half-life for I3C.  Plasma DIM 
peaked two hours following gavage, while an additional acid condensation product, 
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Table 10.  Summary of animal model studies examining indole-3-carbinol and 3,3!-diindolylmethane pharmacokinetics. 
Reference Study Design Outcome Measurement(s) Results Notes 
Stresser et 
al.[170] 
Male Fischer rats fed 
0.32% [3H]I3C for 1d 
then 0.2% [3H]I3C 
for 6d 
Pharmacokinetics 
measured in blood, 
liver, kidney, lungs, 
stomachs, small 
intestines, tongues, 
urine, and feces 
Tissue, blood, urine, and fecal 
radioactivity via scintillation 
counting 
I3C and metabolite 
identification and 
quantification via HPLC, 
NMR, and MS 
 
At steady-state, 77% of I3C excreted via feces and 
23% via urine.  This represents 75% overall 
excretion. 
The highest tissue concentrations of I3C were in 
the liver, followed by lung and blood.  Following 
gavage, the highest concentrations were in the 
liver, followed by kidney, lung, blood, and tongue. 
Six unique I3C metabolites were identified (DIM, 
[2-(indol-3-ylmethyl)-indol-3-yl]indol-3ylmethane 
(LTr1), 1-(3-hydroxymethyl)indolyl-3-
indolylmethane (HI-IM), and 3 structurally 
unidentified compounds). 
pH of stomach 
contents 4.3 ± 0.03. 
Anderton et 
al.[182] 
Female CD-1 mice 
gavaged with 250 
mg/kg crystallized or 
microencapsulated 
DIM 
Pharmacokinetics 
measured in blood, 
liver, kidney, lung, 
heart, and brain 
Blood and tissue DIM and 
other I3C condensation 
products via HPLC 
Peak DIM concentration in all tissues 0.5 to 1 h 
after administration. 
Highest DIM concentrations observed in the livers, 
then lungs, kidneys, and hearts. 
The microencapsulated DIM resulted in higher 
tissue DIM and increased absorption compared to 
crystallized DIM. 
No metabolites of DIM detected in plasma or 
tissues. 
 
Anderton et 
al.[171] 
Female CD-1 mice 
gavaged with 250 
mg/kg I3C or 10 
ml/kg corn oil as 
control 
Pharmacokinetics 
measured in blood, 
liver, kidney, lung, 
heart, and brain 
Plasma I3C, DIM, and LT1 
concentrations via HPLC and 
MS 
Plasma I3C peaked at 15 min after dose and fell 
below the limit of detection with 1 h. 
Highest I3C concentrations in liver, followed by 
kidney, plasma, lung, heart, and brain. 
Peak DIM and LTr1 concentrations 1/6 and 1/10 
those of I3C.  DIM peaked at 2 h, while LTr1 
concentrations continued to increase throughout 
duration of testing (6 h). 
DIM and LTr1 concentrations highest in liver, 
followed by kidney, brain, lung, and heart. 
HI-IM also identified via HPLC-MS and exhibited 
similar pharmacokinetics to DIM.   
DIM, LTr1, and HI-IM remained in plasma and 
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Reference Study Design Outcome Measurement(s) Results Notes 
tissues longer than I3C. 
ICZ also detected in mouse liver at 6 and 24 h. 
I3CA detected in plasma via HPLC and had 
similar pharmacokinetics to I3C.  I3A detected in 
plasma below limit of quantification. 
Abbreviations: 
LTr1 = 2-(indol-3-ylmethyl)-indol-3-yl]indol-3-ylmethane 
HI-IM = 1-(3-hydroxymethyl)indolyl-3-indolylmethane 
ICZ = indolo[3,2b]carbazole 
I3CA = indole-3-carboxylic acid  
I3A = indole-3-carboxyaldehyde 
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2-(indol-3-ylmethyl)-indol-3-yl]indol-3ylmethane (LTr1), continued to increase in 
concentration throughout the measurement period of 6 hours following gavage.  An 
additional metabolite, 1-(3-hydroxymethyl)indolyl-3-indolylmethane (HI-IM), was 
present in similar concentrations and exhibited similar pharmacokinetics to DIM.  Similar 
to the previous study, the highest concentrations for I3C and its condensation products 
were detected in the liver; notably, detectable concentrations of DIM, LTr1, HI-IM 
remained in the liver for at least 24 hours following I3C administration.  Three additional 
I3C metabolites were detected: indolo[3,2b]carbazole (ICZ), indole-3-carboxylic acid 
(I3CA), and indole-3-carboxaldehyde (I3A); however, the authors considered these minor 
compounds with little physiological relevance, given their very low plasma and tissue 
concentrations as well as documented diminished ability to affect cell cycle progression 
compared to I3C and DIM.  
 While pharmacokinetic studies conducted in rodents may offer valuable 
information about the metabolism of I3C and DIM within mammals, there are several 
limitations to such studies.  As mentioned regarding in vitro studies, the quantities of I3C 
and DIM given to the test animals far exceed what could be achieved through the human 
diet.  It is likely that such high doses influence the pharmacokinetic profiles and tissue 
distribution of these dietary bioactives, and the results may not be applicable to controlled 
feeding studies in humans.  Additionally, the authors of these studies acknowledge that a 
major limitation of such work is the relatively high pH of murine stomach acid compared 
to that of humans[170].  It is conceivable that such differences in pH would change the 
amounts and types of acid condensation products formed between murine animals and 
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humans. 
 
Animal model studies of biological effects of DIM and I3C 
 Table 11 summarizes studies examining I3C, DIM, and xenobiotic metabolism 
and/or human cancers in animal model systems.  Leibelt et al.[183] administered various 
quantities of DIM or I3C to male and female Sprague-Dawley rats and monitored 
changes in liver size and enzymatic activity as well as colonic enzyme activity, bone 
density, serum vitamin D, and serum testosterone (in male rats only).  Male rats fed I3C 
or the highest dose of DIM had significantly increased liver somatic indices (the 
percentage of body weight comprised of liver weight) compared to those fed the control 
diet (p = 0.0023 and p = 0.042, respectively).  In both male and female rats, hepatic and 
colonic CYP contents were significantly increased by I3C and DIM supplementation; 
unfortunately, the researchers did not measure CYP activity, which would have indicated 
if I3C and DIM indeed enhanced the functions of CYP.  There were no significant effects 
of I3C or DIM on bone density or serum testosterone.  Additionally, serum vitamin D 
was significantly increased following one year of I3C supplementation (p = 0.0371 in 
males, p = 0.0031 in females).  Decreases in several liver enzymes (aspartate 
aminotransferase, alkaline phosphatase, and creatinine kinase) were detected in male rats, 
which show the absence of liver toxicity from the dietary compounds.  Although this 
study did not specifically address cancer risk, the results suggest that long-term 
supplementation with DIM or I3C is not toxic and may up-regulate key xenobiotic 
metabolizing enzymes to reduce exposure to potentially carcinogenic compounds.
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Table 11.  Summary of animal model studies examining indole-3-carbinol, 3,3!-diindolylmethane, and cancer. 
Reference Study Design 
Outcome 
Measurement(s) Results Notes 
Leibelt et 
al.[183] 
Sprague-Dawley rats, 
n=140 (n=70 of each 
sex) 
3 or 12 months: 
• Control diet 
• 50 mg/kg/d I3C 
• 6.6 mg/kg/d DIM 
• 66 mg/kg/d DIM 
Body and tissue 
weights 
Clinical blood 
chemistry 
Serum 25-
hydroxyvitamin D3 
Serum testosterone (in 
males only) 
Bone density analysis 
via histology 
Liver microsome and 
colon lysate CYP 
concentrations via 
SDS-PAGE 
 
No significant differences in body weights between diets.  
Rats fed I3C had higher liver somatic indices, which was 
statistically significant among male rats only (p = 0.0023).  
Males consuming the highest dose of DIM also had 
significantly increased liver somatic indices (p = 0.042). 
Serum AST was significantly decreased in male rats fed 
I3C or DIM (p = 0.013).  Serum ALP significantly lower in 
male rats fed I3C (p = 0.01) or the highest dose of DIM (p 
= 0.004).  Serum CK was significantly decreased in male 
rats consuming the highest dose of DIM (p = 0.01). 
Serum vitamin D levels were significantly increased after 
12 months of I3C consumption by both male (p = 0.0371) 
and female (p = 0.0031) rats. 
There were no significant changes in serum testosterone or 
estradiol by diet. 
There were no significant effects of diet on histopathology 
or bone density. 
I3C supplementation for 12 months significantly increased 
total hepatic CYP content in males and females (p <0.05).  
Hepatic CYP1A1 and 1A2 were significantly increased in 
males fed I3C (82-fold, p <0.001) or the high-dose of DIM 
(16-fold, p = 0.032).  DIM and I3C also significantly 
increased hepatic CYP1A1/1A2 in female rats (no p values 
given).  Colon CYP1A1 was increased in both male and 
female rats fed I3C or DIM (no p values given).   In female 
rats fed I3C or DIM, colon CYP3A2 was increased, while 
only I3C up-regulated CYP3A2 in male rats (no p values 
given).   
Increase in liver 
mass corresponds 
to increased 
concentrations of 
CYP. 
Chang et 
al.[184] 
Male C57BL/6 mice, 
n=18 
12 w: 
• Control diet 
• High-fat diet 
Adipose tissue 
macrophage 
infiltration via 
immunohistochemistry 
Nitrite production, IL-
High-fat diet significantly increased macrophage 
infiltration compared to the control diet (p = 0.001), while 
the high-fat diet + I3C significantly decreased macrophage 
infiltration compared to the high-fat diet (p = 0.004). 
Treatment of co-cultured cells with at least 10 µM I3C 
No direct 
measurement of 
cancer 
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Reference Study Design 
Outcome 
Measurement(s) Results Notes 
(>55% kcal) 
• High-fat diet + 
I3C (5 mg/kg 
body weight, 3 
times weekly, i.p. 
3T3-L1 preadipocytes 
and primary 
adipocytes harvested 
from experimental 
mouse epididymal 
adipose tissue 
• With or without 
RAW 264.7 
macrophage co-
culture (106 cells) 
for 24 h 
• 0-100 µM I3C for 
24 h 
6 concentration, gene 
expression, and 
adipocyte 
differentiation in 
primary adipocytes 
from epididymal 
adipose tissue with or 
without macrophage 
co-culture 
significantly decreased nitrate production (p for trend 
<0.001), iNOS expression (p for trend = 0.001), and IL-6 
levels in adipocytes in a dose-dependent manner (p <0.05). 
Treatment of co-cultured cells with any amount of I3C 
significantly increased PPAR! expression (p <0.001). 
Treatment of preadipocytes with at least 10 µM I3C 
significantly decreased triglyceride accumulation (p 
<0.05). 
Krajka-
Kuzniak et 
al.[185] 
Male Wistar rats, 
n=121, n=6 per group: 
• Water, 20% 
ethanol:olive oil, 
or olive oil as 
control 
• Cabbage and 
sauerkraut juices 
(1.25 ml/kg body 
weight) for 4, 10, 
or 30 d 
• I3C (100 mg/kg 
body weight) for 
4, 10, or 30 d 
• PEITC (100 
Liver and kidney 
cytosolic NQO1 and 
GST activities via 
substrate 
concentrations 
Liver and kidney GST, 
NQO1, and Nrf2 
protein levels via 
SDS-PAGE 
 
Raw cabbage juice and sauerkraut juice for 4 d 
significantly increased kidney GST activity (p <0.05).  
Raw cabbage juice and sauerkraut juice for 10 d 
significantly increased kidney NQO1 activity (p <0.05). 
I3C significantly increased kidney NQO1 activities at all 
time points (p <0.05) but did not significantly affect GST 
activity. 
PEITC significantly increased kidney GST activity at 4 and 
10 d and significantly increased NQO1 activity at all time 
points (p <0.05). 
Raw cabbage juice for 10 d or sauerkraut juice for 30 d 
significantly increased liver GST ! and µ expression 
compared to control treatment (p <0.05).  Raw cabbage 
juice for 30 d and sauerkraut juice for 4 d significantly 
increased liver GST µ and NQO1 expression, respectively 
(p <0.05). 
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Reference Study Design 
Outcome 
Measurement(s) Results Notes 
mg/kg body 
weight) for 4, 10 
or 30 d 
I3C for 4 d, 10 d, and 30 d significantly increased liver 
GST µ and NQO1 expression (p <0.05).  I3C for 10 and 30 
d also significantly increased liver GST ! expression (p 
<0.05).  Similar results were seen with PEITC. 
Raw cabbage juice and sauerkraut juice for 30 d 
significantly decreased kidney GST " (p <0.05). 
Raw cabbage juice for 30 d significantly increased liver 
nuclear Nrf2 (p <0.05).  I3C and PEITC significantly 
increased nuclear Nrf2 at all time points (p <0.05). 
Qian et 
al.[186] 
Female A/J mice, 
n=100 
Through week 27 
(post-initiation): 
• NNK (4 doses of 
50 mg/kg twice 
weekly for first 5 
weeks prior to I3C 
treatment) with or 
without 10 µmol/g 
diet I3C 
• Untreated mice as 
controls 
Through week 52 
(progression): 
• NNK (4 doses of 
50 mg/kg twice 
weekly for first 5 
weeks prior to I3C 
treatment) with or 
without 10 µmol/g 
diet I3C 
• Untreated mice as 
controls 
Histopathology of lung 
tissues 
Lung cell proliferation 
via Ki-67 staining 
Apoptotic protein 
expression via kit 
Receptor tyrosine 
kinase/PI3K/Akt 
signaling protein 
expression via 
Western blot 
Mice treated with I3C during post-initiation period had 
51% fewer lung tumors than controls (p <0.0001), while 
I3C treatment during progression did not reduce tumor 
multiplicity. 
I3C treatment during both post-initiation and progression 
significantly increased the proportion of lung tumors fewer 
than 2 mm in diameter and significantly decreased the 
proportion of tumors greater than 2 mm in diameter 
compared to mice treated with NNK alone (p <0.05). 
I3C treatment during post-initiation significantly decreased 
the multiplicity of all histopathological lesions compared 
to NNK-treated controls (p <0.05).  I3C treatment during 
progression significantly increased the proportion of 
hyperplastic foci and adenoma while significantly 
decreasing the proportion of adenoma with dysplasia and 
adenocarcinoma of the lung (p <0.05). 
I3C treatment significantly decreased proliferation in 
hyperplastic foci, adenoma, and adenoma with dysplasia 
histological subtypes of lung cells (p <0.05). 
I3C treatment following NNK treatment decreased p-Akt 
and survivin expression, while increasing PARP-cleavage, 
thereby enhancing apoptosis.  I3C treatment also increased 
p-ERK levels, but it is not known what effect this may 
have on the cell cycle. 
Activation of 9 receptor tyrosine kinases was increased 
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Reference Study Design 
Outcome 
Measurement(s) Results Notes 
with I3C treatment, while activation of 1 was decreased.  
I3C treatment increased the activation of 3 intracellular 
serine/threonine/tyrosine kinases, including p53, while the 
activation 8 of these proteins was decreased.  I3C treatment 
up-regulated pro-apoptotic proteins while down-regulating 
anti-apoptotic proteins. 
Sepkovic et 
al.[187] 
Female K14-HPV16 
human cervical cancer 
mouse model, 
transgenic n=75, wild-
type n=90, all mice 
implanted with E2 
pellets (0.25 mg/90 d 
throughout study) 
• Standard diet 
without or with 
500, 1000, 1500, 
2000, or 2500 
ppm DIM 
Histopathology of 
uterus and cervix 
Urinary DIM 
concentration via GC-
MS 
 
There was a significant increase in cervical intraepithelial 
neoplasia with increasing DIM (p <0.0001) in transgenic 
but not wild-type mice.  1000 ppm DIM was identified as 
the minimum effective dose (p = 0.0123).  No cancers were 
documented at 1000 ppm DIM or higher. 
In both genotypes of mice, there was a significant positive 
increase in urinary DIM with increasing DIM (p <0.05). 
 
 
 
 
Transgenic mice 
are homozygous 
for oncogene 
affected by HPV. 
1000 ppm DIM is 
comparable to 
women taking 200 
or 400 mg I3C 
twice daily for 4 
w. 
Abbreviations: 
AST = aspartate aminotransferase 
ALP = alkaline phosphatase 
CK = creatinine kinase 
PEITC = phenethyl isothiocyanate 
NQO1 = NAD(P)H:quinine oxidoreductase 1 
GST = glutathione S-transferase 
Nrf2 = NF-E2-related transcription factor 
NNK = 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone 
PARP = poly ADP ribose polymerase 
E2 = estradiol 
HPV = human papilloma virus
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 Krajka-Kuzniak et al.[185] compared the effects of cabbage and sauerkraut juices 
versus pure I3C or PEITC on xenobiotic metabolism in male Wistar rats over a four-,  
ten-, or 30-day period.  The authors demonstrated that cabbage and sauerkraut juices as 
well as PEITC significantly increased kidney GST activity (p <0.05), while all treatments 
significantly increased kidney NAD(P)H:quinine oxidoreductase 1 (NQO1) activity and 
liver GST and NQO1 expression (p <0.05).  While both cabbage and sauerkraut juices 
significantly decreased kidney GST ! expression following 30 days of supplementation 
(p <0.05), this did not result in a decrease in overall GST activity, and the researchers cite 
evidence that GST ! may activate halogenated compounds to confer an increased risk of 
kidney cancer; therefore, a decrease in GST ! may be interpreted as chemopreventive.  
Lastly, I3C and PEITC at all time points and cabbage juice following 30 days of exposure 
significantly increased the nuclear translocation of Nrf2 (p <0.05), indicating up-
regulation of phase II metabolism as well as intracellular antioxidant systems. 
 In a mouse model of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-
induced lung cancer, Qian et al.[186] distinguished the chemopreventive effects of I3C 
when administered during the post-initiation versus progression phases of lung cancer.  
Mice that received I3C during the post-initiation period (following five-week NNK 
treatment through week 27 of the experiment) showed a 51% reduction in the number of 
lung tumors compared to control animals not treated with I3C (p <0.0001).  I3C 
treatment during the progression period (from week 27 through 52) did not significantly 
reduce the number of lung tumors compared to controls.  However, I3C treatment during 
either period significantly increased the number of smaller lung tumors (two mm or less 
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in diameter) and significantly decreased the number of larger lung tumors (greater than 
two mm in diameter) compared to control mice treated with NNK alone (p <0.05).  
Histopathological examination of the lung tissues showed that I3C treatment during post-
initiation and progression significantly decreased all histopathological lesions and 
hyperplastic foci and adenoma, respectively, supporting the reduction in lung cancer 
transformation and progression with I3C treatment compared to controls (p <0.05).  
Regarding the mechanisms by which I3C decreases lung cancer severity, the researchers 
reported that I3C treatment significantly decreased lung cell proliferation among the 
histopathological lesions (p <0.05) while an important pro-apoptotic marker (PARP-
cleavage) was up-regulated and two anti-apoptotic markers (p-Akt and survivin 
expression) were down-regulated.  This study was also novel in its use of a proteome 
profiler array to identify the effects of I3C on receptor tyrosine kinases and 
serine/threonine/tyrosine kinases, which are involved in intracellular signal transduction; 
I3C treatment increased the expression of several pro-apoptotic proteins, including p53, 
while down-regulating anti-apoptotic proteins, such as Bcl-2, HIF-1!, and p-"-catenin. 
 In a mouse model of human cervical cancer, Sepkovic et al.[187] examined the 
effects of various concentrations of DIM on cervical histology in female mice 
homozygous or heterozygous for a specific oncogene affected by human papillomavirus-
16 (HPV16), an important risk factor for cervical cancer.  The authors concluded that 
mice homozygous for the oncogene were at a significantly decreased risk for cervical 
intraepithelial neoplasia (CIN, a precancerous lesion) with increasing amounts of DIM (p 
for trend <0.0001) and that the minimum effective dose of DIM was 1000 ppm (p = 
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0.0123), which is equivalent to a human dose of 400-800 mg I3C daily.  No cervical or 
uterine cancers were identified in mice given 1000 ppm DIM or greater.  In mice 
heterozygous for the oncogene, there was no significant effect of DIM in reducing CIN.  
The results from this study suggest that DIM is effective at reducing cervical cancer risk 
in individuals at high risk (homozygotes) while it does not have an appreciable effect on 
cervical histology in low risk individuals (heterozygotes), but confirmation in human 
beings is needed. 
 Finally, Chang et al.[184] reported the effects of a high-fat diet with or without I3C 
on inflammatory markers in adipocytes.  I3C treatment significantly reduced the 
infiltration of macrophages into adipose tissue compared to a high-fat diet without I3C (p 
= 0.004).  In the accompanying cell culture experiments, I3C treatment significantly 
decreased nitrate production (p for trend <0.001), inducible nitric oxide synthase (iNOS) 
expression (p for trend = 0.001), and IL-6 expression dose-dependently (p <0.05).  
Additionally, I3C treatment significantly reduced triglyceride accumulation in 
preadipocytes (p <0.05) and increased PPAR! expression in adipose tissue co-cultured 
with macrophages (p <0.001).  Although this study did not specifically address cancer, 
the effects of I3C in decreasing inflammatory markers and increasing PPAR! expression 
are similar to those of n-3 fatty acids (see Chapter 1), and the relationship between these 
mechanisms and the risk of human cancers warrants further study. 
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Human observational study 
 Table 12 includes the sole observational study conducted on glucobrassicins and 
xenobiotic metabolism with regard to lung cancer risk by Hecht et al.[188].  These 
researchers explored the correlations between self-reported dietary intake of cruciferous 
vegetables, total ITC, and glucobrassicin with urinary 4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanol (NNAL) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-but-1-yl-!-O-D- 
glucosiduronic acid (NNAL-Gluc) excretion among healthy Singapore Chinese smokers.  
Additionally, the levels of glucosinolates in cruciferous vegetables purchased in 
Singapore markets were confirmed with HPLC.  Within these vegetables, glucobrassicins 
were the predominant glucosinolates and were present in especially high proportions in 
 
Table 12.  Summary of observational human study examining indole-3-carbinol, 3,3"-diindolylmethane, 
and cancer. 
Reference Study Design Outcome 
Measurement(s) 
Results 
Hecht et 
al.[188] 
Cross-
sectional 
analysis of 
population-
base 
prospective 
cohort 
Healthy 
smoking men 
and women, 
n=84, 45-74 y 
Baseline diet via 
food-frequency 
questionnaire 
Smoking habits via 
in-person interview 
Glucosinolate 
content of 
cruciferous 
vegetables 
purchased in 
Singapore markets 
via HPLC 
Urinary NNAL 
and NNAL-Gluc 
via GC 
Glucobrassicins were the predominant 
glucosinolates in 7 of 9 vegetables studied, 
representing 91% of glucosinolates in broccoli 
and 93% in cauliflower. 
There were significant correlations between 
number of cigarettes smoked daily and NNAL 
excretion (p !0.01). 
Dietary glucobrassicins, dietary ITC, and total 
cruciferous vegetable intakes were significantly 
correlated with one another (R2"0.88, p <0.0001). 
There was a significant inverse association 
between glucobrassicin intake and free (p = 0.01) 
and total NNAL (p = 0.03).  This association was 
borderline significant with NNAL-Gluc (p = 
0.08). 
Data were not shown for total dietary ITC or 
cruciferous vegetable intake and urinary NNAL 
but stated to be similar to glucobrassicin. 
Abbreviations: 
NNAL = 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol 
NNAL-Gluc = 4-(methylnitrosamino)-1-(3-pyridyl)-1-but-1-yl-!-O-D-glucosiduronic acid 
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broccoli and cauliflower.  These values were used to compute the mean daily 
glucobrassicin intake for each study subject, which demonstrated a significant inverse 
association with urinary free (p = 0.01) and total (p = 0.03) NNAL.  These results 
suggested that dietary glucobrassicin enhances oxidative metabolism of NNK, likely 
through the actions of I3C and/or DIM. 
 However, the almost complete absence of epidemiological studies evaluating I3C, 
DIM, and cancer risk presents several challenges for their establishment as 
chemopreventive compounds.  Unlike cell culture studies on this topic, which are 
abundant, epidemiological studies can provide valuable information as to the potential 
chemopreventive effects of DIM and I3C from typical dietary intakes of cruciferous 
vegetables.  The large sample sizes required for such studies would also reduce inter-
individual variability due to genetic differences and plant composition.  Finally, 
consistency between experimental results and associations measured in free-living 
populations is one of the Bradford-Hill criteria to establish causation, and such evidence 
is necessary to establish specific public health recommendations regarding cruciferous 
vegetable intake and cancer risk[189]. 
 
Human pharmacokinetic studies 
 Given the interest in I3C or DIM therapy as potential chemopreventive agents, two 
human studies have established the pharmacokinetic as well as adverse event profiles of 
these compounds (Table 13).  As part of a randomized placebo-controlled trial[190], 
Sepkovic et al.[191] measured urinary DIM in a subset of women with CIN and 
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Table 13.  Summary of human intervention studies examining indole-3-carbinol and 3,3!-diindolylmethane pharmacokinetics. 
Reference Subjects Intervention Outcome 
Measurement(s) 
Results Notes 
Sepkovic 
et al.[191] 
Female patients 
with CIN II-III, 
n=30 
Man of unknown 
health status 
Pharmacokinetic 
evaluation from 
previous study by 
Bell et al.[190] 
I3C daily for 12 
w: 
• Placebo 
• 200 mg 
• 400 mg 
For urinary 
elimination study, 
one man took 150 
mg DIM twice 
daily, and urine 
was collected over 
18 h. 
Urinary DIM via GC-
MS 
Urinary 2-OHE1 and 
16!-OHE1 
Women treated with either amount of I3C 
showed a significant increase in urinary 2-
OHE1:16!-OHE1 compared to women 
treated with placebo (p <0.03). 
After 4 w of treatment, women receving 
200 mg I3C daily (n=5) had mean urinary 
DIM of 12.1 ± 2.5 µg/mg creatinine and 
women receiving 400 mg I3C (n=5) had 
mean urinary DIM of 15.6 ± 22.2 µg/mg, 
which were not statistically different. 
Half-elimination time of DIM for individual 
was 3.5 h. 
 
Reed et 
al.[192] 
Healthy non-
smoking women, 
n=24, 23-58 y 
Subset of 14 
women at 
increased risk of 
breast cancer 
(high Gail score 
or family 
history) used for 
pharmacokinetic 
study 
For 
pharmacokinetic 
study, blood 
collected at 1, 2, 
4, 8, 12, and 24 h 
following: 
• 400 mg I3C 
• 600 mg I3C 
• 800 mg I3C!
• 1000 mg I3C!
• 1200 mg I3C!
For single-dose 
study, 400 mg I3C 
twice daily for 4 
w. 
 
Adverse events via 
self-report 
Plasma DIM via 
HPLC-MS 
Gastrointestinal distress was the main 
adverse event reported at 800 and 1200 mg 
I3C.  Gastrointestinal symptoms were 
present in 25% of women consuming at 
least 600 mg I3C. 
Additional I3C condensation products 
(indolo-[3,2-b]-carbazole, trimers, and 
hydroxylated DIM were not detected. 
I3C was not detected in plasma samples at 
any time points. 
Change in plasma DIM is not linear 
between 600 and 1000 mg I3C. 
The maximum concentration of DIM is 
achieved between 2 and 3 hours following 
supplementation, while the maximum 
concentration following chronic I3C 
6 subjects had highest 
DIM values in pre-dose 
plasma but values for 4 
subjects dropped below 
detection at 12 h.  This 
may be due to 
improperly timed 
supplementation on the 
part of the subjects. 
I3C may have been 
detected if first blood 
sampling had been <1 
h; the half-life of this 
compound in mice was 
previously shown to be 
0.25 h.  Also, the 
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Reference Subjects Intervention Outcome 
Measurement(s) 
Results Notes 
supplementation occurs at 1.3 h. 
The half-life of DIM was between 2 and 5.7 
h following the individual doses; the half-
life of DIM following chronic I3C 
supplementation was 6 h. 
gastric pH in rodents is 
higher than in humans. 
There was substantial 
variation in plasma 
DIM pharmacokinetics 
between individuals. 
Abbreviations: 
CIN = cervical intraepithelial neoplasia 
2-OHE1 = 2-hydroxyestrone 
16!-OHE1 = 16! –hydroxyestrone 
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concluded that the excretion of DIM was not statistically different between women 
consuming 200 and 400 mg I3C per day for four weeks.  From 200 mg I3C, the mean ± 
standard deviation of urinary DIM was 12.1 ± 2.5 µg/mg creatinine, and from 400 mg 
I3C, the corresponding values were 15.6 ± 22.2 µg/mg creatinine.  Although these values 
were not statistically different, there is substantial variation, particularly within women 
receiving the higher dose of I3C.  This deviation suggests a high degree of inter-
individual variation regarding absorption, metabolism, and excretion of I3C and DIM.  
Nevertheless, the researchers measured urinary excretion of DIM within one man over 18 
hours following a single dose of 150 mg DIM and calculated the half-elimination time (a 
corollary to half-life) as 3.5 hours, indicating relatively rapid excretion of DIM.  An 
important limitation of these experiments was the very small sample sizes (n=5 for each 
I3C treatment and n=1 for the DIM treatment), resulting in large variation and preventing 
the extrapolation of results to other populations.  Another major limitation of this study 
was the use during sample preparation of a deconjugation enzyme derived from Helix 
pomatia, which has been shown to be contaminated with several phytonutrients, 
including DIM (see Appendix). 
 In a slightly larger study, Reed et al.[192] calculated the pharmacokinetics of 
plasma DIM in non-smoking women at an increased risk of breast cancer (n=14) given 
400, 600, 800, 1000, or 1200 mg of I3C at one time or 800 mg I3C daily for four weeks.  
The women also reported any adverse events experienced with taking I3C, of which 
gastrointestinal distress was the most common.  Such symptoms were present in 25% of 
all women taking at least 600 mg I3C.  Blood was first collected at one hour following 
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the final dose of I3C, at which time no plasma I3C was detected.  The researchers also 
did not detect the additional condensation products hydroxylated-DIM, trimers, or ICZ.  
Similar to the results of Sepkovic et al.[191], the peak plasma DIM concentration 
appeared between two and three hours following single I3C supplementation, and the 
half-life of plasma DIM was between two and 5.7 hours.  In the women that chronically 
supplemented with I3C over four weeks, the peak concentration of plasma DIM occurred 
at 1.3 hours, and the half-life of plasma DIM was six hours.  Again, these results 
demonstrate the rapid metabolism of I3C to form DIM, which is excreted with a half-life 
between one and six hours.  An intriguing result from this study showed that the change 
in plasma DIM was not linear between the adminstration of 600 and 1200 mg I3C, while 
the peak concentration of plasma DIM with 1200 mg I3C was not greater than with 1000 
mg I3C.  This information suggests that saturation of one or more steps of I3C absorption 
and metabolism and DIM formation occurs at intakes of I3C between 600 and 800 mg 
per day.  Together with the increased frequency of adverse events at 600 mg or greater 
I3C, this information suggests that doses of I3C in excess of 600 mg may not be well-
tolerated or more effective than lower doses. 
 Although the work by Reed et al.[192] was conducted in a greater number of 
subjects, there was considerable variation in DIM pharmacokinetics between subjects, as 
in the work by Sepkovic et al.[191].  Another troubling observation by Reed et al.[192] 
was the presence of the highest concentration of DIM in the plasma of six of fourteen 
subjects participating in the chronic supplementation study prior to the administration of 
I3C for pharmacokinetic measurements.  This fact was attributed to the non-compliance 
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of the subjects regarding timing of their previous dose of I3C, but this may not fully 
explain the high baseline levels in such a large proportion of subjects.  Although the 
authors did not use the H. pomatia enzyme shown to be contaminated with DIM, there 
may be other sources of contamination throughout their assay, poor specificity of their 
equipment or technique, or additional metabolic characteristics of these subjects for 
which the authors did not account (i.e. genotypes of metabolizing enzymes, variations in 
gastric pH, or the use of medications).  Plasma DIM dropped below the limit of detection 
within twelve hours for most of the subjects, reducing the evidence for contamination.  
Nevertheless, these issues need to be satisfactorily addressed to establish a sensitive and 
specific biomarker of I3C exposure as well as the pharmockinetics of I3C and DIM. 
 
Human intervention studies 
 To date, most human intervention trials of DIM or I3C, as summarized in Table 14, 
have focused on hormone-dependent cancer biomarkers among women.  However, an 
early experiment conducted by Taioli et al.[165] evaluated the response to NNK 
metabolism among healthy female smokers given 400 mg I3C daily.  Compared to 
baseline values, I3C supplementation significantly decreased free (23.4%, p = 0.016) and 
total (10.9%, p = 0.023) NNAL while significantly increasing NNAL-Gluc:NNAL by 
nearly 40% (p = 0.046).  These results implicate I3C—or more likely, DIM—in up- 
regulating CYP1A2 metabolism of NNK via !-hydroxylation rather than reduction to 
NNAL; the relative increase in glucuronidated NNAL also suggests an up-regulation of 
UGT enzymes.  Such changes in these enzyme systems are postulated to reduce the
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Table 14.  Summary of human intervention studies examining indole-3-carbinol, 3,3!-diindolylmethane, and cancer. 
Reference Subjects Intervention 
Outcome 
Measurement(s) Results Notes 
Taioli et 
al.[165] 
Healthy female 
smokers, n=13, 
24-60 y 
400 mg/d I3C for 
5 d 
Urinary NNAL and 
NNAL-Gluc via GC 
Urinary cotinine via 
radioimmunoassay 
Urinary creatinine via 
clinical chemistry kit 
Supplementation with I3C significantly 
decreased urinary free NNAL by 23.4% (p 
= 0.016) and total NNAL by 10.9% (p = 
0.023) compared to baseline.  There was 
also a significant 39.9% increase in 
NNAL-Gluc:NNAL compared to baseline 
(p = 0.046). 
There were no significant changes in 
urinary cotinine. 
These results suggest 
I3C induced CYP1A2 
and possibly UGT, 
which may also have 
been saturated.  In 
contrast, previous 
studies have shown 
that PEITC inhibits 
CYP1A2. 
Bell et 
al.[190] 
Female patients 
with CIN II-III, 
n=30 
I3C daily for 12 
w: 
• Placebo 
• 200 mg 
• 400 mg 
CIN via cervical 
biopsy 
HPV status via PCR 
Urinary 2-OHE1 and 
16!-OHE1 
In women treated with either amount of 
I3C, there were significant reductions in 
CIN progression (200 mg: relative risk 
(RR) = 0.50, 95% CI 0.25—0.99, p = 
0.023; 400mg: RR = 0.55, 95% CI 0.31—
0.99, p = 0.032). 
Urinary 2-OHE1:16!-OHE1 increased in a 
dose-dependent manner but did not reach 
statistical significance. 
 
Sepkovic et 
al.[191] 
Female patients 
with CIN II-III, 
n=30 
 
I3C daily for 12 
w: 
• Placebo 
• 200 mg 
• 400 mg 
Urinary DIM via GC-
MS 
Urinary 2-OHE1 and 
16!-OHE1 
Subgroup of women (n=10) treated with 
either amount of I3C showed a significant 
increase in urinary 2-OHE1:16!-OHE1 
compared to women treated with placebo 
(n=7) (p <0.03). 
 
Dalessandri 
et al.[193] 
Non-smoking, 
postmenopausal 
women in 
Marin County, 
CA diagnosed 
with early-stage 
(0-2) breast 
cancer, n=19, 
55-69 y 
Randomized, 
double-blind 
control trial of: 
• Placebo daily 
for 30 d 
• BioResponse 
DIM 108 
mg/d for 30 d 
Urinary E1, E2, and E3 
concentrations via 
GC-MS 
Urinary 2-OHE1 and 
16!-OHE1 via 
immunoassay 
Urinary cortisol and 
6"-OHC via ELISA 
Urinary DIM via 
DIM supplementation significantly 
increased 2-OHE1 compared to placebo (p 
= 0.02).  2-OHE1:16!-OHE1 increased by 
47% due to DIM supplementation (p = 
0.059). 
There were no significant differences in 
urinary and 16!-OHE1, E1, E2, and E3 in 
DIM vs. control. 
DIM supplementation significantly 
Results adjusted for 
baseline DIM.  DIM 
detected in urine of 
placebo group and at 
baseline possibly due 
to use of contaminated 
enzyme. 
DIM believed to have 
less effect on CYP3A4 
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Reference Subjects Intervention 
Outcome 
Measurement(s) Results Notes 
spectrophotometry increased urinary DIM (p = 0.045) and 
cortisol (p = 0.039) relative to control. 
than I3C, explaining 
non-significant 
reduction in 6!-
OHC:cortisol. 
Increase in cortisol 
suggests DIM may 
stimulate adrenal 
glands. 
Reed et 
al.[194] 
Healthy, non-
smoking 
women women 
at increased risk 
of breast cancer 
(high Gail score 
or family 
history), n=17, 
15-65 y 
Following 4 w 
run-in with 
placebo, all 
subjects 
consumed 400 mg 
I3C daily for 4 w, 
then 800 mg/d for 
4 w. 
Adverse events via 
self-report 
Plasma 2-OHE1, 16!-
OHE1, and 6!-OHC 
via immunoassay 
Serum estradiol, 
progesterone, 
luteinizing hormone, 
follicle-stimulating 
hormone, sex hormone 
binding globulin, 
thyroid-stimulating 
hormone, and insulin-
like growth factor 
binding protein-1 and -
3 
CYP1A2, NAT-2, 
xanthine oxidase, and 
FMO3 activities via 
urinary caffeine 
excretion 
CYP2D6 activity via 
urinary 
dextromethorphan 
excretion 
Lymphocyte cytosolic 
There were no serious adverse events 
reported. 
There were no significant changes in 
serum hormone profiles. 
800 mg I3C treatment significantly 
increased CYP1A2 activity 5-fold 
compared to placebo (p <0.0001). 
Among fast acetylators (determined by 
baseline NAT-2 activity), 800 mg I3C 
treatment significantly decreased NAT-2 
activity by 18% (p  = 0.012).  There was 
no significant change among slow 
acetylators. 
800 mg I3C treatment significantly 
decreased FMO3 activity by 60% 
compared to placebo (p = 0.02). There 
were no significant changes in xanthine 
oxidase, CYP2D6, CYP3A (determined by 
urinary 6!-OHC:cortisol) activities with 
I3C supplementation. 
Both doses of I3C significantly increased 
2-OHE1:16!-OHE1 to the same extent 
relative to control (~66%, p <0.0001). 
800 mg I3C treatment significantly 
increased lymphocytic GST activity by 
69% compared to placebo (p = 0.002).  
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Reference Subjects Intervention 
Outcome 
Measurement(s) Results Notes 
NQO1 and GST 
activities via 
spectrophotmetry 
There were no significant changes in 
NQO1 activity. 
Connor et 
al.[195] 
Healthy 
women, n=33 
200 mg I3C twice 
daily for 8 w 
Urinary 2-OHE1 and 
16!-OHE1 via 
Estramet system 
There were no significant changes in 
urinary estrone ratio among morbidly 
obese women.  There was decreased 
response to I3C with increasing BMI. 
The estrone ratio increased to a greater 
degree (71%) in women with low BMI 
compared to those with high BMI (p = 
0.09). 
16!-OHE1 significantly increased among 
obese women with I3C treatment.  
However, significantly fewer women with 
low BMI showed less of an increase 
compared to women with high BMI (p = 
0.04), and the difference in urinary 16!-
OHE1 was significantly different between 
these two groups (p = 0.04). 
Abstract of pilot study 
Low BMI = healthy or 
overweight 
High BMI = obese or 
morbidly obese 
Hauder et 
al.[196] 
Healthy male 
non-smokers, 
n= 76, 50-82 y 
Subjects 
randomly 
assigned to 
consume daily for 
4 w: 
• 200 g/d 
regular 
blanched 
broccoli 
• 200 g/d 
selenium-
fertilized 
broccoli 
• Placebo 
Serum selenium via 
atomic absorption 
spectroscopy 
Plasma and urine 
glucoraphanin 
(sulforaphane, 
sulforaphane-NAC, -
glutathione, -Cys-Gly, 
and –Cys) and 
glucobrassicin (DIM, 
I3C-acetonitrile, -
aldehyde, -carboxylic 
acid, and ascorbigen) 
metabolites via LC-
MS/MS 
Selenium fertilizer increased total 
glucosinolate content of broccoli by 20%. 
Consumption of selenium-fertilized 
broccoli, which contained 25 times more 
selenium than regular broccoli, 
significantly increased serum selenium 
concentrations compared to regular 
broccoli (p <0.001). 
Regular broccoli consumption significantly 
increaed urinary and plasma SFN-Cys-Gly, 
SFN-Cys, and SFN-NAC compared to 
baseline (p <0.05). 
Selenium-fertilized broccoli consumption 
significantly increased urinary and plasma 
SFN and SFN-NAC, urinary SFN-Cys, and 
Free I3C, I3C-
acetonitrile, and DIM 
were not detected in 
any samples. 
SFN-Cys was present 
in baseline urine 
samples from all 
groups and may be a 
long-lived metabolite 
not completely 
excreted from 1 w of 
abstaining from 
cruciferous vegetables 
prior to study. 
I3C-carboxylic acid 
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Reference Subjects Intervention 
Outcome 
Measurement(s) Results Notes 
capsules plasma SFN-Cys-Gly (p <0.05). 
The placebo supplement significantly 
increased plasma SFN-Cys and decreased 
urinary SFN, SFN-Cys-Gly, and SFN-
NAC (p <0.05). 
Regular broccoli consumption significantly 
increased plasma and urinary ascorbigen, 
plasma I3C-carboxylic acid, and urinary 
13C-aldehyde (p <0.05). 
Selenium-fertilized broccoli consumption 
significantly increased plasma and urinary 
I3C-carboxylic acid and ascorbigen and 
urinary I3C-aldehyde (p <0.05). 
and -aldehyde have 
been shown as 
metabolites of 
tryptophan. 
Abbreviations: 
NNAL = 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol 
NNAL-Gluc = 4-(methylnitrosamino)-1-(3-pyridyl)-1-but-1-yl-!-O-D-glucosiduronic acid 
CIN = cervical intraepithelial neoplasia 
2-OHE1 = 2-hydroxyestrone 
16!-OHE1 = 16! –hydroxyestrone 
6!-OHC = 6!-hydroxycortisol 
NAT-2 = N-acetyltransferase-2 
FMO3 = flavin monooxygenase-3
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exposure of an organism to carcinogens from cigarette smoking, thereby reducing cancer 
risk. 
 Bell et al.[190] conducted a randomized placebo-controlled trial of I3C in 30 
women with stage II or III CIN and concluded that 200 or 400 mg of I3C daily for twelve 
weeks significantly decreased the progression of CIN (200 mg: relative risk (RR) = 0.50, 
95% confidence interval (CI) 0.25—0.99, p = 0.023; 400 mg: RR = 0.55, 95% CI 0.31—
0.99, p = 0.032).  In this analysis, the increase in urinary 2-hydroxyestrone (2-
OHE1):16!-hydroxyestrone (16!-OHE1) with I3C supplementation—considered 
protective against tumor growth—did not reach statistical significance.  However, the 
previously mentioned subset analysis from this trial by Sepkovic et al.[191] concluded 
there was a significant increase in urinary 2-OHE1:16!-OHE1 among ten women taking 
200 or 400 mg I3C daily for twelve weeks compared to women consuming a placebo (p 
<0.03). 
 In a placebo-controlled study of 19 women with early-stage breast cancer, 
Dalessandri et al.[193] evaluated the effects of a DIM supplement (108 mg/d for 30 d) on 
urinary estrogen metabolites.  Among women consuming the DIM supplement, urinary 2-
OHE1 significantly increased compared to among women consuming the placebo (p = 
0.03).  There was also a 47% increase in urinary 2-OHE1:16!-OHE1 among women 
taking DIM (p = 0.059).  However, there were no significant differences in urinary 
concentrations of other estrogen metabolites.  The change in urinary 2-OHE1 suggests 
that DIM up-regulates CYP1A1, while the non-significant decrease in urinary 6"-
hydroxycortisol (6"-OHC):cortisol (p = 0.16) suggests that DIM does not appreciably 
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affect CYP3A4.  The researchers noted that baseline DIM was detected in women in the 
placebo group and adjusted all their results for baseline DIM values; again, this is likely 
due to the use of a contaminated enzyme during sample processing. 
 Reed et al.[194] conducted a similar pilot study among 17 women at increased risk 
of breast cancer to monitor adverse events and effects on serum hormones and xenobiotic 
metabolism activity via plasma concentrations and urinary excretion of metabolites.  
Following a four-week run-in period during which all subjects consumed a placebo, the 
women consumed 400 mg of I3C daily for four weeks followed by 800 mg of I3C daily 
for four weeks.  No serious adverse events were reported, and there were no significant 
changes in the serum hormone profiles.  The highest dose of I3C significantly increased 
CYP1A2 activity by five-fold as measured by caffeine excretion (p <0.0001 versus 
placebo).  The researchers elected to divide the subjects based upon baseline N-
acetyltransferase-2 (NAT-2) activity; among women with high NAT-2 activity, 800 mg 
I3C significantly decreased NAT-2 activity by 18% (p = 0.012).  There was no such 
effect among women with low NAT-2 activity at baseline.  In addition, the highest dose 
of I3C significantly decreased flavin monooxygenase-3 (FMO3) activity by 60% (p = 
0.02), but further research is required to confirm this result.  The investigators also 
measured GST and NQO1 activity in lymphocytes extracted from the subjects and 
concluded that GST significantly increased by 69% with 800 mg I3C compared to 
placebo (p = 0.002).  There were no significant changes in NQO1, xanthine oxidase, 
CYP2D6, or CYP3A activities with I3C supplementation.  Similar to other studies, the 
researchers measured a significant 66% increase in plasma 2-OHE1:16!-OHE1 with 
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either dose of I3C compared to placebo (p <0.0001).  These results provide further 
evidence that I3C and DIM may decrease breast cancer risk by up-regulating CYP1A2 
activity to promote the metabolism of estrogen to 2-OHE1, which is considered less 
tumorigenic than 16!-OHE1.  The effect of I3C on other enzymes such as FMO3 and 
GST require further study but may also reduce exposure to compounds that potentially 
cause or promote cancer. 
 In an abstract for a pilot study, Connor et al.[195] reported the effects of 200 mg 
I3C on urinary 2-OHE1:16!-OHE1 in 33 healthy women of various body sizes.  This ratio 
increased to a greater degree among healthy or overweight women compared to obese or 
morbidly obese women (71%, p = 0.09).  Notably, the concentration of 16!-OHE1 
significantly increased among obese women consuming I3C, but this increase was 
significantly lower among healthy or overweight women (p = 0.04).  The authors noted 
an inverse relationship between the effect of I3C and body weight but did not indicate if 
this was a statistically significant trend.  Nevertheless, these results suggest that the 
ability of DIM or I3C to favorably alter estrogen metabolism is likely influenced by body 
weight, an important consideration for further clinical trials and epidemiological studies. 
 Finally, in a validation study not directly related to cancer, Hauder et al.[196] 
quantified the urinary and plasma metabolites of glucoraphanin and glucobrassicin in 76 
healthy men consuming placebo capsules, 200 g regular blanched broccoli, or 200 g 
selenium-fertilized broccoli daily for four weeks.  The researchers also measured the 
glucosinolate content of the broccoli, which increased by 20% with the selenium-
enriched fertilizer.  As expected, consumption of the selenium-fertilized broccoli 
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significantly increased serum selenium compared to consumption of the regular broccoli 
(p <0.001).  SFN metabolites significantly increased among all groups (including the 
placebo) (p <0.05), suggesting these compounds may be relatively persistent in the body.  
Broccoli consumption also significantly increased ascorbigen (formed from the reaction 
of I3C with ascorbic acid), I3CA, and I3A.  Although the LC-MS/MS techniques were 
validated with high sensitivity and specificity, the authors were not able to detect free 
I3C, I3C-acetonitrile, or DIM in any plasma or urine samples.  They suggested that the 
I3C metabolites detected (I3CA and I3A) may have been generated from tryptophan 
metabolism, and the glucobrassicin content of the broccoli remained relatively low (111 
and 107 µg/g fresh weight in regular and selenium-fertilized, respectively), which may 
partially explain their null results.  Additionally, urine samples were collected one day 
after discontinuing the broccoli treatment; given the very short half-life of DIM (less than 
six hours), it is not surprising that these investigators were not able to detect urinary DIM 
from the broccoli consumption 24 hours prior. 
 While several human intervention studies have shown an improvement in estrogen 
metabolism with DIM or I3C supplementation, more research into this field is required.  
Only one study reviewed concluded that I3C reduced the progression of cervical 
neoplasia; quantification of sensitive and specific cancer-related endpoints in large 
numbers of subjects would provide valuable evidence for I3C and DIM as 
chemopreventive agents.  Studies exploring additional cancer sites, especially lung and 
prostate cancer, are also needed to confirm the results from in vitro and in animal studies.  
However, this field remains in relative infancy—especially in the absence of a sensitive 
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and specific biomarker of I3C exposure—and a search of the National Institutes of Health 
clinical trials registry show a total of eleven studies of I3C or DIM and prostate, breast, 
cervical, or all cancers either completed or currently recruiting subjects. 
 
Conclusions 
 The studies reviewed above establish I3C and—more promisingly—DIM as 
potentially effective chemopreventive and chemotherapeutic agents.  In vitro experiments 
demonstrated that these compounds can trigger cancer cell cycle arrest and apoptosis by 
altering gene transcription.  Animal models confirmed these effects in the reduction of 
lung tumor size and multiplicity and cervical neoplasia in the presence of HPV16 as well 
as up-regulation of phase I and II xenobiotic metabolism enzymes.  The prospective 
cohort study suggested that I3C exposure favorably altered metabolism of a tobacco-
specific carcinogen to potentially reduce the risk of tobacco-related cancers.  Finally, the 
clinical trials conducted to date have shown that DIM or I3C supplementation 
beneficially altered estrogen metabolism to possibly reduce the risk of estrogen-
associated cancers.  These data also proved that DIM and I3C up-regulate phase I and II 
metabolism in healthy adults, which may reduce the risk of multiple cancers. 
 However, a significant limitation of the research regarding I3C exposure and cancer 
risk is the lack of observational data in human populations.  I3C cannot typically be 
detected in tissues, and its most prevalent metabolite, DIM, has a relatively short half-life 
of less than six hours.  This creates a challenging scenario for objective assessment of 
I3C exposure in free-living populations.  The development of a highly sensitive, accurate, 
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and reliable biomarker of I3C exposure is the first step to accurately characterize the 
relationship between I3C and cancer risk in healthy populations.  Ideally, this biomarker 
could be broadly applied and measured over time in free-living populations to fully 
ascertain the protection imparted by I3C or DIM against human cancers. 
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Chapter IV: Validation of an assay for the measurement of 3,3'-
diindolylmethane as a marker for indole-3-carbinol exposure in free-
living subjects  
   134 
Introduction 
 Consumption of cruciferous vegetables in the genus Brassica, including broccoli, 
cabbage, cauliflower, and Brussels sprouts, has been inversely associated with the risk of 
several human cancers including lung and colorectal cancers[156, 159].  Glucobrassicin, 
a glucosinolate found in Brassica vegetables, undergoes hydrolysis in the presence of 
myrosinase to form indole-3-carbinol (I3C), which has demonstrated chemopreventive 
properties in vivo but is relatively short-lived in humans[155, 186, 192, 197-199].  At 
gastric pH, I3C oligomerizes to produce several metabolites, the most prevalent of which 
is 3,3'-diindolylmethane (DIM)[191, 192, 194].  Although urinary DIM has been 
measured in individuals participating in clinical trials of DIM and/or I3C 
supplementation, an accurate and reliable technique for the quantification of DIM as an 
objective marker of glucobrassicin intake in large observational studies is lacking[191, 
193].  The objective of these experiments was to validate a sensitive technique to 
quantify urinary DIM using HPLC and mass spectrometry (MS). 
 
Materials and Methods 
Chemicals 
All chemicals were HPLC, LC-MS, or Optima grade.  DIM was purchased from 
LKT Labs (Saint Paul, MN).  Indole, 4-methoxy indole, ammonium acetate, and t-butyl 
methyl ether were obtained from Sigma-Aldrich (St. Louis, MO).  d2-formaldehyde 
(isotopic purity 98%) was obtained from Cambridge Isotope Laboratories, Inc. (Andover, 
MA).  14C-formaldehyde was obtained from Moravek Biochemicals (Brea, CA).  
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Methanol, chloroform, hexane and acetonitrile were obtained from Fisher Scientific 
(Pittsburgh, PA).  !-Glucuronidase/arylsulfatase from Helix pomatia (cat. no. 
10127698001) was purchased from Roche (Penzberg, Germany).  !-Glucuronidase 
preparations from Escherichia coli (G8295) were purchased from Sigma-Aldrich (St. 
Louis, MO).  Dulbecco’s phosphate buffered saline 1X was purchased from Gibco by 
Life Technologies (Grand Island, NY). D2-DIM and 14C-DIM were synthesized as 
previously described[200]. 
 
Experiment 1: Comparison of solid-phase and liquid-liquid extractions 
Control urine samples following abstinence from cruciferous vegetable intake 
were spiked with 0, 1.01, 2.02, 4.05, or 16.2 pmol DIM/mL, and all samples were 
analyzed in duplicate.  Five replicates with 2.02 pmol DIM were included in each 
technique to analyze accuracy and precision.  A flow-chart of the experimental design is 
shown in Figure 21.  A 1 mL urine sample was placed in a 4 mL silanized vial (Chrom 
Tech, Apple Valley, MN) and 80.3 pmol each of d2-DIM and 4-methoxy indole were 
added as internal standards. The pH was adjusted to 5 with the addition of 150 µL of 
2.5M NaOAC (pH 5.8). 20 µL of !-glucuronidase/arylsulfatase (2000 units) were added 
to half of the samples, and the mixtures were incubated for 24 h at 37 0C. The samples 
were loaded on Strata-X-SPE cartridges (33µm polymeric reverse phase 200 mg/6 mL, 
Phenomenex, Torrance, CA) that were previously equilibrated using 6 mL of methanol 
followed by 6 mL of water. The cartridges were sequentially eluted with 3 mL of water, 3 
mL of 10% methanol:water, and 3 mL of 30% which was collected in a 4 mL silanized 
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vial and dried under reduced pressure using a centrifugal vacuum evaporator (Savant 
SpeedVac) or via N2 gas at ambient temperature. The residue was then transferred with 
100 µL 30% chloroform:acetonitrile to a silanized autosampler GC vial with an infused 
300 µL insert and dried again under vacuum.  The final sample volumes were made up to 
100 µL with 30% acetonitrile:10 mM ammonium acetate. 
 
 
Figure 21.  Design for validation Experiment 1.
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 Alternatively, each 1 mL sample with internal standards and sodium acetate were 
treated with or without 2000 U !-glucuronidase/arylsulfatase followed by liquid-liquid 
extraction with an equal volume of t-butyl methyl ether twice[196].  The pooled extracts 
were dried under vacuum or N2 gas and transferred to 300 µL GC vials as above.  The 
final sample volumes were made up to 20 µL (vacuum evaporation) or 100 µL (N2 
evaporation) with 30% acetonitrile:10 mM ammonium acetate.  Three replicates of 
control urine with 20 µL of 14C-DIM were prepared with or without 2000 U !-
glucuronidase/arylsulfatase and liquid-liquid extraction with vacuum or N2 evaporation 
or solid-phase extraction with vacuum evaporation and analyzed for 14C recovery via 
scintillation counting (Beckman Coulter LS6500 Scintillation Counter, Brea, CA). 
 
Experiment 2: Validation of liquid-liquid extraction technique with physiological 
concentrations of DIM 
This experiment utilized the liquid-liquid extraction followed by centrifugal 
vacuum evaporation outlined in Experiment 1; however, 20 pmol d2-DIM were used as 
an internal standard rather than 80.3 pmol.  Control urine samples (in duplicate) were 
spiked with 0, 2.5, 5.1, 10.1, 20.2, or 40.5 pmol DIM.  No !-glucuronidase/arylsulfatase 
was used in the control urine samples. 
 To assess the technique in urine samples from subjects consuming cruciferous 
vegetables, 0.5 mL urine from 24-hour urine collection samples from three individuals 
consuming 50 g Brussels sprouts were analyzed in duplicate, with or without the addition 
of 1000 U ! -glucuronidase/arylsulfatase and sodium acetate.  The samples were prepared 
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identically to the control urine specimens.  Additionally, five replicates of control urine 
spiked with 5.1 pmol DIM without !-glucuronidase/arylsulfatase treatment were analyzed 
for accuracy and precision using the liquid-liquid extraction and vacuum evaporation 
method with 20 pmol internal standard. 
 
Experiment 3: Assessment of inter-day reproducibility and reduced internal standard 
concentration 
The same technique as above was used with 10 pmol d2-DIM rather than 20 pmol 
as an internal standard.  Spot urine samples from ten subjects abstaining from cruciferous 
vegetables for five days and 24-hour urine samples from the same subjects after 
consuming 50 g Brussels sprouts were analyzed in duplicate with the addition of 2000 U 
!-glucuronidase/arylsulfatase, and analyses of five subjects were repeated on three days 
for the spot urines and two days for the Brussels sprouts urines to assess inter-day 
reliability of the technique.  Five samples of each spot and Brussels sprouts urine were 
repeated over two days using a supported liquid-liquid extraction via 3 mL ChemElut 
cartridges (Agilent Technologies, Santa Clara, CA) eluted with hexane followed by t-
butyl methyl ether.  Finally, five Brussels sprouts urine samples were treated with 6000 U 
!-glucuronidase/arylsulfatase to compare quantification of DIM versus 2000 U !-
glucuronidase/arylsulfatase. 
 A water blank treated with internal standard and !-glucuronidase/arylsulfatase 
was included with each day of assays, and upon observing DIM detected in these water 
blanks, four water blanks with 1000 U, 2000 U, 4000 U, or 6000 U !-
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glucuronidase/arylsulfatase were analyzed for DIM contamination. 
 
Experiment 4: Evaluate contamination of H. pomatia !-glucuronidase/arylsulfatase with 
DIM 
One mL HPLC-grade water was treated in duplicate with 2000 U H. pomatia !-
glucuronidase/arylsulfatase from two lots, 2000 U E. coli !-glucuronidase, or no enzyme 
were prepared as in Experiment 2.  Additionally, 1 mL of water treated with Roche !-
glucuronidase or E. coli !-glucuronidase/arylsulfatase was analyzed with or without the 
addition of d2-DIM as an internal standard, and 1 mL of water without enzyme treatment 
was analyzed with the addition of 5 or 10 pmol d2-DIM to quantify the contribution of 
DIM from the internal standard. 
 
Experiment 5: Compare !-glucuronidase from H. pomatia and E. coli to no enzyme 
treatment for DIM quantification and reliability 
This experiment compared the use of 2000 U semi-purified !-
glucuronidase/arylsulfatase from H. pomatia to 2000 U E. coli !-glucuronidase or no 
enzyme treatment in two individuals abstaining from cruciferous vegetables (spot urine 
samples) or following the consumption of 50 g Brussels sprouts (24-hour urine samples).  
Water blanks were included with each method, and control 24-hour urine samples from 
an individual abstaining from cruciferous vegetables for seven days and the same 
individual following the consumption of 200 g Brussels sprouts were included as 
negative and positive controls, respectively.  As in Experiment 3, baseline urine samples 
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were analyzed in duplicate on three days, and Brussels sprouts urine samples were 
analyzed in duplicate on two days (except for the positive control urines, which were 
analyzed on three days) to ascertain inter-day reproducibility of the technique.  The only 
modification to the liquid-liquid extraction technique described above was the use of 5 
pmol d2-DIM as an internal standard rather than 10 pmol to minimize the contribution of 
unlabeled DIM from the internal standard. 
 
Experiment 6: Validate final technique for urinary DIM quantification 
Positive and negative control urine samples (1 mL) were treated with 2000 U E. 
coli !-glucuronidase and 5 pmol d2-DIM and prepared as described previously.  Five 
replicates of each sample were analyzed on two days to assess accuracy, reliability, and 
inter-day reproducibility of the technique.  To validate the method in a range of 
physiological DIM concentrations, negative urine samples containing 20%, 40%, 60%, or 
80% positive control urine were analyzed in duplicate.  Finally, 1.25, 2.55, 5.05, 10.1, 
20.25, or 30.35 pmol DIM were added to negative control urines, which were analyzed to 
further validate the final method. 
 
Quantitation of Urinary DIM by Capillary LC/ESI-MS/MS-SRM 
The analyses were carried out by capillary liquid chromatography-electrospray 
ionization-tandem mass spectrometry-selected reaction monitoring (LC-ESI-MS/MS-
SRM) on a TSQ Quantum Discovery Max instrument (Thermo Fisher Scientific, 
Waltham, MA) in the positive ion mode with N2 as the nebulizing and drying gas. MS 
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parameters were set as follows: spray voltage, 3.2 kV; sheath gas pressure, 25 (arbitrary 
units); capillary temperature, 250 °C; collision energy, 17 V; scan width, 0.05 amu; Q2 
gas pressure 1.0 mTorr; source CID 9 V; and tube lens offset, 104 V. MS data were 
acquired and processed by Xcalibur software version 1.4 (Thermo Electron, Waltham, 
MA).  Eight microliters of the sample were injected from an autosampler into an Agilent 
1100 capillary HPLC system (Agilent Technologies, Palo Alto, CA) equipped with a 
5µm, 150 x 0.5 mm ZorbaxSB-C18 column (Agilent Technologies, Santa Clara, CA) 
eluted at 15 µl/min for the first 3 min then 10 µl/min with a gradient from 60% methanol 
in 15 mM ammonium acetate to 100% methanol in 8 min and held for additional 29 min.  
The mass transitions (parent to daughter) monitored were m/z 247!130 for DIM 
(retention time averaged 16.6 min) and m/z 249!132 for d2-DIM (retention time 
averaged 16.5 min) as an internal standard.  Quantitation was accomplished by 
comparing the MS peak area ratio of DIM to that of the deuterated standard with a 
calibration curve of the concentration of DIM versus the MS peak area ratio 
(DIM:internal standard).  The assay limit of quantitation (LOQ) was 132 fmol. 
 
Statistics 
All statistics were computed with SAS v9.2 (SAS Institute, Inc., Cary, NC).  
Comparisons of urinary DIM before and after exposure to cruciferous vegetables and by 
technique were evaluated with paired t-tests for lognormal distributions.  The change in 
DIM concentration with increasing amounts of Roche H. pomatia !-
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glucuronidase/arylsulfatase was evaluated with linear regression.  The level of 
significance was ! <0.05. 
 
Results 
Experiment 1: Comparison of solid-phase and liquid-liquid extractions 
 Table 15 summarizes the results of the experiment comparing the previous solid-
phase extraction and centrifugal vacuum evaporation technique to the t-butyl methyl 
ether extraction and N2 evaporation technique for urinary DIM quantification.  Overall 
recoveries of both internal standards (d2-DIM and 4-methoxy indole) were low, averaging 
5.68% and 1.26%, respectively.  The t-butyl methyl ether extraction method improved 
recovery of both internal standards.  Given the low recovery and poor accuracy and 
reliability of 4-methoxy indole as an internal standard, d2-DIM was preferable as an 
internal standard and was used in all following methods. 
 Although the calibration curves shown in Figure 22 show the solid-phase extraction 
technique to be more accurate than the t-butyl methyl ether extraction technique 
according to R2 values, the t-butyl methyl ether extraction coupled to evaporation via 
centrifugal evaporation showed the highest rates of d2-DIM recovery (Table 16).  From 
the additional precision and accuracy analyses shown in Table 17, the t-butyl methyl 
ether extraction technique with !-glucuronidase/arylsulfatase treatment had the best 
accuracy and reliability of the four techniques assessed.  Finally, the 14C recovery 
experiment demonstrated the best recovery of DIM with t-butyl methyl ether extraction 
followed by centrifugal vacuum evaporation (Table 18).
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Table 15.  Summary of Experiment 1 comparing solid-phase and liquid-liquid extraction techniques for urinary DIM quantification. 
Sample preparation technique 
Solid-phase extraction and centrifugal vacuum 
evaporation Liquid-liquid extraction and N2 evaporation 
Enzyme 
treatment Sample* 
DIM 
added 
(pmol) 
d2-DIM as internal 
standard 
4-methoxy indole as 
internal standard 
d2-DIM as internal 
standard 
4-methoxy indole as internal 
standard 
% 
recovery 
DIM 
(pmol/mL 
urine or 
water ±  SE) 
% 
recovery 
DIM 
(pmol/mL 
urine or 
water ±  SE) 
% 
recovery 
DIM 
(pmol/mL 
urine or 
water ±  SE) 
% 
recovery 
DIM (pmol/mL 
urine or water±  
SE) 
(-
) !
-
gl
uc
ur
on
id
as
e/
ar
yl
su
lfa
ta
se
 
Water 0 7.02% <LOQ 5.16% 0.22 ± 0.15 22.65% 0.13 ± 0.06 2.34% 31.60 ± 25.42 
Control urine 0 2.18% 1.33 ± 0.03 0.36% 14.06 ± 2.36 9.19% <LOQ 7.94% 0.40 ± 0.33 
Control urine 1 3.86% 1.55 ± 0.31 0.52% 18.45 ± 2.44 1.56% 1.94 ± 1.87 0.39% 44.73 ± 44.66 
Control urine 2 3.91% 2.82 ± 0.77 0.39% 42.41 ± 7.49 6.00% 1.00 ± 0.93 0.47% 86.81 ± 86.74 
Control urine 4 3.57% 2.99 ± 0.14 0.56% 38.99 ± 21.20 2.50% 1.21 ± 1.14 0.31% 59.64 ± 59.57 
Control urine 16.2 3.32% 10.73 ± 1.15 0.30% 178.42 ± 16.48 9.58% 5.69 ± 0.76 0.31% 731.75 ± 164.79 
(+
) !
-
gl
uc
ur
on
id
as
e/
ar
yl
su
lfa
ta
se
 
Water 0 10.84% <LOQ 8.95% 0.53 ± 0.25 13.16% 0.96 ± 0.48 4.59% 101.71 ± 98.03 
Control urine 0 0.80% <LOQ 0.21% <LOQ 6.54% 2.19 ± 0.07 1.09% 89.56 ± 54.28 
Control urine 1 1.00% 0.72 ± 0.65 0.18% 6.00 ± 5.93 5.37% 4.71 ± 0.69 0.47% 68.53 ± 9.40 
Control urine 2 1.17% <LOQ 0.16% <LOQ 5.61% 4.33 ± 0.55 0.78% 65.11 ± 31.70 
Control urine 4 1.14% 2.16 ± 2.09 0.19% 18.60 ± 18.53 5.76% 5.57 ± 0.05 0.39% 110.25 ± 1.24 
Control urine 16.2 0.67% 7.74 ± 0.83 0.24% 49.58 ± 9.79 4.91% 9.55 ± 0.53 0.31% 193.26 ± 2.52 
*Average of 2 replicates 
DIM concentrations <LOQ (132 fmol) were computed as 50% LOQ (0.07 pmol/mL) 
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Table 16.  Results from liquid-liquid extraction with centrifugal vacuum evaporation. 
 
d2-DIM as internal standard 4-methoxy indole as internal standard 
Enzyme treatment Sample* 
DIM 
added 
(pmol) % recovery 
DIM (pmol/mL urine or water ±  
SE) % recovery 
DIM (pmol/mL urine or water ±  
SE) 
(-) !-glucuronidase/ 
arylsulfatase 
Control urine 0 33.63% 0.34 ± 0.27 1.01% 67.31 ± 44.79 
(+) !-
glucuronidase/ 
arylsulfatase 
Control urine 0 11.60% 3.74 ± 0.08 1.01% 166.92 ± 8.47 
*Average of 2 replicates 
DIM concentrations <LOQ (132 fmol) were computed as 50% LOQ (0.07 pmol/mL) 
 
Table 17.  Results from Experiment 1 accuracy and precision analyses. 
Enzyme treatment Sample* 
DIM added 
(pmol) 
Solid-phase extraction and centrifugal vacuum 
evaporation 
Liquid-liquid extraction and N2 
evaporation 
% recovery 
d2-DIM 
DIM (pmol/mL, 
mean ±  SE) %CV 
% recovery 
d2-DIM 
DIM (pmol/mL, 
mean ±  SE) %CV 
(-) !-glucuronidase/ 
arylsulfatase 
Control urine 2 2.58% 1.15 ± 0.61 117.80% 4.79% 1.03 ± 0.26 56.84% 
(+) !-glucuronidase/ 
arylsulfatase 
Control urine 2 0.58% 1.06 ± 0.99 208.85 % 5.48% 2.46 ± 1.10 17.80% 
*Average of 5 replicates 
DIM concentrations <LOQ (132 fmol) were computed as 50% LOQ (0.07 pmol/mL) 
 
Table 18.  Summary of DIM recovery by preparation technique, evaporation method, and enzyme treatment computed via 14C recovery. 
Sample preparation technique Solid-phase extraction Liquid-liquid extraction 
Evaporation method Centrifugal vacuum evaporation N2 evaporation Centrifugal vacuum evaporation 
(-) !-glucuronidase/ 
arylsulfatasea 
-- 61% 69% 
(+) !-glucuronidase/ 
arylsulfataseb 
21% 21% 23% 
aAverage of 3 replicates 
bRepresents 1 sample, 2 replicates excluded due to contamination 
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a.  
b.  
Figure 22.  Calibration curves from Experiment 1.   
(a) Without !-glucuronidase/arylsulfatase; (b) with !-glucuronidase/arylsulfatase. 
! Solid-phase extraction; " t-butyl methyl ether extraction. 
!!Trendline for solid-phase extraction; " ! "trendline for t-butyl methyl ether extraction. 
y = 0.681x
R2 = 0.9085
y = 0.3563x
R2 = 0.6813
0.0000
2.0000
4.0000
6.0000
8.0000
10.0000
12.0000
14.0000
0 2 4 6 8 10 12 14 16 18
DIM added (pmol/mL urine)
DI
M
 m
ea
su
re
d 
(p
m
ol
/m
L 
ur
in
e)
y = 0.4757x
R2 = 0.8744
y = 0.6715x
R2 = 0.214
0.0000
2.0000
4.0000
6.0000
8.0000
10.0000
12.0000
0 2 4 6 8 10 12 14 16 18
DIM added (pmol/mL urine)
DI
M
 m
ea
su
re
d 
(p
m
ol
/m
L 
ur
in
e)
   146 
Experiment 2: Validation of liquid-liquid extraction technique with physiological 
concentrations of DIM 
 Given the results of the 14C recovery experiment, this calibration experiment did 
not utilize deconjugation enzyme treatment with !-glucuronidase/arylsulfatase.  The 
results presented in Table 19 and Figure 23 demonstrate the improved accuracy (R2 = 
0.999) and reliability (average % coefficient of variation (%CV) = 1.85%) of this 
technique over the ranges of spiked DIM concentrations (0—40.5 pmol/mL).  These 
results are further borne out by the accuracy and precision analyses conducted with 5.1 
pmol DIM (Table 20); the measured DIM concentration of 5.06 ± 0.09 pmol/mL did not 
differ from 5.1 pmol/mL, and %CV was 3.5% for the four duplicates. 
 The results of the technique with or without !-glucuronidase/arylsulfatase treatment 
in the urine of three individuals consuming cruciferous vegetables are shown in Table 21.  
Although the overall recovery of d2-DIM is improved in the absence of !-
glucuronidase/arylsulfatase (65.7% vs. 18.2% with !-glucuronidase/arylsulfatase), the 
overall DIM concentrations were increased with the addition of the deconjugation 
enzyme treatment.  When urines were treated with !-glucuronidase/arylsulfatase, the 
average urinary DIM following cruciferous vegetable intake was 29.25 ± 12.68 compared 
to 1.25 ± 0.26 pmol/mL without any enzyme treatment, which was borderline statistically 
significant (p = 0.06), likely due to the small sample size (n=3) and wide variability.  This 
difference suggests that DIM is indeed excreted as a glucuronide and/or sulfonate, and 
that deconjugation enzyme treatment yields higher levels of urinary DIM than no 
treatment.
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Table 19.  Summary of Experiment 2 validating DIM quantification in urine spiked with 0—40.5 pmol DIM 
Sample* DIM added (pmol) % recovery d2-DIM DIM (pmol/mL, mean ±  SE) %CV 
Water 0 71.9% 0.18 n/a 
Control urine 0 8.1% 0.08 ± 0.01 0.01% 
Control urine 5.1 52.9% 5.37 ± 0.05 1.41% 
Control urine 10.1 48.3% 9.77 ± 0.17 2.50% 
Control urine 20.2 53.8% 19.93 ± 0.37 2.60% 
Control urine 40.5 51.4% 40.68 ± 0.79 2.75% 
*Average of 2 replicates, except water 
Samples were not treated with any enzymes. 
DIM concentrations <LOQ (132 fmol) were computed as 50% LOQ (0.07 pmol/mL) 
 
Table 20.  Results from Experiment 2 accuracy and precision analyses. 
Sample* DIM added (pmol) % recovery d2-DIM DIM (pmol/mL, mean ±  SE) %CV 
Control urine 5.1 47.91% 5.06 ± 0.09 3.50% 
*Average of 4 duplicates 
Samples were not treated with any enzymes. 
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Figure 23.  Calibration curve from Experiment 2 t-butyl methyl ether extraction without !-
glucuronidase/arylsulfatase. 
" t-butyl methyl ether extraction. 
! " !Trendline for t-butyl methyl ether extraction. 
 
 
Table 21.  Summary of urinary DIM concentrations after consuming cruciferous vegetables with or without 
!-glucuronidase/arylsulfatase treatment. 
Enzyme 
treatment (-) !-glucuronidase/arylsulfatase (+) !-glucuronidase/arylsulfatase 
Subject* 
% recovery 
d2-DIM 
DIM 
(pmol/mL, 
mean ±  SE) %CV 
% recovery 
d2-DIM 
DIM 
(pmol/mL, 
mean ±  SE) %CV 
A 56.4% 1.30 ± 0.02 2.37% 3.9% 66.14 ± 15.36 32.85% 
B 68.7% 0.53 ± 0.24 64.90% 23.9% 2.64 ± 0.18 9.49% 
C 72.1% 1.91 ± 0.06 4.25% 26.8% 18.98 ± 1.68 12.56 
*Average of 2 replicates 
DIM concentrations <LOQ (132 fmol) were computed as 50% LOQ (0.07 pmol/mL) 
p = 0.06 for urinary DIM in cruciferous vegetable versus baseline
y = x
R2 = 0.9989
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Experiment 3: Assessment of inter-day reproducibility and reduced internal standard 
concentration 
 The results of quantification of DIM via !-glucuronidase/arylsulfatase treatment, t-
butyl methyl ether extraction, and centrifugal vacuum evaporation in ten individuals 
abstaining from or consuming cruciferous vegetables are shown in Table 22.  Intake of 
cruciferous vegetables significantly increased urinary DIM concentrations (p <0.05), as 
expected.  However, in five subjects whose samples were analyzed on three separate 
days, the variability of urinary DIM measured was quite high, particularly in the baseline 
urine samples (average %CV 129.70%).  The use of supported liquid-liquid extraction by 
ChemElut cartridges reduced the variability of the baseline analyses somewhat to an 
average %CV of 75.40% but substantially increased the variability of the cruciferous 
vegetable urinary DIM concentrations to a %CV of 52.40% (Table 23).  Because the goal 
of these experiments was to validate the urinary DIM technique as a biomarker of 
cruciferous vegetable intake rather than avoidance, this increase in variability was 
deemed unacceptable, and supported liquid-liquid extraction was not included in further 
experiments. 
 Revisiting Table 22, the addition of 6000 U rather than 2000 U !-
glucuronidase/arylsulfatase did not triple the yield as might be expected but rather 
increased urinary DIM more than 30-fold.  This result in addition to detectable levels of 
DIM in water blanks from each of the three days of the experiment (Table 24) led us to 
question if contamination had been introduced into the samples by the !-
glucuronidase/arylsulfatase preparation.  Indeed, the treatment of water with increasing 
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Table 22.  Summary of Experiment 3 results. 
 
Subject 
Baseline Urinary DIM (pmol/mL urine)  Cruciferous Vegetable Urinary DIM (pmol/mL urine)* 
Assay Day 
Mean ±  SE %CV 
 Assay Day 
Mean ±  SE %CV 
6000 U !-
glucuronidase/arylsulfatase  1 2 3 1 2 
D 2.81 -- -- -- --  7.18 -- -- -- -- 
E 0.15 -- -- -- --  16.92 -- -- -- -- 
F 0.29 -- -- -- --  11.73 -- -- -- -- 
G 0.42 -- -- -- --  13.15 -- -- -- -- 
H 0.14 -- -- -- --  4.55 -- -- -- -- 
I 0.35 2.45 20.79 7.86 ± 6.49 143.02%  5.93 8.03 6.98 ± 1.05 21.28% 365.41 
J 0.57 0.37 7.19 2.71 ± 2.24 143.16%  2.98 6.42 4.70 ± 1.72 51.68% 245.78 
A 0.20 0.45 6.99 2.55 ± 2.22 151.16%  15.92 17.15 16.53 ± 0.62 5.26% 246.36 
L 5.95 17.51 37.21 20.22 ± 9.13 78.17%  17.35 16.15 16.75 ± 0.60 5.04% 371.26 
M 0.73 3.32 21.52 8.52 ± 6.54 132.98%  6.58 6.90 6.74 ± 0.16 3.31% 248.01 
*All subjects consumed 50 g Brussels sprouts for 1 d, except H, who consumed 50 g cabbage. 
p = 0.01 for urinary DIM in cruciferous vegetable versus baseline urine 
 
 
Table 23.  Results for ChemElut comparison. 
 Baseline Urinary DIM (pmol/mL urine)  Cruciferous Vegetable Urinary DIM (pmol/mL urine)* 
Subject 
Assay Day 
Mean ±  SE %CV 
MTBE 
extraction result 
 Assay Day 
Mean ±  SE %CV 
MTBE 
extraction result 1 2 1 2 
D 11.98 1.69 6.84 ± 5.15 106% 2.81  23.04 10.22 16.63 ± 6.41 55% 7.18 
E 0.87 1.70 2.83 ± 0.42 46% 0.15  27.14 11.29 19.22 ± 7.92 58% 16.92 
G 1.97 3.53 2.75 ± 0.78 40% 0.42  15.22 19.84 17.53 ± 2.31 19% 13.15 
I 2.12 5.55 3.83 ± 1.71 63% 7.86 ± 6.49  10.44 12.96 11.70 ± 1.26 15% 6.98 ± 1.05 
M 9.16 0.69 4.92 ± 4.23 122% 8.52 ± 6.54  32.18 3.31 17.74 ± 14.43 115% 6.74 ± 0.16 
*All subjects consumed 50 g Brussels sprouts on each of 2 d. 
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Table 24.  Summary of daily water blanks prepared via liquid-liquid extraction from Experiment 3. 
 DIM (pmol/mL) 
Assay Day 
Mean ±  SE %CV 1 2 3 
Water 0.54 1.77 13.19 5.17 ± 4.03 135% 
 
 
Table 25.  DIM concentrations in water blanks treated with increasing quantities of H. pomatia !-
glucuronidase/arylsulfatase 
Sample !-glucuronidase/arylsulfatase (U) % recovery d2-DIM DIM (pmol/mL) 
Water 1000 100% 2.80 
Water 2000 86% 5.66 
Water 4000 84% 10.51 
Water 6000 74% 16.64 
 
 
 
Figure 24.  Change in DIM concentration with increasing amounts of H. pomatia !-glucuronidase 
p = 0.0013 for linear regression model 
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quantities of !-glucuronidase/arylsulfatase yielded a significant, positive, and linear 
association with the quantity of DIM detected (Table 25 and Figure 24). 
 
Experiment 4: Evaluate contamination of H. pomatia !-glucuronidase/arylsulfatase with 
DIM 
 The concentrations of DIM detected in two separate lots of Roche H. pomatia !-
glucuronidase/arylsulfatase and !-glucuronidase expressed in E. coli (Sigma) are reported 
in Table 26, and Table 27 summarizes the DIM concentrations detected in various 
preparation of !-glucuronidase with or without the addition of d2-DIM.  Roche !-
glucuronidase/arylsulfatase from H. pomatia yielded detectable DIM concentrations, 
which ranged from 4.41 ± 0.03 to 7.76 ± 2.00 pmol/mL water treated when quantified 
using d2-DIM.  In contrast, !-glucuronidase expressed in E. coli (Sigma) did not elicit 
quantifiable DIM concentrations, and DIM peaks were only evident in the 
chromatograms of water treated with d2-DIM, indicating that the internal standard is the 
predominant source of DIM in water treated with E. coli !-glucuronidase.  The 
percentage of DIM from added d2-DIM was 0.64%, and this value was used to correct all 
calculations of total DIM in the following experiments. 
 
Table 26.  Concentration of DIM detected in multiple preparations of !-glucuronidase. 
!-glucuronidase preparation (2000U) DIM (pmol/mL, mean ±  SE) 
Nonea <LOQ 
Roche H. pomatia lot #70255323b 4.41 ± 0.03 
Roche H. pomatia lot #70331220c 6.21 ± 1.21 
Sigma E. coli G8295c <LOQ 
aAverage of 5 replicates 
bAverage of 4 replicates  
cAverage of 4 replicates 
LOQ = limit of quantitation (132 fmol) 
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Table 27.  Summary of Experiment 4 results. 
Sample* 
!-glucuronidase 
preparation (2000U) 
d2-
DIM 
added 
(pmol) 
% recovery 
d2-DIM 
DIM (mean area counts 
±  SE) 
% DIM peak area relative to d2-
DIM peak area ±  !-glucuronidase 
DIM peak area 
DIM 
(pmol/mL 
water, mean 
±  SE) 
Water Sigma E. coli G8295 0 n/a nd n/a nd 
Water Sigma E. coli G8295 10 77.92% 2,199,037 ± 347,979 1.38% <LOQ 
Water Roche H. pomatia lot 
#70331220 
0 n/a 111,614,442 ± 22,110,455 n/a n/a 
Water Roche H. pomatia lot 
#70331220 
10 74.31% 111,356,190 ± 12,144,120 114.89% 7.76 ± 2.00 
Water None 10 100.37% 1,279,627 ± 278,020 0.64% <LOQ 
Water None 5 94.91% 620,873 ± 133,089 0.64% <LOQ 
*Average of 2 replicates 
nd = not detected 
LOQ = limit of quantitation (132 fmol) 
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Experiment 5: Compare !-glucuronidase from H. pomatia and E. coli to no enzyme 
treatment for DIM quantification and reliability 
 Subsequent to concluding that the previous Roche !-glucuronidase/arylsulfatase 
preparation was contaminated with DIM, urine samples were evaluated with a semi-
purified H. pomatia !-glucuronidase/arylsulfatase (Sigma H5 G1512), the E. coli !-
glucuronidase shown to be free of DIM in Experiment 4, or no enzyme to compare the 
absolute values of DIM quantified in an effort to determine if enzyme treatment was 
necessary.  As shown in Table 28, treatment with either preparation of !-glucuronidase 
did increase the concentrations of urinary DIM detected, particularly following 
cruciferous vegetable consumption; however, no individual treatment reached statistical 
significance from the others.  Due to low volumes of urine and H5 !-
glucuronidase/arylsulfatase, only the control urine samples were evaluated with this 
preparation, which did not demonstrate detectable levels of DIM in the baseline urine but 
increased the quantification of urinary DIM nearly three-fold following cruciferous 
vegetable consumption. 
 However, the testing of water blanks with H5 !-glucuronidase/arylsulfatase 
substantially decreased the recovery of d2-DIM to 1.68%, resulting in a very high 
concentration of DIM detected in 1 mL of treated water (48.47 ± 17.02 pmol, Table 29).  
Conversely, the E. coli !-glucuronidase resulted in a high recovery of d2-DIM (68.04%) 
with no detectable quantities of DIM in the water samples treated.  The improved d2-DIM 
recovery in the E. coli versus H5 preparation of the enzyme compelled us to choose the 
E. coli preparation of !-glucuronidase for the final urinary DIM quantification technique. 
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Table 28.  Summary of Experiment 5 results comparing yield by enzyme preparation. 
  
Baseline Urinary DIM (pmol/mL urine)  
Cruciferous Vegetable Urinary DIM 
(pmol/mL urine) 
Subject 
!-glucuronidase preparation 
(2000U) 
% recovery 
d2-DIM Mean ±  SE %CV  
% recovery 
d2-DIM Mean ±  SE %CV 
Control1,*  None 41.08% 3.28 ± 1.51 113%  37.50% 2.60 ± 0.06 6% 
Control1,*  Sigma E. coli G8295 33.63% 3.20 ± 1.41 108%  24.57% 4.17 ± 0.15 9% 
Control2,*  Sigma H5 purified H. pomatia 
G1512 
25.20% <LOQ n/a  21.37% 11.72 ± 0.03 0.5% 
D3 None 28.52% 0.12 ± 0.04 64%  32.25% 2.26 ± 0.04 2% 
D3 Sigma E. coli G8295 9.47% 6.03 ± 0.19 5%  14.27% 3.19 ± 0.04 2% 
E3  None 67.41% <LOQ n/a  44.88% 4.44 ± 0.41 13% 
E3 Sigma E. coli G8295 30.78% 0.84 ± 0.07 11%  13.46% 11.37 ± 1.80 22% 
1Average of 6 replicates 
2Average of 4 replicates 
3Average of 3 replicates at baseline, 2 replicates following 50 g Brussels sprouts consumption 
*Cruciferous vegetable treatment consisted of 200 g Brussels sprouts consumption 
DIM concentrations <LOQ (132 fmol) were computed as 50% LOQ (0.07 pmol/mL) 
 
 
Table 29.  DIM concentrations in water treated with 2000 U !-glucuronidase from E. coli or purified from H. pomatia. 
!-glucuronidase preparation (2000U)* % recovery d2-DIM DIM (pmol/mL water, mean ±  SE) 
Sigma E. coli G8295 68.04% <LOQ 
Sigma H5 purified H. pomatia G1512 1.68% 48.47 ± 17.02 
*Average of 2 replicates 
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Experiment 6: Validate final technique for urinary DIM quantification 
 This experiment was conducted only with the control urine specimens collected 
following cruciferous vegetable abstinence and consumption.  Two-day inter-assay 
variability was still relatively high at baseline, with a %CV of 46%, but this value in the 
urine sample following cruciferous vegetable exposure was reduced to 16% (Table 30).  
The technique also showed that urinary DIM was higher following cruciferous 
consumption than abstinence (2.51 ± 0.12 versus 0.89 ± 0.13 pmol, respectively). 
 The final technique was calibrated in control baseline urine spiked with increasing 
proportions of urine following cruciferous vegetable exposure (Table 31).  Although the 
results remained somewhat variable, with an average %CV of 9.6%, Figure 25 shows that 
this technique was indeed valid in quantifying a positive linear association between the 
amount of cruciferous vegetable exposure and urinary DIM detected (R2 = 0.999).  This 
experiment also validated the technique in relatively low concentrations of DIM, as might 
be observed in individuals consuming a varied diet with a moderate amount of 
cruciferous vegetables. 
 Lastly, the final method was validated in control baseline urine spiked with 1.25—
30.35 pmol DIM to evaluate its use with a higher level of exposure to I3C.  As shown in 
Table 32, these results were less variable than in the previous calibration shown in Table 
31, with an average %CV of 3 %.  Figure 26 confirms that the technique is valid in a 
range of urinary DIM concentrations (R2 = 0.999). 
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Table 30.  Summary of Experiment 6 results. 
 Baseline Urinary DIM (pmol/mL urine) *  Cruciferous Vegetable Urinary DIM (pmol/mL urine) * 
Assay Day 
Inter-day Mean 
Assay Day 
Inter-day Mean 1 2 1 2 
% recovery d2-DIM 11.88% 12.44% 12.14% 22.78 % 21.88% 22.37% 
Intra-day Mean ±  SE 1.16 ± 0.19 0.62 ± 0.06 0.89 ± 0.13 2.78 ± 0.18 2.24 ± 0.03 2.51 ± 0.12 
%CV 37% 21% 46% 14% 3% 16% 
*Average of 5 replicates per day 
 
 
Table 31.  Summary of Experiment 6 calibration with control and cruciferous vegetable urine samples. 
% Cruciferous vegetable urine* % recovery d2-DIM 
Urinary DIM (pmol/mL urine) 
Mean ±  SE %CV 
20 15.87% 0.72 ± 0.06 0% 
40 13.17% 1.27 ± 0.19 22% 
60 13.65% 1.79 ± 0.17 14% 
80 12.63% 2.40 ± 0.20 12% 
*Average of 2 replicates, cruciferous vegetable treatment consisted of 200 g Brussels sprouts consumption 
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Figure 25.  Calibration of urinary DIM method with control urine samples. 
 
 
Table 32.  Summary of Experiment 6 validating DIM quantification in urine spiked with 1.25—30.35 pmol 
DIM. 
DIM added (pmol)* % recovery d2-DIM DIM (pmol/mL, mean ±  SE) %CV 
1.25 17.35% 1.40 ± 0.11 11% 
2.55 14.20% 2.18 ± 0.04 3% 
5.05 18.53% 4.40 ± 0.11 4% 
10.1 17.66% 8.97 ± 0.12 2% 
20.25 17.10% 18.06 ± 0.11 1% 
30.35 11.90% 28.43 ± 0.05 0.2% 
*Each sample represents 2 duplicates 
DIM concentrations <LOQ (132 fmol) were computed as 50% LOQ (0.07 pmol/mL) 
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Figure 26.  Calibration of urinary DIM method with control urine samples spiked with 1.25—30.35 pmol 
DIM. 
 
 
Discussion 
 The series of experiments described above to validate an LC/MS method to 
quantify urinary DIM as a biomarker of I3C exposure yielded the final experimental 
work-up outlined in Figure 27.  Several procedures were rigorously tested, and the final 
technique is highly sensitive, accurate, and reliable.  It is a notable improvement to 
previously published methods because low levels of DIM resulting from cruciferous 
vegetable consumption rather than DIM or I3C supplementation were detected in the 
control urine samples.  The technique was also accurate and reliable in a range of added 
DIM concentrations, and the use of deuterated DIM as an internal standard further 
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Figure 27.  Final urinary DIM sample preparation technique. 
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increased accuracy by enabling more precise estimations of DIM recovery.  Additionally, 
the use of a recombinant !-glucuronidase expressed in E. coli increased the yield of the 
urinary DIM assay while also eliminating a substantial source of contamination. 
Although the technique demonstrated very low variability in urine samples spiked 
with known amounts of DIM, there remained somewhat wide variability (>10%) in a 
control urine sample from an individual consuming Brussels sprouts.  The low 
concentrations of DIM present in the urine of this individual likely contribute to this 
variability, as subtle differences in peak quality and integration can result in large 
differences in quantitation.  The presence of other compounds in the urine resulting from 
additional metabolites of glucosinolates present in Brussels sprouts or medications 
consumed by the individual may also contribute to the variability if compounds of similar 
molecular weight to DIM are excreted.  However, given that the same variability was not 
observed in the same individual’s urine spiked with pure DIM, the most plausible 
explanation seems to be differences in the excreted forms of DIM versus the pure form 
used for the spiking experiments.  For example, I3C can also dimerize to HI-IM (see 
Figure 14 above), a compound with the same molecular weight as DIM but possibly 
different stability characteristics in stored samples[171].  Notably, it has not been shown 
if HI-IM is excreted in the urine.  Nevertheless, additional urinary metabolites of I3C 
may be responsible for variability in urine samples from individuals consuming low 
amounts of glucobrassicin. 
As mentioned previously, an important development during the process of assay 
validation was the identification of DIM contamination in H. pomatia-sourced !-
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glucuronidase/arylsulfatase and an alternative source of !-glucuronidase free from 
contamination (E. coli).  A majority of the previous human and animal research has 
utilized H. pomatia !-glucuronidase/arylsulfatase, which leads us to question prior results 
using these methods.  Given the potential of DIM to tightly bind proteins, as evidenced 
by the even higher concentrations detected in H. pomatia !-glucuronidase/arylsulfatase 
purified by size-exclusion chromatography, it would be difficult if not impossible to 
predict the effect of a contaminated enzyme across multiple heterogeneous urine samples.  
This precludes the use of corrective equations and requires the re-analysis of all samples 
with an enzyme free from contamination.  The issue of contamination from enzyme 
sources may not have resulted in appreciable errors historically, but with the increasing 
use of highly sensitive instruments such as LC/MS, it is imperative to limit contamination 
as much as possible.  Enzyme sources without exposure to the analytes of interest and the 
use of water blanks with and without internal standards are strongly recommended for 
accurate research in nutrition and cancer employing highly sensitive biomarkers. 
The final method offers an accurate and reliable technique to quantify a range of 
urinary DIM concentrations resulting from cruciferous vegetables.  As will be shown in 
the next chapter, the technique is sufficient to discern individuals consuming low versus 
high glucobrassicin-containing vegetables.  This innovation is key to observational 
studies that address large numbers of individuals consuming diets without any 
experimental control or intervention.  An additional benefit of this technique is the use of 
urine specimens, which are among the least invasive and most easily stored 
biospecimens.   
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However, there remain several limitations to the technique described in this 
chapter.  As previously mentioned, the technique is relatively variable at low 
concentrations of urinary DIM.  In addition, the rapid clearance of DIM, which peaks at 
two hours following a dose of I3C[171], may require multiple urine collections from each 
individual to accurately assess I3C exposure.  Finally in contrast to H. pomatia !-
glucuronidase/arylsulfatase, E. coli !-glucuronidase does not possess any sulfatase 
activity; the use of sulfatase expressed in A. aerogenes may deconjugate an increased 
concentration of DIM in each sample, but the increased expense associated with multiple 
engineered enzymes may limit their use in large epidemiological studies. 
 In conclusion, the series of experiments described above resulted in a valid, 
reliable, and highly sensitive technique to quantify I3C exposure in individuals 
consuming vegetables containing glucobrassicin.  The method is an improvement to 
previously published techniques because it does not introduce contamination and can 
quantify ranges of I3C found in the diet rather than in pharmacological doses.  A further 
improvement to the technique would be its validation in longitudinal I3C exposure.  
However, the preparation of urine samples with E. coli !-glucuronidase and liquid-liquid 
extraction with t-butyl methyl ether followed by quantitation via LC/MS-MS remains a 
valid technique to quantify urinary DIM as a surrogate marker for dietary glucobrassicin 
consumption and will be used in current and upcoming controlled feeding trials of cancer 
chemoprevention by dietary bioactives.
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Chapter V: Urinary 3,3'-diindolylmethane: a biomarker of 
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Introduction 
Brassica vegetables from the genus Brassica such as broccoli, cabbage, and 
Brussels sprouts, are unique in that they contain high levels of glucosinolates, widely 
thought to mediate the anti-cancer effect of these foods[154, 159].  When the plant cells 
are damaged such as by chewing or chopping, inert glucosinolates are hydrolyzed by 
plant myrosinase into indoles (indolyl glucosinolates) and isothiocyanates (isothiocyanate 
glucosinolates)[154, 182, 201].  Only two indolyl glucosinolates are found in abundance 
in Brassica vegetable crops – glucobrassicin (indolylmethyl) and neoglucobrassicin 
(methoxy-3-indolylmethyl)[182].  The relative concentration of glucobrassicin is species- 
and cultivar-dependent and varies according to growth conditions[159].  However, 
glucobrassicin is the predominant glucosinolate among more than 100 known 
glucosinolates in many commonly consumed Brassica vegetables[188, 202, 203]. 
Glucobrassicin is relevant to human health because when plant cells are chewed, 
chopped, or otherwise damaged, it is converted by endogenous myrosinase into indole-3-
carbinol (I3C).  In the acidic environment of the stomach, I3C undergoes acid 
condensation to oligomers, the predominant form and most well characterized of which is 
3,3'-diindolylmethane (DIM)[204].  Both I3C and DIM have demonstrated remarkable 
pleiotropic anti-cancer properties in vitro and in vivo[199, 205].  Our group has shown 
that A/J mice treated with the potent tobacco-smoke carcinogens 4-(methylnitrosamino)-
1-(3-pyridyl)-1-butanone and benzo[a]pyrene develop significantly fewer lung tumors 
after treatment with I3C or DIM as compared to those treated with the carcinogens 
alone[206, 207].  In a placebo-controlled clinical trial, I3C given for 12 weeks resulted in 
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complete regression of cervical dysplasia in approximately half of the women 
studied[190].  Other studies have demonstrated both I3C and DIM modulate estrogen 
metabolism in animals and humans to favor the formation of the anti-proliferative 
estrogen 2-hydroxyestrone (2-OHE1) over the pro-proliferative estrogen 16!-
hydroxyestrone (16-OHE1)[191, 193, 194, 208-214].  Indeed, a higher 2-OHE1:16-OHE1 
ratio is associated with a decreased risk of estrogen-sensitive tumors such as breast 
cancer[215].  Conversely, prolonged exposure to high doses of I3C can result in dose- 
and timing-dependent promotion of carcinogen-induced hepatocarcinogenesis in rainbow 
trout and rat models[216, 217].  A study in rats found that I3C at doses up to 20 mg/kg 
daily by gavage for 28 days or thirteen weeks was not toxic but higher doses induced 
liver toxicity despite withdrawal of I3C[218].  However, the highest non-toxic dose in 
this study (20 mg/kg body weight/day) exceeds the maximum tolerated dose of I3C in 
humans of 400 mg daily[192]. 
Epidemiological evidence links a high intake of Brassica vegetables to a reduction 
in the risk of lung, stomach, bladder, prostate, and other cancers[156, 219-227]; however, 
the association has not been consistently replicated, highlighting the necessity of 
developing biomarkers to quantify the uptake of the phytonutrients within such 
vegetables[160, 228-232].  Several biomarkers of isothiocyanate exposure have been 
evaluated in humans[182, 188, 233-244].  However, no published study has successfully 
correlated consumption of an intact vegetable to glucobrassicin and I3C metabolites in 
humans.  We conducted a randomized, crossover trial with the objective of testing 
whether urinary DIM is a biomarker for the uptake of I3C from Brassica vegetables 
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containing divergent glucobrassicin concentrations.  The hypothesis being tested is that 
glucobrassicin exposure and subsequent I3C uptake is directly related to DIM excreted in 
the urine.  To measure urinary DIM, we developed a novel and powerful liquid 
chromatography-electrospray ionization-tandem mass spectrometry-selected reaction 
monitoring (LC/ESI-MS/MS-SRM) method and compared urinary DIM levels after 
consumption of a Brassica vegetable with relatively high glucobrassicin concentration 
(‘Jade Cross’ Brussels sprouts) to urinary DIM levels after consumption of a Brassica 
vegetable with relatively low glucobrassicin concentration (‘Blue Dynasty’ cabbage). 
 
Materials and Methods 
Study population 
  Healthy, non-vegetarian, non-smoking adults ages 18 to 65 were recruited.  
Former smokers were required to be abstinent from tobacco for at least one year.  Non-
smoking status was confirmed by exhaled carbon monoxide levels.  Subjects with 
medical conditions requiring the active care of a physician, pregnant or breastfeeding 
women, vegetarians, and those taking warfarin were excluded.  Subjects completed 
questionnaires on medical history, medication/supplement use, demographics, and 
smoking history (former smokers).  The protocol and consent form were approved by the 
Institutional Review Board at the University of Minnesota.  All subjects provided 
informed consent. 
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Study design 
This was a randomized, two-period crossover trial.  The study schema is shown in 
Figure 28.  All 25 subjects completed study procedures concurrently.  Subjects were 
asked to abstain from Brassica vegetables and glucosinolate-containing foods starting 
seven days prior to consumption of the first study vegetable (washout period 1) to the end 
of the study.  Compliance was ascertained from self-reported food diaries and DIM level 
in baseline spot urine samples collected at the end of each washout period, immediately 
prior to consumption of the study vegetable.  Subjects were randomized to consume 
either 50 g of raw ‘Jade Cross’ Brussels sprouts or 50 g of raw ‘Blue Dynasty’ cabbage in 
a single sitting at the study center once every 24 h for three consecutive days (Phase 1).  
All urine was collected for each 24 h period after study vegetable feeding.  After a five-
day washout period (washout period 2), subjects consumed 50 g of Brussels sprouts or 
cabbage (whichever they did not consume before) at the study center once every 24 h for 
three consecutive days (Phase 2).  Urine was collected in the same manner as before.  All 
urine was measured and aliquoted the day of collection, and stored at -20°C until 
analysis.  Fasting was not required throughout the study period. 
 
 
Figure 28.  Crossover feeding study design. 
Vegetable feeding 
Brussels sprouts or cabbage were fed once daily for three consecutive days on days 8-10 and 16-18. All 
urine was collected for each 24 h period after vegetable feeding. The sequence of vegetable feeding was 
randomly assigned to each subject at the time of enrollment. Subjects remained abstinent from cruciferous 
vegetables, other than those fed, starting with the first washout period through study completion on day 19.   
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Cultivation of ‘Jade Cross’ Brussels sprouts and ‘Blue Dynasty’ cabbage 
‘Jade Cross’ Brussels sprouts and ‘Blue Dynasty’ cabbage (Jordan Seeds, 
Woodbury, MN) were selected due to their divergent glucobrassicin concentrations 
(unpublished data).  The vegetables were seeded in 48-cell trays (53 ! 27 cm) containing 
moist soilless seeding media (Sunshine SB-300 Universal; Sun-Gro Horticulture, 
Bellevue, WA) for 28 days.  Following an eight-day hardening off period, seedlings were 
planted 46 cm apart in Waukegan silt loam (deep, well-drained glacial soil, 0–1% slope; 
pH = 7.4, 48 ppm phosphorous, 148 ppm potassium, 3.7% organic matter) in Rosemount, 
MN (44.7°N).  Soil was fertilized with 168 kg ha-1 nitrogen (urea) and treated with 0.84 
kg ha-1 trifluralin herbicide (incorporated) prior to planting.  Plants were watered as 
needed with drip irrigation throughout the season.  Cabbage and Brussels sprouts stalks 
were harvested after a total of 65 and 98 days of growth, respectively.  Two days after 
stalk harvest, U.S. No. 1 & 2 grade Brussels sprouts were removed from the stalks[245].  
Approximately 125 g from four different cabbage heads and approximately 200 g from 
three different Brussels sprouts were taken for glucobrassicin analysis as described 
below.  Produce was stored in ventilated plastic bags at approximately 5ºC. 
 
Preparation of ‘Jade Cross’ Brussels sprouts and ‘Blue Dynasty’ cabbage 
Vegetables were delivered to the study center 45 days and 12 days after harvest, 
respectively, on day one of Phase 1 of the study.  One-half of four cabbage heads was 
cored, and ~125 g from each half were taken for glucobrassicin analysis.  The remainder 
of the cabbage halves was chopped into bite-sized pieces (~25 cm2) to make 50 g salads, 
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and 120 g samples (n=3) of these salads were analyzed for glucobrassicin concentration.  
Brussels sprouts were washed, the discolored leaves and the stem were removed, and the 
sprouts were halved to make 50 g salads.  Approximately 100 g (n=3) of these salads 
were taken for glucobrassicin analysis.  Both cabbage and Brussels sprout salads were 
prepared fresh each day prior to administration throughout the study.  Vegetable 
preparation and glucobrassicin quantification of the salads only was done in an identical 
manner at the start of Phase 2 of the study. 
 
Analysis of glucobrassicin concentration in the vegetables 
  Vegetable samples were prepared for glucobrassicin analysis on the day of 
collection.  Sample preparation consisted of boiling the samples in water to deactivate 
myrosinase, blending and homogenizing samples (2 min, 12,000 RPM; Polytron PT 
1300D; Brinkmann Instruments, Westbury, NY), centrifuging to remove debris, 
extracting desulpho-glucobrassicin using strong anion-exchange (SAX) solid-phase 
extraction (SPE), and filtering the extract through a 0.2 !m PTFE syringe filter (pre-
wetted with methanol) before sample storage at -30ºC.  Samples were stored at -10ºC 
after blending until homogenization.  Further details of the methods are described 
elsewhere[246, 247].  HPLC analysis was carried out based on an existing protocol with 
minor modifications[246].  The injection volume was 50 !L.  Analyses were done using 
an Agilent 1200 series HPLC system (Agilent Technologies, Santa Clara, CA) equipped 
with a solvent degasser and diode array detector.  The solvent gradient was as follows (A 
= H2O, B = acetonitrile): 0 to 2 min, 5 to 15% B; 2 to 20 min, 15 to 47% B; 20 to 23 min, 
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47 to 100% B; 23 to 30 min, 100% B; 30 to 33 min, 100 to 5% B.  Peaks were verified 
using known retention times and absorbance spectra, and integrated using Chemstation 
software (Agilent Technologies).  Desulpho-GB was quantified using a desulphosinigrin 
standard curve and a response factor of 0.29[248]. 
 
Chemicals 
All chemicals were HPLC, LC-MS, or Optima grade.  DIM was purchased from 
LKT Labs (Saint Paul, MN).  Indole, ammonium acetate, t-butyl methyl ether, and !-
glucuronidase preparations from Escherichia coli (G8295) were purchased from Sigma-
Aldrich (St. Louis, MO).  d2-Formaldehyde (isotopic purity 98%) was obtained from 
Cambridge Isotope Laboratories, Inc. (Andover, MA).  
 
Synthesis of d2-DIM 
The synthesis of d2-DIM was carried out essentially as previously described[200].  
Briefly, d2-formaldehyde (20% w/w aqueous solution; 1.5 mL) was added to indole (1.17 
mg, 0.01 mol) suspended in a mixture of glacial acetic acid (0.6 g, 0.01 mol) in 2.5 mL of 
D2O.  The mixture was vigorously stirred under nitrogen at 90°C for 5 h, cooled, and 
purified using the HPLC system described below.  The retention time of d2-DIM was 41 
min (0.6 g, 50%, and isotopic purity greater than 99%).  1H NMR (d6-DMSO) showed 
absence of methylene protons, " 10.7 (2#, 1$#, 1!$#), 7.5 (d, J = 15.6 Hz, 
2#, 4#, 4!#), 7.25 (d, J = 16.2 Hz, 2#, 7H, 7!H), 7.18 (d, J = 3.6 Hz, 1#, 2H, 2!H), 7.05 
(dd, J = 1.8, 14.4 Hz, 2#, 5H, 5!H), 6.95 (dd, J = 1.2, 14.4 Hz, 2#, 6H, 6!H).  The MS 
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(positive ion ESI) showed the following: m/z (relative intensity) 249 [M+1] (25); 131[M-
indole-C-d2]. 
 
HPLC system 
The HPLC system consisted of a Waters model 680 gradient controller, two 
Waters 510 pumps, a Waters 440 absorbance detector (254 nm) (Waters, Milford, MA), a 
Hewlett Packard 1100 series autosampler (Palo Alto, CA), and a Luna C18 reverse-phase 
column 250 x 4.6 mm, 5 µm (Phenomenex, Torrance, CA) with a linear gradient from 
10% CH3OH in H2O to 100% CH3OH in 40 min and held for an additional 10 min at a 
flow rate of 0.7 mL/min. 
 
Preparation of urine samples for DIM analysis 
Urine samples were prepared using a published technique with modifications[196, 
249].  Two thousand units of E. coli !-glucuronidase solution in 0.1 mL of phosphate 
buffered saline (0.26%, w/v) and 10 pmol d2-DIM internal standard were added to 1 mL 
of each urine sample.  Following a 20 h incubation at 37°C, each sample was extracted 
two times with an equal volume of t-butyl methyl ether.  The extracts were evaporated to 
dryness using a centrifugal vacuum evaporator (Savant SpeedVac, Thermo Fisher 
Scientific, Waltham, MA) and reconstituted to 20 µL with acetonitrile/10 mM 
ammonium acetate (30/70, v/v).  Positive and negative control urine samples and water 
blanks were included with each assay.  
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Quantitation of urinary DIM by LC-ESI-MS/MS-SRM 
The analyses were carried out by LC-ESI-MS/MS-SRM on a TSQ Quantum 
Discovery Max instrument (Thermo Fisher Scientific, Waltham, MA) in the positive ion 
mode with N2 as the nebulizing and drying gas.  MS parameters were set as follows: 
spray voltage, 3.2 kV; sheath gas 25; capillary temperature, 250°C; collision energy, 17 
V; scan width, 0.05 amu; Q2 gas pressure 1.0 mTorr; source CID 9 V; tube lens offset, 
104 V; Q1 0.2 amu and Q3 0.7 FWHM.  MS data were acquired and processed by 
Xcalibur software version 1.4 (Thermo Electron, Waltham, MA).  Eight µL of the sample 
were injected from an autosampler using an Agilent 1100 capillary LC system (Agilent 
Technologies) equipped with a 5µm, 150 x 0.5 mm Zorbax SB-C18 column (Agilent 
Technologies).  The flow rate was15 µL/min for the first 3 min then 10 µL/min with a 
gradient from 60% methanol in 15 mM NH4OAc to 100% methanol in 8 min and held for 
additional 29 min.  The mass transitions monitored were m/z 247.12!130.07 for DIM 
(typical retention time of 16.6 min) and m/z 249.12!132.07 for d2-DIM (typical 
retention time of 16.5 min).  Quantitation was done by comparing the MS peak area ratio 
of DIM to that of d2-DIM using a calibration curve prepared before each analysis. The 
calibration curve was prepared by plotting the MS peak area ratio of DIM to d2-DIM 
against their concentration ratios using standard mixes containing constant levels of d2-
DIM and varying levels of DIM.  The assay limit of quantitation (LOQ) was 132 fmol 
(32.5 pg).  Results below the assay LOQ were computed as 50% LOQ (0.07 pmol/mL). 
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Accuracy and precision of urinary DIM quantification 
  Accuracy and precision were determined using two 24 h urine collections from an 
individual who abstained from Brassica vegetables for seven days (negative control 
urine) and then consumed 200 g of commercial Brussels sprouts (positive control urine).  
Five replicates of 1 mL of positive control urine treated with 2000 units of E. coli !-
glucuronidase and 5 pmol d2-DIM were analyzed on two different days to determine the 
accuracy, reliability, and reproducibility of the assay.  To validate the method over a 
range of DIM concentrations, 1.25, 2.55, 5.05, 10.1, 20.25, or 30.35 pmol of pure DIM 
was added to 1 mL of negative control urine and analyzed in duplicate. 
 
Urine creatinine measurements 
  Urine creatinine in each urine collection was measured at the University of 
Minnesota Medical Center, Fairview Diagnostic Laboratatory, a CLIA-certified lab. 
 
Statistical analysis 
Log-transformed means were compared using t-tests.  A linear regression model 
was used to analyze the effect of body mass index (BMI), sex, age, and race/ethnicity on 
urinary DIM.  The coefficient of variation (%CV) was calculated as standard 
deviation/mean x 100.  A 5% significance level was used for all tests.  Analysis was done 
using SAS 9.2 (Cary, NC). 
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Results 
Subject characteristics 
  Ten males and 15 females (total n=25) ranging in age from 22 to 63 years (mean 
35.8 ± 11.8 years) completed the study.  There were 20 Caucasians, two African 
Americans, and three Asians.  The average BMI was 26.7 ± 5.0.  Twenty subjects (80%) 
were never smokers.  All subjects consumed the vegetable salads as scheduled.  No 
adverse events were observed.  No subjects were taking proton pump inhibitors, H2-
antagonists, other antacids, or antibiotics.  Compliance was excellent.  Six of the 150 
twenty four-hour urine collections (4%) from five different subjects were missing one 
partial urine void per collection.  There were no major devations abstaining from Brassica 
vegetables during the study period as ascertained from self-reported food diaries and 
baseline urinary DIM levels. !
Glucobrassicin concentration 
  The glucobrassicin concentration in the vegetables analyzed at three timepoints 
during the study is shown in Table 33.  The mean glucobrassicin concentration in the 
cabbage was approximately four-fold lower than in the Brussels sprouts at all sampling 
timepoints, and remained consistent from the time of harvest to the time of 
administration. 
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Table 33.  Glucobrassicin coneentration (± SEM) of harvested vegetables and salads. 
 !mol glucobrassicin/100 gfw 
  Harvest Phase 1 Phase 2 Mean 
Cabbage 47.4 ± 13.3 44.2 ± 1.4 45.3 ± 2.0 45.8 ± 5.0* 
Brussels sprouts 165.3 ± 2.2 194.8 ± 6.4 191.6 ± 5.5 183.9 ± 6.4 
Halved cabbages (n=4) were sampled at harvest.  Brussels sprouts were sampled on the day they were 
separated from stalks, 2 days after harvest (n=3).  Brussels sprout and cabbage salads were sampled on the 
first day of each phase (n=4 and 3, respectively).  The mean glucobrassicin concentration was significantly 
higher in Brussels sprouts than in cabbage (*p <0.001).  Abbreviations: gfw = gram food weight. 
 
Accuracy and precision of urinary DIM quantification 
  Accuracy data are shown in Figure 29.  Accuracy averaged 93% (range 86-
112%).  The intra-day precision averaged 8.5%, and the inter-day variability averaged 
16% (n=5 positive control urine samples for each).  Duplicates were evaluated at each 
concentration of negative control urine to which known amounts of DIM were added, and 
precision averaged 3%.  The correlation between the amount of DIM added to the urine 
and the amount measured was excellent (R2 = 0.999). 
 
Figure 29.  Measured versus added DIM in negative control urine samples to which known amounts of 
DIM were added.  R2=0.999.  Slope = 0.92. 
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Analysis of urinary DIM levels 
  Typical LC-ESI-MS/MS-SRM chromatograms obtained at baseline and after 
consumption of Brussels sprouts are illustrated in Figure 30.  Urinary DIM was 
undetectable in 38 of the 50 baseline urine samples; nine subjects produced a peak at the 
retention time of DIM.  Baseline urinary DIM levels were not significantly different after 
each washout period when analyzed according to the order of vegetable feeding (p = 0.89 
for Period 1, p = 0.85 for Period 2).  No period or carryover effects were observed (p = 
0.21 and 0.27, respectively). 
 
 
 
Figure 30.  Representative LC/MS traces. 
Representative LC-ESI-MS/MS-SRM chromatograms obtained upon analysis of A, standard DIM (top) and 
internal standard d2-DIM (bottom); B, a urine sample from a subject before eating Brussels sprouts (top) 
and internal standard d2-DIM (bottom), and C, a urine sample from a subject after eating Brussels sprouts 
(top) and internal standard d2-DIM (bottom). 
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  Mean 24 h urinary DIM level in each of the 25 subjects is summarized in Table 
34, and was consistently higher after consumption of either cabbage or Brussels sprouts 
compared to baseline (p <0.001 for both).  Within each subject, Brussels sprouts 
consumption consistently led to higher mean urinary DIM than cabbage consumption.  
The mean difference was 8.64 ± 1.65 pmol/mg creatinine (range 1.40 – 42.53 pmol/mg 
creatinine).  As shown in Figure 31, among the entire group, overall mean urinary DIM 
after consumption of Brussels sprouts was significantly higher than the overall mean 
urinary DIM after consumption of cabbage (geometric mean 7.07 ± 1.14 pmol/mg 
creatinine vs. 0.29 ± 1.22 pmol/mg creatinine, p <0.0001).  The excreted urinary DIM 
averaged 0.03 ± 0.01% (Brussels sprouts) and 0.01 ± 0.00% (cabbage) of the 
glucobrassicin administered. 
  Wide inter-individual variability was observed within each type of vegetable 
feeding.  Mean urinary DIM ranged from 1.40 to 44.00 pmol/mg creatinine after Brussels 
sprouts feeding and 0 to 1.47 pmol/mg creatinine after cabbage feeding.  Urinary DIM 
was undetectable in four subjects after cabbage feeding.  Mean urinary DIM after 
Brussels sprouts in these four subjects was 5.76, 5.22, 8.89, and 5.76 pmol/mg creatinine, 
respectively. 
 The potential effect of subject characteristics on urinary DIM after Brussels 
sprouts feeding was analyzed using a linear model that included BMI, ethnicity, and age.  
Mean urinary DIM did not correlate with these variables (p = 0.23 for overall model).   
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Table 34.  Mean 24 h urinary DIM among each of the 25 subjects after consumption of Brussels sprouts or 
cabbage once daily for 3 consecutive days.   
Subject # 
Mean 24 h Urinary DIM  
(pmol/mg creatinine) Feeding order 
B C 
1 9.18 0.60 C 
2 9.83 0.44 B 
3 44.0 1.47 C 
4 5.33 1.03 B 
5 5.40 0.24 B 
6 5.84 0.42 B 
7 13.1 0.56 B 
8 11.7 0.62 B 
9 5.17 0.28 B 
10 5.22 0.00 C 
11 21.8 0.85 C 
12 4.88 0.05 C 
13 7.02 0.12 C 
14 15.6 0.41 B 
15 5.17 0.17 C 
16 3.08 0.20 B 
17 8.89 0.00 C 
18 5.22 0.51 B 
19 1.40 0.00 B 
20 7.58 0.12 C 
21 6.12 0.48 B 
22 10.2 0.56 C 
23 5.76 0.00 C 
24 4.03 0.14 C 
25 4.66 0.92 B 
Overall 9.05 ± 1.70 0.41 ± 0.07  
Each value represents the mean of three 24 h urine collections.  Feeding order refers to which vegetable – 
Brussels sprouts or cabbage – the subject was randomized to eat during Phase I of the study.  Overall mean 
values are reported ± standard error.  Abbreviations: C, cabbage; B, Brussels sprouts 
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Figure 31.  Overall mean urinary DIM among the 25 subjects after consumption of Brussels sprouts or 
cabbage, after feeding once daily for 3 consecutive days (p <0.0001). 
 
 
Discussion 
This study is the first to successfully quantify urinary DIM, a biomarker of I3C 
uptake, after feeding Brassica vegetables, and the first to show that higher glucobrassicin 
exposure from food consistently results in higher I3C uptake and higher urinary DIM 
levels as hypothesized.  This proof-of-principle is essential to establish urinary DIM as a 
non-invasive, reproducible measure of I3C uptake from Brassica vegetables that can be 
applied in prospective epidemiological and chemoprevention studies.  Our highly 
sensitive LC/ESI-MS/MS-SRM technique makes it possible to quantify the relatively 
small quantities of DIM in urine that result from food consumption, an obstacle not 
encountered with I3C or DIM supplements, which are dosed at levels significantly higher 
than can be achieved with food[193]. 
Characterizing I3C uptake using urinary DIM is advantageous.  The glucosinolate 
concentration in the same cultivar of Brassica vegetable can vary based on factors such as 
growth conditions and preparation technique, making random estimations of 
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glucosinolate exposure impractical[202, 239, 240].  Measuring glucosinolate uptake 
based on the type and quantity of Brassica vegetable consumed is also unreliable, and is a 
potential factor in the inconsistent correlation between high Brassica vegetable 
consumption and decreased cancer risk observed in some epidemiologic studies.  
Furthermore, measurement of I3C itself is problematic since I3C readily undergoes 
oligomerization in the acidic conditions of the stomach and is undetectable in blood 
within one hour after I3C administration to both mice and humans[171, 192]. 
Our method of measuring urinary DIM represents a notable improvement to 
previously published assays[191-193, 196, 214, 249].  The use of d2-DIM as internal 
standard results in more precise identification of DIM as it is structurally more similar to 
DIM compared with previously used internal standards such as 4-methoxyindole or 4,4'-
dichloro-DIM.  Additionally, we used recombinant E. coli !-glucuronidase, which 
ameliorated the confounding from H. pomatia-derived !-glucuronidase observed during 
our assay development and in assays used by others[250-252]. 
Previous studies have attempted to characterize I3C uptake after Brassica 
vegetable feeding. In one study, healthy volunteers were fed blanched broccoli, selenium-
fortified blanched broccoli, or placebo once daily for four weeks[196].  Blood and urine 
were collected prior to the intervention and the day following the last broccoli feeding.  
The glucobrassicin concentrations in the diet were 111 and 107 µg/g fresh weight of 
broccoli and selenium-fertilized broccoli, respectively.  Neither DIM nor I3C was 
detectable in the urine or blood.  The authors hypothesized that this was due to factors 
such as the ascorbic acid content in the vegetables favoring the formation of ascorbigen, 
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or the ~24 h duration between the end of the intervention and sample collection.  Other 
studies have analyzed DIM in plasma or urine after administration of I3C or DIM 
supplements.  After dosing I3C at 200 mg daily for four weeks (n=5), mean urinary DIM 
was 12.1 ± 2.5 (SD) µg/mg creatinine (49,125 pmol/mg creatinine, approximately 5,000 
times greater than in our subjects who ate Brussels sprouts), which was not significantly 
different from mean urinary DIM after 400 mg daily for four weeks[191].  Absorption-
enhanced DIM (BioResponse-DIM®, BioResponse LLC, Boulder, CO) dosed at 108 mg 
per day for 30 days resulted in a significant increase in mean urinary DIM (collected the 
day following the final DIM dose) to 101.3 ± 36.1 ng/mg creatinine[193].  Finally, after 
dosing patients with thyroid proliferative disease intending to undergo thyroidectomy 
with absorption-enhanced DIM at 300 mg daily for fourteen days, the mean increase in 
urinary DIM was 383.5 ng/mg creatinine[214].  The current study resulted in 
substantially lower urinary DIM levels, consistent with the micro-dosing achievable from 
food. 
The proportion of glucobrassicin consumed that was excreted in the urine as DIM 
was low.  A major factor is likely a low rate of conversion of I3C to DIM in the stomach 
due to the complex heterogeneity of gastric contents after eating.  Additionally, the major 
route of I3C or DIM excretion in humans is not known.  Several studies have examined 
the tissue distribution and metabolism of I3C based on administration of radiolabeled I3C 
in animal models, but did not directly quantify I3C or DIM[170, 253, 254].  In F344 rats, 
after administering [3H] I3C in the diet for seven days, the feces was the predominant 
route of excretion of the recovered radiolabel (75%); only 23% was excreted in the 
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urine[170].  In mice, after administration of 250 mg/kg of I3C once by gavage, the 
concentration of I3C and DIM was highest in liver, then kidney[171].  Overall, the data 
suggest that I3C and DIM may not be readily absorbed by the gut or are excreted 
primarily by biliary excretion, as suggested in rainbow trout[254]. 
The widely variable inter-individual difference in urinary DIM excretion was 
expected, and is consistent with other studies after administration of I3C, DIM, or 
cruciferous vegetables[192, 239, 242, 255, 256].  We did not require subjects to fast 
before or after vegetable feeding sessions, which could favor heterodimerization of I3C 
to higher-order oligomers owing to differences in gastric pH or contribute to variability in 
I3C/DIM absorption.  We also did not require a uniform method of chewing, which might 
affect myrosinase release, although the extent of minimal vegetable preparation to reach 
an edible sample was kept consistent for this reason.  Taken together, our findings and 
those of others suggest that inter-individual variations in urinary DIM excretion are 
probably explained by uncharacterized factors that may have an implication on the 
relative benefit an individual might derive from Brassica vegetable consumption.  
Furthermore, the relative chemopreventive effect is likely to be heterogeneous based on 
polymorphisms in genes encoding Phase I and II biotransformation enzymes (i.e. CYP 
and GST), which are modulated by glucosinolates[154, 257-263].  Further studies are 
required to examine these hypotheses. 
Other important questions remain before urinary DIM can be widely used as a 
biomarker of I3C uptake from Brassica vegetables.  First, the pharmacokinetics of I3C 
and DIM after Brassica vegetable consumption must be delineated.  Second, like any 
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biomarker with a relatively short half-life, use of urinary DIM as a biomarker of an 
individual’s Brassica vegetable intake may need to be assessed longitudinally.  Finally, it 
is not clear whether the benefit of glucobrassicin exposure reaches a plateau nor do we 
know what a biologically relevant dose in humans may be.  Further study into these 
questions is underway. 
In summary, urinary DIM is an objective measure of assessing I3C uptake from 
Brassica vegetables containing divergent glucobrassicin concentrations.  The 
development of a highly sensitive LC/ESI-MS/MS-SRM method and the results of our 
study provide a strong foundation to further validate urinary DIM for use in larger 
populations and in chemopreventive interventions using Brassica vegetables. 
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Part III: Dietary fish, fat, and antioxidant consumption 
and the risk of gastric cancer in the Singapore Chinese 
Health Study 
 
 
Introduction 
 Gastric cancer is among the deadliest malignancies worldwide.  Although infection 
of the stomach with Helicobacter pylori (H. pylori) is an established risk factor for 
gastric cancer, environmental exposures including diet have been shown to modulate the 
risk of gastric cancer with or without H. pylori infection.  Diets rich in anti-inflammatory 
compounds, such as n-3, may reduce the risk of gastric cancer by reducing inflammation 
or triggering cancer cell death; however, these data are somewhat limited in vitro and in 
animal models, and results have been contradictory in human observational studies.  
Additional longitudinal research examining dietary fat, fish, and antioxidant intakes and 
gastric cancer risk in an established prospective cohort would yield valuable information 
regarding the effects of fish, fat, and antioxidant intakes on gastric cancer risk. 
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Chapter VI: Literature Review 
 
Prevalence of and risk factors for gastric cancer 
 Gastric cancer is the third leading cause of cancer death in men and fifth leading 
cause of cancer death in women worldwide[264].  In the United States, the age-
standardized rates for all gastric cancers are 7.0 and 3.2 per 100,000 men and women, 
respectively[265].  While rates of non-cardia gastric cancer have been steadily declining 
in developed countries, the rates of cancer affecting the gastric cardia have been 
increasing[266].  Recently, it was reported that the rates of adenocarcinoma of the 
esophagogastric junction, including cancer of the gastric cardia, are increasing the most 
rapidly of any solid tumors in Europe and North America[267]. 
 The rates of gastric cancer are especially high in Asian countries such as Japan 
due in part to traditional diets rich in salt and fermented foods[268, 269].  Although the 
incidence rates of gastric cancer in Singapore do not reach the levels of Japan (46.8 per 
100,000 males, 18.2 per 100,000 females) and Korea (62.2 per 100,000 males, 24.6 per 
100,000 females), the age-standardized rates for men and women are much higher than in 
the United States, at 21.5 and 10.8 per 100,000, respectively[265, 270].  A similar trend 
of decreasing non-cardia and increasing cardia gastric cancers has also been observed in 
Singapore, where it was recently reported that 16% of all gastric cancers affect the cardia, 
double the proportion reported from 1993-1997[267]. 
 Infection of the stomach with Helicobacter pylori (H. pylori) is a risk factor for 
gastric cancer, and the International Agency for Research on Cancer classified infection 
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as a group 1 human carcinogen in 1994[271].  Many large epidemiological studies have 
concluded that H. pylori infection significantly increases the risk for non-cardia gastric 
cancer[269, 272, 273].  However, the role of H. pylori infection in cardia gastric cancer is 
less clear, possibly due to historically low numbers of cases and the preferential 
colonization of the gastric antrum by H. pylori[271, 274]. 
 Although H. pylori infection is a strong risk factor for non-cardia gastric cancer, 
dietary intake modulates the risk of both non-cardia and cardia gastric cancer.  Studies 
have shown that high salt intake interacts synergistically with H. pylori infection to 
increase the risk of non-cardia gastric cancer, while a few studies demonstrated a 
significant protective effect of vitamin C or fresh fruit for all gastric cancers irrespective 
of H. pylori status[273, 275].  Additionally, consumption of allium vegetables, such as 
garlic and onions, has been shown to reduce the risk of gastric cancer[266].  One possible 
explanation for the latter effect is the sulfur provided by allium vegetables contributing to 
the production of the endogenous antioxidant glutathione (GSH, see Chapter 1). 
Because gastric cancer etiology is linked strongly to chronic inflammation, it is 
conceivable that the anti-inflammatory effects of dietary n-3 may reduce the risk of such 
cancers[271].  Additionally, gastric tissue is unique with respect to exposure to lipid 
peroxidation metabolites that may serve to up-regulate antioxidant and detoxification 
functions and eliminate cancer cells (see Chapter 1); lipid peroxidation can occur at 
gastric pH levels[276].  Consequently, the stomach would be exposed to lipid 
peroxidation metabolites found in food products, formed during the digestion of dietary 
n-3, and from n-3 present within its cellular membranes. 
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In an exploration of the association between fish and dietary n-3 consumption and 
the risk of gastric cancer, a recent meta-analysis by Wu et al.[277] concluded that high 
fish consumption reduced the risk of gastric cancer by thirteen percent (odds ratio (OR) = 
0.87, 95% CI = 0.71 – 1.07) based upon data from 15 case-control and two prospective 
cohort studies.  Because of the limited data from prospective cohort studies, an analysis 
of the Singapore Chinese Health Study is warranted.  In this study of more than 60,000 
individuals, detailed dietary information was collected at baseline prior to the diagnosis 
of any cancer, and participants were followed for an average of twelve years[278-280].  
Biospecimens (including blood) were collected from a randomly selected three percent of 
the subjects at baseline beginning in 1994 and from all consenting subjects in 2000.  By 
2005, 32,543 subjects had provided biospecimens (28,330 bloods, 4400 buccal cells from 
blood refusals, and 31,965 urines).  This number represents a consent rate of 
approximately 60% once subjects who had died were excluded.  All extracted 
components from the biospecimens have been stored in -80°C freezers[278].  The 
collection of biospecimens allows for H. pylori testing to control for this important risk 
factor, which may be present in 43% of Singapore Chinese individuals[278, 281]. 
 
Dietary fish, fat, and antioxidant consumption and the risk of gastric cancer 
In vitro and animal model studies 
 Few primary in vitro and animal model studies have been conducted to explore 
the relationship between diet and gastric cancer risk, and a majority of the literature on 
this topic has been derived from epidemiological studies, which will be reviewed in the 
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next section.  A study conducted by Miwa et al.[282] tested the effect of a high-fat (15% 
of energy) or low-fat (0.5% of energy) diet on male Wistar rats following a partial 
gastrectomy or sham surgery as control.  The rats consuming the high-fat diet following 
the gastrectomy exhibited a significantly increased incidence of gastric carcinoma (41% 
of rats fed the high-fat diet versus 15% of rats fed the low-fat diet, p <0.05) and adenoma 
(38% of rats fed the high-fat diet versus 15% of rats fed the low-fat diet, p <0.05) 
compared to the rats consuming the low-fat diet.  However, the rats that received the 
sham surgery did not develop any tumors, regardless of diet; the authors attributed this 
effect to the absence of duodenogastric reflux following the partial gastrectomy that 
exposed the experimental rats to carcinogenic N-nitroso compounds.  Additionally, the 
high amounts of LA present in the soybean oil used for the diets (52.7% by weight) likely 
promoted inflammation following the surgery. 
 
Cross-sectional and ecological studies 
 Studies addressing the relationship between dietary fat, fish, and antioxidant 
intake and the risk of gastric cancer via cross-sectional or ecological designs are 
summarized in Table 35.  Two cross-sectional studies of Swedish fishermen and their 
wives were conducted by Rylander, Hagmar, and Svensson et al.[283, 284] to examine 
differences in mortality rates and causes in these individuals compared to the general 
population of Sweden.  The authors found a significantly higher rate of gastric cancer 
incidence (standardized incidence ratio (SIR) = 1.59, 95% CI 1.03—2.39) and a non-
significantly increased rate of gastric cancer mortality among east coast Swedish 
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Table 35.  Summary of cross-sectional and ecological human studies examining dietary fat, fish, and antioxidant intakes and the risk of gastric cancer. 
Reference Study Design 
Outcome 
Measurement(s) Results Notes 
Rylander and 
Hagmar[284] 
Cross-sectional fisherman’s 
wives in Sweden 
n=8594 
n=400 with dietary interviews 
Expected mortality and cancer 
incidences calculated for each 
county based on death and 
population statistics 
Cause-specific 
mortality ratios 
Standardized cancer 
incidence ratios 
No difference in overall mortality in fisherman’s wives 
compared to the general population.  Cohort members on 
the east coast had sig. increased breast cancer mortality. 
There were trends for decreased ischemic heart disease 
and cancer mortality in the west coast cohort. 
There were no differences in stomach cancer incidences, 
but a low number of cases were expected. 
East coast fishermen 
shown to have higher 
levels of dioxin-like 
organochlorine 
compounds than west 
coast fishermen. 
Svensson et 
al.[283] 
Cross-sectional Swedish 
fishermen 
n=11,373  
Expected mortality and cancer 
incidences calculated for each 
county based on death and 
population statistics 
Cause-specific 
mortality ratios 
Standardized cancer 
incidence ratios 
East coast fisherman had significantly reduced overall 
mortality and cardiovascular disease mortality compared 
to the general population.  There was a trend for decreased 
cancer incidence among east coast fisherman, but there 
was a non-significant increase in stomach cancer deaths 
compared to the general population.  Stomach cancer 
incidence was sig. higher among east coast fishermen than 
the general population (standardized incidence ratio 
(SIR)=1.59, 95%CI 1.03—2.39). 
West coast fishermen had significantly reduced overall 
mortality compared to the general population.  There was a 
significant increase in death from ischemic heart disease.  
There were no differences in stomach cancer rates 
compared to the general population. 
The east coast fishermen had significantly increased 
incidences of stomach cancer compared to the west coast 
fishermen (incidence rate ratio (IRR)=2.15, 95%CI 1.32—
3.50). 
East coast fishermen 
shown to have higher 
levels of dioxin-like 
organochlorine 
compounds than west 
coast fishermen. 
East coast fishermen 
consume smoked fish 
twice as often as west 
coast fishermen. 
East coast fishermen 
smoked more than 
west coast fisherman 
or the general 
population. 
Johnson et 
al.[285] 
Cross-sectional retrospective 
cohort of American seafood 
workers, n=4116 
Cause of death via 
National Death 
Index, Social 
Security 
Administration, state 
Departments of Vital 
Records, 
Significant excess in deaths due to gastric cancer among 
the seafood workers (proportional mortality rate (PMR)= 
2.2, 95% CI 1.2—3.8), particularly among females 
(PMR=3.3, 95% CI 1.7—6.3). 
PMR for occlusion or stenosis of the pre-cerebral or 
cerebral arteries were significantly lower among the cohort 
members (PMR=0.5, 95% CI 0.3—0.9). 
No dietary (or other 
environmental 
exposure) information 
collected. 
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Reference Study Design 
Outcome 
Measurement(s) Results Notes 
Departments of 
Motor Vehicles, 
personal contact, and 
internet tracing 
Standardized US 
mortality rates from 
University of 
Pittsburgh database 
Among white females, deaths due to ischemic heart 
disease were significantly lower among seafood workers 
compared to the general population (standardized 
mortality ratio (SMR)=0.8, 95% CI 0.6—1.0). 
Palli et 
al.[286] 
Cross-sectional study of tissue 
samples from gastric cancer 
patients 
n=105 
p53 mutation 
prevalence 
Dietary and lifestyle 
factors from in-
person interview 
p53 mutations detected in 31.4% of tissues, more 
commonly in cardia or fundus tumors and intestinal or 
unclassified tumors; mutations also more common among 
women and older subjects.  There were no associations 
between mutations and H. pylori infection, smoking, 
socioeconomic status, education level, and family history 
of gastric cancer. 
There were significant associations between increasing 
consumption of raw vegetables (lettuce, chicory, and 
carrots) and decreased p53 mutations (OR=0.2, 95%CI 
0.1—0.9) and increasing consumption of nitrites (OR=3.4, 
95%CI 1.0—11.4) and increased p53 mutations. 
Traditional soups (OR=40.5, 95%CI 5.7—504), nitrite 
(OR=16.5, 95%CI 1.8—151.2), protein (OR=9.8, 95%CI 
1.04—93.8), animal protein (OR=14.3, 95%CI 1.4—
143.5), and animal lipids (OR=12.0, 95%CI 1.5—93.9) 
were associated with an increased risk of non-CpG 
mutations.  Total lipids were borderline associated 
(OR=5.8, 95%CI 0.9—38.1, p = 0.066) 
Histological 
determination of H. 
pylori infection may 
underestimate 
proportion affected. 
Moore et 
al.[287] 
Ecological study of Western 
countries 
n=34 countries 
 
Age- and sex-specific 
mortality from 
cancers, diseases of 
the circulatory 
system, and 
cerebrovascular 
disease from the 
There were significant positive correlations between 
cerebrovascular disease and gastric cancer incidence in 
both men (r = 0.7649, p <0.001) and women (r = 0.0559, p 
<0.001) across countries. 
Hypertension 
considered a risk factor 
for gastric cardia 
cancer. 
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Reference Study Design 
Outcome 
Measurement(s) Results Notes 
World Health 
Organization 
Heart disease 
mortality calculated 
by subtracting 
cerebrovascular 
disease mortality 
from circulatory 
disease mortality 
Cai et 
al.[288] 
Ecological study of Fujian 
Province, China 
n=55 townships 
In-person interview 
about lifestyle and 
dietary habits and 
history of gastric 
diseases 
There was a significant positive correlation between fish 
sauce consumption and gastric cancer mortality in both 
men (r = 0.5170, p <0.01) and women (r = 0.4261, p 
<0.01).  The significant positive association persisted after 
multivariate adjustment (men: p = 0.0001, women: p = 
0.0019). 
Fish sauce is salted 
and produced by 
prolonged 
fermentation.  It has 
been shown to be 
carcinogenic. 
Ahn et 
al.[289] 
Cross-sectional study of 
cancerous and noncancerous 
gastric tissue from gastric 
cancer patients 
n=9 
Stomach mucosa 
fatty acid 
composition 
Relative saturated fatty acids (cancer:noncancer = 1.08, p 
= 0.05) and PUFA were sig. higher (cancer:noncancer = 
1.35, p = 0.002) and MUFA sig. lower (cancer:noncancer 
= 0.72, p = 0.001) in cancerous vs. noncancerous tissues. 
Arachidonic acid (cancer:noncancer = 1.99, p = 0.0005) 
and n-6:n-3 sig. higher in cancerous vs. noncancerous 
tissues (cancer:noncancer = 2.27, p = 0.003, in 
phospholipids). 
Total n-3 sig. lower in cancerous vs. noncancerous tissues 
phospholipids (cancer:noncancer = 0.43, p = 0.04). 
Higher desaturation indices of n-6 in cancerous vs. 
noncancerous mucosa. 
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fishermen compared to the general population (SIR = 1.37, 95% CI 0.82—2.23)[283].  
Compared to the west coast fishermen, those living and working on the east coast had 
more than twice the rate of gastric cancer incidence (incidence rate ratio (IRR) = 2.15, 
95% CI 1.32—3.50).  The authors cited evidence that east coast fishermen have higher 
levels of dioxin-like organochlorine compounds detected compared to west coast 
fishermen as an explanatory factor; additionally, the east coast fishermen smoked more 
cigarettes and consumed more smoked fish than the west coast fishermen.  When the 
authors studied the wives of the fishermen, no significant differences in gastric cancer 
incidence or mortality were observed, although dietary interviews showed that the 
fishermen’s wives consumed approximately twice as much fish as the general 
population[284]. 
 A similar cross-sectional retrospective cohort study was conducted in American 
seafood workers by Johnson et al.[285].  When compared to the general population, there 
was a significant excess in deaths due to gastric cancer among the seafood workers 
(proportional mortality rate (PMR) = 2.2, 95% CI 1.2—3.8), particularly among females 
(PMR = 3.3, 95% CI 1.7—6.3).  However, it was not known if seafood consumption 
among these workers differed from the general population.  It is noteworthy that the PMR 
for occlusion or stenosis of the pre-cerebral or cerebral arteries were significantly lower 
among the seafood workers (PMR = 0.5, 95% CI 0.3—0.9), and among white female 
seafood workers, deaths due to ischemic heart disease were significantly lower among 
seafood workers compared to the general population (standardized mortality ratio (SMR) 
= 0.8, 95% CI 0.6—1.0).  These differences may be due in part to the beneficial effects of 
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seafood consumption on cardiovascular and cerebrovascular diseases, but it is impossible 
to determine this from the data provided[2, 5]. 
 In an ecological study that did not directly assess nutritional risk factors, Moore et 
al.[287] reported significant positive correlations between cerebrovascular disease and 
gastric cancer incidence in both men (correlation coefficient (r) = 0.7649, p <0.001) and 
women (r = 0.0559, p <0.001) in 34 Western countries.  Given the relationship between 
dietary factors and cardiovascular disease risk, this link (although practically nonexistent 
among women) may be partially explained by dietary intake and intimates a negative 
association between fatty fish intake and gastric cancer incidence.  Cai et al.[288] 
conducted an ecological study across 55 townships in the Fujian province of China to 
explore the correlation between dietary habits and gastric diseases.  These authors 
demonstrated a significant positive correlation between fish sauce consumption and 
gastric cancer mortality among men (r = 0.5170, p <0.01) and women (r = 0.4261, p 
<0.01).  The fish sauce that is consumed in this region is produced via prolonged 
fermentation and had been shown previously to be carcinogenic, suggesting that N-
nitroso compounds present in the fish sauce confer an increased risk of gastric cancer. 
 Two cross-sectional studies included in Table 35 conducted biochemical analyses 
of gastric tissue from gastric cancer patients.  Palli et al.[286] linked self-reported dietary 
habits to H. pylori infection and p53 mutations among 105 gastric cancer patients, and 
concluded that although there were no significant associations between H. pylori 
infection and p53 mutation prevalence, significantly increased prevalence of p53 
mutations were seen in individuals that consumed higher amounts of traditional soups, 
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polenta, and nitrites (OR in multivariate model = 3.4, 95% CI 1.0—11.4).  More frequent 
consumption of raw vegetables was associated with a significantly decreased prevalence 
of p53 mutations (OR = 0.2, 95% CI 0.1—0.9).  In a subgroup analysis of p53 mutations 
not occurring in cytosine- and guanine-rich segments of DNA (non-CpG mutations), 
traditional soups (OR = 40.5, 95% CI 5.7—504), nitrite (OR = 16.5, 95% CI 1.8—151.2), 
protein (OR = 9.8, 95% CI 1.04—93.8), animal protein (OR = 14.3, 95% CI 1.4—143.5), 
and animal lipids (OR = 12.0, 95% CI 1.5—93.9) were associated with substantially 
increased odds of p53 mutations.  There was a borderline positive association between 
the highest quintile of total lipids intake and non-CpG mutations (OR = 5.8, 95% CI 
0.9—38.1, p = 0.066).  These results suggest that—independently of H. pylori 
infection—dietary factors including high sodium foods, animal fats and protein, and food 
sources of nitrite may promote gastric cancer via mutations of the tumor suppressor gene 
p53.  However, the sub-analysis of non-CpG p53 mutations was conducted in a small 
number of subjects (n=14), resulting in very wide confidence intervals that may not apply 
to larger populations. 
 In a small study of nine gastric cancer patients, Ahn et al.[289] compared the fatty 
acid composition of cancerous versus noncancerous gastric mucosa.  Compared to the 
noncancerous tissues, cancerous tissues had significantly higher relative amounts of 
saturated fatty acids (cancer:noncancer = 1.08, p = 0.05) and PUFA (cancer:noncancer = 
1.35, p = 0.002) and significantly lower relative amounts of monounsaturated fatty acids 
(MUFA, cancer:noncancer = 0.72, p = 0.001) measured from total fatty acids.  
Specifically, AA was significantly higher (cancer:noncancer = 1.99, p = 0.0005) and the 
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n-6:n-3 ratio was relatively similar in total fatty acids but significantly higher in 
phospholipids (cancer:noncancer = 2.27, p = 0.003) in cancerous versus noncancerous 
tissues.  Total phospholipid n-3 were significantly lower (cancer:noncancer = 0.43, p = 
0.04).  Although this study was conducted with a very small number of subjects, the 
results suggest an association between gastric mucosa fatty acid composition and gastric 
cancer progression, with phospholipids low in n-3 relatively enriched in cancerous gastric 
tissues.  Nevertheless, a limitation of all the studies included in Table 35 is the inability to 
infer causation as all measurements are conducted at one time point only. 
 
Case-control studies 
 Many case-control studies have explored the associations between dietary fat, 
antioxidants, and gastric cancer risk, and these studies are summarized in Table 36.  A 
majority of the studies assessed dietary intake and environmental exposures through an 
in-person interview with a food frequency questionnaire (FFQ) in individuals recently 
diagnosed with gastric cancer and control individuals without gastric cancer.  Compared 
to cross-sectional and ecological studies, case-control studies offer more information 
regarding the dietary determinants of cancer risk because they are retrospective in design; 
however, case-control studies are also subject to several limitations, in particular recall 
bias, which was defined in Chapter 1.  Because of the high mortality rate of gastric 
cancers, a number of the case-control studies utilized proxy interviews of family 
members or friends of the cancer patient, likely contributing additional information 
biases.
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Table 36.  Summary of case-control human studies examining dietary fat, fish, and antioxidant intakes and the risk of gastric cancer. 
Reference Study Design Outcome Measurement(s) Results Notes 
Kabat et 
al.[290] 
Hospital-based 
case-control 
Distal 
esophageal/gastric 
cancer cases, 
n=173 
Non-GI or 
tobacco-related 
cancer patient 
controls, n=4544 
In-person food frequency 
questionnaire 
Tobacco, alcohol, and 
supplement use and 
occupational exposures assessed 
via interview 
Male current (OR=2.3, 95%CI 1.4—3.9) and ex-smokers 
(OR=1.9, 95%CI 1.2—3.0) at significantly higher odds for 
gastric cardia cancer than never smokers.  Female current 
smokers at significantly higher odds for both gastric cardia 
(OR=4.8, 95%CI 1.7—14.0, vs. never smokers) and distal 
stomach cancer (OR=3.2, 95%CI 1.3—7.7, vs. never 
smokers). 
Alcohol consumption was associated with significantly higher 
odds for gastric cardia cancer among men only (OR=2.3, 
95%CI 1.3—4.3 for 4+ oz whisky equivalents/d vs. 
nondrinkers); the effect was significant for occasional hard 
liquor only (OR=1.8, 95%CI 1.2—2.7, vs. nondrinkers).  In 
women, daily beer consumption was significantly associated 
with increased odds for gastric cardia cancer (OR=4.9, 95%CI 
1.1—22.8, vs. nondrinkers). 
There was a significant trend for increased gastric cardia 
cancer odds with increasing fat intake (OR=2.9, 95%CI 1.5—
5.6, highest vs. lowest quartile, p for trend <0.001).  A similar 
trend was seen with vitamin A from animal sources (OR=2.4, 
95%CI 1.3—4.6, highest vs. lowest quartile, p for trend 
<0.01). 
Increasing fiber intake was associated with a significant 
decrease in gastric cardia cancer (OR=3.2, 95%CI 1.5—7.0, 
lowest vs. highest, quartile, p for trend <0.01). 
30-item food 
frequency 
questionnaire 
Ji et al.[291] Population-based 
case-control 
Gastric cancer 
cases, n=1124 
Frequency-
matched controls, 
n=1451 
In person dietary and lifestyle 
interview 
Significant trend for increased gastric cancer odds with 
increasing preserved vegetable intake in women only (OR=1.9, 
95%CI 1.3—2.8, highest vs. lowest quartile, p for trend = 
0.002). 
Significant inverse trend for poultry intake and gastric cancer 
in men only (OR=0.7, 95%CI 0.5—0.9, highest vs. lowest, p 
for trend = 0.0005).  Significant inverse trends for all 
vegetables (OR=0.4, 95%CI 0.3—0.5, highest vs. lowest, p for 
trend <0.0001), yellow/green vegetables (OR=0.5, 95%CI 
0.4—0.7, highest vs. lowest, p for trend = 0.0001), and 
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Reference Study Design Outcome Measurement(s) Results Notes 
soybean and products (OR=0.5, 95%CI 0.4—0.7, highest vs. 
lowest, p for trend = 0.0001) in men only. 
Significant inverse trends for egg (men: OR=0.6, 95%CI 0.4—
0.8, highest vs. lowest, p for trend = 0.001; women: OR=0.5, 
95%CI 0.4—0.8, highest vs. lowest, p for trend = 0.003), fresh 
fruit (men: OR=0.4, 95%CI 0.3—0.6, p for trend <0.0001; 
women: OR=0.5, 95%CI 0.3—0.8, highest vs. lowest, p for 
trend = 0.0006), and plant oil (men: OR=0.7, 95%CI 0.5—0.9, 
highest vs. lowest, p for trend = 0.001; women: OR=0.6, 
95%CI 0.4—0.9, highest vs. lowest, p for trend = 0.005) intake 
and gastric cancer in both sexes. 
Significant inverse association between protein (men: OR=0.7, 
95%CI 0.5—0.9, highest vs. lowest, p for trend = 0.003; 
women: OR=0.6, 95%CI 0.4—1.0, highest vs. lowest, p for 
trend = 0.01) and fiber (men: OR=0.6, 95%CI 0.4—0.8, 
highest vs. lowest, p for trend = 0.002; women: OR=0.6, 
95%CI 0.3—0.9, highest vs. lowest, p for trend = 0.007) intake 
and gastric cancer risk in both sexes.  Significant positive 
association between carbohydrate (men: OR=1.5, 95%CI 
1.1—2.1, highest vs. lowest, p for trend=0.002; women: OR= 
1.9, 95%CI 1.3—2.9, highest vs. lowest, p for trend = 0.0007) 
intake and gastric cancer risk in both sexes. 
Among women, there was a significant inverse association 
between fat intake and gastric cancer odds (OR=0.6, 95%CI 
0.4—0.8, highest vs. lowest, p for trend = 0.006). 
In men, ascorbic acid (OR=0.5, 95%CI 0.3—0.7, highest vs. 
lowest, p for trend <0.0001), carotene (OR=0.4, 95%CI 0.3—
0.6, highest vs. lowest, p for trend <0.0001), riboflavin 
(OR=0.4, 95%CI 0.3—0.6, highest vs. lowest, p for trend 
<0.0001), vitamin A (OR=0.7, 95%CI 0.5—1.0, highest vs. 
lowest, p for trend = 0.02), and vitamin E (OR=0.5, 95%CI 
0.3—0.7, highest vs. lowest, p for trend <0.0001) were 
significantly associated with reduced gastric cancer odds.  In 
women, significant negative associations were seen only with 
carotene (OR=0.7, 95%CI 0.5—1.1, highest vs. lowest, p for 
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Reference Study Design Outcome Measurement(s) Results Notes 
trend = 0.02), riboflavin (OR=0.5, 95%CI 0.3—0.9, highest vs. 
lowest, p for trend = 0.003), and vitamin E (OR=0.5, 95%CI 
0.3—0.8, highest vs. lowest, p for trend = 0.0002). 
In both sexes, increasing frequency of salted food consumption 
(overall: OR=1.7, 95%CI 1.3—2.4, frequently vs. 
occasionally, p for trend = 0.001; distal: OR=1.8, 95%CI 1.3—
2.7, frequently vs. occasionally, p for trend = 0.002), 
preference for saltiness (overall: OR=2.3, 95%CI 1.0—4.9, 
very salty vs. low salty, p for trend = 0.0005; distal: OR=1.5, 
95%CI 0.6—4.0, very salty vs. low salty, p for trend = 0.008), 
and increasing consumption of fried foods (overall: OR=2.3, 
95%CI 1.6—3.2, frequently vs. occasionally, p for trend = 
0.0001; distal: OR=2.0, 95%CI 1.3—3.0, frequently vs. 
occasionally, p for trend = 0.004) were significantly associated 
with increased overall and distal gastric cancer odds.  
Increasing temperature of soup or porridge (overall: OR=1.9, 
95%CI 1.5—2.5, burning hot vs. not hot, p for trend <0.0001; 
cardia: OR=2.9, 95%CI 1.7—4.9, burning hot vs. not hot, p for 
trend <0.0001; distal: OR=1.9, 95%CI 1.4—2.5, burning hot 
vs. not hot, p for trend <0.0001), frequency of irregular meals 
(overall: OR=3.6, 95%CI 2.7—4.9, frequently vs. never, p for 
trend <0.0001; cardia: OR=4.0, 95%CI 2.4—6.5, frequently 
vs. never, p for trend <0.0001; distal: OR=3.7, 95%CI 2.7—
5.2, frequently vs. never, p for trend <0.0001), speed of eating 
(overall: OR=2.0, 95%CI 1.8—2.5, fast vs. moderate, p for 
trend <0.0001; cardia: OR= 3.8, 95%CI 2.5—5.7, fast vs. 
moderate, p for trend <0.0001; distal: OR=1.8, 95%CI 1.5—
2.2, fast vs. moderate, p for trend <0.0001), and propensity for 
binge eating (overall: OR= 2.5, 95%CI 2.0—3.1, yes vs. no; 
cardia: OR=3.0, 95%CI 2.0—4.4, yes vs. no; distal: OR=2.4, 
95%CI 1.9—3.1, yes vs. no) were significantly associated with 
increased odds for overall, cardia, and distal gastric cancers. 
Frequent consumption of raw and fresh foods was significantly 
associated with reduced odds for overall (OR=0.6, 95%CI 
0.5—0.8, frequently vs. occasionally, p for trend = 0.0001), 
   200 
Reference Study Design Outcome Measurement(s) Results Notes 
cardia (OR=0.5, 95%CI 0.3—1.0, frequently vs. occasionally, 
p for trend = 0.02), and distal (OR=0.6, 95%CI 0.4—0.8, 
frequently vs. occasionally, p for trend = 0.003) gastric 
cancers. 
Kaaks et 
al.[292] 
Population-based 
case-control 
Gastric cancer 
cases, n=301 
Population 
controls, n=2851 
In-person food frequency 
questionnaire 
Overall, total protein (OR=0.64, highest vs. lowest quartile, p 
for trend = 0.024), total vegetable protein (OR=0.53, highest 
vs. lowest quartile, p for trend = 0.001), total polysaccharides 
(OR=0.63, highest vs. lowest quartile, p for trend = 0.002), 
linoleic acid (OR=0.53, highest vs. lowest quartile, p for trend 
<0.001), dietary fiber (OR=0.31, highest vs. lowest quartile, p 
for trend <0.001), vitamin C (OR=0.43, highest vs. lowest 
quartile, p for trend <0.001), beta-carotene (OR=0.50, highest 
vs. lowest quartile, p for trend <0.001), vitamin B1 (thiamin, 
OR=0.27, highest vs. lowest quartile, p for trend <0.001), 
vitamin B3 (niacin, OR=0.54, highest vs. lowest quartile, p for 
trend <0.001), and vitamin B6 (OR=0.39, highest vs. lowest 
quartile, p for trend <0.001) were significantly associated with 
decreased risk for gastric cancer.  Total energy (OR=2.19, 
highest vs. lowest quartile, p for trend <0.001), total mono- 
and disaccharides (OR=1.88, highest vs. lowest quartile, p for 
trend <0.001), retinol (OR=2.26, highest vs. lowest quartile, p 
for trend <0.001), and vitamin B2 (riboflavin, OR=1.58, 
highest vs. lowest quartile, p for trend = 0.004) were 
associated with significantly increased risk for gastric cancer.  
Associations for MUFA (OR=0.75, highest vs. lowest quartile, 
p for trend = 0.064) and PUFA (OR=0.69, highest vs. lowest 
quartile, p for trend = 0.065) were borderline significantly 
inverse. 
 
Ye et al.[293] Population-based 
case-control 
Gastric cancer 
cases, n=272 
Population 
controls, n=544 
In-person food frequency 
questionnaire and lifestyle habits 
interview 
Consumption of fish sauce (OR=2.57, 95%CI 1.89—3.50), 
0.4+ kg/m vs. <0.4 kg/m, p <0.01), moldy foods (OR=2.32, 
95%CI 1.73—3.09, yes vs. no, p <0.01), irregular dinners 
(OR=5.47, 95%CI 4.22—7.09, 3+ times/w vs. <3 times/w, p 
<0.01), salted vegetables (OR=1.41, 95%CI 1.09—1.83, 2+ 
kg/y vs. <2 kg/y, p <0.05), salted fermented sea foods 
(OR=1.57, 95%CI 1.21—2.02, 1.5+ kg/y vs. <1.5 kg/y, p 
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<0.01), and family history of cancer (OR=3.27, 95%CI 2.48—
4.31, yes vs. no, p <0.01) significantly increased the risk of 
gastric cancer in univariate analysis. 
Consumption of green tea (OR=1.72, 95%CI 1.26—2.36, 
!0.75 kg/y vs. >0.75 kg/y, p <0.01), citrus fruits (OR=1.41, 
95%CI 1.03—1.92, !2.5 kg/y vs. >2.5 kg/y, p <0.05), other 
fruits (OR=1.31, 95%CI 1.01—1.71, !2.5 kg/y vs. >2/5 kg/y, 
p <0.05), and fresh vegetables (OR=1.95, 95%CI 1.41—2.70, 
!25 kg/y vs. >25 kg/y, p <0.01) significantly decreased the 
risk of gastric cancer in univariate analysis. 
Results for fish sauce (adjusted attributable risk (AAR)= 
17.81%, p <0.01), irregular dinners (AAR=48.93%, p <0.01), 
salted sea foods (AAR=19.69%, p <0.05), and family history 
(AAR=27.41%, p <0.01) were also significant in conditional 
logistic regression. 
Fernandez et 
al.[294] 
Hospital-based 
case-control 
Gastric cancer 
cases, n=745 
Noncancer 
controls, n=7990 
In-person food frequency 
questionnaire and lifestyle habits 
interview 
There was a significant inverse trend between fish 
consumption and gastric cancer odds (OR=0.7, 95%CI 0.5—
0.8, 2+ servings/w vs. 1 serving/w; OR=0.8, 95%CI 0.7—0.9, 
continuous per 1 serving/w, p <0.05). 
Series of studies 
that included 
multiple cancer 
sites 
Ward and 
Lopez-
Carrillo[295] 
Population-based 
case-control 
Gastric cancer 
cases, n=220 
Population 
controls, n=752 
Food frequency questionnaire There were significant positive associations between fresh 
meat (OR=3.1, 95%CI 1.6—6.2, 9+ times/w vs. <4 times/w, p 
for trend = 0.001), processed meat (OR=3.2, 95%CI 1.5—6.6, 
6+ times/w vs. <1 time/w, p for trend = 0.002), dairy products 
(OR=2.7, 95%CI 1.4—5.0, 17+ times/w vs. <5 times/w, p for 
trend = 0.003), and fish (OR=2.2, 95%CI 1.2—3.8, 6+ times/w 
vs. <1 time/w, p for trend = 0.001) intakes and gastric cancer 
odds.  These associations were significant for intestinal but not 
diffuse types of gastric cancer, except for fish intake, which 
was not significant in either. 
There were significant negative associations between all 
vegetables (OR=0.3, 95%CI 0.1—0.6, 6+ times/d vs. <4 
times/d, p for trend = 0.001), yellow/orange vegetables 
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(OR=0.2, 95%CI 0.1—0.3, 15+ times/w vs. <9 times/w, p for 
trend <0.001), and bean (OR=0.2, 95%CI 0.1—0.3, 7+ 
times/w vs. !1 times/w, p for trend <0.001) consumption and 
gastric cancer odds, which were significant for both intestinal 
and diffuse types.  There was a borderline negative association 
with citrus fruit consumption (OR=0.7, 95%CI 0.3—1.5, 9+ 
times/w vs. <2 times/w, p for trend = 0.07). 
There was a significant positive association between salt 
snacks/cracker consumption frequency and gastric cancer odds 
(OR=1.8, 95%CI 1.2—2.8, >2 times/m vs. never, p for trend = 
0.008), which was also significant for intestinal gastric cancer.  
There was a borderline positive trend for soda and sweets and 
gastric cancer risk (OR=1.7, 95%CI 0.9—3.2, 15+ times/w vs. 
<6 times/w, p for trend = 0.06). 
Mayne et 
al.[296] 
Population-based 
case-control 
Gastric cardia 
cases, n=255 
Gastric non-
cardia cases, 
n=352 
Population 
controls, n=687 
In-person interview and food 
frequency questionnaire 
24% of cases’ and 33% of 
controls’ blood tested for H. 
pylori but results not included in 
this analysis due to missing data 
Significant positive association with total saturated fat 
(OR=1.51, 95%CI 1.04—2.19, 75th vs. 25th percentile), dietary 
sodium (OR=1.46, 95%CI 1.00—2.15, 75th vs. 25th percentile), 
and nitrites (OR=1.64, 95%CI 1.30—2.07, 75th vs. 25th 
percentile) and risk of gastric non-cardia cancer.  Significant 
association with sodium not present after adjustment for 
nitrites. 
Significant positive associations for total starch (cardia: 
OR=1.61, 95%CI 1.14—2.28, 75th vs. 25th percentile; non-
cardia: OR=2.07, 95%CI 1.51—2.83, 75th vs. 25th percentile), 
total protein (cardia: OR=1.64, 95%CI 1.11—2.42, 75th vs. 
25th percentile; non-cardia: OR=1.52, 95%CI 1.08—2.15, 75th 
vs. 25th percentile), animal protein (cardia: OR=1.60, 95%CI 
1.19—2.15, 75th vs. 25th percentile; non-cardia: OR=1.58, 
95%CI 1.22—2.06, 75th vs. 25th percentile), cholesterol 
(cardia: OR=1.50, 95%CI 1.19—1.90, 75th vs. 25th percentile; 
non-cardia: OR=1.68, 95%CI 1.35—2.09, 75th vs. 25th 
percentile), and vitamin B12 (cardia: OR=1.27, 95%CI 1.01—
1.60, 75th vs. 25th percentile; non-cardia: OR=1.38, 95%CI 
1.13—1.68, 75th vs. 25th percentile) and all gastric cancers. 
Significant negative associations for PUFA (OR=0.66, 95%CI 
“Proxy” interviews 
for ~30% of cases 
(protocol not 
defined). 
Also evaluated 
esophageal cancer 
risk. 
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0.47—0.93, 75th vs. 25th percentile) and vegetable protein 
(OR=0.63, 95%CI 0.45—0.87, 75th vs. 25th percentile) and 
non-cardia cancer.  Significant negative association for dietary 
fiber and all gastric cancers (cardia: OR=0.43, 95%CI 0.30—
0.61, 75th vs. 25th percentile; non-cardia: OR=0.38, 95%CI 
0.28—0.53, 75th vs. 25th percentile). 
Increasing beta-carotene (cardia: OR=0.46, 95%CI 0.34—
0.62, 75th vs. 25th percentile; non-cardia: OR=0.58, 95%CI 
0.46—0.75, 75th vs. 25th percentile), folate (cardia: OR=0.73, 
95%CI 0.55—0.97, 75th vs. 25th percentile; non-cardia: 
OR=0.67, 95%CI 0.51—0.88, 75th vs. 25th percentile), vitamin 
C (cardia: OR=0.64, 95%CI 0.49—0.84, 75th vs. 25th 
percentile; non-cardia: OR=0.59, 95%CI 0.45—0.76, 75th vs. 
25th percentile), and vitamin B6 (cardia: OR=0.65, 95%CI 
0.47—0.88, 75th vs. 25th percentile; non-cardia: OR=0.59, 
95%CI 0.45—0.79, 75th vs. 25th percentile) intake was 
associated with a significant decreased risk for all stomach 
cancers.  Vitamin E intake was inversely associated with 
significantly decreased risk of non-cardia gastric cancer 
(OR=0.71, 95%CI 0.54—0.94, 75th vs. 25th percentile) 
(borderline significant for cardia (OR=0.75, 95%CI 0.55—
1.02, 75th vs. 25th percentile).  Supplemental vitamin C 
inversely associated with gastric non-cardia cancer risk 
(OR=0.60, 95%CI 0.41—0.88, used supplement 1+ times/w 
for 6 or more mos). 
Palli et 
al.[297] 
Population-based 
case-control 
Gastric cancer 
cases, n=382 
Population 
controls, n=561 
In-person interview and food 
frequency questionnaire 
Significant positive associations for total protein (OR=1.7, 
95%CI 1.2—2.5, highest vs. lowest tertile, p for trend = 
0.002), sodium (OR=1.7, 95%CI 1.2—2.4, highest vs. lowest 
tertile, p for trend = 0.002), and nitrite (OR=1.4, 95%CI 1.0—
2.0, highest vs. lowest tertile, p for trend = 0.04) and gastric 
cancer risk. 
Significant negative associations for vegetable fat (OR=0.7, 
95%CI 0.5—1.0, highest vs. lowest tertile, p for trend = 0.04), 
linoleic acid (OR=0.7, 95%CI 0.6—1.0, highest vs. lowest 
tertile, p for trend = 0.04), sugar (OR=0.6, 95%CI 0.4—0.8, 
Nitrates are good 
indicators of 
vegetable intake. 
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highest vs. lowest tertile, p for trend = 0.002), vitamin C 
(OR=0.6, 95%CI 0.4—0.8, highest vs. lowest tertile, p for 
trend = 0.001), beta-carotene (OR=0.6, 95%CI 0.4—0.8, 
highest vs. lowest tertile, p for trend = 0.0009), vitamin E 
(OR=0.4, 95%CI 0.3—0.7, highest vs. lowest tertile, p for 
trend = 0.0001), and nitrates (OR=0.6, 95%CI 0.4—0.9, 
highest vs. lowest tertile, p for trend = 0.01) and gastric cancer 
risk.  Borderline inverse association for PUFA (OR=0.7, 
95%CI 0.5—1.0, highest vs. lowest tertile, p for trend = 0.08). 
From factor analysis, traditional diet significantly associated 
with increased (OR=3.0, 95%CI 1.8—4.8, highest vs. lowest 
tertile, p for trend = 0.0001) but vitamin-rich diet significantly 
associated with decreased risk (OR=0.5, 95%CI 0.4—0.7, 
highest vs. lowest tertile, p for trend = 0.0003) of gastric 
cancer. 
Chen et 
al.[298] 
Population-based 
case-control 
Distal gastric 
cancer cases, 
n=124 
Population 
controls, n=449 
Telephone interview and food 
frequency questionnaire 
Significant inverse associations for vitamin C (OR=0.6, 
95%CI 0.3—1.2, highest vs. lowest quartile, p for trend = 
0.04), carbohydrate (OR=0.4, 95%CI 0.2—0.8, highest vs. 
lowest quartile, p for trend = 0.004), and fiber (OR=0.4, 
95%CI 0.2—0.8, highest vs. lowest quartile, p for trend = 
0.007) intake and the risk of distal gastric cancer.  Non-
significant negative association with !-cryptoxanthin and 
gastric cancer risk (OR=0.6, 95%CI 0.3—1.2, highest vs. 
lowest quartile, p for trend = 0.08). 
There was a significant positive association between saturated 
fat intake and gastric cancer risk among self-respondents but 
not among proxy interviewees (OR=3.6, 95% CI 1.0—12.0, 
highest vs. lowest tertile, p for trend  =0.03). 
Use of any vitamin supplement significant associated with a 
decreased risk of gastric cancer (OR=0.6, 95%CI 0.3—1.0). 
80% of gastric 
cancer cases 
assessed via proxy 
interviews of 
spouses, children, 
parents or other 
relatives or friends. 
No definition for 
distal stomach 
cancer, presumably 
all stomach cancer 
sites. 
Also evaluated 
esophageal cancer 
risk. 
Ito et al.[299] Hospital-based 
case-control of 
women only 
Gastric cancer 
cases, n=508 
Self-administered lifestyle and 
food frequency questionnaire 
Significant inverse associations between raw vegetables 
(OR=0.68, 95%CI 0.42—0.82, everyday vs. less than 
everyday), fruit (OR=0.71, 95%CI 0.59—0.85, everyday vs. 
less than everyday), green vegetables (OR=0.81, 95%CI 
0.68—0.97, 3+ times/w vs. <3 times/w), and carrot (OR=0.73, 
H. pylori shown to 
affect risks of 
differentiated and 
undifferentiated 
gastric cancers 
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Non-cancer 
outpatient 
controls, 
n=36,490 
95%CI 0.61—0.87, 3+ times/w vs. <3 times/w) intakes and 
gastric cancer odds. 
Significant inverse association between cooked fish intake and 
all types (OR=0.60, 95%CI 0.40—0.90, highest vs. lowest 
quartile, p for trend <0.05) and non-differentiated (OR=0.44, 
95%CI 0.26—0.77, highest vs. lowest quartile, p for trend 
<0.005) gastric cancers. 
equally. 
Lee et 
al.[300] 
Hospital-based 
case-control 
Early gastric 
cancer cases, 
n=69 
Healthy patient 
controls, n=199 
In-person interview and food 
frequency questionnaire 
Serum H. pylori by ELISA 
Family history of gastric cancer (OR=11.6, 95%CI 4.3—31.8, 
yes vs. no), H. pylori infection (OR=5.3, 95%CI 1.7—16.5, 
yes vs. no), and preference for high salty taste significantly 
associated with an increased risk of early gastric cancer (p 
<0.01). 
Significant trend for increased gastric cancer risk with 
increasing number of cigarettes smoked daily (OR=3.1, 95% 
CI 1.0—9.5, 21+ cigarettes/d vs. none). 
Significant trends for decreased gastric cancer risk with 
increasing clear broth (low salt but no concentration given) 
(OR=0.2, 95%CI 0.1—0.8, >3 times/w vs. <1 time/w, p for 
trend = 0.01), raw vegetables (OR=0.2, 95%CI 0.1—0.5, >6 
times/w vs. <4/w), fruits (OR=0.3, 95%CI 0.1—0.7, >5 
times/w vs. <3/w), fruit or vegetable juice (OR=0.6, 95%CI 
0.2—1.2, >9 times/mo vs. <2/mo, p for trend <0.01), and 
soybean curd (OR=0.3, 95%CI 0.2—0.8, 1+ times/mo vs. 
<1/mo). 
Significant trends for increased gastric cancer risk with more 
frequent salt-fermented fish (OR=2.4, 95%CI 1.0—5.7, 1+ 
times/mo vs. <1/mo) and kimchi intakes (OR=1.9, 95%CI 
1.3—2.8, 2+ times/d vs. <2/d). 
Significant interaction between H. pylori infection and 
preferences for salty food and the risk of gastric cancer (p = 
0.047).  Among H. pylori positive subjects, preference for 
salty foods (>0.3% NaCl) conferred increased odds for gastric 
cancer (OR=10.1, 95%CI 3.4—30.0).  H. pylori positive 
subjects with salty preference !0.3% NaCl did not have 
significantly increased odds for gastric cancer (OR=1.7, 
Definition of early 
gastric cancer 
included patients 
newly diagnosed 
without previous 
gastric surgery, no 
mention of 
stage/grade. 
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95%CI 0.6—4.7). 
Kim et 
al.[301] 
Hospital-based 
case-control 
Gastric cancer 
cases, n=136 
Surgical/clinic 
patient controls, 
n=136 
In-person interview and food 
frequency questionnaire 
Serum H. pylori by ELISA 
Significant inverse associations between dietary fiber 
(OR=0.37, 95%CI 0.17—0.79, highest vs. lowest tertile, p for 
trend = 0.009), vegetable protein (OR=0.39, 95%CI 0.18—
0.82, highest vs. lowest tertile, p for trend = 0.013), calcium 
(OR=0.43, 95%CI 0.21—0.90, highest vs. lowest tertile, p for 
trend = 0.025), phosphorus (OR=0.38, 95%CI 0.16—0.88, 
highest vs. lowest tertile, p for trend = 0.025), potassium 
(OR=0.36, 95%CI 0.17—0.77, highest vs. lowest tertile, p for 
trend = 0.007), vitamin A (OR=0.36, 95%CI 0.17—0.77, 
highest vs. lowest tertile, p for trend = 0.008), !-carotene 
(OR=0.35, 95%CI 0.16—0.75, highest vs. lowest tertile, p for 
trend = 0.007), thiamin (OR=0.42, 95%CI 0.19—0.91, highest 
vs. lowest tertile, p for trend = 0.039), riboflavin (OR=0.37, 
95%CI 0.18—0.77, highest vs. lowest tertile, p for trend = 
0.007), vitamin B6 (OR=0.35, 95%CI 0.15—0.80, highest vs. 
lowest tertile, p for trend = 0.009), vitamin E (OR=0.48, 
95%CI 0.24—0.98, highest vs. lowest tertile, p for trend = 
0.037), and folate (OR=0.40, 95%CI 0.20—0.83, highest vs. 
lowest tertile, p for trend = 0.014) intakes and gastric cancer 
risk in adjusted model (includes adjustment for H. pylori 
infection).  Vegetable fat inverse trend borderline significant, 
but tertile ORs significant (OR=0.49, 95%CI 0.24—0.99, 
highest vs. lowest tertile, p for trend = 0.055).  Riboflavin 
(OR=0.42, 95%CI 0.21—0.89, highest vs. lowest tertile, p for 
trend = 0.021) and vitamin C (OR=0.35, 95%CI 0.17—0.74, 
highest vs. lowest tertile, p for trend = 0.006) also significantly 
associated with reduced gastric cancer risk when dietary intake 
combined with supplement use. 
Significant protective effects of vitamins E (OR=0.16, 95%CI 
0.03—0.83, highest vs. lowest tertile, p for trend = 0.028) and 
C (OR=0.10, 95%CI 0.02—0.63, highest vs. lowest tertile, p 
for trend = 0.015) were evident among H. pylori-positive 
subjects.  Interaction not statistically significant. 
Effect of vegetable 
fat not significant 
when adjusted for 
vitamin E. 
Study population 
consumed 
relatively high 
amounts of PUFA 
and MUFA 
compared to 
saturated fats. 
Dietary 
antioxidants may 
inhibit the 
formation of N-
nitroso compounds 
from secondary 
amines and nitrites 
in the stomach by 
reducing nitrites to 
nitric oxide or 
modifying amines. 
 
 
 
Phukan et Hospital-based In-person interview and food Significant positive trends with smoked dried salted fish  
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al.[302] case-control 
Gastric cancer 
cases, n=329 
Non-cancer 
patient controls, 
n=665 
frequency questionnaire 
Spot urease from biopsy sample 
(for H. pylori) 
Serum H. pylori by ELISA 
(OR=2.8, 95%CI 1.8—8.4, 2+ times/w vs. never, p for trend 
<0.001) and meat (OR=2.8, 95%CI 1.7—8.8, 2+ times/w vs. 
never, p for trend <0.001) consumption and gastric cancer 
odds.  Significant positive trends also seen with sa-um 
(fermented pork fat) (OR=3.4, 95%CI 1.7—10.3, 2+ times/w 
vs. never, p for trend <0.001) and soda (OR=2.9, 95%CI 1.2—
6.5, 2+ times/w vs. never, p for trend <0.001) added as a food 
preservative. 
Significant interaction between H. pylori infection and smoked 
salted meat (OR=1.9, p <0.046) or sa-um (OR=2.1, p <0.02) 
intake and gastric cancer risk. 
Kuriki et 
al.[303] 
Hospital-based 
case-control 
Gastric cancer 
cases, n=179 
Outpatient 
controls, n=357 
In-person interview and food 
frequency questionnaire 
Erythrocyte fatty acid 
composition 
Significantly increased odds for gastric cancer with increasing 
sodium intake (poorly differentiated: OR=1.97, 95%CI 1.19—
3.25, highest vs. lowest tertile, p for trend <0.05; well-
differentiated: OR=2.67, 95%CI 0.97—5.79, p for trend = 
0.06).  Sodium intake positively correlated to fish (r = 0.41, p 
<0.0001) and seafood (r = 0.45, p <0.0001) intake but not 
erythrocyte PUFAs. 
Significant positive associations between erythrocyte saturated 
fat (OR=2.3, 95%CI 1.39—3.90), highest vs. lowest tertile, p 
for trend <0.005) and palmitic acid (OR=3.14, 95%CI 1.77—
5.70, highest vs. lowest tertile, p for trend <0.001) composition 
and gastric cancer odds. 
Significant inverse associations between erythrocyte DHA 
(OR=0.47, 95%CI 0.28—0.79, highest vs. lowest tertile, p for 
trend <0.01), docosapentaenoic acid (OR=0.32, 95%CI 0.18—
0.56, highest vs. lowest tertile, p for trend = 0.0005) and total 
n-3 highly unsaturated fatty acids (at least 20 carbons, 
OR=0.39, 95%CI 0.23—0.68, highest vs. lowest tertile, p for 
trend <0.005) and gastric cancer odds. 
 
Wu et 
al.[304] 
Population-based 
case-control 
Gastric cardia 
cancer cases, 
n=257 
In-person interview and food 
frequency questionnaire 
Gastric cardia cancer odds significantly increased with 
increasing total fat (OR=1.44, 95%CI 0.9—2.2, highest vs. 
lowest quartile, p for trend = 0.046), saturated fat (OR=1.52, 
95%CI 1.0—2.4, highest vs. lowest quartile, p for trend = 
0.004), and MUFA (OR=1.31, 95%CI 0.9—2.0, highest vs. 
Also evaluated 
esophageal cancer 
risk. 
H. pylori results for 
33-50% of subjects 
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Distal gastric 
cancer cases, 
n=366 
Population 
controls, n=1308 
lowest quartile, p for trend = 0.08) intakes. 
Distal gastric cancer odds significantly increased with 
increasing cholesterol intake (OR=2.39, 95%CI 1.6—3.5, 
highest vs. lowest quartile, p for trend <0.001). 
Carbohydrate intake significantly inversely associated with 
gastric cancer odds (cardia: OR=0.58, 95%CI 0.4—0.9, 
highest vs. lowest quartile, p for trend = 0.016; distal: 
OR=0.58, 95%CI 0.4—0.9, highest vs. lowest quartile, p for 
trend = 0.003).  Highest vs. lowest fiber intake significantly 
protective for all gastric cancers (cardia: OR=0.58, 95%CI 
0.4—0.9; non-cardia: OR=0.69, 95%CI 0.5—1.0, p for trend = 
0.15), but quartile trend significant in cardia cancer only (p for 
trend = 0.016).  Association with total fat no longer present 
when adjusting for fiber. 
Gastric cancer odds significantly increased with increasing 
meat (including fish) intake (cardia: OR=1.67, 95%CI 1.03—
2.7, highest vs. lowest quartile, p for trend = 0.027; distal: 
OR=1.91, 95% CI 1.3—2.9, highest vs. lowest quartile, p for 
trend = 0.004).  Significant positive trends for red meat and 
gastric cardia cancer risk (OR=1.56, 95%CI 0.97—2.5, highest 
vs. lowest quartile, p for trend = 0.031) and processed meat 
and distal gastric cancer risk (OR=1.65, 95%CI 1.1—2.5, 
highest vs. lowest quartile, p for trend = 0.049). 
from previous 
analysis did not 
impact fiber, fat, 
and cholesterol 
results. 
Hu et al.[305] Population-based 
case-control 
Gastric cancer 
cases, n=1182 
Population 
controls, n=5039 
Mailed questionnaire with food 
frequency questionnaire 
Total meat (OR=1.6, 95%CI 1.3—2.1, highest vs. lowest 
quartile, p for trend = 0.0001), processed meat (OR=1.7, 
95%CI 1.3—2.2, highest vs. lowest quartile, p for trend = 
0.0001), and total fish (OR=1.3, 95% CI 1.0—1.6, p for trend 
= 0.05) consumption significantly associated with increased 
gastric cancer odds. 
High poultry intake was significantly associated with 
decreased gastric cancer odds in men only (OR=0.7, p for 
interaction <0.05). 
 
Navarro 
Silvera et 
al.[306] 
Population-based 
case-control 
Gastric cardia 
In-person interview and food 
frequency questionnaire 
All meats (OR=1.37, 95%CI 1.08—1.73, continuous based on 
increase of 1 serving/d), poultry (OR=1.89, 95%CI 1.15—
3.11, continuous based on increase of 1 serving/d), grains 
Also evaluated 
esophageal 
cancers. 
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cancer cases, 
n=255 
Gastric non-
cardia cancer 
cases, n=352 
Population 
controls, n=687 
(OR=1.20, 1.02—1.42, continuous based on increase of 1 
serving/d), and high-fat dairy (OR=1.23, 95%CI 1.01—1.51, 
continuous based on increase of 1 serving/d) significantly 
associated with increased gastric cardia cancer odds. 
All meats (OR=1.39, 95%CI 1.12—1.71, continuous based on 
increase of 1 serving/d), poultry (OR=1.90, 95%CI 1.19—
3.03, continuous based on increase of 1 serving/d), high-nitrite 
meats (OR=1.88, 95%CI 1.24—2.84, continuous based on 
increase of 1 serving/d), grains (OR=1.36, 95%CI1.17—1.59, 
continuous based on increase of 1 serving/d), and refined 
grains (OR=1.51, 95%CI 1.25—1.82, continuous based on 
increase of 1 serving/d) significantly associated with increased 
gastric non-cardia cancer odds. 
Borderline significant inverse association between non-citrus 
fruits and gastric cardia cancer risk (OR=0.84, 95%CI 0.68—
1.03, continuous based on increase of 1 serving/d). 
Significantly decreased risk for gastric non-cardia cancer with 
increasing low-fat dairy intake (OR=0.60, 95%CI 0.41—0.88, 
continuous based on increase of 1 serving/d). 
Lucenteforte 
et al.[307] 
Hospital-based 
case-control 
Gastric cancer 
cases, n=230 
Non-cancer 
patient controls, 
n=547 
In-person interview and food 
frequency questionnaire 
Significant positive trend with total energy intake and gastric 
cancer odds (OR=1.79, 95% CI 1.16—2.76, highest vs. lowest 
tertile, p for trend = 0.01). 
Significant inverse associations with total vegetable fats 
(OR=0.65, 95%CI 0.43—0.98, highest vs. lowest tertile, p for 
trend = 0.06), PUFA (OR=0.66, 95%CI 0.44—0.97, highest 
vs. lowest tertile, p for trend = 0.03), and linoleic acid 
(OR=0.67, 95%CI 0.45—1.00, highest vs. lowest tertile, p for 
trend = 0.05) and gastric cancer odds. 
 
Pourfarzi et 
al.[308] 
Population-based 
case-control 
Gastric cancer 
cases, n=217 
Population 
controls, n=394 
In-person interview and dietary 
questionnaire 
Serum H. pylori by ELISA 
Significant increased odds for gastric cancer with positive H. 
pylori status (OR=1.72, 95%CI 1.12—2.63, positive vs. 
negative). 
Daily consumption of red meats (OR=3.40, 95%CI 1.76—
6.46, at least once daily vs. 2 or fewer time/w, p for trend 
<0.01) and dairy products (OR=2.28, 95%CI 1.23—4.22, at 
least once daily vs. 2 or fewer times/w, p for trend <0.01) 
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Reference Study Design Outcome Measurement(s) Results Notes 
significantly increased gastric cancer odds. 
Allium vegetables (garlic (OR=0.35, 95%CI 0.13—0.95, 3 or 
more times/w vs. never or infrequently, p for trend <0.01) and 
onions (OR=0.34, 95%CI 0.019—0.62, at least once daily vs. 
2 or fewer times/w, p for trend = 0.02)), fresh fruits (OR=0.45, 
95%CI 0.29—0.68, at least 3 times/w vs. never or 
infrequently, p for trend <0.01), citrus fruits (OR=0.31, 95%CI 
0.17—0.59, at least 3 times/w vs. never or infrequently, p for 
trend <0.01), and fresh fish (OR=0.37, 95%CI 0.19—0.70, at 
least once weekly vs. never or infrequently) consumption 
significantly inversely associated with gastric cancer odds.   
Significantly increased risk for gastric cancer with hot 
(OR=2.85, 95%CI 1.65—4.91, hot vs. not hot) and strong 
(OR=2.64, 95%CI 1.45—4.80, strong vs. not strong) tea 
consumption and preference for high salt intake (OR=3.10, 
95%CI 1.88—5.10, salty vs. not salty). 
These results (except fresh fruits) include adjustment for H. 
pylori status and salt preference. 
Sumathi et 
al.[309] 
Hospital-based 
case-control 
Gastric cancer 
cases, n=89 
Non-cancer 
dyspeptic 
controls, n=89 
In-person interview and food 
frequency questionnaire 
Significant positive associations between alcohol consumption 
(OR=2.3, 95%CI 1.1—4.9, p = 0.04) and pickled foods 
(OR=1.8, 95%CI 1.2—3.9, p = 0.05) and gastric cancer odds. 
Significant inverse association between pulses (legumes, 
OR=0.4, 95%CI 0.2—0.9, p = 0.05) and gastric cancer odds. 
 
Pakseresht et 
al.[310] 
Population-based 
case-control 
Gastric cancer 
cases, n=286 
Population 
controls, n=304 
In-person interview and food 
frequency questionnaire 
Serum H. pylori and CagA via 
Western blot 
No significant difference in proportion of H. pylori-positive 
subjects in cases vs. controls (both groups at least 97% 
positive, p = 0.16).  Cases significantly more likely to be CagA 
positive (p = 0.04). 
Significant inverse associations between protein (OR=0.87, 
95%CI 0.76—0.99, per 10 g), vitamin C (OR=0.82, 95%CI 
0.76—0.87, per 10 mg), zinc (OR=0.47, 95%CI 0.32—0.70, 
per 5 mg), and iron (OR=0.37, 95%CI 0.32—0.70, per 5 mg) 
intakes and gastric cancer odds, with adjustment for H. pylori 
status. 
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Reference Study Design Outcome Measurement(s) Results Notes 
Significant positive association for total fat and gastric cancer 
odds, with adjustment for H. pylori status (OR=1.33, 95%CI 
1.12—1.57, per 20 g) 
Icli et 
al.[311] 
Hospital-based 
case-control 
Gastric cancer 
cases, n=253 
Friends and 
relatives of cases 
as controls, n=253 
In-person interview and food 
frequency questionnaire 
Significant inverse associations for salad (OR=0.2, 95%CI 
0.1—0.7, highest vs. lowest tertile, p for trend = 0.006), coffee 
(OR=0.3, 95% CI 0.2—0.7, highest vs. lowest tertile, p for 
trend <0.0001), tomatoes and cucumbers at breakfast (OR=0.6, 
95%CI 0.4—0.9, preference versus no preference, p = 0.009), 
and fish (OR=0.6, 95% CI 0.4—1.0, preference vs. no 
preference, p = 0.036) and dried legumes (OR=0.7, 95%CI 
0.5—1.0, preference vs. no preference, p = 0.043) at lunch and 
dinner and gastric cancer odds in multivariate model. 
Significant positive association between animal-derived 
cooking oil use and gastric cancer odds in multivariate model 
(OR=1.9, 95% CI 1.2—3.0, animal vs. plant oil, p = 0.003). 
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The association between fat intake and gastric cancer risk appears to be complex.  
Kabat et al.[290] reported a significant positive trend for gastric cardia cancer risk with 
increasing fat intake (OR = 2.9, 95% CI 1.5—5.6, highest versus lowest quartile, p for 
trend <0.001).  However, subsequent studies detected inverse associations between fat, 
particularly plant fats, and gastric cancer risk.  Ji et al.[291] demonstrated significantly 
decreased odds for gastric cancer with increasing fat intake among women (OR = 0.6, 
95% CI 0.4—0.8, highest versus lowest quartile, p for trend = 0.006) and with increasing 
plant oil intake among both sexes (men: OR = 0.7, 95% CI 0.5—0.9, p for trend = 0.001; 
women: OR = 0.6, 95% CI 0.4—1.0, p for trend = 0.01, highest versus lowest quartile).  
The results of Kaaks et al.[292] show a significant reduction in gastric cancer risk with 
increasing intake of LA (OR = 0.53, highest versus lowest quartile, p for trend <0.001) 
and borderline inverse associations for MUFA (OR = 0.75, highest versus lowest quartile, 
p for trend = 0.064) and PUFA (OR = 0.69, highest versus lowest quartile, p for trend = 
0.065).  Additionally, Palli et al.[297] concluded that increased consumption of vegetable 
fat (OR = 0.7, 95% CI 0.5—1.0, highest versus lowest tertile, p for trend = 0.04) and LA 
(OR = 0.7, 95% CI 0.6—1.0, highest versus lowest tertile, p for trend = 0.04) conferred a 
significant 30% reduction in gastric cancer risk, while PUFA were borderline 
significantly inversely associated with gastric cancer risk (OR = 0.7, 95% CI 0.5—1.0, 
highest versus lowest tertile, p for trend = 0.08).  Kim et al.[301] reported a significant 
decrease in gastric cancer odds with increased vegetable fat intake (OR = 0.49, 95% CI 
0.24—0.99, highest versus lowest tertile, p for trend = 0.055), but this association was no 
longer present when adjusting for vitamin E, suggesting that the protective effect was due 
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to the vitamin E present in the vegetable fat.  Inverse associations for total vegetable fats 
(OR = 0.65, 95% CI 0.43—0.98, highest versus lowest tertile, p for trend = 0.06), PUFA 
(OR = 0.66, 95% CI 0.44—0.97, highest versus lowest tertile, p for trend = 0.03), and 
linoleic acid (OR = 0.67, 95% CI 0.45—1.00, highest versus lowest tertile, p for trend = 
0.05) and gastric cancer odds were also detected by Lucenteforte et al.[307]. 
Mayne et al.[296] reported a significant positive association between saturated fat 
and gastric non-cardia cancer odds (OR = 1.51, 95% CI 1.04—2.19, 75th versus 25th 
percentile), while PUFA were significantly inversely associated with this cancer site (OR 
= 0.66, 95% CI 0.47—0.93, 75th versus 25th percentile).  Significant positive associations 
for total fat (OR = 1.44, 95% CI 0.9—2.2, highest versus lowest quartile, p for trend = 
0.046), saturated fat (OR = 1.52, 95% CI 1.0—2.4, highest versus lowest quartile, p for 
trend = 0.004), and MUFA (OR = 1.31, 95% CI 0.9—2.0, highest versus lowest quartile, 
p for trend = 0.08) and gastric cardia cancer odds were demonstrated by Wu et al.[304]; 
however, the association for total fat was no longer significant when adjusting for fiber 
intake.  Subsequently, Navarro Silvera et al.[306] concluded that high-fat dairy intake 
was significantly positively associated with gastric cardia cancer odds (OR = 1.23, 95% 
CI 1.01—1.51, based on an increase of one serving per day).  A recent study by 
Pakseresht et al.[310] reported a significant positive association between total fat intake 
and gastric cancer odds (OR = 1.33, 95% CI 1.12—1.57, per each 20 g increase in 
intake).  In addition to subjective dietary data, Kuriki et al.[303] evaluated erythrocyte 
fatty acid composition and demonstrated significant positive associations between 
concentration of saturated fat (OR = 2.3, 95% CI 1.39—3.90, highest versus lowest 
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tertile, p for trend <0.0005) and palmitic acid (OR = 3.14, 95% CI 1.77—5.70, highest 
versus lowest tertile, p for trend <0.001) and gastric cancer odds and significant negative 
associations between DHA (OR = 0.47, 95% CI 0.28—0.79, highest versus lowest tertile, 
p for trend <0.01) and total highly-unsaturated n-3 (at least 20 carbons, OR = 0.39, 95% 
CI 0.23—0.68, highest versus lowest tertile, p for trend <0.005) and gastric cancer odds.  
Although case-control studies conducted to date indicate that high total fat and saturated 
fat intakes may increase the risk of both cardia and non-cardia gastric cancer, evidence 
suggests an inverse association between vegetable fats, MUFA, PUFA, n-3, and LA and 
gastric cancer risk. 
 Similar to the results seen with fat intake, the association between fish intake and 
gastric cancer risk evaluated via case-control studies is equivocal.  In a series of case-
control studies of multiple cancer sites, Fernandez et al.[294] concluded that fish 
consumption at least twice weekly significantly decreased gastric cancer odds by 30% 
compared to fish consumption once per week (OR = 0.7, 95% CI 0.5—0.8).  More 
recently, Pourfarzi et al.[308] detected a significant inverse association between fresh fish 
consumption and gastric cancer odds (OR = 0.37, 95% CI 0.19—0.70, at least once 
weekly versus never or infrequently), and Ito et al.[299] measured significantly decreased 
gastric cancer odds with increasing intake of cooked fish in a case-control study of 
women only (OR = 0.60, 95% CI 0.40—0.90, highest versus lowest quartile, p for trend 
<0.05).  Icli et al.[311] calculated significantly decreased gastric cancer odds with fish 
intake at lunch and dinner (OR = 0.6, 95% CI 0.4—1.0, preference versus no preference, 
p = 0.036).  Conversely, several studies have linked fish intake to increased gastric cancer 
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odds.  Ward and Lopez-Carrillo[295] concluded that total fish intake more than doubled 
gastric cancer odds (OR = 2.2, 95% CI 1.2—3.8, at least six servings per week versus 
less than one serving per week, p for trend = 0.001).  Additionally, Hu et al.[305] showed 
that increasing total fish consumption was significantly associated with a moderate 
increase in gastric cancer odds (OR = 1.3, 95% CI 1.0—1.6, highest versus lowest 
quartile, p for trend = 0.05). 
 In contrast, case-control studies that have examined the intake of salted or 
fermented fish products have tended to show a positive association between the 
consumption of such products and gastric cancer risk.  Ye et al.[293] showed that fish 
sauce (OR = 2.57, 95% CI 1.89—3.50, at least 0.4 kg/month versus less than 0.4 
kg/month, p <0.01) and salted, fermented sea foods (OR = 1.57, 95% CI 1.21—2.02, at 
least 1.5 kg/year versus less than 1.5 kg/year, p <0.01) were significantly associated with 
increased odds of gastric cancer.  Conditional logistic regression models demonstrated 
that fish sauce and salted sea foods were attributable for 17.81% (p <0.01) and 19.69% (p 
<0.05) of gastric cancer cases, respectively.  In a smaller study, Lee et al.[300] reported 
that monthly consumption of salt-fermented fish significantly increased gastric cancer 
risk compared to less than monthly intake (OR = 2.4, 95% CI 1.0—5.7).  Phukan et 
al.[302] demonstrated that frequent intake of smoked salted fish nearly tripled gastric 
cancer odds (OR = 2.8, 95% CI 1.8—8.4, at least weekly versus never, p for trend 
<0.001).  When considered with the evidence from the ecological study previously 
reviewed, it appears likely that fermented fish products—fish sauce, in particular—
increase the risk of gastric cancer when consumed frequently.  However, more accurate 
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assessment of the types of fish consumed and preparation techniques employed are 
needed to further characterize the associations between fish consumption and gastric 
cancer risk among the general population. 
 Similar associations were seen regarding fruit and vegetable intake in case-control 
studies; fresh fruits and vegetables have been linked to decreased risk for gastric cancer, 
while pickled or preserved vegetables (which are high in salt) show an increased risk of 
gastric cancer with increasing consumption.  Ji et al.[291] concluded that preserved 
vegetable intake significantly increases the risk of gastric cancer in women only (OR = 
1.9, 95% CI 1.3—2.8, highest versus lowest quartile, p for trend = 0.002) but 
demonstrated significant inverse associations between all vegetables (OR = 0.4, 95% CI 
0.3—0.5, highest versus lowest quartile, p for trend <0.0001), yellow or green vegetables 
(OR = 0.5, 95% CI 0.4—0.7, highest versus lowest quartile, p for trend = 0.0001), and 
soybean products (OR = 0.5, 95% CI 0.4—0.7, highest versus lowest quartile, p for trend 
= 0.0001) and gastric cancer risk among the males participating in the study.  A 
significant inverse trend was also observed for fresh fruit intake and gastric cancer risk 
among both genders (men: OR = 0.4, 95% CI 0.3—0.6, p for trend <0.0001; women: OR 
= 0.5, 95% CI 0.3—0.8, highest vs. lowest, p for trend = 0.0006).  A subsequent study by 
Ye et al.[293] showed a significant reduction in gastric cancer risk with more frequent 
consumption of citrus (OR = 1.41, 95% CI 1.03—1.92, !2.5 kg per year versus >2.5 
kg/y, p <0.05) and other fruits (OR = 1.31, 95% CI 1.01—1.71, !2.5 kg per year versus  
>2/5 kg per year, p <0.05) and fresh vegetables (OR = 1.95, 95% CI 1.41—2.70, !25 kg 
per year versus >25 kg per year, p <0.01) and a significant increase in risk with 
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consumption of salted vegetables (OR = 1.41, 95% CI 1.09—1.83, !2 kg per year versus 
<2 kg per year, p <0.05), but these results were not adjusted for important factors such as 
age, gender, and total energy intake.  All vegetables (OR = 0.3, 95% CI 0.1—0.6, at least 
six times daily versus less than four times daily, p for trend = 0.001) and yellow or 
orange vegetables specifically (OR = 0.2, 95% CI 0.1—0.3, at least 15 servings weekly 
versus fewer than nine servings weekly, p for trend <0.001) were significantly and 
negatively associated with gastric cancer odds in a study by Ward and Lopez-
Carrillo[295], which also detected a borderline inverse association between citrus fruit 
consumption and gastric cancer odds (OR = 0.7, 95% CI 0.3—1.5, at least nine servings 
weekly versus less than two servings weekly, p for trend = 0.07).  In a case-control study 
of women only, Ito et al.[299] concluded that increased raw vegetable (OR = 0.68, 95% 
CI 0.42—0.82, everyday versus less than everyday), fruit (OR = 0.71, 95% CI 0.59—
0.85, everyday versus less than everyday), green vegetable (OR = 0.81, 95% CI 0.68—
0.97, at least three servings weekly versus less than three servings weekly), and carrot 
(OR = 0.73, 95% CI 0.61—0.87, at least three servings weekly versus less than three 
servings weekly) intakes were significantly associated with decreased odds for gastric 
cancer.  Lee et al.[300] measured significant inverse trends for raw vegetables (OR = 0.2, 
95% CI 0.1—0.5, more than six times per week versus less than four times per week), 
fruits (OR = 0.3, 95% CI 0.1—0.7, more than five times per week versus less than three 
times per week), fruit or vegetable juice (OR = 0.6, 95% CI 0.2—1.2, more than nine 
times monthly versus less than two times monthly, p for trend <0.01), and soybean curd 
(OR = 0.3, 95% CI 0.2—0.8, at least monthly versus less than monthly) consumption and 
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the risk of early gastric cancer in a small case-control study (n=69 cases).  A borderline 
significant inverse association between non-citrus fruit consumption and gastric cardia 
cancer risk was detected by Navarro Silvera et al.[306] (OR = 0.84, 95% CI 0.68—1.03, 
with each increase of one serving per day).  Pourfarzi et al.[308] concluded that increased 
consumption of allium vegetables such as garlic (OR = 0.35, 95% CI 0.13—0.95, three or 
more times per week versus never or infrequently, p for trend <0.01) and onions (OR = 
0.34, 95% CI 0.019—0.62, at least once daily versus twice or fewer times per week, p for 
trend = 0.02), fresh fruits (OR = 0.45, 95% CI 0.29—0.68, at least three servings per 
week versus never or infrequently, p for trend <0.01), and citrus fruits (OR = 0.31, 95% 
CI 0.17—0.59, at least three servings per week versus never or infrequently, p for trend 
<0.01) was significantly associated with decreased odds for gastric cancer.  More 
recently, Icli et al.[311] noted a significant inverse association between a preference for 
consuming tomatoes and cucumbers at breakfast (OR = 0.6, 95% CI 0.4—0.9, p = 0.009) 
and increased frequency of salad consumption (OR = 0.2, 95% CI 0.1—0.7, highest 
versus lowest tertile, p for trend = 0.006) and the risk of gastric cancer in a Turkish case-
control study.  However, this study used friends and relatives of the cancer cases as 
control subjects, which may have contributed bias to the results. 
 When quantifying antioxidant nutrient intakes associated with fruit and vegetable 
consumption, Ji et al.[291] concluded that increasing vitamin E (men: OR = 0.5, 95% CI 
0.3—0.7, highest versus lowest quartile, p for trend = 0.0002; women: OR = 0.5, 95% CI 
0.3—0.8, highest versus lowest quartile, p for trend = 0.0002) and carotene (men: OR = 
0.4, 95% CI 0.3—0.6, highest versus lowest quartile, p for trend <0.0001; women: OR = 
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0.7, 95% CI 0.5—1.1, highest versus lowest quartile, p for trend = 0.02) intakes 
significantly decreased the risk for gastric cancer among men and women.  A significant 
inverse trend was also noted for vitamin C among men, with the highest quartile of intake 
conferring a 50% reduction in odds (OR = 0.5, 95% CI 0.3—0.7, versus lowest quartile, p 
for trend <0.0001).  Kaaks et al.[292] also detected significant inverse associations 
between vitamin C (OR = 0.43, highest versus lowest quartile, p for trend <0.001) and !-
carotene (OR = 0.50, highest versus lowest quartile, p for trend <0.001) and gastric 
cancer risk.  Similar significant inverse associations with !-carotene (cardia: OR = 0.46, 
95% CI 0.34—0.62, 75th vs. 25th percentile; non-cardia: OR = 0.58, 95% CI 0.46—0.75, 
75th vs. 25th percentile) and vitamin C from supplements (non-cardia: OR = 0.60, 95% CI 
0.41—0.88, used supplement at least once weekly for at least six months versus no use) 
or food (cardia: OR = 0.64, 95% CI 0.49—0.84, 75th versus 25th percentile; non-cardia: 
OR = 0.59, 95% CI 0.45—0.76, 75th versus 25th percentile) were observed for gastric 
cancers by Mayne et al.[296], who also noted a significantly decreased risk for non-
cardia gastric cancer with increasing vitamin E intake (OR = 0.71, 95% CI 0.54—0.94, 
75th versus 25th percentile).  This association was borderline significant for cardia gastric 
cancer (OR = 0.75, 95% CI 0.55—1.02, 75th versus 25th percentile). 
 In a subsequent study, Palli et al.[297] demonstrated significant inverse 
associations between vitamin C (OR = 0.6, 95% CI 0.4—0.8, highest versus lowest 
tertile, p for trend = 0.001), !-carotene (OR = 0.6, 95% CI 0.4—0.8, highest versus 
lowest tertile, p for trend = 0.0009), vitamin E (OR=0.4, 95% CI 0.3—0.7, highest versus 
lowest tertile, p for trend = 0.0001), and nitrates (as a marker of vegetable consumption, 
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OR = 0.6, 95% CI 0.4—0.9, highest versus lowest tertile, p for trend = 0.01) and risk of 
gastric cancer.  Vitamin C intake was also shown to be significantly inversely associated 
with distal gastric cancer risk by Chen et al.[298] (OR = 0.6, 95% CI 0.3—1.2, highest 
versus lowest quartile, p for trend = 0.04); however, the authors did not define distal 
gastric cancer, and 80% of the interviews for gastric cancer cases were conducted with 
spouses, children, parents, or other relatives or friends of the subjects due to the high 
mortality rate among gastric cancer cases.   
 From a hospital based case-control study, Kim et al.[301] detected significant 
inverse associations between !-carotene (OR = 0.35, 95% CI 0.16—0.75, highest versus 
lowest tertile, p for trend = 0.007), vitamin E, (OR = 0.48, 95% CI 0.24—0.98, highest 
versus lowest tertile, p for trend = 0.037), and total vitamin C (from supplements and 
food, OR = 0.35, 95% CI 0.17—0.74, highest versus lowest tertile, p for trend = 0.006) 
intake and gastric cancer risk; these results included adjustment for H. pylori infection 
status.  Finally, Pakseresht et al.[310] concluded that vitamin C (OR = 0.82, 95% CI 
0.76—0.87, per 10 mg), zinc (OR = 0.47, 95% CI 0.32—0.70, per 5 mg), and iron (OR = 
0.37, 95% CI 0.32—0.70, per 5 mg) intakes were significantly inversely associated with 
gastric cancer risk, with adjustment for H. pylori. 
 Case-control studies have also provided evidence for associations between 
additional dietary factors, such as alcohol, total energy, protein, carbohydrate, fiber, 
legume, coffee, and tea consumption, as well as eating habits and dietary patterns and the 
risk of gastric cancer.  Kabat et al.[290] concluded that increasing alcohol consumption, 
particularly hard liquor, increased the risk of gastric cardia cancer among men (OR = 2.3, 
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95% CI 1.3—4.3, at least 4 oz. whiskey equivalents per day versus nondrinkers); among 
women, daily beer consumption significantly increased the odds of gastric cardia cancer 
by nearly five-fold (OR = 4.9, 95% CI 1.1—22.8, versus nondrinkers). Sumathi et 
al.[309] also detected a substantial increased risk for gastric cancer with increasing 
alcohol intake (OR = 2.3, 95% CI 1.1—4.9, p = 0.04). 
 In addition, Kabat et al.[290] reported a significant inverse association between 
fiber intake and gastric cardia cancer risk (OR = 3.2, 95% CI 1.5—7.0, lowest versus 
highest quartile, p for trend <0.01).  Ji et al.[291] detected significant inverse associations 
between fiber (men: OR = 0.6, 95% CI 0.4—0.8, highest versus lowest, p for trend = 
0.002; women: OR = 0.6, 95% CI 0.3—0.9, highest versus lowest, p for trend = 0.007) 
and protein intake (men: OR = 0.7, 95% CI 0.5—0.9, highest versus lowest, p for trend = 
0.003; women: OR = 0.6, 95% CI 0.4—1.0, highest versus lowest, p for trend = 0.01) and 
gastric cancer risk and a significant positive trend for carbohydrate intake and gastric 
cancer risk among both men women (men: OR = 1.5, 95% CI 1.1—2.1, highest versus 
lowest, p for trend = 0.002; women: OR = 1.9, 95% CI 1.3—2.9, highest versus lowest, p 
for trend = 0.0007).  Kaaks et al.[292] concluded that total protein (OR = 0.64, highest 
versus lowest quartile, p for trend = 0.024), total vegetable protein (OR = 0.53, highest 
versus lowest quartile, p for trend = 0.001), total polysaccharides (OR = 0.63, highest 
versus lowest quartile, p for trend = 0.002), and total dietary fiber (OR = 0.31, highest 
versus lowest quartile, p for trend <0.001) intakes were significantly inversely associated 
with gastric cancer odds, while total energy (OR = 2.19, highest versus lowest quartile, p 
for trend <0.001) and total mono- and disaccharides (OR = 1.88, highest versus lowest 
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quartile, p for trend <0.001) intakes were significantly associated with increased gastric 
cancer odds.  Ward and Lopez-Carrillo[295] detected a significant inverse association 
between bean consumption and gastric cancer odds (OR = 0.2, 95% CI 0.1—0.3, at least 
seven servings per week versus one or fewer servings per week, p for trend <0.001) but a 
borderline positive trend for soda and sweets intakes and gastric cancer odds (OR = 1.7, 
95% CI 0.9—3.2, 15 or more servings per week versus less than six servings per week, p 
for trend = 0.06).  Mayne et al.[296] concluded that increasing total starch (cardia: OR = 
1.61, 95% CI 1.14—2.28, 75th versus 25th percentile; non-cardia: OR = 2.07, 95% CI 
1.51—2.83, 75th versus 25th percentile), total protein (cardia: OR = 1.64, 95% CI 1.11—
2.42, 75th versus 25th percentile; non-cardia: OR = 1.52, 95% CI 1.08—2.15, 75th versus 
25th percentile), and animal protein (cardia: OR = 1.60, 95% CI 1.19—2.15, 75th versus 
25th percentile; non-cardia: OR = 1.58, 95% CI 1.22—2.06, 75th versus 25th percentile) 
consumption significantly increased the risk for all gastric cancers while increasing 
dietary fiber intake significantly decreased the risk for all gastric cancers (cardia: OR = 
0.43, 95% CI 0.30—0.61, 75th versus 25th percentile; non-cardia: OR = 0.38, 95% CI 
0.28—0.53, 75th versus 25th percentile) and increasing vegetable protein intake 
significantly decreased the risk for non-cardia gastric cancers (OR = 0.63, 95% CI 0.45—
0.87, 75th versus 25th percentile).  A significant positive association for total protein 
intake and gastric cancer risk was also detected by Palli et al.[297] (OR = 1.7, 95% CI 
1.2—2.5, highest versus lowest tertile, p for trend = 0.002).  Chen et al.[298] concluded 
that carbohydrate (OR = 0.4, 95% CI 0.2—0.8, highest versus lowest quartile, p for trend 
= 0.004) and fiber intakes (OR = 0.4, 95% CI 0.2—0.8, highest versus lowest quartile, p 
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for trend = 0.007) significantly reduced distal gastric cancer odds by 60%; as mentioned 
previously, this study largely relied on proxy interviews which may have biased the 
results.  Kim et al.[301] demonstrated significant inverse associations between dietary 
fiber (OR = 0.37, 95% CI 0.17—0.79, highest versus lowest tertile, p for trend = 0.009) 
and vegetable protein (OR = 0.39, 95% CI 0.18—0.82, highest versus lowest tertile, p for 
trend = 0.013) consumption and gastric cancer risk after adjustment for H. pylori status.  
Wu et al.[304] concluded that carbohydrate intake was significantly inversely associated 
with gastric cancer risk (cardia: OR = 0.58, 95% CI 0.4—0.9, highest versus lowest 
quartile, p for trend = 0.016; distal: OR = 0.58, 95% CI 0.4—0.9, highest versus lowest 
quartile, p for trend = 0.003) and that the highest quartile of fiber intake significantly 
reduced the risk for all gastric cancers when compared to the lowest quartile (cardia: OR 
= 0.58, 95% CI 0.4—0.9; non-cardia: OR = 0.69, 95% CI 0.5—1.0, p for trend = 0.15), 
but the inverse trend was significant in gastric cardia cancers only (p for trend = 0.016).  
Navarro Silvera et al.[306] demonstrated a significant positive association between grain 
intake and gastric non-cardia cancer risk, with each additional serving per day conferring 
a 20% increase in odds (OR = 1.20, 95% CI 1.02—1.42).  Lucenteforte et al.[307] 
detected a significant positive trend between total energy intake and gastric cancer risk 
(OR = 1.79, 95% CI 1.16—2.76, highest versus lowest tertile, p for trend = 0.01).  
Sumathi et al.[309] detected a significant inverse association between legume intake and 
gastric cancer risk (OR = 0.4, 95% CI 0.2—0.9, p = 0.05).  Finally, Icli et al.[311] 
concluded that a preference for dried legumes at dinner (OR = 0.7, 95% CI 0.5—1.0, 
versus no preference, p = 0.043) and frequent coffee consumption (OR = 0.3, 95% CI 
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0.2—0.7, highest versus lowest tertile, p for trend <0.0001) were significantly and 
inversely associated with gastric cancer odds. 
 With regards to eating habits, Ji et al.[291] demonstrated that increasing 
temperatures of hot soup or porridge (overall: OR = 1.9, 95% CI 1.5—2.5, burning hot 
versus not hot, p for trend <0.0001; cardia: OR = 2.9, 95% CI 1.7—4.9, burning hot 
versus not hot, p for trend <0.0001; distal: OR = 1.9, 95% CI 1.4—2.5, burning hot 
versus not hot, p for trend <0.0001), frequency of irregular meals (overall: OR = 3.6, 
95% CI 2.7—4.9, frequently versus never, p for trend <0.0001; cardia: OR = 4.0, 95% CI 
2.4—6.5, frequently versus never, p for trend <0.0001; distal: OR = 3.7, 95% CI 2.7—
5.2, frequently versus never, p for trend <0.0001), speed of eating (overall: OR = 2.0, 
95% CI 1.8—2.5, fast versus moderate, p for trend <0.0001; cardia: OR = 3.8, 95% CI 
2.5—5.7, fast versus moderate, p for trend <0.0001; distal: OR = 1.8, 95% CI 1.5—2.2, 
fast versus moderate, p for trend <0.0001), and inclination for binge eating (overall: OR = 
2.5, 95% CI 2.0—3.1, yes versus no; cardia: OR = 3.0, 95% CI 2.0—4.4, yes versus no; 
distal: OR = 2.4, 95% CI 1.9—3.1, yes versus no) significantly increased the risks for 
overall, cardia, and distal gastric cancers; however, no standard definitions were provided 
for these variables, and the results may be subject to information bias.  Ye et al.[293] 
demonstrated significant positive associations between consumption of moldy foods (OR 
= 2.32, 95% CI 1.73—3.09, yes versus no, p <0.01) and irregular dinners (OR = 5.47, 
95% CI 4.22—7.09, at least three times per week versus less than three times per week, p 
<0.01) and the risk of gastric cancer; however, only the association for irregular dinners 
remained significant upon adjustment for gender, nationality, age, and location of 
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residence.  The authors calculated an adjusted attributable risk of 48.93% of all gastric 
cancers among the subjects due to irregular dinner patterns (p <0.01).  Pourfarzi et 
al.[308] demonstrated that increasing consumption of hot (OR = 2.85, 95% CI 1.65—
4.91, hot versus not hot) and strong tea (OR = 2.64, 95% CI 1.45—4.80, strong versus 
not strong) significantly increased the odds for gastric cancer in their study population.  
Compared to dietary components alone, these unhealthy eating behaviors appear to 
substantially increase gastric cancer risk, but information bias or residual confounding of 
other diet and lifestyle factors associated with poor eating habits may influence the 
results. 
 Table 37 summarizes case-control studies that have evaluated the associations 
between diet and gastric cancer risk by defining unique dietary patterns among their 
study populations, largely through the use of principal components analysis.  The case-
control study by Palli et al.[297] included factor analyses of dietary patterns; increasing 
consumption of a traditional diet (rich in protein, starch, alcohol, and nitrites) tripled the 
risk of gastric cancer (OR = 3.0, 95% CI 0.4—0.9, highest versus lowest tertile, p for 
trend = 0.0001) while a vitamin-rich diet (rich in antioxidant vitamins, fiber, and nitrates) 
was significantly associated with a 50% reduction in gastric cancer odds (OR = 0.5, 95% 
CI 0.4—0.7, highest versus lowest tertile, p for trend = 0.0003).  In a subsequent analysis 
from a study cited above, Chen et al.[312] concluded that there were significant 
differences in distal gastric cancer risk across the six dietary patterns established (p = 
0.04) and that high-meat (OR = 2.9, 95% CI 0.89—9.2, p = 0.1) and high-dairy (OR = 
2.2, 95% CI 0.68—7.0, p = 0.4) dietary patterns were associated with a non-significant 
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Table 37.  Summary of case-control human studies examining dietary intake patterns and the risk of gastric cancer. 
Reference Study Design Outcome Measurement(s) Results Notes 
Chen et 
al.[312] 
Population-
based case-
control 
Distal gastric 
cancer cases, 
n=124 
Population 
controls, 
n=407 
Telephone interview and 
food frequency 
questionnaire 
Six dietary patterns 
identified via cluster 
analysis 
Overall significant difference in distal gastric cancer risk 
across dietary patterns (p = 0.04). 
Non-significant increased risk for distal gastric cancer with 
high-meat (OR=2.9, 95%CI 0.89—9.2, p = 0.1) and high-milk 
(OR=2.2, 95%CI 0.68—7.0, p = 0.4) dietary patterns compared 
to healthy dietary pattern. 
Intake of red meat significant increased the odds of distal 
gastric cancer (OR=2.0, 95%CI 0.85—4.7, highest vs. lowest 
quartile, p for trend = 0.05). 
Increased intake of fish significantly decreased the risk of 
esophageal cancer (OR=0.14, 95%CI 0.04—0.48, highest vs. 
lowest quartile, p for trend = 0.0001). 
Also evaluated 
esophageal cancer 
(significant inverse 
trend and quartile ORs 
for fish intake) 
Bahmanyar 
and Ye[313] 
Population-
based case-
control 
Gastric cardia 
cancer cases, 
n=258 
Population 
controls, 
n=815 
In-person interview and 
food frequency 
questionnaire 
Three dietary patterns 
identified via principal 
components analysis 
Increasing Western dietary pattern (high in processed meats, 
red meat, sweets, high-fat dairy, and high-fat gravy) 
significantly increased odds for gastric cardia cancer (OR=1.8, 
95%CI 1.1—2.9, highest vs. lowest tertile of Western diet, p 
for trend = 0.04). 
Non-significant decreased odds for gastric cardia cancer with 
increasing healthy dietary pattern (including fish) (OR=0.7, 
95%CI 0.5—1.1, highest vs. lowest tertile of healthy diet, p for 
trend = 0.13). 
Also evaluated 
esophageal cancer 
Bastos et 
al.[314] 
Population-
based case-
control 
Gastric cancer 
cases, n=591 
Population 
controls, 
n=1463 
In-person interview and 
food frequency 
questionnaire 
Serum H. pylori status via 
ELISA 
Three dietary patterns 
identified via principal 
components analysis 
Low consumption of dairy, fish and seafood, fruits, salads, 
vegetables, and meats significantly associated with increased 
odds of gastric cancer compared to high consumption of dairy, 
fruits, salads, and vegetables and low consumption of meat and 
alcohol (OR=1.68, 95%CI 1.31—2.14).  This association was 
similar in cardia (OR=1.71, 95%CI 0.97—3.00) and non-cardia 
(OR=1.64, 95%CI 1.25—2.14) cancers but stronger in 
intestinal (OR=1.87, 95% CI 1.30—2.67) versus diffuse 
(OR=1.32, 95%CI 0.83—2.08) histological type of gastric 
cancer. 
H. pylori infection was not a significant effect modifier (p = 
0.17). 
 
Bertuccio et Hospital-based In-person interview and Significantly increased risk for gastric cancer with increasing  
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Reference Study Design Outcome Measurement(s) Results Notes 
al.[315] case-control 
Gastric cancer 
cases, n=230 
Non-cancer 
controls, 
n=547 
food frequency 
questionnaire 
Four dietary patterns 
identified via principal 
components analysis 
intake of animal products (OR=2.13, 95%CI 1.34—3.40, 
highest vs. lowest quartile, p for trend = 0.0003) or starch-rich 
(OR=1.67, 95%CI 1.01—2.77, highest vs. lowest quartile, p 
for trend = 0.0463) dietary patterns.  Significantly decreased 
risk for gastric cancer with increasing vitamins and fiber 
dietary pattern (OR=0.60, 95%CI 0.37—0.99, highest vs. 
lowest quartile, p for trend = 0.0861).  Non-significant inverse 
association between vegetable unsaturated fatty acids pattern 
and gastric cancer risk (OR=0.89, 95%CI 0.56—1.42, highest 
vs. lowest quartile, p for trend = 0.7325). 
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increase in distal gastric cancer risk compared to a healthy diet pattern (comprised mainly 
of fruits, vegetables, fish, poultry, and dark breads).  Bahmanyar and Ye[313] 
demonstrated that increasing consumption of a Western dietary pattern, high in processed 
meats, red meat, sweets, high-fat dairy, and high-fat gravy, significantly increased the 
risk for gastric cardia cancer (OR = 1.8, 95% CI 1.1—2.9, highest versus lowest tertile of 
Western diet, p for trend = 0.04)., while a healthy dietary pattern, which included 
frequent consumption of fish, non-significantly decreased the risk for gastric cardia 
cancer (OR = 0.7, 95% CI 0.5—1.1, highest versus lowest tertile of healthy diet, p for 
trend = 0.13).  Bastos et al.[314] concluded that a diet pattern with low consumption of 
dairy, fish and seafood, fruits, salads, vegetables, and meats significantly increased the 
odds of gastric cancer when compared to a diet pattern that emphasized consumption of 
dairy, fruits, salads, and vegetables with low meat consumption (OR = 1.68, 95% CI 
1.31—2.14).  This association was consistent for both cardia (OR = 1.71, 95% CI 0.97—
3.00) and non-cardia (OR = 1.64, 95% CI 1.25—2.14) gastric cancers but stronger in 
intestinal (OR = 1.87, 95% CI 1.30—2.67) versus diffuse (OR = 1.32, 95% CI 0.83—
2.08) histological types of gastric cancer.  Lastly, Bertuccio et al.[315] concluded that 
diet patterns with high intakes of animal or starchy foods significantly increased the risk 
for gastric cancer (OR = 2.13, 95% CI 1.34—3.40, highest versus lowest quartile, p for 
trend = 0.0003), whereas a vitamin- and fiber-rich diet pattern significantly decreased the 
risk for gastric cancer (OR = 0.60, 95% CI 0.37—0.99, highest versus lowest quartile, p 
for trend = 0.0861).  The authors failed to detect a significant association between a diet 
pattern rich in vegetable unsaturated fatty acids and the risk of gastric cancer (OR = 0.89, 
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95% CI 0.56—1.42, highest versus lowest quartile, p for trend = 0.7325).  The evaluation 
of overall dietary patterns rather than individual dietary components may provide more 
reliable data regarding the associations between diet and cancer because they are more 
robust to measurement error and information bias of single components but may result in 
misclassification bias of individuals that share characteristics of multiple patterns. 
 A majority of the information regarding diet and gastric cancer risk has been 
gleaned from case-control studies, which are consistent with respect to negative 
associations between fruits, fresh vegetables, vitamin C, fiber, and vegetable protein 
intakes and gastric cancer risk.  Associations between fish, fat, and animal or total protein 
consumption and gastric cancer risk have been less conclusive, but there is some 
evidence of inverse relationships with vegetable and unsaturated fats and fresh or cooked 
fish and gastric cancer risk, while preserved or fermented seafood products have been 
linked to an increased risk for gastric cancer.  Additionally, studies that have evaluated 
total, red, and processed meat consumption have shown positive trends of these foods 
with gastric cancer risk.  Relatively few case-control studies included measurement of H. 
pylori infection status in addition to dietary habits; these studies will be addressed in a 
subsequent section. 
 
Prospective studies 
 Compared to retrospective case-control studies, prospective cohort studies 
provide better evidence of causation for environmental factors such as diet in promoting 
or reducing cancer risk because of the collection of exposure data prior to any cancer 
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Table 38.  Summary of prospective cohort human studies examining dietary fat, fish, and antioxidant intakes and the risk of gastric cancer. 
Reference Study Design Outcome Measurement(s) Results Notes 
Kneller et 
al.[316] 
Prospective 
cohort of white 
male life 
insurance policy 
holders, 
n=17,633 
Self-administered lifestyle and 
food frequency questionnaire 
Death certificates for cause of 
death and other significant 
conditions 
Cigarette use significantly associated with increased risk 
of gastric cancer death (HR=2.6, 95%CI 1.1—5.8). 
Significant increased risk of gastric cancer death with 
consumption of fresh or frozen fish 1-2 times/month 
(HR=2.1, 95%CI 1.21—3.55), bacon or side pork 6-13 
times/month (HR=2.0, 95% CI 1.02—3.90), greater than 4 
cups of milk/day (HR=2.4, 95%CI 1.10—5.04), and apples 
more than 14 times/month in season (HR=3.2, 95%CI 
1.10—9.17).  Positive trends between apples, total 
carbohydrates, and cooked cereals and risk of gastric 
cancer death were significant. 
 
Galanis et 
al.[275] 
Population-based 
prospective 
cohort of 
Japanese 
Hawaiians, 
n=11,907 
Self-administered lifestyle and 
food frequency questionnaire 
Cancer incidence via state 
registry 
There was a significant decrease in gastric cancer risk with 
fruit consumption at least 7 times/week (HR=0.6, 95%CI 
0.4—0.9).  There was a significant inverse association 
between fresh fruit and vegetable consumption and gastric 
cancer risk (8-13 times/week HR=0.5, 95%CI 0.3—0.9; 
14+ times/week HR=0.5, 95%CI 0.3—0.8; p for trend = 
0.02). 
FFQ based on 13 foods 
and 6 beverages over 
one week. 
Ngoan et 
al.[317] 
Prospective 
cohort study in 
Fukuoka 
Prefecture, 
Japan, n=13,250 
Self-administered lifestyle and 
food frequency questionnaire 
High intake of processed meat (HR=3.4, 95%CI 1.4—8.1) 
and pickled food (HR=2.6, 95%CI 1.1—5.8) significantly 
increased gastric cancer incidence risk in men only.  
Medium (HR=2.2, 95%CI 1.2—5.2) and high (HR=2.7, 
95%CI 1.2—6.1) use of cooking oil significantly increased 
risk of gastric cancer incidence in men only (p for trend 
<0.05). 
High intake of liver significantly increased gastric cancer 
incidence risk in women only (HR=2.9, 95%CI 1.1—7.5, 
significant trend). 
High intake of suimono soup significantly increased risk of 
gastric cancer incidence in both sexes (for men HR=2.4, 
95%CI 1.0—5.8, p for trend <0.05; for women HR=4.1, 
95%CI 1.2—14.2, p for trend <0.05). 
Positive trends for processed meats and cooking oil 
significant when excluding the first 3 years of follow-up (p 
Authors did not indicate 
how gastric cancer 
incidence and deaths 
were ascertained. 
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Reference Study Design Outcome Measurement(s) Results Notes 
for trend <0.05).  Inverse trend for green and yellow 
vegetables significant when excluding the first 3 years of 
follow-up (p for trend <0.05). 
Tsugane et 
al.[318] 
Population-based 
prospective 
cohort of 
Japanese adults, 
n=39,065 
Self-administered lifestyle and 
food frequency questionnaire 
Gastric cancer incidence via 
national registry 
Mortality data via death 
certificates 
 
There was a significant positive association between salt 
intake and gastric cancer risk in men only (p for trend 
<0.001).  There was a borderline significant positive 
association between miso soup consumption and gastric 
cancer risk in men only (HR=1.40, 95%CI 0.97—2.03, 3+ 
cups/day versus not daily).  Significant positive trends for 
salted fish roe (HR=2.21, 95%CI 1.24—3.92, almost 
everyday versus almost none, adjusted for demographics 
and salt intake) and salted fish preserves (HR=2.76, 
95%CI 1.44—5.27, almost everyday versus almost none, 
adjusted for demographics and salt intake) were also 
detected.  Significant positive trends for pickled vegetables 
and dried or salted fish were attenuated after adjustment 
for salt intake and residential area. 
In women, there was a significant positive trend for salted 
fish roe and gastric cancer risk (HR=3.37, 95%CI 1.48—
7.66, almost everyday versus almost none, adjusted for 
demographics and salt intake) and a borderline significant 
positive trend for pickled vegetables intake and gastric 
cancer risk (HR=2.01, 95%CI 0.97—4.17, almost 
everyday versus almost none, adjusted for demographics 
and salt intake).  These trends were attenuated following 
adjustment for salt intake and residential area. 
 
Lee et 
al.[319] 
Population-based 
prospective 
cohort of women 
in Iowa, 
n=34,708 
Self-administered lifestyle and 
food frequency questionnaire 
Gastric cancer incidence via 
state registry 
There was a significant inverse association between 
dietary zinc and gastric or esophageal cancer risk 
(HR=0.13, 05%CI 0.03—0.63, highest versus lowest 
intake, p for trend <0.01).  There was a borderline positive 
trend between dietary heme iron and gastric or esophageal 
cancer risk (HR=2.83, 95%CI 0.84—9.54, highest versus 
lowest intake, p for trend = 0.06). 
Also evaluated 
esophageal cancer risk 
Larsson et 
al.[320] 
Population-based 
prospective 
Self-administered lifestyle and 
food frequency questionnaire 
There was a significant positive association between 
processed meat consumption and gastric cancer risk 
Second questionnaire 
sent to all participants 7 
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Reference Study Design Outcome Measurement(s) Results Notes 
cohort of 
Swedish women, 
n=61,433 
Gastric cancer incidence and 
mortality data via national 
registries 
(HR=1.66, 95%CI 1.13—2.45, highest versus lowest 
intake, p for trend = 0.01). 
There were no significant trends for fish intake. 
There was a significant positive association between 
NDMA intake and gastric cancer risk (HR=1.96, 95%CI 
1.08—3.58, highest versus lowest intake, p for trend = 
0.02).  There was a borderline significant interaction 
between NDMA and fruit and vegetable consumption with 
regards to gastric cancer risk (p = 0.06). 
years following end of 
recruitment 
Takachi et 
al.[321] 
Population-based 
prospective 
cohort of 
Japanese adults, 
n=77,500 
Self-administered lifestyle and 
food frequency questionnaire 
Gastric cancer incidence and 
mortality data via patient 
notification and national 
registries 
There were significant positive trends for pickled 
vegetables (HR=2.24, 95%CI 1.71—2.93, highest versus 
lowest intake, p for trend <0.01) and salted fish roe 
(HR=1.66, 95%CI 1.32—2.09, highest versus lowest 
intake, p for trend <0.01) and gastric cancer risk.  Dried 
and salted fish intake in the top 4 quintiles significantly 
increased the risk for gastric cancer, but the linear trend 
was not significant (HR=1.46, 95%CI 1.14—1.88, highest 
versus lowest intake, p for trend = 0.12).  
Second questionnaire 
sent to all participants 5 
years following end of 
recruitment 
Also evaluated other 
cancers and 
cardiovascular diseases 
Abbreviation: 
NDMA = N-nitrosodimethylamine 
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diagnosis; however, these studies are subject to limitations such as loss to follow-up or 
measurement error.  Given the much larger sample sizes of prospective cohort studies, 
most employ self-administered measures of dietary intake, such as FFQs, which may lead 
to information biases due to inaccurate or incomplete reporting on the part of the subject 
or substantial changes in dietary habits during the years of follow-up.   
 Several prospective cohort studies have examined fish, fat, and antioxidant intake 
with respect to gastric cancer risk and are summarized in Table 38.  Kneller et al.[316] 
established a cohort of white male life insurance customers in the United States; after 20 
years of follow-up, consumption of fresh or frozen fish once or twice monthly was 
associated with a significantly increased risk of death due to gastric cancer (hazard ratio 
(HR) = 2.2, 95% CI 1.21—3.55).  High intakes of bacon or side pork (HR = 2.0, 95% CI 
1.02—3.90, six to thirteen times per month versus less than three times per month), milk 
(HR = 2.4, 95% CI 1.10—5.04, greater than four cups per day versus less than one cup 
per day), and apples (HR = 3.2, 95% CI 1.10—9.17, more than fourteen servings versus 
less than one serving per month in season) were also associated with significantly 
increased risks for gastric cancer death. 
 In a prospective cohort study of men and women of Japanese descent residing in 
Hawaii, Galanis et al.[275] noted a significant decrease in gastric cancer risk with 
consumption of fresh fruit at least seven times per week (HR = 0.6, 95% CI 0.4—0.9).  A 
similar significant trend was seen when high intakes (at least eight times per week) of 
fresh fruit and vegetables were compared to intakes of seven or fewer times per week.  
However, a drawback of this study was the assessment of dietary intakes with an FFQ 
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consisting of only thirteen foods and six beverages over one week; such measurement 
may not accurately reflect typical dietary intake over long periods of time. 
 Ngoan et al.[317] conducted a large prospective cohort study in the Fukuoka 
Prefecture in Japan.  Among men, consuming pickled foods at least twice daily conferred 
a significantly increased risk of developing gastric cancer (HR = 2.6, 95% CI 1.1—5.8, 
versus two to four servings per week), while consuming processed meat at least once 
daily more than tripled gastric cancer risk (HR = 3.4, 95% CI 1.4—8.1, versus four or 
fewer servings per month).  The use of any cooking oil at least twice weekly also 
significantly increased the risk of gastric cancer in a dose-dependent manner (for use two 
to four times weekly: HR = 2.2, 95% CI 1.2—5.2; for daily use: HR = 2.7, 95% CI 1.2—
6.1; p for trend <0.05, versus four or fewer servings per month).  Among women, 
consuming liver at least twice weekly significantly increased the risk for gastric cancer 
(HR = 2.9, 95% CI 1.1—7.5, versus seldom or never).  Within both sexes, consumption 
of suimono soup (a clear soup made from pig stomach or intestines and mushrooms[322]) 
at least daily significantly increased the risk for gastric cancer (for men HR = 2.4, 95% CI 
1.0—5.8; for women HR = 4.1, 95% CI 1.2—14.2, versus four or fewer servings per 
month).  Additional analyses excluding the first three years of follow-up demonstrated 
significant positive trends for processed meat and cooking oil and significant negative 
trends for green and yellow vegetables among the overall cohort (p <0.05); exclusion of 
the first few years of follow-up would eliminate individuals with pre-clinical gastric 
cancer at baseline who may have changed their dietary patterns compared to earlier in 
their lives. 
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 In another prospective cohort study of Japanese adults, Tsugane et al.[318] 
demonstrated significant positive trends for salted fish roe (HR = 2.21, 95% CI 1.24—
3.92, almost every day versus almost none, adjusted for demographics and salt intake) 
and salted fish preserves (HR = 2.76, 95% CI 1.44—5.27, almost every day versus almost 
none, adjusted for demographics and salt intake) and gastric cancer incidence among men 
only.  There was a borderline significant positive trend between miso soup intake and 
gastric cancer risk (HR = 1.40, 95% CI 0.97—2.03, at least three cups daily versus less 
than daily).  Among female cohort members, increasing intake of salted fish roe was 
associated with a significant increase in gastric cancer risk (HR = 3.37, 95% CI 1.48—
7.66, almost every day versus almost none, adjusted for demographics and salt intake), 
while the positive association between pickled vegetables and gastric cancer risk was 
borderline significant (HR = 2.01, 95% CI 0.97—4.17, almost every day versus almost 
none, adjusted for demographics and salt intake).  Many of these associations were 
attenuated upon adjustment for residential area but suggested that high intakes of salted 
foods increase the risk of gastric cancer in both men and women. 
 Although antioxidant function or consumption were not directly addressed, Lee et 
al.[319] measured a significant inverse association between dietary zinc (a component of 
many enzymes, including SOD) and gastric and esophageal cancer risk among women in 
the Iowa Women’s Health Study (HR = 0.13, 95% CI 0.03—0.93, highest versus lowest 
intake, p for trend <0.01).  Conversely, heme iron (a component of catalase) was 
positively associated with gastric and esophageal cancer risk (HR = 2.83, 95% CI 0.84—
9.54, highest versus lowest intake, p for trend = 0.06).  Additional analyses showed that 
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the inverse association for dietary zinc remained significant for gastric cancer incidence 
alone (p = 0.03); however, the positive association between heme iron and gastric cancer 
was not significant (p = 0.18). 
 In a subsequent prospective cohort of Swedish women, Larsson et al.[320] 
documented a significant positive association between the consumption of processed 
meat and the risk of gastric cancer (HR = 1.66, 95% CI 1.13—2.45, highest versus lowest 
tertile, p for trend = 0.01).  A specific marker of nitrosamines (carcinogenic compounds) 
frequently found in processed meats, N-nitrosodimethylamine (NDMA), was also 
significantly associated with an increased risk of gastric cancer (HR = 1.96, 95% CI 
1.08—3.58, highest versus lowest quintile, p for trend = 0.02).  When NDMA exposure 
was evaluated in conjunction with fruit and vegetable intake due to the latter’s putative 
preventive effects, there was a borderline significant interaction between fruits and 
vegetables and NDMA (p for trend = 0.06). 
 Finally, a Japanese cohort study conducted by Takachi et al.[321] evaluated the 
risks of multiple cancers and cardiovascular disease with respect to frequent consumption 
of salt and salted foods.  In this population, the highest intake of salted vegetables 
imparted more than doubled the risk of developing gastric cancer (HR = 2.24, 95% CI 
1.71—2.93, highest versus lowest quintile, p for trend <0.01), while frequent intake of 
salted fish roe increased the risk of gastric cancer by 66% (HR = 1.66, 95% CI 1.32—
2.09, highest versus lowest quintile, p for trend <0.01).  Frequent intake of dried and 
salted fish was also associated with a significant increase in gastric cancer risk, although 
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the linear trend among the quintiles was not significant (HR = 1.46, 95% CI 1.14—1.88, 
highest versus lowest quintile, p for trend = 0.12). 
 In summation, although limited in scope and country of origin, prospective cohort 
studies that have evaluated fish, fat, and antioxidant consumption and the risk of gastric 
cancer have shown positive associations between salted fish products, preserved meats, 
and salted vegetables and gastric cancer risk as well as negative associations with regards 
to fruit and vegetable consumption.  Additionally, one study showed a positive 
association with fresh or frozen fish consumption, and another study concluded that the 
use of cooking oil increased the risk of gastric cancer; however, both of these results were 
demonstrated in men only.  Prospective cohort studies offer a number of strengths 
compared to case-control studies but are more costly and time-consuming, thereby 
resulting in fewer studies from which to draw conclusions.  The associations between 
salted or processed fish, vegetables, or meat and increased gastric cancer risk shown by 
many case-control studies were borne out by the prospective cohort studies conducted, 
but there are too few data to conclude that frequent consumption of fresh or frozen fish or 
vegetable oils increase or decrease the risk of gastric cancer. 
 
Intervention trials 
 Human clinical intervention trials for antioxidant intake and gastric cancer risk 
are limited; there have been no studies examining interventions of dietary fish or fat and 
gastric cancer incidence or risk biomarkers.  Table 39 describes relevant human 
intervention studies of dietary or anti-inflammatory treatments and gastric cancer risk and 
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Table 39.  Summary of human intervention studies examining dietary intake patterns and the risk of gastric cancer. 
Reference Subjects Intervention 
Outcome 
Measurement(s) Results Notes 
Takahashi 
et al.[323] 
Healthy 
volunteers, 40-
69 y, n=550 
1-year crossover: 
• Education to decrease 
sodium intake and 
increase carotene and 
vitamin C intake during 
the first year 
• Education to decrease 
sodium intake and 
increase carotene and 
vitamin C intake during 
the second year 
Dietary energy, 
sodium, carotene, 
and vitamin via self-
administered food 
frequency 
questionnaire 
Urinary sodium 
Serum alpha- and 
beta-carotene 
Serum ascorbic acid 
Significant 384 mg/d decrease in sodium 
intake in intervention group versus 255 
mg/d increase in control group (p <0.001). 
Significant 418 !g/d increase in carotene 
intake in intervention group versus 220 !g/d 
increase in control group (p <0.05). 
Significant 13 mg/d increase in vitamin C 
intake in intervention group versus 2 mg/d 
increase in control group (p <0.05). 
These changes corresponded to changes in 
consumption of salted foods and green and 
yellow vegetables. 
There were significant differences in the 
changes of urinary sodium excretion in the 
intervention versus control groups (p 
<0.001). 
Only serum alpha-carotene differed 
significantly between the intervention and 
control groups (p <0.01). 
Although study 
objectives 
mentioned gastric 
cancer, outcomes 
assessed for 
intervention 
effectiveness not 
gastric cancer risk 
reduction. 
Hao et 
al.[324] 
Individuals 
with medical 
history of 
stomach 
disorder, 
family history 
of cancer, or 
smoking 
and/or alcohol 
use, 34-74 y, 
n=5033 
Double-blind 2-year intervention 
with 10 y follow-up: 
• 2 200 mg synthetic 
allitridum daily and 100 
!g selenium every other 
day for one month 
during each year 
• Placebo capsules of corn 
oil and starch in the 
same pattern 
Gastric cancer 
incidence via village 
doctor monitoring 
Cause of death from 
death certificates 
Assessed for first 5 
y of follow-up 
Gastric cancer incidence declined by 47.3% 
in the intervention compared to control 
group (not stated if statistically significant). 
There was a significant reduction in gastric 
cancer incidence in men only in the 
intervention group (OR=0.36, 95%CI 
0.14—0.92), after controlling for age, 
family history, smoking, alcohol, and 
history of stomach illness. 
Allitridum 
comprises almost 
45% of garlic oil. 
Too few person-
years among 
females to 
determine effect of 
intervention. 
You et 
al.[325] 
Randomly 
selected 
healthy 
Randomized double-blind 
factorial design following 
stratification by H. pylori 
H. pylori via ELISA 
Gastroscopy 
including biopsy 
For H. pylori treatment group, histological 
distributions different significantly from 
placebo group (p = 0.009 for 1999 and p = 
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Reference Subjects Intervention 
Outcome 
Measurement(s) Results Notes 
individuals, 
35-64 y, 
n=3365 
infection status: 
• Placebo twice daily for 2 
w 
• 1 g amoxicillin and 20 
mg omeprazole twice 
daily for 2 w 
• 250 mg vitamin C, 100 
IU vitamin E, and 37.5 
!g selenium twice daily 
for 7.3 y 
• Placebo twice daily for 
7.3 y 
• 200 mg aged garlic 
extract and 1 mg steam-
distilled garlic oil twice 
daily for 7.3 y 
• Placebo twice daily for 
7.3 y 
• All possible 
combinations of above 
and 
histopathological 
scoring of gastritis, 
metaplasia, 
dysplasia, and 
cancer 
Gastric cancer 
diagnosis via 
medical records 
0.0001 for 2003 follow-ups).  Treatment 
groups had higher mild chronic and 
superficial gastritis and less deep intestinal 
metaplasia than placebo group. 
H. pylori treatment significant decreased the 
odds of an advanced gastric lesion 
(OR=0.77, 95%CI 0.62—0.95 in 1995; 
OR=0.60, 95%CI 0.47—0.75 in 2003). 
There were no significant effects of vitamin 
or garlic interventions on gastric cancer 
incidence or gastric  
histopathological distribution. 
There were no significant differences in 
mortality between any of the groups. 
Tu et 
al.[326] 
Randomly 
selected 
healthy 
individuals, 
35-64 y, 
n=3355 
Sub-analysis by MnSOD 
genotype of above study 
Randomized double-blind 
factorial design following 
stratification by H. pylori 
infection status: 
• Placebo twice daily for 2 
w 
• 1 g amoxicillin and 20 
mg omeprazole twice 
daily for 2 w 
H. pylori via ELISA 
Gastroscopy 
including biopsy 
and 
histopathological 
scoring of gastritis, 
metaplasia, 
dysplasia, and 
cancer 
MnSOD genotyping 
by PCR 
There was a weak positive association 
between the variant MnSOD alleles and 
dysplasia risk (OR=1.31, 95%CI 1.02—
1.68), after controlling for age, sex, H. 
pylori, smoking, and drinking. 
The risk from the variant alleles was 
significantly higher among H. pylori-
positive versus H. pylori-negative subjects 
(OR=4.01, 95%CI 2.80—5.75 for 
dysplasia). 
Among smokers, the risk from the variant 
alleles was significantly increased 
Variant MnSOD 
predicted to 
decrease MnSOD 
transport into 
mitochondria, 
therefore 
increasing ROS 
exposure. 
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Reference Subjects Intervention 
Outcome 
Measurement(s) Results Notes 
• 250 mg vitamin C, 100 
IU vitamin E, and 37.5 
!g selenium twice daily 
for 7.3 y 
• Placebo twice daily for 
7.3 y 
• 200 mg aged garlic 
extract and 1 mg steam-
distilled garlic oil twice 
daily for 7.3 y 
• Placebo twice daily for 
7.3 y 
• All possible 
combinations of above 
compared to non-smokers (OR=1.96, 
95%CI 1.27—3.03). 
Among individuals receiving the vitamin 
intervention, H. pylori-positive subjects 
with the variant alleles had significantly 
increased gastric pathological regression 
(OR=2.45, 95%CI 1.37—4.38) compared to 
the wild-type allele. 
Ma et 
al.[327] 
Randomly 
selected 
healthy 
individuals, 
35-64 y, 
n=3365 
14.7 y follow-up of above study 
Randomized double-blind 
factorial design following 
stratification by H. pylori 
infection status: 
• Placebo twice daily for 2 
w 
• 1 g amoxicillin and 20 
mg omeprazole twice 
daily for 2 w 
• 250 mg vitamin C, 100 
IU vitamin E, and 37.5 
!g selenium twice daily 
for 7.3 y 
• Placebo twice daily for 
7.3 y 
• 200 mg aged garlic 
H. pylori via ELISA 
Gastroscopy 
including biopsy 
and 
histopathological 
scoring of gastritis, 
metaplasia, 
dysplasia, and 
cancer 
Gastric cancer 
diagnosis via 
medical records 
There was a significant decrease in gastric 
cancer incidence among subjects receiving 
H. pylori treatment compared to the placebo 
group (OR=0.61, 95%CI 0.38—0.96). 
The vitamin treatment group experienced 
significantly fewer deaths from gastric or 
esophageal cancer than the placebo group 
(HR=0.51, 95%CI 0.30—0.87).  This 
association was borderline significant when 
looking at gastric cancer deaths only (p = 
0.06). 
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Reference Subjects Intervention 
Outcome 
Measurement(s) Results Notes 
extract and 1 mg steam-
distilled garlic oil twice 
daily for 7.3 y 
• Placebo twice daily for 
7.3 y 
All possible combinations of 
above 
Wong et 
al.[328] 
Randomly 
selected H. 
pylori-positive 
subjects with 
atrophic 
gastritis, 
metaplasia, or 
dysplasia from 
above study, 
35-64 y, 
n=1024 
Randomized double-blind 
factorial intervention: 
• H. pylori placebo for 1 w 
followed by celecoxib 
placebo for 24 mos 
• 20 mg omeprazole, 1 g 
amoxicillin, 500 mg 
clarithromycin twice 
daily for 1 w followed 
by 200 mg celecoxib 
twice daily for 24 mos 
• 20 mg omeprazole, 1 g 
amoxicillin, 500 mg 
clarithromycin twice 
daily for 1 w followed 
by 200 mg celecoxib 
twice daily for 24 mos 
celecoxib placebo for 24 
mos 
• Placebo of H. pylori 
treatment for 1 w 
followed by celecoxib 
placebo for 24 mos 
13C-UBT breath test 
for H. pylori 
Gastroscopy 
including biopsy 
and 
histopathological 
scoring of gastritis, 
metaplasia, 
dysplasia, and 
cancer 
Gastric cancer 
diagnosis via 
medical records 
Celecoxib (OR=1.55, 95%CI 1.01—2.38) 
and H. pylori (OR=1.80, 95%CI 1.16—
2.78) treatments significantly increased 
regression compared to placebos.  Effect of 
two treatments together was not significant. 
7 of 9 gastric cancer cases were diagnosed 
during treatment, so cancer incidence was 
not evaluated as an endpoint. 
COX-2 
overexpression 
seen in H. pylori-
associated gastric 
cancers. 
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biomarkers.  Each of these studies was conducted in the high-risk countries of Japan or 
China. 
 Takahashi et al.[323] established a one-year crossover intervention trial involving 
education on a diet low in sodium and high in vitamin C and carotenoids in an effort to 
reduce the risk of gastric cancer and cardiovascular disease in this high-risk population.  
Although the intervention appeared effective—subjects receiving the intervention 
significantly reduced sodium intake and increased vitamin C and carotene intake—data 
have not been published so far quantifying the effect of the intervention on gastric cancer 
risk[329, 330].  It is not clear if the investigators intend to collect such data. 
 In a large clinical trial of individuals with a history of gastric disorders, family 
history of cancer, or use of tobacco and/or alcohol, Hao et al.[324] tested the effects of 
allitridum (a component of garlic oil) and selenium on gastric cancer incidence and 
mortality.  The treatment continued for two years, and subjects were continuously 
followed for an additional ten years.  After five years of follow-up, gastric cancer 
incidence decreased by 47.3% in the treatment group compared to the control group; it 
was not reported if this difference was statistically significant.  In logistic regression 
models that controlled for multiple confounding factors, a significant reduction in gastric 
cancer risk with allitridum and selenium treatment was evident only among men in the 
study (OR = 0.36, 95% CI 0.14—0.92).  This association was not seen among the women 
in the study possibly due to low numbers of gastric cancer cases among the female 
subjects. 
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 You et al.[325] first reported a population-based randomized double-blind clinical 
trial involving several treatments (anti-H. pylori medication; vitamin C, vitamin E, and 
selenium; aged garlic extract and garlic oil) and combinations thereof.  Subjects were 
monitored via gastric biopsy for histological changes predictive of cancer as well as frank 
gastric cancer diagnosis via active medical follow-up.  Anti-H. pylori treatment 
significantly reduced the risk of an advanced gastric lesion compared to placebo (OR = 
0.60, 95% CI 0.47—0.75 at the 2003 follow-up).  However, there were no significant 
effects of the vitamin/mineral or garlic supplements on gastric histopathology or cancer 
incidence.  All further intervention studies discussed are additional analyses of this parent 
study. 
 To assess the effects of genetic polymorphisms of an enzyme involved in the 
clearance of ROS, MnSOD, Tu et al.[326] concluded that variant forms of this enzyme 
with impaired effectiveness significantly increased the risk of gastric dysplasia, 
especially among individuals positive for H. pylori (OR = 4.01, 95% CI 2.80—5.75).  A 
significant increase in risk was also observed among smokers with the variant allele 
compared to smokers with the wild-type allele (OR = 1.96, 95% CI 1.27—3.03).  When 
comparing the treatments in concert with MnSOD genotype, the authors showed that H. 
pylori-positive, variant MnSOD subjects receiving the vitamin/mineral supplement 
showed an increased rate of gastric pathological regression compared to those with the 
wild type allele (OR = 2.45, 95% CI 1.37—4.38).  This result suggests that the 
vitamin/mineral supplement was able to counteract the pro-oxidant effects of H. pylori 
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infection in the presence reduced MnSOD activity, thereby delaying the progression of 
mild gastric conditions to pre-cancerous lesions. 
 After nearly 15 years of follow-up, Ma et al.[327] confirmed that the subjects 
receiving the H. pylori treatment had significantly decreased risk of gastric cancer 
compared to subjects receiving the placebo (OR = 0.61, 95% CI 0.38—0.96).  However, 
no significant differences in gastric cancer incidence were observed in the 
vitamin/mineral or garlic supplement groups.  When gastric and esophageal cancer deaths 
were evaluated together, the vitamin/mineral supplement significantly decreased 
mortality compared to the placebo group (HR = 0.51, 95% CI 0.30—0.87).  This 
association was borderline significant for gastric cancer death alone as an endpoint (HR = 
0.55, 95% CI 0.29—1.03, p = 0.06). 
 Lastly, Wong et al.[328] conducted an additional intervention in those subjects 
that were positive for H. pylori infection and atrophic gastritis, metaplasia, or dysplasia 
from the gastric biopsy.  These subjects were randomly assigned to a one-week H. pylori 
treatment with or without subsequent two-year celecoxib (a COX-2 inhibitor) treatment 
or respective placebos.  Either treatment on its own significantly increased the regression 
of gastric histopathology relative to its treatments (celecoxib: OR = 1.55, 95% CI 1.01—
2.38; H. pylori treatment: OR = 1.80, 95% CI 1.16—2.78); however, the effect of both 
treatments together was not significant when compared to treatment with a placebo.  This 
suggests that the treatments share a common mechanism of decreasing inflammation, and 
both treatments together do not confer any additional benefit.  Because a majority of the 
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gastric cancers diagnosed among the study subjects occurred during the treatment period, 
gastric cancer incidence was not assessed as an outcome. 
 From the available clinical data, it appears unlikely that garlic and antioxidant 
nutrient supplementation decreases the risk of gastric cancer.  However, each study 
utilized oral supplements of purified components, such as ascorbic acid or allitridum.  It 
is not clear what effects elevated intakes of vitamins C and/or E, selenium, and garlic as 
part of an overall healthy diet low in fat, processed foods, and red meat would have on 
gastric cancer risk or gastric histopathology.  Although no intervention trial directly 
evaluated dietary PUFA or fish intake on gastric cancer incidence, the most recent study 
by Wong et al.[328] implicated COX-2 inhibition in promoting regression of pre-
cancerous gastric conditions.  This finding may apply to n-3 PUFA such as DHA and 
ALA, which have been shown to inhibit COX-2[3, 148, 331].  More clinical intervention 
research with human subjects is needed on dietary PUFA and fish intake and gastric 
cancer incidence. 
 
Interaction of dietary factors with H. pylori infection 
 As mentioned previously, a majority of population-based studies of dietary 
intakes and gastric cancer risk have not included evaluation of H. pylori infection status; 
this is likely as result of the expense of such tests as well as their low sensitivity and 
specificity in cases of chronic gastritis[332].  There is some evidence from the studies 
presented in Table 36 demonstrating an interaction between H. pylori infection and 
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certain dietary components, such as sodium and antioxidants, in increasing or decreasing 
the odds of gastric cancer. 
 Lee et al.[300] concluded that H. pylori-positive individuals with a taste 
preference for salty foods (>0.3% NaCl) had ten times the risk of gastric cancer 
compared to H. pylori-negative subjects with a low salt preference (OR = 10.1, 95% CI 
3.4—30.0).  Among H. pylori-positive subjects with a preference for less salty foods 
(!0.3% NaCl), there was an insignificant increase in gastric cancer risk (OR = 1.7, 95% 
CI 0.6—4.7).  Because the number of subjects in this study was relatively small (n=69 
cases), the confidence intervals are wide, and the results may not apply to the general 
population.  Nevertheless, the authors determined that the interaction between H. pylori 
infection and preference of salt was statistically significant in their study population (p = 
0.047).  Subsequently, a larger hospital-based case-control study (n=329 cases) 
conducted by Phukan et al.[302] also showed significant associations between H. pylori 
infection and the salt-rich foods smoked salted meat (OR = 1.9, p <0.046) and sa-um 
(fermented pork fat, OR = 2.1, p <0.02). 
 A hospital-based case-control study conducted by Kim et al.[301] showed 
significant protective effects of vitamins E (OR = 0.16, 95% CI 0.03—0.83, highest 
versus lowest tertile, p for trend = 0.028) and C (OR = 0.10, 95% CI 0.02—0.63, highest 
versus lowest tertile, p for trend = 0.015) among H. pylori-positive subjects; however, the 
interactions of these antioxidants with H. pylori infection were not statistically 
significant.  The results from Pourfarzi et al.[308] and Pakseresht et al.[310] previously 
discussed included adjustment for H. pylori status, suggesting that the protective effects 
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of allium vegetables, fruits, fish, protein, vitamin C, zinc, and iron and risk-enhancing 
effects of red meat, dairy products, and fat observed in these studies are independent of 
H. pylori infection.  Additionally, the population-based case-control study conducted by 
Wu et al.[304] mentioned that exploratory analyses of the 33-50% of subjects with H. 
pylori results did not affect the positive association with total fat or inverse association 
with dietary fiber.  Because H. pylori infection is considered a greater risk factor for non-
cardia than cardia gastric cancers, it is not surprising that dietary factors appear to alter 
the risk of gastric cancers irrespective of H. pylori infection status, especially those 
cancers affecting the gastric cardia, as in Wu et al.[304]. 
 
Conclusions 
 Although gastric cancer remains one of the deadliest cancers worldwide, data 
regarding the role of diet as a risk modifier of gastric cancer are relatively limited.  There 
are few in vitro and animal model studies examining the associations between diet and 
gastric cancer onset and progression.  Case-control studies have provided some evidence 
that plant fats and PUFA reduce the risk while saturated fatty acids increase the risk of 
gastric cancer.  There is also evidence that increased consumption of fresh fruits and 
vegetables may decrease the risk of gastric cancer, possibly due to antioxidants and/or 
dietary fiber present within the plants.  Frequent consumption of salted or fermented fish, 
meat, or vegetables likely increases the risk of gastric cancer; however, it has not been 
demonstrated conclusively that fresh fish intake increases or decreases the risk of gastric 
cancer. 
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 Data from the numerous case-control studies have been somewhat supported by 
the small number of prospective cohort studies.  Consumption of pickled or salted foods 
(including fish) imparted significantly increased risks for gastric cancers in Swedish and 
Japanese populations, but the prospective studies did not yield sufficient data regarding 
fresh fish or dietary fat intakes and the risk of gastric cancer.  These studies were also 
limited regarding their assessment of antioxidant exposure or status; future prospective 
analyses would benefit from the use of objective measures of antioxidant status to 
examine the association of multiple antioxidants (both endogenous and exogenous) with 
gastric cancer risk. 
 While there have been several clinical trials involving antioxidant 
supplementation and gastric cancer risk, most have shown that supplementation was not 
adequate to reduce the risk of cancer in individuals positive for H. pylori infection.  A 
notable exception was individuals with the variant MnSOD gene, who benefited from the 
vitamin and mineral supplement[326].  All intervention studies were conducted in the 
high-risk countries of Japan and China, which have very high rates of H. pylori 
prevalence.  While a high-risk population is often necessary for dietary intervention 
studies, data gleaned from such studies are generally not applicable to a healthy 
population.  The presence of H. pylori infection adds an additional limitation, as it is a 
major risk factor for non-cardia—but not cardia—gastric cancer.  Cardia cancer may be 
more susceptible to risk reduction via dietary intervention, but its prevalence is only 
beginning to increase.  Future research regarding gastric cardia cancer risk reduction will 
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require further evaluation of diet and this specific cancer site, especially through 
laboratory-based and prospective cohort studies. 
 Unfortunately, H. pylori infection remains a substantial burden in many parts of 
the world.  There are promising data suggesting a protective effect of dietary antioxidant 
intake among H. pylori-positive individuals regarding gastric cancer development, and 
high intakes of salt and salted foods may act synergistically with H. pylori infection to 
increase the risk of gastric cancer.  More research is needed to ascertain if the anti-
inflammatory effects of n-3 attenuate the risk of gastric cancer among H. pylori-positive 
individuals.  The relationships between dietary fish, fat, and antioxidants and the risk of 
gastric cancer remain inconclusive and poorly characterized and would benefit from 
additional prospective analyses. 
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Chapter VII: Dietary fish, fat, and antioxidant consumption and the 
risk of gastric cancer in the Singapore Chinese Health Study 
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Introduction 
 Gastric cancer is the third leading cause of cancer death in men and fifth leading 
cause of cancer death in women worldwide[264].  Infection with Helicobacter pylori (H. 
pylori) is an established risk factor for non-cardia gastric cancer, the incidence of which 
has decreased over the past three decades, likely due to increased sanitation and access to 
refrigeration and antibiotic treatment[266, 272-274].  However, the incidence of cardia 
gastric cancer has been increasing in wealthy countries, and dietary factors such as fat, 
fiber, red meat, fruits, and high-fat dairy have been shown to modify the risk of cardia 
gastric cancer[266, 304, 306, 313, 333].  In Singapore, it has been recently reported that 
16% of all gastric cancers affect the cardia, double the proportion reported from 1993-
1997[267].  
 Of particular interest regarding nutritional risk factors for gastric cancer is the 
intake of fish and dietary fat.  Omega-3 fatty acids (n-3), such as those found in fish as 
well as nuts and seeds, have been shown to reduce the risk of breast and prostate cancers, 
possibly due to decreased inflammatory responses, modifications of signal transduction 
pathways, and stimulation of tumor cell apoptosis by lipid peroxidation at gastric pH[2, 6, 
7, 276, 334].  On the other hand, lipid peroxidation produces reactive metabolites that 
may modify DNA, leading to point mutations of the tumor suppressor p53[276, 335, 
336].  As one of the first tissues exposed to lipid peroxidation metabolites following 
dietary consumption of n-3, an examination of modulation of gastric cancer risk by 
dietary fish and fat intake would provide additional information on the roles of n-3 intake 
and subsequent lipid peroxidation in the risk of human cancers. 
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 A recent meta-analysis by Wu et al.[277] concluded that high fish consumption 
reduced the risk of gastric cancer by thirteen percent (OR = 0.87, 95% CI = 0.71 – 1.07) 
based upon data from 15 case-control and two prospective cohort studies.  Because of the 
limited data from prospective cohort studies, an analysis of the Singapore Chinese Health 
Study is warranted.  In this study of more than 60,000 individuals, detailed dietary 
information was collected at baseline prior to the diagnosis of any cancer, and 
participants were followed for an average of twelve years[278, 279].  If significant 
associations are detected in the overall cohort, the collection of biospecimens from 
approximately 60% of participants would allow for H. pylori testing to control for this 
important risk factor, which may be present in 43% of Singapore Chinese 
individuals[278, 281].  We hypothesize that fish and n-3 intakes are inversely associated 
with gastric cancer risk in the Singapore Chinese Health Study. 
 
Materials and Methods 
Singapore Chinese Health Study 
The design and inclusionary and exclusionary criteria for the Singapore Chinese 
Health Study have been previously described[280].  Cohort members were selected from 
permanent residents or citizens of Singapore residing in government housing and 
between the ages of 45 and 74; all cohort members belonged to one of the two major 
Chinese dialect groups (Cantonese and Hokkien)[279].  At baseline, all cohort members 
completed an in-person interview with a trained study staff member that included a 
validated 165-item food frequency questionnaire (FFQ).  In conjunction with the FFQ 
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validation, the Singapore Food Composition Database was developed using food 
composition data from China, Malaysia, Taiwan, and Hawaii; from this database, mean 
daily consumption values for 96 dietary components including fats and micronutrients 
were ascertained for each cohort member[279].  The Singapore Chinese Health Study 
was approved by the Institutional Review Boards at the National University of Singapore 
and the University of Pittsburgh. 
Cancer diagnoses and deaths from cancer were identified by linking cohort 
members to the Singapore Cancer Registry and the Singapore Registry of Births and 
Deaths.  This comprehensive national registry was established in 1968, and as of April 
2008, only 27 cases were lost to follow-up due to migration out of Singapore.  We used 
data from the 27,293 men and 34,028 women who did not have a history of cancer 
diagnosis at baseline, based on self-report and computer-assisted record linkage analysis 
with the Singapore Cancer Registry.  As of December 31, 2008 (an average follow-up of 
12.3 years), 519 of these cohort members had been diagnosed with gastric cancer (ICD-
10 16.0).  Of these cases, 73 affected the gastric cardia (ICD-10 C16.0), 345 affected the 
gastric non-cardia (ICD-10 C16.1 – C16.8), and 101 were unspecified (ICD-10 C16.9). 
 
Cox proportional hazards regression analysis of diet, environmental factors, and gastric 
cancer incidence 
Person-years of follow-up were computed from the recruitment date to the date of 
gastric cancer diagnosis, death, migration, or December 31, 2008, whichever occurred 
first.  A series of Cox proportional hazards regression models were performed to test the 
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associations between dietary fish, fat, and antioxidant intakes and gastric cancer 
incidence.  For dietary fish, fat, and micronutrient antioxidants, exposures were 
quantified from sex-specific nutrient density (food or nutrient weight relative to daily 
energy intake) quartiles based upon the distribution across the entire cohort.  For tea and 
coffee consumption, the lowest quartile consisted of never drinkers, and the top three 
quartiles were based upon the distribution among ever drinkers.  A complete list of all 
exposures evaluated is provided in Table 40.  To control for confounding, the following 
were included as covariates: sex (male/female), dialect group (Cantonese/Hokkien), age 
(years), interview year (1993-1995/1996-1998), education (less than secondary/secondary 
or higher), tobacco smoking (ever/never), alcohol use (ever/never), body mass index 
(<20, 20-<24, 24-<28, or !28 kg/m2), and daily energy intake (kcal/d). 
 
Table 40.  Fish, fat, and antioxidant variables evaluated via Cox proportional hazards regression. 
Primary Exposure Variables  
(food or nutrient density quartiles) 
Antioxidant Exposure Variables  
(nutrient density quartiles) 
All fish and shellfish (g/kcal) Selenium (µg/kcal) 
Fresh fish and shellfish (g/kcal) Total carotenoids (µg/kcal) 
Preserved fish and shellfish (g/kcal) !-carotene (µg/kcal) 
Fish, fresh and preserved (g/kcal) "-carotene (µg/kcal) 
Shellfish, fresh and preserved (g/kcal) "-cryptoxanthin (µg/kcal) 
Total fat (g/kcal) Lycopene (µg/kcal) 
Saturated fat (g/kcal) Lutein (µg/kcal) 
Monounsaturated fat (g/kcal) Total vitamin C (mg/kcal) 
PUFA (g/kcal) Total vitamin E (mg !-tocopherol equivalents/kcal) 
n-3 fat (g/kcal) Total soy isoflavones (mg/kcal) 
Marine n-3 (g/kcal) Genistein (mg/kcal) 
Non-marine n-3 (g/kcal) Daidzein (mg/kcal) 
n-6 fat (g/kcal) Glycitein (mg/kcal) 
Animal fat (g/kcal) Total isothiocyanate (µmol/kcal) 
Red meat fat (g/kcal) Black tea (cups/month) 
Plant fat (g/kcal) Green tea (cups/month) 
Cholesterol (mg/kcal) Any tea (cups/month) 
Coffee (cups/week) 
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Statistical analysis 
SAS v9.2 (SAS Institute, Inc., Cary, NC) was used for statistical analyses.  
Statistical analyses were conducted for the overall cohort, within men, and within women 
for all gastric cancers, cardia gastric cancers, non-cardia gastric cancers, and unspecified 
gastric cancers.  All hazard ratios (HRs) and 95% confidence intervals (CIs) reported 
were two-sided and computed relative to the lowest quartile or category of intake, and ! 
= 0.05 was set as the cutoff for determining statistical significance.  The linear tests for 
exposure-gastric cancer trends were computed based on ordinal values for the categories 
(0,1,2,3, etc.). 
 
Results 
 The distributions of demographic characteristics of cohort members within each 
quartile of total fat intake and stratified by sex are shown in Table 41.  Individuals in the 
highest quartile of fat intake were more likely to be younger, have achieved a higher level 
of education, have prevalent diabetes, and have higher intakes of total energy and 
preserved fish and shellfish than individuals in the lowest quartile of fat intake at 
baseline.  Compared to male cohort members, female cohort members were less likely to 
be smokers or consume alcohol, have achieved a secondary level of education or higher, 
or be members of the Hokkien dialect.  Although women tended to consume less energy 
overall than men, there were no notable differences in fat intakes between the two sexes.
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Table 41.  Demographics of male and female members of the Singapore Chinese Health Study stratified by quartile of fat intake. 
 Men (n=27,293) Women (n=34,028) 
Quartile of total fat 
intake Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 
Characteristic         
Person-years of follow-up 80,643 82,034 82,402 81,195 107,810 108,572 108,088 106,314 
Mean age at baseline, y 
(SD) 57.73 ± 7.90 56.88 ± 7.98 56.32 ± 7.91 55.50 ± 7.84 58.43 ± 8.15 56.79 ± 7.97 55.52 ± 7.77 
54.18 ± 
7.55 
Hokkien dialect (%) 55.6 56.6 55.8 55.6 52.3 52.4 52.4 51.5 
Body mass index, kg/m2 
(%)         
     <20 16 16 15 15 15 15 14 15 
     20-<24 56 53 53 50 57 55 54 53 
     24-<28 22 25 26 26 21 22 23 24 
     !28 5 6 6 8 7 8 8 9 
Secondary level of 
education or higher (%) 28 36 40 47 13 18 23 30 
Smoking status (%)         
     Never 39 42 44 43 89 92 92 92 
     Ex-smoker 22 21 21 21 3 2 3 2 
     Current 39 37 34 36 8 6 5 5 
Weekly or daily alcohol 
consumption (%) 24 21 19 18 4 4 4 5 
Self-reported history of 
ulcer at baseline (%) 4 5 5 5 2 2 2 2 
Self-reported history of 
diabetes at baseline (%) 7 8 9 11 8 9 9 10 
Total energy intake, kcal 
(mean ± SD) 
1652.05 ± 
516.53 
1676.97 ± 
568.34 
1738.65 ± 
591.93 
1944.50 ± 
703.68 
1272.77 ± 
420.00 
1318.72 ± 
393.60 
1421.63 ± 
452.47 
1582.25 ± 
548.32 
Total fat intake, % kcal 
(mean ± SD) 17.09 ± 2.71 22.58 ± 1.14 26.32 ± 1.10 31.69 ± 2.76 18.60 ± 2.71 23.84 ± 1.07 24.47 ± 1.09 
32.64 ± 
2.65 
Total preserved fish and 
shellfish intake, g/kcal 
(mean ± SD) 
1.32 ± 1.61 1.70 ± 1.76 2.02 ± 2.15 2.56 ± 2.66 1.26 ± 1.63 1.61 ± 1.81 1.89 ± 2.16 2.36 ± 2.49 
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 There were no significant associations between fish intake and the risk of gastric 
cancer in the overall cohort (Table 42).  Among men, there was a borderline statistically 
significant inverse trend between total fish and shellfish intake and the risk of gastric 
cancer (p = 0.14), with a significant 31% decrease in risk in the second quartile of 
exposure.  There were no statistically significant trends or HRs among women with 
regards to fish intake. 
 Fat intakes were not significantly associated with gastric cancer risk among the 
entire cohort (Table 43).  There were borderline significant positive trends between 
animal fat intake (p = 0.12) and cholesterol (p = 0.08) intake and gastric cancer risk 
among male cohort members, but no HRs were statistically significant.  Among women, 
there was a significant inverse association between red meat fat intake and gastric cancer 
risk (p = 0.005), with the highest quartile of intake imparting a 46% decreased risk of 
gastric cancer. 
 In the overall cohort, there were borderline statistically significant inverse 
associations between total carotenoids (p = 0.11), !-cryptoxanthin (p = 0.06), and vitamin 
C (p = 0.10) and the risk of gastric cancer (Table 44).  The second quartiles of total 
carotenoids or vitamin C exposure were associated with significant 24% and 22% 
decreases in gastric cancer risk, respectively, while the highest quartile of !-
cryptoxanthin intake conferred a significant 23% reduction in gastric cancer risk.  Among 
male cohort members, the inverse trend between !-cryptoxanthin and gastric cancer risk 
was statistically significant (p = 0.04), but no individual HRs achieved statistical 
significance.  In women, the inverse trend between total carotenoids and gastric cancer 
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Table 42.  Hazard ratios (HRs) and 95% confidence intervals (95% CIs) for quartiles of fish intake and the risk of gastric cancer in the Singapore Chinese Health 
Study. 
 Overall Men Women 
Median 
intake (g/kcal, 
±  SD) Cases, n 
HR 
(95% CI)* 
Median 
intake 
(g/kcal, ±  
SD) 
Cases, 
n 
HR 
(95% CI)* 
Median 
intake 
(g/kcal, ±  
SD) 
Cases, 
n 
HR 
(95% CI)* 
Total fish and 
shellfish 
         
     Q1 17.60 ± 6.04 141 1.00 (ref) 16.49 ± 5.49 92 1.00 (ref) 18.67 ± 6.34 49 1.00 (ref) 
     Q2 29.10 ± 3.25 120 0.86 
(0.68—1.10) 
27.61 ± 2.81 65 0.69 
(0.50—0.95) 
30.46 ± 3.02 55 1.19 
(0.81—1.75) 
     Q3 39.46 ± 3.80 127 0.90 
(0.71—1.15) 
37.46 ± 3.26 79 0.83 
(0.61—1.12) 
41.06 ± 3.43 48 1.02 
(0.69—1.53) 
     Q4 55.58 ± 13.99 131 0.90 
(0.71—1.15) 
53.05 ± 
13.55 
81 0.83 
(0.61—1.12) 
57.42 ± 
14.01 
50 1.03 
(0.69—1.53) 
     p for trend   0.66   0.14  ! 0.79 
Fresh fish and 
shellfish 
         
     Q1 15.91 ± 5.73 139 1.00 (ref) 14.80 ± 5.18 90 1.00 (ref) 17.08 ± 6.02 49 1.00 (ref) 
     Q2 27.27 ± 3.24 121 0.88 
(0.69—1.12) 
25.73 ± 2.76 68 0.73 
(0.53—1.00) 
28.60 ± 3.00 53 1.14 
(0.77—1.68) 
     Q3 37.54 ± 3.81 126 0.90 
(0.71—1.15) 
35.45 ± 3.23 75 0.80 
(0.59—1.08) 
39.19 ± 3.41 51 1.09 
(0.73—1.61) 
     Q4 53.50 ± 14.01 133 0.93 
(0.73—1.18) 
50.85 ± 
13.55 
84 0.88 
(0.65—1.19) 
55.52 ± 
14.02 
49 0.99 
(0.67—1.48) 
     p for trend   0.74   0.23   0.88 
Preserved fish 
and shellfish 
        !
     Q1 0.16 ± 0.13 137 1.00 (ref) 0.19 ± 0.15 84 1.00 (ref) 0.15 ± 0.12 53 1.00 (ref) 
     Q2 0.80 ± 0.25 12 0.91 
(0.71—1.16) 
0.88 ± 0.24 75 0.89 
(0.65—1.22) 
0.73 ± 0.23 49 0.95 
(0.64—1.40) 
     Q3 1.79 ± 0.37 121 0.88 
(0.69—1.13) 
1.85 ± 0.36 71 0.83 
(0.60—1.13) 
1.73 ± 0.36 50 0.99 
(0.67—1.47) 
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 Overall Men Women 
Median 
intake (g/kcal, 
±  SD) Cases, n 
HR 
(95% CI)* 
Median 
intake 
(g/kcal, ±  
SD) 
Cases, 
n 
HR 
(95% CI)* 
Median 
intake 
(g/kcal, ±  
SD) 
Cases, 
n 
HR 
(95% CI)* 
     Q4 3.75 ± 2.57 137 1.01 
(0.80—1.29) 
3.83 ± 2.59 87 1.02 
(0.75—1.38) 
3.69 ± 2.56 50 1.02 
(0.69—1.50) 
     p for trend   0.60   0.52  ! 0.99 
Fish, fresh and 
preserved 
         
     Q1 15.03 ± 5.50 135 1.00 (ref) 13.95 ± 4.96 85 1.00 (ref) 16.11 ± 5.78 50 1.00 (ref) 
     Q2 25.93 ± 3.13 135 1.00 
(0.79—1.27) 
24.44 ± 2.69 81 0.92 
(0.67—1.24) 
27.21 ± 2.86 54 1.13 
(0.77—1.66) 
     Q3 35.90 ± 3.74 110 0.80 
(0.62—1.02) 
33.82 ± 3.13 69 0.76 
(0.55—1.04) 
37.57 ± 3.37 41 0.84 
(0.56—1.27) 
     Q4 51.73 ± 13.95 139 0.97 
(0.76—1.23) 
53.06 ± 
13.52 
82 0.88 
(0.65—1.20) 
53.69 ± 
13.93 
57 1.11 
(0.76—1.63) 
     p for trend   0.24   0.40   0.47 
Shellfish, fresh 
and preserved 
         
     Q1 0.69 ± 0.41 153 1.00 (ref) 0.81 ± 0.43 89 1.00 (ref) 0.61 ± 0.38 64 1.00 (ref) 
     Q2 1.92 ± 0.36 129 0.93 
(0.74—1.18) 
2.03 ± 0.34 72 0.88 
(0.65—1.20) 
1.82 ± 0.35 57 1.02 
(0.71—1.46) 
     Q3 3.26 ± 0.50 111 0.85 
(0.67—1.09) 
3.34 ± 0.47 74 0.96 
(0.70—1.31) 
3.19 ± 0.51 37 0.70 
(0.47—1.06) 
     Q4 6.06 ± 3.19 126 0.98 
(0.77—1.25) 
6.02 ± 2.87 82 1.05 
(0.77—1.43) 
6.11 ± 3.42 44 0.87 
(0.59—1.30) 
     p for trend   0.60   0.74   0.30 
*Adjusted for age (years), gender (male/female, in overall model only), interview year (1993-1995/1996-1998), dialect (Hokkien/Cantonese), education (less than 
secondary/secondary or greater), tobacco smoking (never/ever), alcohol consumption (never/ever), body mass index (<20, 20-<24, 24-<28, or !28 kg/m2), and 
total energy intake (kcal/day) 
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Table 43.  Hazard ratios (HRs) and 95% confidence intervals (95% CIs) for quartiles of fat intakes and the risk of gastric cancer in the Singapore Chinese Health 
Study. 
 Overall Men Women 
Median 
intake 
(g/kcal, ±  
SD) Cases, n 
HR 
(95% CI)* 
Median 
intake 
(g/kcal, ±  
SD) Cases, n 
HR 
(95% CI)* 
Median 
intake 
(g/kcal, ±  
SD) Cases, n 
HR 
(95% CI)* 
Total Fat          
     Q1 18.57 ± 2.81 143 1.00 (ref) 17.71 ± 2.71 82 1.00 (ref) 19.29 ± 2.71 61 1.00 (ref) 
     Q2 23.33 ± 1.26 134 1.03 
(0.81—1.30) 
22.62 ± 1.14 82 1.06 
(0.78—1.45) 
23.88 ± 1.07 52 0.98 
(0.67—1.41) 
     Q3 26.93 ± 1.23 136 1.13 
(0.89—1.43) 
26.27 ± 1.10 86 1.18 
(0.87—1.59) 
27.44 ± 1.09 50 1.06 
(0.73—1.56) 
     Q4 31.60 ± 2.74 106 0.99 
(0.76—1.28) 
31.05 ± 2.76 67 1.00 
(0.72—1.39) 
32.02 ± 2.65 39 0.97 
(0.64—1.47) 
p for trend   0.70  ! 0.70   0.97 
Saturated 
Fat 
       ! !
     Q1 5.92 ± 1.01 138 1.00 (ref) 5.76 ± 0.99 79 1.00 (ref) 6.06 ± 1.01 59 1.00 (ref) 
     Q2 7.93 ± 0.51 132 1.06 
(0.84—1.35) 
7.77 ± 0.49 83 1.16 
(0.85—1.58) 
8.16 ± 0.49 49 0.94 
(0.64—1.38) 
     Q3 9.61 ± 0.54 135 1.16 
(0.91—1.47) 
9.41 ± 0.52 82 1.20 
(0.88—1.63) 
9.75 ± 0.52 53 1.12 
(0.76—1.63) 
     Q4 11.85 ± 1.33 114 1.06 
(0.82—1.37) 
11.67 ± 1.34 73 1.14 
(0.82—1.58) 
12.01 ± 1.31 41 0.97 
(0.64—1.46) 
p for trend   0.69   0.69 ! ! 0.84 
MUFA          
     Q1 6.10 ± 0.96 137 1.00 (ref) 5.87 ± 0.93 83 1.00 (ref) 6.30 ± 0.93 54 1.00 (ref) 
     Q2 7.79 ± 0.43 130 1.04 
(0.82—1.32) 
7.59 ± 0.40 74 0.94 
(0.69—1.29) 
7.94 ± 0.39 56 1.19 
(0.82—1.73) 
     Q3 9.11 ± 0.43 136 1.16 
(0.91—1.47) 
8.94 ± 0.41 83 1.11 
(0.81—1.50) 
9.25 ± 0.40 53 1.25 
(0.85—1.84) 
     Q4 10.88 ± 1.09 116 1.09 
(0.84—1.40) 
10.73 ± 1.10 77 1.10 
(0.80—1.51) 
10.99 ± 1.07 39 1.05 
(0.68—1.61) 
p for trend   0.65   0.70   0.64 
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 Overall Men Women 
Median 
intake 
(g/kcal, ±  
SD) Cases, n 
HR 
(95% CI)* 
Median 
intake 
(g/kcal, ±  
SD) Cases, n 
HR 
(95% CI)* 
Median 
intake 
(g/kcal, ±  
SD) Cases, n 
HR 
(95% CI)* 
PUFA ! ! ! ! !     
     Q1 3.24 ± 0.55 163 1.00 (ref) 3.09 ± 0.52 96 1.00 (ref) 3.38 ± 0.54 67 1.00 (ref) 
     Q2 4.26 ± 0.31 117 0.79 
(0.63—1.01) 
4.08 ± 0.25 74 0.82 
(0.61—1.12) 
4.42 ± 0.27 43 0.75 
(0.51—1.10) 
     Q3 5.27 ± 0.43 118 0.85 
(0.67—1.09) 
5.03 ± 0.34 68 0.79 
(0.57—1.08) 
5.45 ± 0.39 50 0.95 
(0.65—1.38) 
     Q4 7.30 ± 1.48 121 0.90 
(0.70—1.14) 
6.90 ± 1.38 79 0.94 
(0.69—1.27) 
7.62 ± 1.49 42 0.81 
(0.55—1.21) 
p for trend   0.27   0.40  ! 0.44 
Total n-3          
     Q1 0.36 ± 0.055 140 1.00 (ref) 0.34 ± 0.051 83 1.00 (ref) 0.38 ± 0.054 57 1.00 (ref) 
     Q2 0.45 ± 0.030 128 0.97 
(0.76—1.23) 
0.43 ± 0.022 71 0.87 
(0.63—1.20) 
0.47 ± 0.023 57 1.11 
(0.76—1.60) 
     Q3 0.53 ± 0.033 131 0.99 
(0.72—1.18) 
0.51 ± 0.025 91 1.09 
(0.80—1.46) 
0.55 ± 0.026 40 0.81 
(0.54—1.22) 
     Q4 0.67 ± 0.18 120 0.92 
(0.72—1.18) 
0.64 ± 0.16 72 0.87 
(0.63—1.19) 
0.69 ± 0.19 48 1.01 
(0.68—1.48) 
p for trend   0.93   0.40   0.52 
Marine n-3          
     Q1 0.092 ± 
0.032 
146 1.00 (ref) 0.087 ± 
0.029 
90 1.00 (ref) 0.097 ± 
0.033 
56 1.00 (ref) 
     Q2 0.15 ± 0.017 116 0.81 
(0.63—1.03) 
0.15 ± 0.015 68 0.74 
(0.54—1.02) 
0.16 ± 0.016 48 0.91 
(0.62—1.34) 
     Q3 0.21 ± 0.019 131 0.90 
(0.72—1.14) 
0.20 ± 0.017 81 0.87 
(0.64—1.18) 
0.21 ± 0.018 50 0.93 
(0.64—1.37) 
     Q4 0.29 ± 0.072 126 0.84 
(0.66—1.07) 
0.28 ± 0.071 78 0.82 
(0.60—1.11) 
0.30 ± 0.072 48 0.87 
(0.59—1.28) 
p for trend   0.33   0.29   0.91 
Non-marine 
n-3 
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 Overall Men Women 
Median 
intake 
(g/kcal, ±  
SD) Cases, n 
HR 
(95% CI)* 
Median 
intake 
(g/kcal, ±  
SD) Cases, n 
HR 
(95% CI)* 
Median 
intake 
(g/kcal, ±  
SD) Cases, n 
HR 
(95% CI)* 
     Q1 0.21 ± 0.033 157 1.00 (ref) 0.21 ± 0.030 92 1.00 (ref) 0.22 ± 0.032 65 1.00 (ref) 
     Q2 0.28 ± 0.019 123 0.86 
(0.68—1.09) 
0.26 ± 0.015 78 0.89 
(0.66—1.20) 
0.29 ± 0.015 45 0.81 
(0.55—1.19) 
     Q3 0.33 ± 0.021 114 0.82 
(0.64—1.04) 
0.31 ± 0.017 71 0.82 
(0.60—1.12) 
0.34 ± 0.018 43 0.81 
(0.55—1.20) 
     Q4 0.42 ± 0.18 125 0.91 
(0.72—1.16) 
0.40 ± 0.16 76 0.86 
(0.63—1.18) 
0.44 ± 0.19 49 0.97 
(0.66—1.42) 
p for trend   0.38   0.63   0.58 
Total n-6 ! ! ! ! ! ! ! ! !
     Q1 2.82 ± 0.49 161 1.00 (ref) 2.69 ± 0.46 93 1.00 (ref) 2.95 ± 0.48 68 1.00 (ref) 
     Q2 3.75 ± 0.29 121 0.83 
(0.66—1.06) 
3.59 ± 0.23 78 0.89 
(0.66—1.21) 
3.89 ± 0.25 43 0.74 
(0.50—1.09) 
     Q3 4.70 ± 0.41 114 0.84 
(0.66—1.07) 
4.47 ± 0.32 65 0.78 
(0.57—1.08) 
4.87 ± 0.38 49 0.91 
(0.63—1.32) 
     Q4 6.64 ± 1.40 123 0.92 
(0.72—1.17) 
6.26 ± 1.30 81 0.99 
(0.73—1.35) 
6.95 ± 1.40 42 0.80 
(0.54—1.18) 
p for trend   0.37   0.41   0.42 
Total 
animal fat 
     ! ! ! !
     Q1 4.57 ± 1.27 152 1.00 (ref) 4.82 ± 1.30 88 1.00 (ref) 4.41 ± 1.21 64! 1.00 (ref)!
     Q2 7.14 ± 0.70 121 0.87 
(0.68—1.10) 
7.49 ± 0.64 74 0.90 
(0.66—1.23) 
6.87 ± 0.61 47 0.83 
(0.57—1.22) 
     Q3 9.31 ± 0.78 125 0.97 
(0.76—1.23) 
9.70 ± 0.71 67 0.86 
(0.62—1.18) 
8.99 ± 0.66 58 1.14 
(0.79—1.64) 
     Q4 12.40 ± 2.23 121 1.02 
(0.80—1.30) 
12.93 ± 2.23 88 1.22 
(0.90—1.66) 
11.93 ± 2.12 33 0.72 
(0.46—1.10) 
p for trend   0.60   0.12   0.14 
Total red 
meat fat 
         
     Q1 1.08 ± 0.49 153 1.00 (ref) 1.25 ± 0.51 75 1.00 (ref) 0.96 ± 0.44 78 1.00 (ref) 
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 Overall Men Women 
Median 
intake 
(g/kcal, ±  
SD) Cases, n 
HR 
(95% CI)* 
Median 
intake 
(g/kcal, ±  
SD) Cases, n 
HR 
(95% CI)* 
Median 
intake 
(g/kcal, ±  
SD) Cases, n 
HR 
(95% CI)* 
     Q2 2.20 ± 0.34 123 0.85 
(0.67—1.07) 
2.40 ± 0.30 74 1.04 
(0.76—1.44) 
2.05 ± 0.29 49 0.67 
(0.47—0.96) 
     Q3 3.28 ± 0.43 117 0.84 
(0.66—1.06) 
3.52 ± 0.38 77 1.11 
(0.80—1.52) 
3.08 ± 0.36 40 0.58 
(0.39—0.85) 
     Q4 5.08 ± 1.58 126 0.94 
(0.74—1.20) 
5.40 ± 1.63 91 1.36 
(0.99—1.86) 
4.81 ± 1.47 35 0.54 
(0.36—0.81) 
p for trend   0.39   0.21   0.005 
Total plant 
fat 
         
     Q1 11.65 ± 2.02 139 1.00 (ref) 10.74 ± 1.76 91 1.00 (ref) 12.61 ± 1.85 48 1.00 (ref) 
     Q2 15.06 ± 1.23 126 0.96 
(0.75—1.22) 
14.03 ± 0.80 70 0.78 
(0.57—1.07) 
15.92 ± 0.79 56 1.30 
(0.88—1.91) 
     Q3 17.80 ± 1.28 134 1.09 
(0.86—1.38) 
16.71 ± 0.83 76 0.88 
(0.65—1.20) 
18.63 ± 0.86 58 1.47 
(1.00—2.17) 
     Q4 21.74 ± 2.92 120 1.03 
(0.81—1.33) 
20.48 ± 2.72 80 0.98 
(0.72—1.33) 
22.52 ± 2.76 40 1.10 
(0.72—1.68) 
p for trend  ! 0.78   0.41   0.20 
Total 
cholesterol 
         
     Q1 62.53 ± 
15.42 
148 1.00 (ref) 62.88 ± 
15.37 
84 1.00 (ref) 62.30 ± 
15.45 
64 1.00 (ref) 
     Q2 92.04 ± 7.33 112 0.84 
(0.66—1.08) 
93.16 ± 7.37 63 0.82 
(0.59—1.14) 
90.98 ± 7.16 49 0.88 
(0.60—1.28) 
     Q3 116.95 ± 
8.35 
127 1.02 
(0.81—1.30) 
118.83 ± 
8.56 
81 1.10 
(0.81—1.50) 
115.49 ± 
7.85 
46 0.91 
(0.62—1.34) 
     Q4 156.29 ± 
42.14 
132 1.12  
0.88—1.42) 
161.28 ± 
47.29 
89 1.25 
(0.93—1.70) 
152.25 ± 
36.47 
43 0.92 
(0.62—1.37) 
p for trend   0.18   0.08   0.92 
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*Adjusted for age (years), gender (male/female, in overall model only), interview year (1993-1995/1996-1998), dialect (Hokkien/Cantonese), education (less than 
secondary/secondary or greater), tobacco smoking (never/ever), alcohol consumption (never/ever), body mass index (<20, 20-<24, 24-<28, or !28 kg/m2), and 
total energy intake (kcal/day) 
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Table 44.  Hazard ratios (HRs) and 95% confidence intervals (95% CIs) for quartiles of antioxidant intake and the risk of gastric cancer in the Singapore Chinese 
Health Study. 
 Overall Men Women 
Median 
intake ±  SD 
Cases, 
n 
HR 
(95% CI)* 
Median 
intake ±  SD Cases, n 
HR 
(95% CI)* 
Median 
intake ±  SD 
Cases, 
n 
HR 
(95% CI)* 
Total selenium 
(µg/kcal) 
         
     Q1 53.81 ± 5.07 135 1.00 (ref) 53.76 ± 4.85 79 1.00 (ref) 53.83 ± 5.25 56 1.00 (ref) 
     Q2 61.56 ± 1.88 109 0.79 
(0.61—1.01) 
61.09 ± 1.75 63 0.78 
(0.56—1.09) 
61.96 ± 1.90 46 0.80 
(0.54—1.18) 
     Q3 67.82 ± 2.11 138 0.97 
(0.76—1.23) 
67.11 ± 1.94 88 1.05 
(0.78—1.43) 
68.37 ± 2.07 50 0.85 
(0.58—1.25) 
     Q4 77.31 ± 8.75 137 0.92 
(0.72—1.17) 
76.03 ± 7.95 87 1.01 
(0.74—1.37) 
78.19 ± 9.23 50 0.79 
(0.54—1.16) 
     p for trend   0.27   0.30   0.60 
Total 
carotenoids 
(µg/kcal) 
         
     Q1 1771.00 ± 
499.15 
173 1.00 (ref) 1569.97 ± 
430.42 
101 1.00 (ref) 1980.15 ± 
476.48 
72 1.00 (ref) 
     Q2 2795.98 ± 
376.33 
118 0.76 
(0.60—0.96) 
2524.97 ± 
256.31 
74 0.79 
(0.58—1.07) 
3045.52 ± 
283.47 
44 0.69 
(0.48—1.01) 
     Q3 3844.34 ± 
487.95 
116 0.82 
(0.64—1.03) 
3486.02 ± 
340.25 
77 0.89 
(0.66—1.21) 
4125.13 ± 
385.84 
39 0.67 
(0.45—1.00) 
     Q4 5811.57 ± 
1948.95 
112 0.87 
(0.69—1.11) 
5265.59 ± 
1754.35 
65 0.84 
(0.61—1.15) 
6201.37 ± 
1980.48 
47 0.89 
(0.61—1.30) 
     p for trend   0.11   0.46   0.12 
!-carotene 
(µg/kcal) 
         
     Q1 29.86 ± 20.52 148 1.00 (ref) 20.07 ± 
13.44 
95 1.00 (ref) 42.03 ± 21.37 53 1.00 (ref) 
     Q2 85.81 ± 22.09 131 0.89 
(0.66—1.07) 
68.89 ± 
13.81 
77 0.78 
(0.58—1.06) 
100.43 ± 
16.50 
54 1.05 
(0.72—1.53) 
     Q3 153.81 ± 121 0.84 126.96 ± 75 0.77 176.40 ± 46 0.93 
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 Overall Men Women 
Median 
intake ±  SD 
Cases, 
n 
HR 
(95% CI)* 
Median 
intake ±  SD Cases, n 
HR 
(95% CI)* 
Median 
intake ±  SD 
Cases, 
n 
HR 
(95% CI)* 
36.78 (0.66—1.07) 23.53 (0.57—1.05) 30.25 (0.62—1.38) 
     Q4 332.95 ± 
224.87 
119 0.88 
(0.69—1.13) 
278.20 ± 
187.03 
70 0.76 
(0.56—1.04) 
375.39 ± 
239.39 
49 1.07 
(0.73—1.59) 
     p for trend   0.52   0.23   0.90 
!-carotene 
(µg/kcal) 
         
     Q1 635.74 ± 
201.97 
151 1.00 (ref) 538.81 ± 
160.12 
90 1.00 (ref) 747.12 ± 
186.11 
61 1.00 (ref) 
     Q2 1038.41 ± 
171.11 
146 1.04 
(0.83—1.31) 
898.74 ± 
97.04 
91 1.07 
(0.80—1.43) 
1164.68 ± 
116.11 
55 0.98 
(0.68—1.41) 
     Q3 1465.99 ± 
232.05 
105 0.80 
(0.62—1.03) 
1275.45 ± 
132.95 
67 0.83 
(0.60—1.14) 
1626.14 ± 
164.74 
38! 0.73 
(0.48—1.09)!
     Q4 2299.51 ± 
880.12 
117 0.96 
(0.75—1.22) 
1975.03 ± 
741.98 
69 0.91 
(0.66—1.25) 
2521.20 ± 
892.44 
48 1.00 
(0.68—1.47) 
     p for trend   0.19   0.42   0.39 
!-cryptoxanthin 
(µg/kcal) 
     ! ! ! !
     Q1 12.06 ± 14.35 160 1.00 (ref) 13.28 ± 
14.40 
86 1.00 (ref) 10.73 ± 14.30 74 1.00 (ref) 
     Q2 71.46 ± 17.14 120 0.88 
(0.69—1.12) 
69.13 ± 
15.88 
77 0.99 
(0.73—1.35) 
73.50 ± 17.87 43 0.72 
(0.49—1.06) 
     Q3 142.32 ± 
28.18 
138 1.07 
(0.85—1.36) 
136.38 ± 
26.63 
94 1.26 
(0.93—1.69) 
147.06 ± 
28.41 
44 0.80 
(0.54—1.17) 
     Q4 323.55 ± 
283.03 
101 0.77 
(0.60—1.00) 
309.38 ± 
254.88 
60 0.78 
(0.55—1.09) 
333.47 ± 
302.25 
41 0.74 
(0.50—1.09) 
     p for trend   0.06   0.04   0.28 
Lycopene 
(µg/kcal) 
         
     Q1 90.53 ± 61.09 173 1.00 (ref) 105.40 ± 
65.89 
101 1.00 (ref) 80.26 ± 54.58 72 1.00 (ref) 
     Q2 312.87 ± 117 0.79 345.30 ± 74 0.83 287.52 ± 43 0.71 
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 Overall Men Women 
Median 
intake ±  SD 
Cases, 
n 
HR 
(95% CI)* 
Median 
intake ±  SD Cases, n 
HR 
(95% CI)* 
Median 
intake ±  SD 
Cases, 
n 
HR 
(95% CI)* 
79.75 (0.62—1.00) 78.00 (0.62—1.13) 72.27 (0.49—1.04) 
     Q3 627.01 ± 
119.05 
124 0.91 
(0.72—1.16) 
657.09 ± 
111.43 
78 0.95 
(0.71—1.29) 
603.63 ± 
119.41 
46 0.85 
(0.58—1.24) 
     Q4 1311.77 ± 
1210.93 
105 0.90 
(0.70—1.15) 
1396.34 ± 
1196.84 
64 0.92 
(0.66—1.26) 
1245.72 ± 
1219.55 
41 0.85 
(0.57—1.27) 
     p for trend   0.26   0.70   0.38 
Lutein (µg/kcal)          
     Q1 597.01 ± 
173.40 
141 1.00 (ref) 520.16 ± 
139.35 
87 1.00 (ref) 688.74 ± 
163.54 
54 1.00 (ref) 
     Q2 939.52 ± 
143.27 
145 1.12 
(0.89—1.42) 
825.32 ± 
81.85 
82 1.01 
(0.75—1.37) 
1045.90 ± 
97.82 
63 1.28 
(0.89—1.84) 
     Q3 1296.07 ± 
191.42 
116 0.95 
(0.74—1.21) 
1132.96 ± 
110.31 
76 1.00 
(0.73—1.36) 
1427.47 ± 
134.42 
40 0.85 
(0.56—1.28) 
     Q4 1949.59 ± 
639.28 
117 0.99 
(0.77-1.27) 
1684.55 ± 
518.06 
72 0.97 
(0.71—1.33) 
2128.98 45 0.99 
(0.66—1.48) 
     p for trend   0.56   0.99   0.21 
Total vitamin C 
(mg/kcal) 
! ! ! ! ! ! ! ! !
     Q1 21.66 ± 6.76 169 1.00 (ref) 19.99 ± 6.50 93 1.00 (ref) 23.02 ± 6.68 76 1.00 (ref) 
     Q2 39.63 ± 5.71 114 0.78 
(0.61—0.99) 
37.35 ± 4.99 71 0.83 
(0.61—1.14) 
41.60 ± 5.50 43 0.69 
(0.47—1.01) 
     Q3 60.24 ± 8.33 132 1.00 
(0.80—1.27) 
56.55 ± 6.84 91 1.16 
(0.87—1.56) 
63.40 ± 8.09 41 0.74 
(0.50—1.09) 
     Q4 102.73 ± 
151.60 
104 0.83 
(0.65—1.07) 
94.37 ± 
127.18 
62 0.82 
(0.59—1.14) 
108.74 ± 
167.54 
42 0.81 
(0.55—1.20) 
     p for trend ! ! 0.10   0.09   0.21 
Total vitamin E 
(mg !-
tocopherol 
equivalents/kcal) 
         
     Q1 2.59 ± 0.47 151 1.00 (ref) 2.38 ± 0.40 92 1.00 (ref) 2.84 ± 0.43 59 1.00 (ref) 
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 Overall Men Women 
Median 
intake ±  SD 
Cases, 
n 
HR 
(95% CI)* 
Median 
intake ±  SD Cases, n 
HR 
(95% CI)* 
Median 
intake ±  SD 
Cases, 
n 
HR 
(95% CI)* 
     Q2 3.41 ± 0.31 130 0.95 
(0.75—1.21) 
3.14 ± 0.19 76 0.89 
(0.66—1.21) 
3.64 ± 0.20 54 1.05 
(0.72—1.52) 
     Q3 4.10 ± 0.34 124 0.99 
(0.78—1.25) 
3.80 ± 0.21 72 0.89 
(0.65—1.21) 
4.33 ± 0.23 52 1.13 
(0.77—1.64) 
     Q4 5.25 ± 64.00 114 0.96 
(0.75—1.23) 
4.85 ± 54.66 77 0.99 
(0.72—1.34) 
5.49 ± 70.52 37 0.87 
(0.57—1.33) 
     p for trend   0.98   0.81   0.69 
Total soy 
isoflavones 
(mg/kcal) 
         
     Q1 3.63 ± 1.65 143 1.00 (ref) 3.25 ± 1.45 91 1.00 (ref) 4.00 ± 1.72 52 1.00 (ref) 
     Q2 7.74 ± 1.35 129 0.94 
(0.74—1.20) 
7.02 ± 1.07 72 0.80 
(0.59—1.10) 
8.37 ± 1.24 57 1.18 
(0.81—1.72) 
     Q3 12.24 ± 1.87 136 1.03 
(0.81—1.31) 
11.12 ± 1.46 84 0.96 
(0.71—1.29) 
13.15 ± 1.66 52 1.15 
(0.78—1.70) 
     Q4 20.72 ± 9.85 111 0.85 
(0.66—1.10) 
19.12 ± 8.76 70 0.80 
(0.58—1.09) 
22.00 ± 10.39 41 0.95 
(0.63—1.43) 
     p for trend   0.48   0.35   0.64 
Genistein 
(mg/kcal) 
         
     Q1 1.70 ± 0.76 142 1.00 (ref) 1.52 ± 0.67 91 1.00 (ref) 1.88 ± 0.80 51 1.00 (ref) 
     Q2 3.58 ± 0.62 136 1.01 
(0.79—1.27) 
3.24 ± 0.49 77 0.87 
(0.64—1.18) 
3.87 ± 0.56 59 1.25 
(0.86—1.83) 
     Q3 5.63 ± 0.85 129 0.98 
(0.77—1.25) 
5.10 ± 0.66 78 0.88 
(0.65—1.19) 
6.04 ± 0.75 51 1.15 
(0.78—1.71) 
     Q4 9.46 ± 4.37 112 0.87 
(0.68—1.12) 
8.72 ± 3.90 71 0.81 
(0.59—1.11) 
10.04 ± 4.59 41 0.97 
(0.64—1.47) 
     p for trend   0.65   0.60   0.53 
Daidzein 
(mg/kcal) 
   ! ! ! ! ! !
     Q1 1.69 ± 0.78 143 1.00 (ref) 1.52 ± 0.69 89 1.00 (ref) 1.86 ± 0.81 54 1.00 (ref) 
     Q2 3.65 ± 0.64 130 0.95 3.31 ± 0.52 73 0.84 3.96 ± 0.59 57 1.14 
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 Overall Men Women 
Median 
intake ±  SD 
Cases, 
n 
HR 
(95% CI)* 
Median 
intake ±  SD Cases, n 
HR 
(95% CI)* 
Median 
intake ±  SD 
Cases, 
n 
HR 
(95% CI)* 
(0.75—1.21) (0.61—1.14) (0.79—1.66) 
     Q3 5.81 ± 0.90 135 1.03 
(0.81—1.30) 
5.28 ± 0.70 86 1.01 
(0.75—1.36) 
6.24 ± 0.80 49 1.05 
(0.71—1.54) 
     Q4 9.92 ± 4.84 111 0.86 
(0.67—1.10) 
9.14 ± 4.29 69 0.80 
(0.58—1.10) 
10.55 ± 5.12 42 0.94 
(0.62—1.41) 
     p for trend  ! 0.50   0.35   0.79 
Glycitein 
(mg/kcal) 
         
     Q1 0.24 ± 0.11 146 1.00 (ref) 0.21 ± 0.096 91 1.00 (ref) 0.26 ± 0.11 55 1.00 (ref) 
     Q2 0.51 ± 0.087 127 0.91 
(0.72—1.15) 
0.46 ± 0.070 72 0.81 
(0.59—1.10) 
0.55 ± 0.080 55 1.08 
(0.74—1.57) 
     Q3 0.80 ± 0.12 137 1.02 
(0.81—1.29) 
0.73 ± 0.096 86 0.99 
(0.73—1.33) 
0.86 ± 0.11 51 1.07 
(0.73—1.57) 
     Q4 1.36 ± 0.65 109 0.82 
(0.64—1.05) 
1.25 ± 0.58 68 0.77 
(0.56—1.06) 
1.44 ± 0.69 41 0.89 
(0.59—1.35) 
     p for trend  ! 0.30   0.24   0.80 
Total 
isothiocyanate 
(µmol/kcal) 
       ! !
     Q1 2.39 ± 0.84 140 1.00 (ref) 2.06 ± 0.71 90 1.00 (ref) 2.71 ± 0.83 50 1.00 (ref) 
     Q2 4.26 ± 0.68 135 1.04 
(0.82—1.32) 
3.79 ± 0.48 72 0.85 
(0.62—1.16) 
4.68 ± 0.54 63 1.37 
(0.94—1.99) 
     Q3 6.25 ± 0.92 134 1.09 
(0.86—1.39) 
5.59 ± 0.66 86 1.09 
(0.81—1.47) 
6.77 ± 0.75 48 1.09 
(0.73—1.62) 
     Q4 10.08 ± 4.36 110 0.94 
(0.73—1.21) 
9.08 ± 3.79 69 0.90 
(0.66—1.24) 
10.81 ± 4.58 41 0.97 
(0.64—1.48) 
     p for trend   0.67   0.40   0.26 
*Adjusted for age (years), gender (male/female, in overall model only), interview year (1993-1995/1996-1998), dialect (Hokkien/Cantonese), education (less than 
secondary/secondary or greater), tobacco smoking (never/ever), alcohol consumption (never/ever), body mass index (<20, 20-<24, 24-<28, or !28 kg/m2), and 
total energy intake (kcal/day) 
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risk remained borderline statistically significant (p = 0.12), and individuals in the third 
quartile of intake had a significant 33% reduction of gastric cancer risk.  There were no 
significant associations between selenium, lycopene, lutein, soy isoflavones, or 
isothiocyanates and gastric cancer risk in the cohort. 
 Green tea, black tea, and coffee consumption were not significantly associated 
with gastric cancer risk within the overall cohort or among men (Table 45).  In women, 
there was a borderline statistically significant trend between coffee consumption and 
gastric cancer risk (p = 0.07), and daily coffee consumption was associated with a 
significant 34% decrease in gastric cancer risk.  There were no significant associations 
between tea consumption and gastric cancer risk within the cohort or among men or 
women. 
 Data from the above analyses stratified by gastric cancer site (cardia, non-cardia, 
or unspecified) are included in the appendix.  Among men, there was a borderline 
statistically significant inverse association between fresh fish and shellfish intake and the 
risk of gastric cardia cancer (p for trend = 0.11), and the second quartile of intake was 
associated with a 60% decrease in risk (HR = 0.40, 95% CI 0.18—0.92).  Increased total 
PUFA intake was borderline significantly associated with decreased gastric cardia cancer 
risk in the overall cohort and among women (p for trend = 0.06 and 0.15, respectively).  
There was also a borderline statistically significant inverse association between total n-3 
intake and gastric cardia cancer risk among men (p for trend = 0.15), with the highest 
quartile of intake imparting a borderline significant 57% reduction in risk (HR = 0.43, 
95% CI 0.17—1.06).  Among the overall cohort, non-marine n-3 and total n-6 were 
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Table 45.  Hazard ratios (HRs) and 95% confidence intervals (95% CIs) for tea and coffee intakes and the risk of gastric cancer in the Singapore Chinese Health 
Study. 
 Overall Men Women 
Median 
intake ±  
SD Cases, n 
HR 
(95% CI)* 
Median 
intake ±  
SD Cases, n 
HR 
(95% CI)* 
Median 
intake ±  
SD Cases, n 
HR 
(95% CI)* 
Black tea 
(cups/month) 
         
     Q1 0.00 331 1.00 (ref) 0.00 187 1.00 (ref) 0.00 144 1.00 (ref) 
     Q2 2.00 ± 1.14 69 1.12 
(0.86—1.45) 
2.00 ± 1.14 39 0.98 
(0.69—1.38) 
2.00 ± 1.13 30 1.37 
(0.92—2.03) 
     Q3 10.70 ± 
4.48 
47 0.84 
(0.62—1.15) 
10.70 ± 
4.61 
33 0.79 
(0.55—1.15) 
10.70 ± 
4.30 
14 0.95 
(0.55—1.65) 
     Q4 30.00 ± 
26.28 
72 1.24 
(0.95—1.60) 
30.00 ± 
27.73 
58 1.25 
(0.92—1.68) 
30.00 ± 
23.36 
14 1.12 
(0.64—1.95) 
     p for trend   0.17   0.21   0.46 
Green tea 
(cups/month) 
         
     Q1 0.00 305 1.00 (ref) 0.00 179 1.00 (ref) 0.00 126 1.00 (ref) 
     Q2 2.00 ± 1.11 91 1.06 
(0.84—1.34) 
2.00 ± 1.11 47 0.87 
(0.63—1.20) 
2.00 ± 1.10 44 1.36 
(0.96—1.92) 
     Q3 10.70 ± 
4.28 
51 0.96 
(0.71—1.29) 
10.70 ± 
4.44 
36 0.91 
(0.64—1.31) 
10.70 ± 
4.09 
15 0.99 
(0.58—1.70) 
     Q4 30.00 ± 
40.71 
72 1.08 
(0.83—1.41) 
75.00 ± 
42.47 
55 1.04 
(0.76—1.41) 
30.00 ± 
38.12 
17 1.04 
(0.62—1.74) 
     p for trend   0.88   0.77   0.36 
Any tea 
(cups/month) 
         
     Q1 0.00 214 1.00 (ref) 0.00 115 1.00 (ref) 0.00 99! 1.00 (ref)!
     Q2 4.00 ± 1.83! 103! 1.04 
(0.82—1.32)!
4.00 ± 1.87! 51! 0.84 
(0.60—1.16)!
4.00 ± 1.79! 52! 1.34 
(0.95—1.87)!
     Q3 10.70 ± 
4.96!
72! 0.89 
(0.68—1.17)!
12.70 ± 
5.09!
49! 0.82 
(0.59—1.15)!
10.70 ± 
4.80!
23! 0.98 
(0.62—1.56)!
     Q4 40.70 ± 
39.87!
130! 1.09 
(0.87—1.37)!
40.70 ± 
41.56!
102! 1.05 
(0.80—1.37)!
34.30 ± 
37.07!
28! 1.03 
(0.67—1.57)!
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 Overall Men Women 
Median 
intake ±  
SD Cases, n 
HR 
(95% CI)* 
Median 
intake ±  
SD Cases, n 
HR 
(95% CI)* 
Median 
intake ±  
SD Cases, n 
HR 
(95% CI)* 
     p for trend   0.58   0.38   0.36 
Coffee 
(cups/week) 
         
     Never 0.00 101 1.00 (ref) 0.00 56 1.00 (ref) 0.00 45 1.00 (ref) 
     Monthly 0.46 ± 0.15 10 0.99 
(0.52—1.90) 
0.46 ± 0.15 6 1.07 
(0.46—2.49) 
0.46 ± 0.15 4 0.92 
(0.33—2.56) 
     Weekly 2.50 ± 1.46 49 1.03 
(0.73—1.45) 
2.50 ± 1.45 24 0.88 
(0.54—1.42) 
2.50 ± 1.47 25 1.28 
(0.78—2.09) 
     1 cup/day 7.02 ± 0.79 160 0.83 
(0.64—1.06) 
7.02 ± 0.83 97 0.99 
(0.71—1.38) 
7.02 ± 0.77 63 0.66 
(0.45—0.97) 
     2-3 cups/day 17.56 ± 
1.96 
176 1.01 
(0.79—1.29) 
17.56 ± 
1.97 
119 1.12 
(0.81—1.55) 
17.56 ± 
1.96 
57 0.92 
(0.62—1.36) 
     !4 cups/day 31.60 ± 
5.19 
23 0.92 
(0.58—1.46) 
31.60 ± 
4.68 
15 0.89 
(0.50—1.59) 
31.60 ± 
5.95 
8 1.22 
(0.57—2.61) 
     p for trend   0.50   0.84   0.07 
*Adjusted for age (years), gender (male/female, in overall model only), interview year (1993-1995/1996-1998), dialect (Hokkien/Cantonese), education (less than 
secondary/secondary or greater), tobacco smoking (never/ever), alcohol consumption (never/ever), body mass index (<20, 20-<24, 24-<28, or !28 kg/m2), and 
total energy intake (kcal/day) 
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borderline significantly inversely associated with gastric cardia cancer risk (p for trend = 
0.10 for both).  Lastly, total plant fat intake showed a borderline statistically significant 
inverse trend regarding gastric cardia cancer risk among both men and women (p for 
trend = 0.15 and 0.12, respectively) but not in the overall cohort. 
 With respect to gastric non-cardia cancer risk, there was a borderline inverse 
association for all shellfish among women only (p for trend = 0.07), and women in the 
highest quartile of intake had a 41% reduction in risk (HR = 0.59, 95% CI 0.36—0.97).  
In the overall cohort and among women, increased consumption of saturated fat was 
associated with a borderline statistically significant increase in gastric non-cardia cancer 
risk (p for trend = 0.13 for both).  Among men, there was a borderline significant—
though somewhat U-shaped—trend between total n-3 intake and gastric non-cardia 
cancer risk (p for linear trend = 0.12; third quartile: HR = 1.26, 95% CI 0.88—1.80; 
fourth quartile: HR = 0.93, 95% CI 0.63—1.37).  Among women, there was a statistically 
significant inverse trend between total red meat fat intake and gastric non-cardia cancer 
risk (p for trend = 0.005, fourth quartile: HR = 0.40, 95% CI 0.23—0.68) and a 
borderline significant positive trend between total plant fat intake and gastric non-cardia 
cancer risk (p for trend = 0.13).  Women in the third quartile of plant fat consumption 
were at an 81% increased risk of gastric non-cardia cancer (HR = 1.81, 95% CI 1.11—
2.96).  Cholesterol intake was borderline statistically significantly positively associated 
with gastric non-cardia cancer risk among men only (p for trend = 0.15).  Total selenium 
and lycopene intakes demonstrated a borderline significant inverse association with 
gastric non-cardia cancer risk within the overall cohort (p for trend = 0.07 for both). 
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 There were no statistically significant associations between fish intake and the 
risk of unspecificed gastric cancer, which refers to cases that could not be classified as 
either cardia or non-cardia due to lack of a pathological examination.  In men, there was a 
borderline significant positive trend between animal fat and unspecified gastric cancer 
risk (p for trend = 0.12), and among women, there was a borderline significant inverse 
trend between marine n-3 intake and unspecified gastric cancer risk (p for trend = 0.13).  
There was also a borderline inverse trend between consumption of total carotenoids and 
unspecified gastric cancer risk among female cohort members, with the second quartile of 
intake associated with a significant 62% reduction in risk (HR = 0.38, 95% CI 0.16—
0.89, p for trend = 0.11).  Male members of the cohort exhibited a borderline significant 
decreased risk of unspecified gastric cancer with increasing consumption of !-
cryptoxanthin (p for trend = 0.07), and lutein intake was associated with a borderline 
significant inverse association among the overall cohort (p for trend = 0.06). 
 Notably, total soy isoflavones, genistein, daidzein, and glycitein were borderline 
statistically significantly inversely associated with unspecified gastric cancer risk among 
men only (p for trends = 0.06, 0.07, 0.07, and 0.09, respectively).  Among both men and 
women, increased total isothiocyanate consumption was associated with a significantly 
decreased risk of unspecified gastric cancer (p for trends = 0.05 and 0.02, respectively); 
however, there remained no significant association when the cohort was analyzed as a 
whole. 
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Discussion 
 The absence of statistically significant associations between fish intake and n-3 
fatty acid intake and gastric cancer risk does not support the hypothesis that increased 
consumption of these dietary components decrease the risk of gastric cancer among the 
Singapore Chinese population.  The antioxidants vitamin C, total carotenoids, and !-
cryptoxanthin exhibited borderline statistically significant inverse trends within the 
cohort with regards to gastric cancer risk.  Among women, there was a borderline 
significant inverse association between coffee consumption and gastric cancer risk that 
will be further examined in the subsequent chapter.  There was a significant inverse trend 
between red meat fat intake and gastric cancer risk among women. 
The inability to detect an association between fish consumption and the risk of 
gastric cancer among Singapore Chinese individuals may be due to low consumption of 
fish rich in n-3 among this population.  Although the FFQ used in the study has been 
validated, it does not include different variables for specific types of fish.  The exposure 
variables used for fish (all fish and shellfish, fresh fish and shellfish, preserved fish and 
shellfish, and fresh and preserved fish) would include fish and shellfish relatively low in 
n-3, such as shrimp, pollock, and crab, as well as the cold water fatty fish, such as 
salmon, mackerel, and sardines, which are considered good sources of long-chain 
PUFA[2, 6].  Independent analyses for n-3 from both marine and other sources also 
yielded null results in general, but there was a borderline trend for decreased gastric 
cardia cancer risk with increased non-marine n-3 intake, possibly due to anti-
inflammatory effects or transcriptional regulation[23, 25, 337].  In this population, non-
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marine n-3 intake accounts for approximately 62% of total n-3 intake, and the primary 
sources of non-marine n-3 are grains, cooking oils, soy products, and legumes[338].  
However, a similar trend was observed with total n-6 and gastric cardia cancer, 
suggesting that modulation of inflammation may not be the predominant mechanism for 
chemoprevention.  Given that both n-3 and n-6 are susceptible to lipid peroxidation, 
which has been shown to have chemopreventive and chemostatic effects, it is possible 
that PUFA may reduce the risk of gastric cardia cancer by this mechanism[76, 98, 103, 
107, 335].  But it is important to note that the results were not significant and multiple 
comparisons were conducted, and these results may be spurious. 
Although several epidemiological studies have implicated the carotenoids !- and 
"-carotene and total retinol equivalents in the prevention of gastric cancer[339-341], this 
is one of the first analyses to suggest "-cryptoxanthin is negatively associated with 
gastric cancer risk, especially among men.  In a nested case-control analysis from the 
European Prospective Investigation into Cancer and Nutrition study, plasma "-
cryptoxanthin concentrations were significantly lower in gastric cancer cases compared to 
controls (p = 0.01), and there was a significant negative trend for gastric cancer odds with 
increasing plasma "-cryptoxanthin after adjusting for several variables including H. 
pylori infection status (p for trend = 0.006)[342].  More research will be needed to 
elucidate potential mechanisms by which "-cryptoxanthin may reduce gastric cancer risk, 
but its chemoprevention may be due to antioxidant activity and transcriptional regulation, 
similar to other carotenoids[343, 344].  Given that this borderline significant association 
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is observed only with unspecified gastric cancer and not specific cancer sites, it is 
challenging to interpret, and it is possible that this result is spurious. 
One of the surprising results of these analyses was the significant negative 
association between red meat fat and gastric cancer risk among Singapore Chinese 
women.  Red meat is a particularly rich source of saturated fat, and excessive cooking 
may result in the formation of pro-carcinogenic compounds[268, 320, 345, 346].  It 
seems likely that there may be an underlying compounding factor, such as socioeconomic 
status, that would confer a reduced risk of gastric cancer among frequent consumers of 
red meat.  In the Singapore Chinese Health Study, education level is assessed as a 
surrogate for socioeconomic status, and among women there is a statistically significant 
interaction between red meat fat and education with regards to gastric cancer risk (p = 
0.01).  Women who consume red meat more frequently may have better access to health 
care and other preventive factors including diets lower in sodium and higher in fruits and 
vegetables.  Given that this significant association remains only with regard to gastric 
non-cardia cancer risk, H. pylori infection likely contributes additional confounding.  
Indeed, in a nested case-control study from this cohort, the association between red meat 
and gastric cancer risk was no longer significant among women when H. pylori infection 
and chronic atrophic gastritis were included in the unconditional logistic regression 
model (OR = 0.71, 95% CI 0.24—2.11, fourth quartile versus first quartile, p for trend = 
0.31, data not shown). 
 The inverse association between soy isoflavones and unspecified gastric cancer 
risk in male Singapore Chinese cohort members was not expected; however it is 
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supported by previous research.  In a recent in vitro study of a human gastric cancer cell 
line, Tang et al.[347] demonstrated significant up-regulation of apoptosis with increasing 
concentrations of daidzein.  Naginata et al.[348] detected a significant reduction in gastric 
cancer mortality among Japanese men consuming the highest tertile of soy products (HR 
= 0.50, 95% CI 0.26—0.93, p for trend = 0.03).  In a Korean nested case-control study, 
Ko et al.[349] concluded that the highest plasma concentrations of genistein and daidzein 
significantly decreased the odds of gastric cancer (OR = 0.54, 95% CI 0.31—0.93 for 
genistein; OR = 0.21, 95% CI 0.08—0.58 for daidzein).  However, in a Japanese 
prospective cohort study, Hara et al.[350] did not detect any significant associations 
between total soy isoflavone intake and gastric cancer.  This study was the only one to 
report results by gastric cancer site—which did not differ.  From the previous studies, it 
was not evident if the associations between soy isoflavones and a reduction in gastric 
cancer risk were site-specific, although given the countries in which the studies were 
conducted (Japan and Korea), it is likely that most gastric cancer cases affected the non-
cardia portion of the stomach.  In the present analysis, the association between soy 
isoflavones is only observed for unspecified gastric cancer among men; therefore, it is 
difficult to ascertain the biological mechanisms by which soy isoflavones may reduce the 
risk of gastric cancer. 
Among both male and female cohort members, there were significant inverse 
associations between total isothiocyanate intake and unspecified gastric cancer risk.  
Isothiocyanates are produced in plants such as cruciferous vegetables (broccoli, cabbage, 
Brussels sprouts, etc.) as glucosinolates, which are converted into isothiocyanates when 
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the plant tissues are processed or chewed[155].  Isothiocyanates, such as SFN and I3C, 
have demonstrated chemopreventive effects in several experiments (Chapter III)[169, 
176-178, 180, 186, 193, 197, 351].  Previously, SFN was shown to inhibit the growth and 
trigger the death of H. pylori in vitro and significantly decrease tumor multiplicity in a 
mouse model of gastric cancer[352].  In a prospective cohort of Chinese men, Moy et 
al.[353] concluded that men in the highest tertile of urinary isothiocyanate concentration 
were at a significant 34% reduction in gastric cancer risk (OR = 0.66, 95% CI 0.47—
0.97, p for trend = 0.02), and this association was even stronger among men with 
homozygous deletion of glutathione S-transferase (GST) enzyme genes, suggesting that 
increased exposure to isothiocyanates enhanced gastric chemoprevention.  These 
associations persisted even after adjustment for H. pylori, and the chemopreventive 
effects of isothiocyanates may function via xenobiotic metabolism alterations rather than 
H. pylori inhibition.  However, as with the previous studies, this study did not report the 
distribution of gastric cancer sites among its cases.  Given that the present results are seen 
only in unspecified gastric cancer and not overall gastric cancer, it is possible that the 
results are spurious. 
As with all epidemiological research, there are a number of limitations to the 
present study.  Dietary intake was assessed only at baseline and may have been subject to 
measurement error on the part of the subject or interviewer; cohort members may also 
have changed their dietary patterns substantially throughout the follow-up period, 
resulting in potential misclassification bias regarding dietary exposure.  The number of 
comparisons made for these analyses also increased the risk for chance or spurious 
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findings, as previously mentioned.  For the prospective analyses, no information 
regarding H. pylori infection or chronic atrophic gastritis status was included.  These two 
important risk factors for gastric cancer may have contributed confounding or other 
biases to the results.  Lastly, the lack of site determination for nearly 20% of gastric 
cancer cases precludes accurate interpretation of results for unspecified gastric cancers. 
To conclude, there were no significant associations between total fish or fat 
intakes and the risk of gastric cancer among Singapore Chinese adults.  There was 
evidence of inverse trends between antioxidant intakes and gastric cancer risk and coffee 
intake and gastric cancer risk among female members of the cohort.  Additional analyses 
of the Singapore Chinese Health Study including increased follow-up time and gastric 
cancer cases may reveal statistically significant associations between fish, fat, and 
antioxidant intakes and gastric cancer risk in this population. 
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Introduction 
Gastric cancer is the third leading cause of cancer death in men and fifth leading 
cause of cancer death in women worldwide[264].  The incidence of gastric cancer is 
especially high in Asian populations due in part to traditional diets rich in salt and 
fermented foods.  In Singapore, the age-standardized gastric cancer incidence rates are 
relatively high.  The average annual incidence was 21.5 and 10.8 per 100,000 from 1998 
to 2002, among men and women, respectively[265, 266, 270].  Infection of the stomach 
with Helicobacter pylori (H. pylori) is a strong risk factor for gastric cancer and was 
classified as a group 1 human carcinogen in 1994, and there is substantial evidence that 
H. pylori infection significantly increases the risk for non-cardia gastric cancer[269, 271-
273].  Given the higher prevalence of H. pylori infection in Asian countries compared to 
Western countries, rates of non-cardia gastric cancer are especially high in countries such 
as Singapore[354].  In addition to H. pylori, chronic atrophic gastritis, a condition of loss 
of glandular differentiation in the stomach tissue caused by an infection or autoimmune 
response, is considered a precancerous condition, and screening for serum pepsinogens 
leaked from gastric cells has been established as a sensitive technique to detect 
individuals at high-risk of gastric cancer[355, 356].  In a recent analysis of a prospective 
cohort study conducted in Japan, the sensitivity and specificity of this technique were 
71.0% and 69.2%, respectively, among individuals over 40 years of age with no history 
of gastric cancer or gastrectomy[357]. 
 Although H. pylori infection is a strong risk factor for non-cardia gastric cancer, 
certain dietary factors are associated with risk of both non-cardia and cardia gastric 
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cancer.  Epidemiologic studies have shown that high salt intake interacts synergistically 
with H. pylori infection to increase the risk of non-cardia gastric cancer, while a few 
studies demonstrated a statistically significant protective effect of vitamin C or fresh fruit 
for all gastric cancers regardless of H. pylori status[271, 273, 275, 301].  Additionally, 
consumption of allium vegetables, such as garlic and onions, has been inversely 
associated with risk of gastric cancer[266].  However, there are limited data addressing 
gastric cancer risk modulation by beverage sources of antioxidants, such as coffee. 
 Coffee is one of the most frequently consumed beverages worldwide, and 
consumption rates are higher in Singapore compared to other Asian countries, possibly 
due its history as a British colony[358, 359].  Kahweol and cafestol are polyphenols in 
coffee that have demonstrated chemopreventive properties in cell and animal models of 
various cancers[360-364].  In Singapore, coffee grounds are typically boiled in water and 
then filtered through a muslin bag, a process that may result in brewed coffee that has 
higher concentrations of the diterpenes kahweol and cafestol relative to the use of a paper 
filter, as in most Western populations[359, 365]. 
 In addition to providing diterpenes and antioxidants such as chlorogenic acids, 
coffee is a source of melanoidins, a heterogeneous group of compounds that has shown 
antimicrobial effects against H. pylori in vitro[366-368].  A meta-analysis of seven cohort 
and 16 case-control studies by Botelho et al.[369] concluded that coffee consumption was 
not associated with gastric cancer risk (OR = 0.97; 95% CI: 0.86, 1.09), but the studies 
included were conducted in the United States, Japan, and Europe only.  To explore 
whether there are associations between coffee consumption and the risk of gastric cancer 
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in the Singapore Chinese population, we conducted prospective analyses with the 
Singapore Chinese Health Study database, a population-based prospective cohort of 
Chinese men and women living in Singapore.  Furthermore, the availability of 
biospecimens from this cohort allowed for testing of H. pylori infection and atrophic 
gastritis prevalence to explore the interaction between these high-risk conditions and 
coffee consumption with regard to gastric cancer risk, for which data are currently 
lacking. 
 
Materials and Methods 
Singapore Chinese Health Study 
The design and inclusionary and exclusionary criteria for the Singapore Chinese 
Health Study have been previously described[280].  Members of the cohort were selected 
from permanent residents or citizens of Singapore aged 45 to 74 years living in 
government housing estates and belonging to one of the two major Chinese dialect 
groups (Cantonese and Hokkien)[279].  At baseline, all cohort members completed an in-
person interview with a trained study staff member that included a validated 165-item 
food frequency questionnaire (FFQ) that assessed coffee intake at nine defined levels: 
never or hardly ever, one to three times per month, once per week, two to three times per 
week, four to six times per week, once per day, two to three times per day, four to five 
times per day, and six or more times per day[279].  Because of the infrequent 
consumption of decaffeinated coffee among Singapore Chinese, only caffeinated coffee 
intake was assessed during the baseline interview.  In concert with the FFQ validation, 
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the Singapore Food Composition Database was developed using food composition data 
from China, Malaysia, Taiwan, and Hawaii; from this database, mean daily consumption 
values for 96 dietary components including caffeine were ascertained for each cohort 
member[279].  
We collected biospecimens from 3% of random samples of cohort participants 
beginning in 1994 and from all consenting subjects in 2000. By April 2005, biospecimens 
were obtained from 32,543 subjects (28,330 bloods; 4,400 buccal cells from refusals 
donating blood; 31,895 urines), representing a consent rate of approximately 60% after 
excluding death. All extracted components from the biospecimens have been stored in –
80oC freezers.  The Singapore Chinese Health Study was approved by the Institutional 
Review Boards at the National University of Singapore and the University of Pittsburgh. 
Cancer diagnoses and deaths from cancer were identified by linking cohort 
members to the Singapore Cancer Registry and the Singapore Registry of Births and 
Deaths.  This comprehensive national registry was established in 1968, and as of April 
2008, only 27 cases were lost to follow-up due to migration out of Singapore.  We used 
data from the 27,293 men and 34,028 women who did not have a history of cancer 
diagnosis at baseline, based on self-report and computer-assisted record linkage analysis 
with the Singapore Cancer Registry.  As of December 31, 2008 (an average follow-up of 
12.3 years), 519 of these cohort members had been diagnosed with gastric cancer (ICD-
10 16.0).  Of these cases, 73 affected the gastric cardia (ICD-10 C16.0), 345 affected the 
gastric non-cardia (ICD-10 C16.1 – C16.8), and 101 were unspecified (ICD-10 C16.9).   
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Cox proportional hazards regression analysis of diet, environmental factors, and gastric 
cancer incidence 
Person-years of follow-up were computed from the recruitment date to the date of 
gastric cancer diagnosis, death, migration, or December 31, 2008, whichever occurred 
first.  A series of Cox proportional hazards regression models were performed to test the 
associations between coffee and gastric cancer incidence.  Defined categories of coffee 
intake frequencies (cups/week) were evaluated as exposure variables.  Quartiles of 
caffeine exposure were derived from the intake distribution among the entire cohort.  To 
control for confounding, the following were included as covariates: sex (male/female), 
dialect group (Cantonese/Hokkien), age (years), interview year (1993-1995/1996-1998), 
education (less than secondary/secondary or higher), tobacco smoking (ever/never), 
alcohol use (ever/never), and body mass index (<20, 20-<24, 24-<28, or !28 kg/m2).  
Additionally, daily energy intake (kcal/day) and daily caffeine intake (mg/day) were 
included as covariates in the final model to control for dietary factors associated with 
coffee consumption. 
Statistical analyses were conducted for the overall cohort, within men, and within 
women for all gastric cancers, cardia gastric cancers, non-cardia gastric cancers, and 
unspecified gastric cancers.  Within women, stratified analyses were conducted by 
median length of follow-up (e.g., seven years) to test the effects of coffee on gastric 
cancer risk by length of follow-up.  All hazard ratios (HR) and 95% confidence intervals 
(CI) reported were two-sided and computed relative to the lowest quartile or category of 
intake, and " = 0.05 was set as the cutoff for determining statistical significance.  The 
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linear tests for coffee-gastric cancer trends were computed base on ordinal values for the 
categories (0,1,2,3, etc.). 
Given previous results from the cohort, demographic factors (sex and education 
level) and self-reported history of diabetes were tested for multiplicative interaction in the 
adjusted proportional hazards models.  There were no significant interactions between 
sex, history of diabetes, or reproductive factors (number of live births, menopausal status) 
and coffee among women with regards to gastric cancer risk.  Adjustment for additional 
dietary factors (i.e. dairy, protein, fruit and vegetable, and preserved meat and fish 
intakes) did not change the association between coffee and gastric cancer in the overall 
cohort or among either sexes, and adjustment for reproductive factors (i.e. age at first 
period, number of live births, and menopausal status) in the proportional hazards model 
did not affect the association for coffee and gastric cancer risk among women. 
 
Selection of subjects for case-control analyses 
Gastric cancer cases for the case-control study were selected from individuals 
diagnosed with cancer through December 31, 2008, who donated blood samples at 
baseline or during follow-up (n=142).  After excluding nine cases due to missing 
specimens or incident gastric cancer at baseline, 133 gastric cancer cases were included 
in the analyses.  Gastric cancer-free controls who donated a blood sample were matched 
on age at study enrollment (within three years), sex, dialect, date of baseline interview 
(within two years), and date of sample collection (within six months), and 389 matched 
controls were included.  Unconditional logistic regression was performed to calculate 
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adjusted odds ratios (OR) and 95% CIs for coffee and gastric cancer with adjustment for 
H. pylori infection and atrophic gastritis status. 
 
H. pylori and chronic atrophic gastritis testing 
Serum samples were tested for anti-H. pylori antigens by Western blot (Helico 
Blot 2.1, MP Biomedicals, Singapore) (unpublished data).  Subjects were classified as H. 
pylori-positive according to kit specifications, which have been validated with 96% 
sensitivity and 95% specificity by the manufacturer.  Serum pepsinogen I (PG I) and II 
(PG II) were measured with a latex agglination turbidimetric immunoassay kit (LZ Test 
“Eiken” Pepsinogen I and II, Tokyo, Japan) and an automated analyzer (Siemens Advia 
2400).  Subjects were classified as positive for atrophic gastritis if PG I <70 ng/mL and 
PG I:II <3, as recommended by the manufacturer.  All assays were conducted by lab 
personnel blinded to the case-control status in sets of three or four subjects containing at 
least one case.  
 
Statistical analysis 
SAS v9.2 (SAS Institute, Inc. Cary, NC) was used for statistical analyses.  All p 
values were two-sided and considered statistically significant if <0.05. 
 
Results 
 The distribution of demographic characteristics of cohort members by coffee 
intake frequency are presented overall and stratified by sex (Table 46).  The proportions 
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of current or former smokers increased with increasing coffee intake, and alcohol 
consumption was also slightly higher among cohort members drinking four or more cups 
of coffee per day compared to those consuming coffee less frequently.  Compared to 
individuals consuming coffee weekly or less, those who drank more than four cups of 
coffee per day were less likely to have achieved a secondary or higher level of education, 
and women were less likely than men to have completed secondary or higher education.  
Additionally, the proportions of women that had smoked cigarettes or consumed alcohol 
regularly were lower than the proportions among men.  Among women, the distribution 
of selected reproductive factors (age at first period, number of live births, and 
menopausal status) was similar across categories of coffee consumption (data not shown).   
 Overall, there was a weak, statistically non-significant inverse association for 
daily versus never/monthly coffee intake and gastric cancer risk (Table 47).  After 
stratification by sex, the inverse relationship was clearest among women.  Compared with 
never/monthly coffee intake, consuming at least one cup of coffee per day was associated 
with a statistically significant 37% reduction in gastric cancer risk among women, 
independent of caffeine intake.  Among women, caffeine intake had a suggestive inverse 
association at low levels (e.g., second and third quartiles versus first quartile), but there 
was no association with the highest versus the lowest quartile in relation to gastric cancer 
risk.  The inverse association with coffee and gastric cancer risk among women was 
present regardless of subsite (cardia and non-cardia) (data not shown).  There was no 
association among men with coffee and caffeine intake and gastric cancer risk, regardless 
of subsite.   
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Table 46.  Distribution of selected baseline characteristics stratified by sex and coffee intake frequency 
Demographic 
Characteristic (unit of 
measurement) 
Men  Women 
Coffee intake  Coffee intake 
!weekly 1 cup/day 2-3 cups/day "4 cups/day  !weekly 1 cup/day 2-3 cups/day "4 cups/day 
Person years of follow-up 91,753 100,265 115,621 18,632  129,208 172,831 117,255 11,489 
Hokkien dialect (%) 54.8 55.6 56.0 62.9  50.8 51.4 53.8 62.8 
Mean age at baseline , y 
(SD) 
56.99 ± 
8.32 
56.98 ± 7.98 56.17 ± 7.67 55.30 ± 7.32  56.09 ± 8.24 56.44 ± 8.02 56.06 ± 7.76 56.38 ± 7.74 
Body mass index, kg/m2 
(%) 
         
 <20 13.6 15.6 17.0 20.1  15.9 14.1 14.4 15.3 
 20-<24 51.8 53.0 54.2 54.2  54.6 54.7 55.2 56.2 
 24-<28 27.5 25.3 23.1 20.5  21.5 23.3 22.5 20.3 
 !28 7.1 6.2 5.8 5.2  8.0 7.9 7.9 8.2 
Secondary level of 
education or higher (%) 
43.1 37.8 34.9 33.9  26.1 19.4 17.0 15.3 
Smoking status (%)          
 Never 53.4 44.1 35.0 19.4  94.7 91.6 88.4 76.7 
 Ex-smoker 23.5 22.4 19.9 14.4  2.1 2.7 2.6 3.4 
 Current 23.1 33.5 45.1 66.2  3.2 5.8 9.1 20.0 
Weekly or daily alcohol 
consumption (%) 
16.7 22.3 22.5 21.8  3.3 4.3 5.6 8.2 
Self-reported history of 
ulcer at baseline (%) 
6.6 4.1 3.7 5.6  3.3 1.8 1.8 3.0 
Self-reported history of 
diabetes at baseline (%) 
10.9 8.9 7.0 6.0  10.8 9.3 7.5 5.0 
Total energy intake, kcal 
(mean ± SD) 
1697.34 
± 584.07 
1702.37 ± 
599.13 
1815.74 ± 
618.44 
1928.99 ± 
673.97 
 1368.51 ± 
465.30 
1366.00 ± 
450.84 
1466.24 ± 
492.60 
1567.88 ± 
558.33 
Total caffeine intake (mean 
± SD) 
72.74 ± 
70.11 
126.25 ± 
54.48 
248.65 ± 
58.24 
439.52 ± 
77.52 
 43.60 ± 51.18 108.20 ± 
42.68 
230.82 ± 
51.33 
430.55 ± 
81.98 
Non tea drinkers, n (%) 1778 (22.8) 
2780 (32.9) 3755 (39.4) 762 (49.9)  4489 (43.4) 6415 (47.0) 4760 (52.1) 554 (61.9) 
Total protein intake, % 
kcal (mean ± SD) 
15.1 ± 
2.5 
14.9 ± 2.4 14.7 ± 2.4 14.5 ± 2.5  15.8 ± 2.5 15.5 ± 2.5 15.1 ± 2.3 14.8 ± 2.4 
Total dairy intake, g/kcal 46.61 ± 34.06 ± 30.89 ± 51.01 26.96 ±  70.10 ± 96.89 52.33 ± 81.36 43.67 ± 68.96 35.67 ± 
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Demographic 
Characteristic (unit of 
measurement) 
Men  Women 
Coffee intake  Coffee intake 
!weekly 1 cup/day 2-3 cups/day "4 cups/day  !weekly 1 cup/day 2-3 cups/day "4 cups/day 
(mean ± SD) 72.49 58.30 45.26 61.51 
Total fruit intake, g/kcal 
(mean ± SD) 
132.76 ± 
96.82 
129.04 ± 
91.57 
110.46 ± 
83.10 
92.57 ± 
75.27 
 146.83 ± 
108.67 
142.98 ± 
102.83 
121.94 ± 
92.63 
97.28 ± 
93.17 
Total vegetable intake, 
g/kcal (mean ± SD) 
67.29 ± 
32.53 
65.93 ± 
30.33 
61.51 ± 29.51 56.46 ± 
27.57 
 82.54 ± 38.99 80.86 ± 36.01 74.44 ± 34.18 70.19 ± 
34.33 
Total preserved fish and 
shellfish intake, g/kcal 
(mean ± SD) 
1.86 ± 
2.16 
1.87 ± 2.12 1.92 ± 2.09 2.13 ± 2.34  1.73 ± 2.12 1.75 ± 2.01 1.85 ± 2.06 2.13 ± 2.98 
Total preserved meat 
intake, g/kcal (mean ± SD) 
1.60 ± 
2.49 
1.60 ± 2.46 1.68 ± 2.52 1.91 ± 2.86  1.49 ± 2.50 1.51 ± 2.50 1.59 ± 2.34 1.79 ± 3.00 
          
Nested case-control, n  97 101 127 10  55 86 41 5 
H. pylori positive (%)  83.5 89.1 89.0 90.0  87.3 76.7 95.1 60.0 
Current infection marker 
positive (%)  
73.2 74.3 73.2 80.0  80.0 66.3 82.9 60.0 
Atrophic gastritis positive 
(%)  
16.5 15.8 23.6 20.0  18.2 15.1 22.0 0.0 
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Table 47.  Coffee and caffeine intake and gastric cancer risk in the Singapore Chinese Health Study 
 Overall  Men  Women 
Cases, n HR (95% CI)  Cases, n HR (95% CI)  Cases, n HR (95% CI) 
Coffee intake*         
  Never/monthly1 111 1.00  62 1.00  49 1.00 
  Weekly 49 1.02 (0.73 – 1.44)  24 0.87 (0.54 – 1.40)  25 1.27 (0.78 – 2.08) 
  Daily 160 0.82 (0.63 – 1.06)  97 0.98 (0.70 – 1.37)  63 0.65 (0.42 – 0.99) 
  2-3 cups/day 176 0.97 (0.67 – 1.41)  119 1.09 (0.70 – 1.72)  57 0.85 (0.42 – 1.69) 
  !4 cups/day 23 0.85 (0.41 – 1.78)  15 0.85 (0.35 – 2.05)  8 1.03 (0.26 – 4.13) 
  p for trend  0.37   0.77   0.04 
           
  Never/monthly2 111 1.00  62 1.00  49 1.00 
  Weekly 49 1.02 (0.73 – 1.43)  24 0.87 (0.54 – 1.39)  25 1.24 (0.76 – 2.01) 
  !Daily 359 0.85 (0.66 – 1.09)  231 1.03 (0.74 – 1.42)  128 0.63 (0.42 – 0.94) 
  p for trend  0.32   0.77   0.009 
         
Caffeine intake†,3         
  Q1 (lowest) 143 1.00  84 1.00  59 1.00 
  Q2 115 0.86 (0.68 – 1.10)  71 0.96 (0.70 – 1.32)  44 0.72 (0.49 – 1.07) 
  Q3 132 0.92 (0.73 – 1.17)  84 1.09 (0.80 – 1.48)  48 0.74 (0.51 – 1.09) 
  Q4 (highest) 129 1.03 (0.81 – 1.32)  78 1.04 (0.76 – 1.43)  51 1.08 (0.74 – 1.59) 
  p for trend  0.49   0.88   0.10 
*Adjusted for age (years), gender (male/female, in overall model only), interview year (1993-1995/1996-1998), dialect (Hokkien/Cantonese), education (less than 
secondary/secondary or greater), tobacco smoking (never/ever), alcohol consumption (never/ever), body mass index (<20, 20-<24, 24-<28, or !28 kg/m2), 
caffeine (mg/day), and total energy intake (kcal/day) 
†Adjusted for age (years), gender (male/female, in overall model only), interview year (1993-1995/1996-1998), dialect (Hokkien/Cantonese), education (less than 
secondary/secondary or greater), tobacco smoking (never/ever), alcohol consumption (never/ever), body mass index (<20, 20-<24, 24-<28, or !28 kg/m2), and 
total energy intake (kcal) 
1p for sex interaction = 0.33 
2p for sex interaction = 0.11 
3p for sex interaction = 0.73 
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 We conducted stratified analyses by duration of follow-up to investigate whether 
the relationship between coffee intake and gastric cancer was consistent with an early- or 
late-acting effect along the carcinogenesis pathway (Table 48).  A statistically significant 
inverse association was confined to those with a longer duration of follow-up (e.g., !7 
years).  These findings are consistent with an early-acting protective effect of coffee 
intake on gastric cancer risk in women.  The exclusion of cases diagnosed within the first 
two years of follow-up did not appreciably change the association between coffee and 
gastric cancer (at least daily versus less than daily: HR = 0.59; 95% CI: 0.39, 0.91, p for 
trend = 0.01, data not shown). 
 
Table 48.  Coffee intake in relation to gastric cancer risk among female members of the Singapore Chinese 
Health Study by duration of follow-up 
Length of follow-up <7 years 7+ years 
Cases, n HR (95% CI) Cases, n HR (95% CI) 
Coffee intake*     
  Never/monthly 23 1.0 (ref) 26 1.0 (ref) 
  Weekly 14 1.14 (0.72 – 1.81) 11 1.02 (0.50 – 2.07) 
  Daily 67 1.13 (0.80 – 1.60) 61 0.46 (0.26 – 0.81) 
p for trend  0.76  0.01 
*Adjusted for age (years), interview year (1993-1995/1996-1998), dialect (Hokkien/Cantonese), education 
(less than secondary/secondary or greater), tobacco smoking (never/ever), alcohol consumption 
(never/ever), body mass index (<20, 20-<24, 24-<28, or !28 kg/m2), caffeine (mg/day), and total energy 
intake (kcal/day) 
 
 When examining covariates for confounding via stratification, the protective 
effect for coffee among female cohort members appeared to be confined to those women 
with less than secondary education (Table 49).  Among these women, daily or greater 
coffee consumption was associated with a significant 27% reduction in gastric cancer 
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Table 49.  Coffee intake in relation to gastric cancer risk among female members of the Singapore Chinese Health Study by education and preserved meat intake 
 All women  Highest Education Achieved 
Cases, n HR (95% CI)  Less Than Secondary  Secondary or Higher 
Coffee intake*    Cases, n HR (95% CI)  Cases, n HR (95% CI) 
  Never/monthly 49 1.00  42 1.00  7 1.00 
  Weekly 25 1.27 (0.78 – 2.08)  24 1.16 (0.80 - 1.67)  1 0.54 (0.20 - 1.45) 
  Daily 63 0.65 (0.42 – 0.99)  55 0.72 (0.54 - 0.96)  8 1.21 (0.64 - 2.28) 
  2-3 cups/day 57 0.85 (0.42 – 1.69)  52 0.77 (0.52 – 1.16)  5 2.15 (0.82 – 5.59) 
  !4 cups/day 8 1.03 (0.26 – 4.13)  7 0.50 (0.22 - 1.13)  1 5.23 (0.84 - 32.63) 
  p for trend  0.04   0.04   0.19 
           
  <Daily 74 1.00  66 1.00  8 1.00 
  !Daily 128 0.60 (0.42 – 0.85)  114 0.73 (0.57 – 0.93)  14 1.35 (0.78 – 2.34) 
         
    Quartile of Preserved Meat Intake 
    1 and 2  3 and 4 
  <Daily    50 1.00  24 1.00 
  !Daily    61 0.40 (0.25—0.65)  67 1.00 (0.57—1.75) 
*Adjusted for age (years), interview year (1993-1995/1996-1998), dialect (Hokkien/Cantonese), tobacco smoking (never/ever), alcohol consumption (never/ever), 
body mass index (<20, 20-<24, 24-<28, or !28 kg/m2), caffeine (mg/day), and total energy intake (kcal/day) 
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risk, while among women with secondary or higher education, daily or greater coffee 
intake non-significantly increased gastric cancer risk by 35%.  The interaction between 
education and coffee intake among women was statistically significant (p for interaction 
<0.05).  When women were stratified by intake of preserved meat, the significant inverse 
association between daily coffee intake and gastric risk remained among those in the 
lowest quartiles of intake only.  There remained no significant associations between 
coffee intake and gastric cancer risk among men after stratification by education level or 
preserved meat intake (data not shown).   
 In Table 50, we present the coffee- and caffeine-gastric cancer associations 
among the nested case-control dataset for which we have measured several biomarkers of 
H. pylori infection.  In this subset, daily coffee drinking was inversely associated with 
gastric cancer risk overall, with the strongest inverse association among women.  After 
adjustment for H. pylori infection status and atrophic gastritis, the associations became 
stronger.  Among women, daily coffee intake was associated with a statistically 
significant 76% decrease in gastric cancer risk.   
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Table 50.  Odds ratios (ORs) and 95% confidence intervals (95% CIs) for gastric cancer risk by coffee and caffeine intake in nested case-control study of the 
Singapore Chinese Health Study 
Coffee 
Intake 
Overall Men Women 
Cases/ 
Controls, 
n 
OR 
(95% CI)* 
Infection-
adjusted OR** 
Cases/ 
Controls, 
n 
OR 
(95% CI)† 
Infection-
adjusted OR‡ 
Cases/ 
Controls, 
n 
OR 
(95% CI)† 
Infection-adjusted 
OR‡ 
<Daily 45/107 1.00 1.00 25/72 1.00 1.00 20/35 1.00 1.00 
!Daily 88/282 0.55 
(0.33—0.93) 
0.51 
(0.29—0.90) 
60/178 0.86 
(0.44—1.69) 
0.74 
(0.36—1.53) 
28/104 0.25 
(0.10—0.64) 
0.24 
(0.09—0.64) 
          
Caffeine 
(mg/day) 
         
T1 
(lowest) 
46/119 1.00 1.00 23/69 1.00 1.00 23/50 1.00 1.00 
T2 37/132 0.70 
(0.42—1.19) 
0.68 
(0.39—1.20) 
26/76 1.04 
(0.54—2.02) 
1.01 
(0.50—2.04) 
11/56 0.37 
(0.16—0.87) 
0.38 
(0.15—0.92) 
T3 
(highest) 
50/138 0.92 
(0.55—1.53) 
0.81 
(0.47—1.41) 
36/105 0.97 
(0.51—1.84) 
0.84 
(0.43—1.66) 
14/33 0.88 
(0.37—2.10) 
0.95 
(0.39—2.34) 
p for 
trend 
 0.39 0.42  0.97 0.82  0.06 0.08 
*ORs (95% CIs) computed using conditional logistic regression adjusted for education (less than secondary/secondary or greater), smoking (never/ever), alcohol 
(never/ever), total energy intake (kcal/d), body mass index (<20, 20-<24, 24-<28, or !28 kg/m2), and caffeine (mg/day, for coffee analyses only) 
**ORs (95% CIs) computed using conditional logistic regression, adjusted for education (less than secondary/secondary or greater), smoking (never/ever), alcohol 
(never/ever), total energy intake (kcal/d), body mass index (<20, 20-<24, 24-<28, or !28 kg/m2), caffeine (mg/day, for coffee analyses only), H. pylori infection 
status (positive/negative), and chronic atrophic gastritis status (positive/negative) 
†ORs (95% CIs) computed using unconditional logistic regression, adjusted for matching factors (i.e., age (y), dialect group (Hokkien/Cantonese), interview year 
(1993-1995/1996-1998), year of blood collection), and education (less than secondary/secondary or greater), smoking (never/ever), alcohol (never/ever), total 
energy intake (kcal/d), body mass index (<20, 20-<24, 24-<28, or !28 kg/m2), and caffeine (mg/day, for coffee analyses only) 
‡ORs (95% CIs) computed using unconditional logistic regression, adjusted for matching factors (i.e., age (y), dialect group (Hokkien/Cantonese), interview year 
(1993-1995/1996-1998), year of blood collection), and education (less than secondary/secondary or greater), smoking (never/ever), alcohol (never/ever), total 
energy intake (kcal/d), body mass index (<20, 20-<24, 24-<28, or !28 kg/m2), caffeine (mg/day, for coffee analyses only), H. pylori infection status 
(positive/negative), and chronic atrophic gastritis status (positive/negative) 
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Discussion 
In the present study, novel results from analyses of coffee intake and gastric 
cancer risk were presented using the Singapore Chinese Health Study database, a well-
established cohort with a mean follow-up of more than twelve years.  Unlike other Asian 
populations, Singapore Chinese are frequent consumers of coffee, and the preparation 
techniques employed in the country may increase the exposure to chemopreventive 
substances in this beverage.  Indeed, we reported that Singapore Chinese women who 
drank coffee at least once daily, compared with none or monthly intake, had a statistically 
significant 37% decreased risk for gastric cancer, a common cancer with relatively high 
mortality among this population. 
Our results are similar to those of Icli et al.[311], who detected a statistically 
significant 50% reduction in gastric cancer risk in men and women consuming one cup of 
coffee per day compared to those drinking coffee less than 3 times weekly.  However, the 
majority of research on coffee and gastric cancer has yielded null or positive associations.  
Botehlo et al.[369] conducted a systematic review and meta-analysis in 2006 and 
reported no association between coffee and gastric cancer risk (OR = 0.97; 95% CI: 0.86, 
1.09) among both case-control and prospective cohort studies.  Apart from one study 
conducted in Japan, all studies included in this meta-analysis were from Western 
populations; the Singapore Chinese population may differ appreciably in their 
relationship between coffee and gastric cancer due to coffee brewing techniques as well 
as higher rates of gastric cancer and H. pylori infection compared to Western populations.  
A recent examination of coffee intake and overall cancer risk in the European Prospective 
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Investigation into Cancer and Nutrition showed no significant protective effects[370].  
Additionally, Ngoan et al.[317] did not detect an association between coffee drinking and 
gastric cancer risk in a prospective cohort of Japanese men and women (HR = 1.0; 95% 
CI: 0.9, 1.1), but relatively few subjects were daily coffee drinkers compared to 
Singapore Chinese (approximately 35% in the former versus approximately 87% in the 
latter).  
In a previous prospective analysis, Larsson et al.[371] examined the association 
between coffee and gastric cancer risk in a cohort of Swedish women.  In contrast to our 
findings, the authors concluded that consuming coffee at least four times daily conferred 
a significantly increased risk of gastric cancer compared to one cup or less daily (HR = 
1.86; 95% CI: 1.07, 3.25).  When the authors compared daily to less than daily coffee 
drinking, daily coffee consumption showed a statistically non-significant positive 
association (HR = 1.17; 95% CI: 0.51, 2.66).  The differences in our results may be due 
to the much higher prevalence of female ever smokers in the Swedish versus Singapore 
Chinese cohort (57.8% versus 23.4% among those who drank at least four cups of coffee 
daily, respectively), for which the data of Larsson et al. were not adjusted.  Another 
plausible explanation may be the differences in distribution of gastric cancer sites 
between Swedish and Singapore Chinese individuals; within the Singapore Chinese 
cohort, 14% of gastric cancers affected the gastric cardia, whereas this proportion was 
recently reported as 29% among the Swedish population[372].  Although there were no 
differences between coffee and gastric cancer risk by subsite in the present study, the 
higher proportions of gastric cardia cancers among Swedish people may account for the 
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positive association between coffee and gastric cancer risk.  More research will be needed 
to characterize the effects of coffee on the etiology of gastric cardia versus non-cardia 
cancers.   
More recently, Gallus et al.[373] measured a borderline significant positive trend 
between coffee drinking and gastric cancer risk in two Italian case-control studies with 
both male and female subjects (OR = 1.24; 95% CI: 0.94, 1.65; four or more cups per day 
versus non-drinkers; p for trend = 0.069).  Ren et al.[374] examined the association of 
several beverages, including coffee, and upper gastrointestinal cancers in a large 
American cohort and concluded that coffee drinking significantly increased the risk of 
gastric cardia cancer (HR = 1.57; 95% CI: 1.03, 2.39; more than three cups daily versus 
less than one cup daily; p for trend = 0.039), while the risk of non-cardia gastric cancer 
was not associated with coffee consumption (HR = 1.06; 95% CI: 0.68, 1.64; more than 
three cups daily versus less than one cup daily; p for trend = 0.67).  Again, the differences 
in etiology between gastric cardia and non-cardia cancers may explain this disparity.  
However, neither of these studies were conducted in an Asian population, and our results 
may be due to the higher prevalence of gastric cancer among such a population as well as 
genetic and cultural factors, such as coffee preparation techniques, that differ from the 
previous studies. 
Our study also included a nested case-control analysis with adjustment for H. 
pylori infection and chronic atrophic gastritis, important risk factors for gastric cancer.  
Daily coffee drinking exerted a protective effect among women even when taking into 
account these risk factors, suggesting that coffee may prevent gastric cancer in a 
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mechanism independent of H. pylori infection or atrophic gastritis.  However, males did 
not exhibit a significantly reduced risk of gastric cancer with any level of coffee 
consumption.  It appears unlikely that the primary mechanism by which coffee reduces 
the risk of gastric cancer is by modulating these risk factors.  Nevertheless, the 
antioxidants present in coffee may decrease gastritis inflammation with or without either 
of these conditions, thereby reducing the likelihood of mutagenesis and cancer 
progression[336, 366]. 
An additional mechanism by which coffee consumption may reduce the risk of 
gastric cancer is by the prevention of carcinogenesis by the nitrosamine, N-
nitrosodimethylamine (NDMA), present in foods frequently consumed in Asian 
countries, such as fermented fish sauce or salted meats[268, 288, 346, 356].  Indeed, an in 
vitro study of a colon cancer cell line by Majer et al.[360] showed significant protective 
effects of the coffee diterpenes cafestol and kahweol against DNA damage.  The 
diterpenes were shown to decrease the activation of procarcinogens and up-regulate the 
excretion of toxic metabolites by UDP-glucuronosyltransferases and glutathione.  It is 
conceivable that such a mechanism could inhibit gastric cancer in humans[375].  
However, in our study, coffee did not show a significant protective effect against gastric 
cancer in the highest two quartiles of preserved meat intake, suggesting that coffee 
drinking does not reduce the risk of gastric cancer with high nitrosamine exposure. 
Nevertheless, these mechanisms do not explain the differing results between men 
and women in this analysis, which could not be accounted for by hormonal variables, 
such as parity or menopausal status.  From Table 46, it is evident that men and women 
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have different exposures to certain covariates, including protein, dairy products, fruits, 
and vegetables, which are consumed more frequently among females than males, and 
preserved fish, shellfish, and meat, which are consumed slightly less often among 
females than males.  Cigarette smoking is much more common among males than 
females.  Although each of these covariates was not significant when formally analyzed 
for confounding, the effects of all together may be responsible for residual confounding.  
There is also potential for effect modification by education status, as shown in Table 49; 
less than secondary education may be a surrogate for lifestyle factors that would reduce 
the risk of gastric cancer, such as increased physical activity, access to healthcare, and 
consumption of fresh fruits and vegetables rather than convenience meals.  An additional 
factor contributing to the differences in odds ratios between men and women in the 
nested case-control study is the relatively smaller number of women included in this 
analysis.  The associations between coffee and gastric cancer vary between the 
proportional hazards regression and logistic regression analyses, and the women included 
in the nested case-control analyses may not be representative of the entire cohort with 
respect to H. pylori infection and chronic atrophic gastritis prevalence.  This may result in 
selection bias that differentially affects the association between gastric cancer and coffee 
by gender.  Finally, the lower number of female gastric cancer cases included in this 
study reduced the precision of relative risk measurements compared to males; the gender-
specific results may be spurious and should be interpreted cautiously. 
Despite the aforementioned limitations of this study, there are a number of 
strengths to our analyses.  The prospective nature of the Singapore Chinese Health Study 
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allows for ascertainment of dietary and environmental exposures prior to diagnosis of 
cancer, thereby limiting recall bias, and the cohort has lost less than 1% of subjects to 
follow-up.  This analysis is also unique because it is the first to examine coffee drinking 
habits and gastric cancer risk among the high-risk Singapore Chinese population, who 
consume coffee more frequently than other high-risk Asian populations.  Finally, the 
inclusion of biomarkers benefits the analysis by providing information about the 
important risk factors H. pylori infection and chronic atrophic gastritis. 
In conclusion, daily coffee consumption was associated with a significant 
reduction in gastric cancer risk among Singapore Chinese women.  When adjustment for 
H. pylori and atrophic gastritis was included in a subset of the cohort, the negative 
association between coffee and gastric cancer strengthened among women.  More 
research will be needed to elucidate the mechanisms by which coffee reduces the risk of 
gastric cancer as well as the differences between men and women with respect to coffee 
and gastric cancer risk. 
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The burgeoning interest in health benefits of plant bioactive compounds coupled 
with greater access to increasingly sensitive analytical instrumentation have increased 
efforts to develop biomarkers of dietary exposure to these compounds.  However, despite 
substantial improvements in analytical instrumentation, many of the sample preparation 
steps preceding analyses have not similarly improved.  One example of this is the 
enzymatic hydrolysis of the conjugated analyte of interest.  Helix pomatia (snail) 
digestive juice is one typical enzyme source, which provides !-glucuronidase and 
sulfatase activities and returns the analyte to its unconjugated form for analysis.  
Nonetheless, we propose that herbivore-sourced enzyme preparations are problematic 
when applied to methods that quantify exposure to plant bioactives, especially when trace 
level analyses are required.  We are in the process of validating sensitive urinary 
biomarkers for exposure to bioactive components found in cruciferous and apiaceous 
vegetables, represented by 3,3"-diindolylmethane (DIM) and the furanocoumarins 8-
methoxypsoralen (8-MOP) and 5-methoxypsoralen (5-MOP), respectively.  It became 
evident that H2O blanks treated only with the enzyme mixture and internal standard 
yielded detectable levels of DIM, 8-MOP, and 5-MOP.  Because of the frequent 
experimental use of this enzyme formulation, it is imperative to inform the research 
community of its potential for contamination with numerous dietary components.  Our 
objectives here are to characterize the contamination of multiple formulations of H. 
pomatia !-glucuronidase/arylsulfatase with DIM, 8-MOP, and 5-MOP and identify an 
alternative source of the enzyme. 
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 To establish that H. pomatia !-glucuronidase/arylsulfatase (Roche cat. no. 
10127698001, lot no. 70255323, Penzberg, Germany) was the source of DIM 
contamination, 1 mL of HPLC grade H2O was treated with 1000, 2000, 4000, or 6000 U 
of the enzyme and 10 pmol of d2-DIM (synthesized as previously described from d2-
formaldehyde, Cambridge Isotope Laboratories, Andover, MA, USA, and indole, Sigma-
Aldrich, St. Louis, MO, USA [200]) as an internal standard.  Additional samples were 
treated with 2000 U of a different lot number of the same enzyme (Roche cat. no. 
10127698001, lot no. 70331220, Penzberg, Germany) or 2000 U of E. coli !-
glucuronidase (G8295, Sigma-Aldrich) solution in phosphate buffered saline (0.26%, 
w/v) and internal standard.  Additional replicates were treated with enzyme but no 
internal standard to eliminate the contribution of DIM from the deuterated internal 
standard.  Each sample was extracted two times with an equal volume of t-butyl methyl 
ether.  The extracts were evaporated to dryness and reconstituted to 20 µL with 
acetonitrile/10mM ammonium acetate (30/70, v/v). 
 To quantify furanocoumarin contamination, 3000 U of !-glucuronidase 
preparations from H. pomatia (G7017, G0751, and G1512, Sigma-Aldrich) or 
Escherichia coli (G8295, Sigma-Aldrich) were added to 750 µL LC-MS grade H2O and 
750 fmol of both internal standards (8-MOP-d3 and 5-MOP-d3, TLC Pharmachem, 
Vaughan, Ontario, Canada).  Samples were extracted using Trace N SPE columns (10 
mg/1 mL) on a System 96 II positive pressure manifold from SPEware (Baldwin Park, 
CA, USA).  SPE columns were conditioned with 200 µL methanol and equilibrated with 
200 µL H2O.  After the samples were loaded, columns were washed with 1 mL LC-MS 
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H2O and 250 µL 85/15 (v/v) H2O/isopropanol, followed by drying under N2 for 8 min.  
Analytes were eluted with 800 µL 80/20 (v/v) hexane/ethyl acetate, and eluates were 
evaporated to dryness under N2 at 40 °C.  Extracts were reconstituted in 50 µL 10/90 (v/v) 
methanol/H2O. 
 DIM quantitation was carried out by capillary liquid chromatography-electrospray 
ionization-tandem mass spectrometry-selected reaction monitoring (LC-ESI-MS/MS-
SRM) on an Agilent 1100 capillary HPLC system (Agilent Technologies, Palo Alto, CA, 
USA) and TSQ Quantum Discovery Max instrument (Thermo Fisher Scientific, 
Waltham, MA, USA). MS data were acquired and processed by Xcalibur software 
version 1.4 (Thermo Electron, Waltham, MA, USA).  Urinary DIM was quantitated in the 
positive ion mode with N2 as the nebulizing and drying gas. Mass spectrometry (MS) 
parameters were set as follows: spray voltage, 3.2 kV; sheath gas pressure, 25; capillary 
temperature, 250 °C; collision energy, 17 V; scan width, 0.05 amu; Q2 gas pressure 1.0 
mTorr; source CID 9 V; and tube lens offset, 104 V. Eight microliters of the sample were 
injected from an autosampler into the ESI source using the HPLC system equipped with a 
5 µm, 150 x 0.5 mm ZorbaxSB-C18 column (Agilent Technologies, Santa Clara, CA).  
To optimize performance, the samples were eluted at 15 µl/min for the first 3 min then 10 
µl/min with a gradient from 60% methanol in 15 mM NH4OAc to 100% methanol in 8 
min and held for additional 29 min.  The mass transitions (parent to daughter) monitored 
were m/z 247!130 for DIM (retention time ranged from 16.3-17.6 min) and m/z 
249!132 for d2-DIM (retention time ranged from 16.1-17.5 min) as an internal standard.  
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 Quantitation of 8-MOP and 5-MOP utilized liquid chromatography coupled with 
atmospheric pressure chemical ionization-tandem mass spectrometry (APCI-MS/MS).  
Isocratic LC separations were performed on a Restek Ultra II Aromax column (150 x 3.2 
mm i.d., 3 µm, Bellefonte, PA, USA) at 600 µL/min and 50 °C, utilizing 45/15/40 
methanol/acetonitrile/H2O (v/v/v) with 0.1% acetic acid as the mobile phase.  Eluent was 
sent to waste for the first 4 min of each run and was then introduced into the MS using a 
Thermo Ion Max source in APCI mode.  Ionization parameters were: corona voltage, 
4000 V; discharge current, 4.0 µA; vaporizer temperature, 340 °C; sheath and auxiliary 
gas pressure, 17 (N2, arbitrary units); capillary temperature, 250 °C; capillary offset, 35 
V; tube lens offset, 100 V; skimmer offset, -9 V; argon collision pressure, 1.6 mtorr.  
Retention times for 8-MOP and 8-MOP-d3 were 5.4 min, and those for 5-MOP and 5-
MOP-d3 were 8.5 min.  The nominal mass transitions m/z 217 ! 90 (analytes) and m/z 
220 ! 90 (internal standards) were monitored in SRM mode for quantitation (collision 
energy = 32 eV), while m/z 217 ! 174 and m/z 220 ! 174 were monitored for 
confirmation (CE = 37 eV). 
Calibration curves were constructed by plotting the peak area ratio of each analyte 
to its internal standard (STD:ISTD) vs. analyte concentration, and analyte concentrations 
within each enzyme sample were quantified by comparing the analyte:internal standard 
ratios from the samples to the calibration curves. The limit of quantitation (LOQ) for 
DIM was 132 fmol, and the LOQs of 8-MOP and 5-MOP were 113 fmol for both 
analytes.  SAS v9.2 (SAS Institute, Inc., Cary, NC) was used for statistical analyses.  The 
change in DIM concentration with increasing amounts of Roche H. pomatia !-
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glucuronidase/arylsulfatase was evaluated with linear regression.  The level of 
significance was ! <0.05.  
 As shown in Figure 32, the treatment of H2O with increasing volumes of H. 
pomatia !-glucuronidase/arylsulfatase yielded a significant positive linear association 
between quantity of enzyme and concentration of DIM (R2 = 1, p = 0.0013).  To verify 
that the contamination was not isolated to a single vial or lot of enzyme, an additional 
enzyme lot and an E. coli source of the enzyme were tested for DIM contamination and 
the results are shown in Table 51.  Two separate lots of !-glucuronidase/arylsulfatase 
obtained from H. pomatia elicited mean DIM concentrations of 4.41 and 4.66 pmol/mL 
H2O, whereas H2O without any enzyme or with E. coli !-glucuronidase did not yield 
quantifiable concentrations of DIM.   
 
 
Figure 32.  Change in DIM concentration with increasing amounts of H. pomatia !-glucuronidase 
p = 0.0013 for linear regression model 
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 Table 51 also presents the results of 8-MOP and 5-MOP concentrations in several 
different preparations of H. pomatia !-glucuronidase/arylsulfatase and the same E. coli 
source of !-glucuronidase used to test for DIM.  The mean concentrations of 8-MOP in 
crude and size-exclusion chromatography-purified preparations of H. pomatia !-
glucuronidase/arylsulfatase were 3.27 and 6.03 pmol/mL H2O, respectively.  With regard 
to 5-MOP, the quantities detected in H. pomatia !-glucuronidase/arylsulfatase were 
lower than 8-MOP, with an average of 0.17 pmol/mL H2O in the crude enzyme and 0.40 
pmol/mL H2O in the purified enzyme preparations.  Concentrations of 8-MOP and  
 
Table 51.  Concentrations of DIM, 8-MOP, and 5-MOP detected in multiple preparations of !-
glucuronidase. 
!-glucuronidase 
preparation  
DIM (pmol/mL 
H2O, mean ±  
standard error)c 
8-MOP (pmol/mL 
H2O, mean ±  
standard error)d 
5-MOP (pmol/mL 
H2O, mean ±  standard 
error)d 
Nonea <LOQ* nd nd 
Roche H. pomatia lot 
#70255323b 4.41 ± 0.03   
Roche H. pomatia lot 
#70331220b 4.66 ± 0.18   
Sigma H. pomatia G7017 
HP-2, crude solutionb  3.27 ± 0.01 0.17 ± 0.01 
Sigma H. pomatia G0751 
H-1, partially purified 
powder (lot 
068K38091V)  <LOQ <LOQ 
Sigma H. pomatia G0751 
H-1, partially purified 
powder (lot 071M7024V)  <LOQ <LOQ 
Sigma H. pomatia G1512 
H-5, lyophilized powderb  6.03 ± 0.03 0.40 ± 0.02 
Sigma E. coli G8295b nd nd nd 
*Detectable levels of DIM due to contribution of d2-DIM
 
aAverage of 5 replicates 
bAverage of 2 replicates  
cValues represent 2000 U of each enzyme 
dValues represent 3000 U of each enzyme 
LOQ = limit of quantitation (132 fmol for DIM, 113 fmol for 8-MOP and 5-MOP) 
 
   336 
5-MOP below the LOQ were detected in two lots of a partially purified H. pomatia !-
glucuronidase/arylsulfatase. 
 The results demonstrate that !-glucuronidase/arylsulfatase from H. pomatia is 
contaminated with appreciable amounts of DIM (Roche cat. no. 10127698001) as well as 
8-MOP and 5-MOP (Sigma-Aldrich G7017 and G1512), thereby limiting its use in urine 
sample preparation for the measurement of these compounds.  Additionally, 8-MOP and 
5-MOP were most concentrated in a preparation purified by size-exclusion 
chromatography (Sigma-Aldrich G1512), demonstrating that this technique is insufficient 
to eliminate contaminants that may bind with high affinity to proteins in the preparation 
[376].  Although a partially purified preparation of !-glucuronidase/arylsulfatase from H. 
pomatia (Sigma-Aldrich G0751) did not demonstrate quantifiable contamination with 8-
MOP or 5-MOP, the difficulty in predicting the distribution of contamination across 
samples when using a snail-sourced enzyme due to the low solubility and high protein 
binding of 8-MOP and 5-MOP precludes its use in these highly sensitive analyses.  In 
contrast, recombinant !-glucuronidase produced by E. coli does not contain significant 
amounts of DIM, 8-MOP, or 5-MOP; however, it should be noted that this preparation 
lacks sulfatase activity.  Sulfatase produced by another bacterial source, A. aerogenes, 
may be an option if this activity is also desired [377]. The identification of these 
compounds in !-glucuronidase/arylsulfatase from the herbivore H. pomatia adds to a 
growing list of contaminants that includes phytoestrogens and catechins [252, 377, 378].  
This suggests additional plant bioactives may be present in preparations from H. pomatia, 
and underscores the risk of false positive results and misclassification of exposure status 
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when applying this enzyme preparation to dietary biomarker methods.  We recommend 
cautious planning for experiments that require the use of enzyme treatment and 
consideration of the potential exposures of enzymes to analytes of interest and other 
interferences. By demonstrating that enzymes from H. pomatia are contaminated with 
plant bioactive compounds, we hope to save investigators from the time and expense 
associated with contamination during method development.  The value of blank samples, 
especially those containing neither the analytical nor the internal standards, cannot be 
overemphasized. 
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Supplemental Tables from Chapter VII: Dietary fish, fat, and antioxidant consumption and the risk of 
gastric cancer in the Singapore Chinese Health Study 
 
Table 52.  Demographic characteristics of Singapore Chinese Healthy Study cohort members stratified by site of gastric cancer. 
Characteristic 
Subjects with 
cardia gastric 
cancer (n=73) 
Subjects with non-
cardia gastric 
cancer (n=345) 
Subjects with 
unspecified gastric 
cancer (n=101) 
Subjects without 
gastric cancer 
(n=60,802) 
Male (%) 68 61 54 44 
Person-years of follow-up 567 2420 631 753,440 
Age at baseline, y (mean ± SD) 60.01 ± 8.39 61.29 ± 7.39 61.63 ± 7.85 56.36 ± 7.98 
Hokkien dialect (%) 68 67 74 54 
Body mass index, kg/m2 (%)     
     <20 10 13 12 15 
     20-<24 53 58 62 54 
     24-<28 23 21 20 24 
     !28 14 8 6 7 
Secondary level of education or higher (%) 19 18 17 29 
Smoking status (%)     
     Never 51 54 58 70 
     Ex-smoker 21 12 14 11 
     Current 29 24 28 19 
Weekly or daily alcohol consumption (%) 12 16 12 12 
Self-reported history of ulcer at baseline (%) 1 4 7 3 
Self-reported history of diabetes at baseline (%) 11 10 5 9 
Total energy intake, kcal (mean ± SD) 1617.94 ± 581.29 1539.51 ± 557.58 1467.54 ± 484.74 1556.81 ± 566.35 
Total fat intake, % kcal (mean ± SD) 24.43 ± 5.58 24.47 ± 5.73 24.19 ± 5.80 25.11 ± 5.64 
Total preserved fish and shellfish intake, g/kcal (mean ± 
SD) 
1.73 ± 2.04 1.84 ± 1.79 1.62 ± 1.44 1.83 ± 2.11 
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Table 53.  Hazard ratios (HRs) and 95% confidence intervals (95% CIs) for quartiles of fish intake and the risk of cardia gastric cancer in the Singapore Chinese 
Health Study. 
 Overall Men Women 
Median 
intake 
(g/kcal, ±  
SD) 
Cases, 
n 
HR 
(95% CI) * 
Median 
intake 
(g/kcal, ±  
SD) 
Cases, 
n 
HR 
(95% CI) * 
Median 
intake 
(g/kcal, ±  
SD) 
Cases, 
n 
HR 
(95% CI) * 
Total fish and 
shellfish 
         
     Q1 17.60 ± 6.04 22 1.00 (ref) 16.49 ± 
5.49 
18 1.00 (ref) 18.67 ± 
6.34 
4 1.00 (ref) 
     Q2 29.10 ± 3.25 14 0.62 
(0.32—1.22) 
27.61 ± 
2.81 
9 0.47 
(0.21—1.05) 
30.46 ± 
3.02 
5 1.37 
(0.37—5.13) 
     Q3 39.46 ± 3.80 16 0.70 
(0.37—1.34) 
37.46 ± 
3.26 
11 0.56 
(0.26—1.19) 
41.06 ± 
3.43 
5 1.40 
(0.38—5.26) 
     Q4 55.58 ± 13.99 21 0.90 
(0.50—1.65) 
53.05 ± 
13.55 
12 0.60 
(0.29—1.26) 
57.42 ± 
14.01 
9 2.33 
(0.71—7.64) 
     p for trend   0.48   0.22   0.51 
Fresh fish and 
shellfish 
         
     Q1 15.91 ± 5.73 23 1.00 (ref) 14.80 ± 
5.18 
19 1.00 (ref) 17.08 ± 
6.02 
4 1.00 (ref) 
     Q2 27.27 ± 3.24 13 0.55 
(0.28—1.09) 
25.73 ± 
2.76 
8 0.40 
(0.18—0.92) 
28.60 ± 
3.00 
5 1.37 
(0.37—5.11) 
     Q3 37.54 ± 3.81 17 0.71 
(0.38—1.34) 
35.45 ± 
3.23 
11 0.53 
(0.25—1.13) 
39.19 ± 
3.41 
6 1.68 
(0.47—5.97) 
     Q4 53.50 ± 14.01 20 0.82 
(0.45—1.51) 
50.85 ± 
13.55 
12 0.58 
(0.28—1.21) 
55.52 ± 
14.02 
8 2.03 
(0.61—6.80) 
     p for trend   0.37   0.11   0.70 
Preserved fish 
and shellfish 
         
     Q1 0.16 ± 0.13 23 1.00 (ref) 0.19 ± 0.15 17 1.00 (ref) 0.15 ± 0.12 6 1.00 (ref) 
     Q2 0.80 ± 0.25 20 0.85 0.88 ± 0.24 14 0.77 0.73 ± 0.23 6 1.11 
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 Overall Men Women 
Median 
intake 
(g/kcal, ±  
SD) 
Cases, 
n 
HR 
(95% CI) * 
Median 
intake 
(g/kcal, ±  
SD) 
Cases, 
n 
HR 
(95% CI) * 
Median 
intake 
(g/kcal, ±  
SD) 
Cases, 
n 
HR 
(95% CI) * 
(0.47—1.56) (0.38—1.58) (0.36—3.45) 
     Q3 1.79 ± 0.37 11 0.46 
(0.22—0.95) 
1.85 ± 0.36 8 0.42 
(0.18—0.98) 
1.73 ± 0.36 3 0.60 
(0.15—2.43) 
     Q4 3.75 ± 2.57 19 0.79 
(0.43—1.47) 
3.83 ± 2.59 11 0.56 
(0.26—1.20) 
3.69 ± 2.56 8 1.69 
(0.57—4.97) 
     p for trend   0.21   0.19   0.47 
Fish, fresh and 
preserved 
         
     Q1 15.03 ± 5.50 21 1.00 (ref) 13.95 ± 
4.96 
18 1.00 (ref) 16.11 ± 
5.78 
3 1.00 (ref) 
     Q2 25.93 ± 3.13 17 0.79 
(0.42—1.50) 
24.44 ± 
2.69 
10 0.52 
(0.24—1.13) 
27.21 ± 
2.86 
7 2.55 
(0.66—9.89) 
     Q3 35.90 ± 3.74 16 0.72 
(0.38—1.39) 
33.82 ± 
3.13 
12 0.60 
(0.29—1.25) 
37.57 ± 
3.37 
4 1.48 
(0.33—6.66) 
     Q4 51.73 ± 13.95 19 0.84 
(0.45—1.57) 
53.06 ± 
13.52 
10 0.49 
(0.23—1.08) 
53.69 ± 
13.93 
9 3.04 
(0.82—11.33) 
     p for trend   0.79   0.21   0.32 
Shellfish, fresh 
and preserved 
         
     Q1 0.69 ± 0.41 18 1.00 (ref) 0.81 ± 0.43 13 1.00 (ref) 0.61 ± 0.38 5 1.00 (ref) 
     Q2 1.92 ± 0.36 18 1.06 
(0.55—2.05) 
2.03 ± 0.34 12 0.94 
(0.43—2.06) 
1.82 ± 0.35 6 1.46 
(0.44—4.83) 
     Q3 3.26 ± 0.50 17 1.05 
(0.54—2.05) 
3.34 ± 0.47 13 1.05 
(0.48—2.28) 
3.19 ± 0.51 4 1.05 
(0.28—3.96) 
     Q4 6.06 ± 3.19 20 1.21 
(0.63—2.32) 
6.02 ± 2.87 12 0.93 
(0.42—2.07) 
6.11 ± 3.42 8 2.14 
(0.68—6.71) 
     p for trend   0.94   0.99   0.52 
   341 
* adjusted for age (years), gender (male/female, in overall model only), interview year (1993-1995/1996-1998), dialect (Hokkien/Cantonese), education (less than 
secondary/secondary or greater), tobacco smoking (never/ever), alcohol consumption (never/ever), body mass index (<20, 20-<24, 24-<28, or !28 kg/m2), and 
total energy intake (kcal/day) 
 
 
Table 54.  Hazard ratios (HRs) and 95% confidence intervals (95% CIs) for quartiles of fat intakes and the risk of cardia gastric cancer in the Singapore Chinese 
Health Study.. 
 Overall Men Women 
Median 
intake 
(g/kcal, ±  SD) Cases, n 
HR 
(95% CI) * 
Median 
intake 
(g/kcal, ±  
SD) Cases, n 
HR 
(95% CI) * 
Median 
intake 
(g/kcal, ±  
SD) Cases, n 
HR 
(95% CI) * 
Total Fat          
     Q1 18.57 ± 2.81 19 1.00 (ref) 17.71 ± 
2.71 
10 1.00 (ref) 19.29 ± 
2.71 
9 1.00 (ref) 
     Q2 23.33 ± 1.26 17 0.95 
(0.50—1.84) 
22.62 ± 
1.14 
12 1.25 
(0.54—2.90) 
23.88 ± 
1.07 
5 0.64 
(0.21—1.93) 
     Q3 26.93 ± 1.23 23 1.33 
(0.72—2.46) 
26.27 ± 
1.10 
16 1.67 
(0.75—3.70) 
27.44 ± 
1.09 
7 1.02 
(0.37—2.82) 
     Q4 31.60 ± 2.74 14 0.85 
(0.42—1.74) 
31.05 ± 
2.76 
12 1.25 
(0.53—2.98) 
32.02 ± 
2.65 
2 0.34 
(0.07—1.66) 
     p for trend   0.56   0.63   0.48 
Saturated Fat          
     Q1 5.92 ± 1.01 17 1.00 (ref) 5.76 ± 0.99 9 1.00 (ref) 6.06 ± 1.01 8 1.00 (ref) 
     Q2 7.93 ± 0.51 25 1.57 
(0.84—2.91) 
7.77 ± 0.49 18 2.09 
(0.94—4.67) 
8.16 ± 0.49 7 0.97 
(0.35—2.70) 
     Q3 9.61 ± 0.54 15 0.96 
(0.48—1.94) 
9.41 ± 0.52 10 1.16 
(0.47—2.88) 
9.75 ± 0.52 5 0.74 
(0.24—2.32) 
     Q4 11.85 ± 1.33 16 1.05 
(0.52—2.12) 
11.67 ± 
1.34 
13 1.51 
(0.63—3.62) 
12.01 ± 
1.31 
3 0.49 
(0.13—1.93) 
     p for trend   0.35   0.25   0.74 
MUFA          
     Q1 6.10 ± 0.96 13 1.00 (ref) 5.87 ± 0.93 7 1.00 (ref) 6.30 ± 0.93 6 1.00 (ref) 
     Q2 7.79 ± 0.43 24 1.97 7.59 ± 0.40 15 2.20 7.94 ± 0.39 9 1.76 
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 Overall Men Women 
Median 
intake 
(g/kcal, ±  SD) Cases, n 
HR 
(95% CI) * 
Median 
intake 
(g/kcal, ±  
SD) Cases, n 
HR 
(95% CI) * 
Median 
intake 
(g/kcal, ±  
SD) Cases, n 
HR 
(95% CI) * 
(1.00—3.87) (0.90—5.41) (0.62—4.97) 
     Q3 9.11 ± 0.43 17 1.44 
(0.70—2.98) 
8.94 ± 0.41 12 1.79 
(0.70—4.57) 
9.25 ± 0.40 5 1.10 
(0.33—3.67) 
     Q4 10.88 ± 1.09 19 1.69 
(0.82—3.48) 
10.73 ± 
1.10 
16 2.41 
(0.97—5.97) 
10.99 ± 
1.07 
3 0.76 
(0.18—3.17) 
     p for trend   0.25   0.26   0.55 
PUFA       ! ! !
     Q1 3.24 ± 0.55 28 1.00 (ref) 3.09 ± 0.52 16 1.00 (ref) 3.38 ± 0.54 12 1.00 (ref) 
     Q2 4.26 ± 0.31 13 0.49 
(0.25—0.95) 
4.08 ± 0.25 11 0.70 
(0.33—1.52) 
4.42 ± 0.27 2 0.20 
(0.04—0.89) 
     Q3 5.27 ± 0.43 12 0.47 
(0.24—0.93) 
5.03 ± 0.34 8 0.51 
(0.21—1.20) 
5.45 ± 0.39 4 0.46 
(0.14—1.44) 
     Q4 7.30 ± 1.48 20 0.81 
(0.45—1.46) 
6.90 ± 1.38 15 0.97 
(0.47—2.01) 
7.62 ± 1.49 5 0.60 
(0.21—1.77) 
     p for trend   0.06   0.37   0.15 
Total n-3          
     Q1 0.36 ± 0.055 22 1.00 (ref) 0.34 ± 
0.051 
15 1.00 (ref) 0.38 ± 
0.054 
7 1.00 (ref) 
     Q2 0.45 ± 0.030 23 1.06 
(0.59—1.90) 
0.43 ± 
0.022 
17 1.10 
(0.55—2.21) 
0.47 ± 
0.023 
6 1.00 
(0.33—3.00) 
     Q3 0.53 ± 0.033 14 0.64 
(0.32—1.25) 
0.51 ± 
0.025 
11 0.68 
(0.31—1.48) 
0.55 ± 
0.026 
3 0.53 
(0.14—2.07) 
     Q4 0.67 ± 0.18 14 0.64 
(0.33—1.26) 
0.64 ± 0.16 7 0.43 
(0.17—1.06) 
0.69 ± 0.19 7 1.29 
(0.45—3.74) 
     p for trend   0.27   0.15   0.64 
Marine n-3          
     Q1 0.092 ± 0.032 23 1.00 (ref) 0.087 ± 
0.029 
18 1.00 (ref) 0.097 ± 
0.033 
5 1.00 (ref) 
     Q2 0.15 ± 0.017 14 0.60 0.15 ± 10 0.53 0.16 ± 4 0.89 
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 Overall Men Women 
Median 
intake 
(g/kcal, ±  SD) Cases, n 
HR 
(95% CI) * 
Median 
intake 
(g/kcal, ±  
SD) Cases, n 
HR 
(95% CI) * 
Median 
intake 
(g/kcal, ±  
SD) Cases, n 
HR 
(95% CI) * 
(0.31—1.17) 0.015 (0.24—1.14) 0.016 (0.24—3.31) 
     Q3 0.21 ± 0.019 16 0.67 
(0.36—1.28) 
0.20 ± 
0.017 
12 0.61 
(0.30—1.28) 
0.21 ± 
0.018 
4 0.91 
(0.24—3.40) 
     Q4 0.29 ± 0.072 20 0.82 
(0.45—1.51) 
0.28 ± 
0.071 
10 0.50 
(0.23—1.09) 
0.30 ± 
0.072 
10 2.12 
(0.72—6.26) 
     p for trend   0.43   0.22   0.29 
Non-marine n-3          
     Q1 0.21 ± 0.033 25 1.00 (ref) 0.21 ± 
0.030 
12 1.00 (ref) 0.22 ± 
0.032 
13 1.00 (ref) 
     Q2 0.28 ± 0.019 21 0.87 
(0.48—1.56) 
0.26 ± 
0.015 
18 1.49 
(0.71—3.11) 
0.29 ± 
0.015 
3 0.27 
(0.08—0.97) 
     Q3 0.33 ± 0.021 18 0.75 
(0.41—1.39) 
0.31 ± 
0.017 
13 1.07 
(0.48—2.38) 
0.34 ± 
0.018 
5 0.48 
(0.17—1.39) 
     Q4 0.42 ± 0.18 9 0.38 
(0.18—0.82) 
0.40 ± 0.16 7 0.57 
(0.22—1.47) 
0.44 ± 0.19 2 0.21 
(0.05—0.93) 
     p for trend   0.10   0.19   0.06 
Total n-6          
     Q1 2.82 ± 0.49 27 1.00 (ref) 2.69 ± 0.46 15 1.00 (ref) 2.95 ± 0.48 12 1.00 (ref) 
     Q2 3.75 ± 0.29 15 0.59 
(0.31—1.10) 
3.59 ± 0.23 12 0.82 
(0.38—1.75) 
3.89 ± 0.25 3 0.30 
(0.08—1.07) 
     Q3 4.70 ± 0.41 11 0.45 
(0.22—0.91) 
4.47 ± 0.32 8 0.54 
(0.23—1.30) 
4.87 ± 0.38 3 0.34 
(0.09—1.22) 
     Q4 6.64 ± 1.40 20 0.84 
(0.46—1.52) 
6.26 ± 1.30 15 1.04 
(0.50—2.18) 
6.95 ± 1.40 5 0.60 
(0.20—1.75) 
     p for trend   0.10   0.46   0.16 
Total animal fat          
     Q1 4.57 ± 1.27 21 1.00 (ref) 4.82 ± 1.30 13 1.00 (ref) 4.41 ± 1.21 8 1.00 (ref) 
     Q2 7.14 ± 0.70 17 0.86 
(0.45—1.63) 
7.49 ± 0.64 13 1.04 
(0.48—2.25) 
6.87 ± 0.61 4 0.59 
(0.18—1.98) 
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 Overall Men Women 
Median 
intake 
(g/kcal, ±  SD) Cases, n 
HR 
(95% CI) * 
Median 
intake 
(g/kcal, ±  
SD) Cases, n 
HR 
(95% CI) * 
Median 
intake 
(g/kcal, ±  
SD) Cases, n 
HR 
(95% CI) * 
     Q3 9.31 ± 0.78 17 0.90 
(0.47—1.72) 
9.70 ± 0.71 8 0.65 
(0.27—1.58) 
8.99 ± 0.66 9 1.53 
(0.58—4.06) 
     Q4 12.40 ± 2.23 18 0.99 
(0.52—1.90) 
12.93 ± 
2.23 
16 1.31 
(0.61—2.80) 
11.93 ± 
2.12 
2 0.38 
(0.08—1.85) 
     p for trend   0.96   0.46   0.21 
Total red meat 
fat 
         
     Q1 1.08 ± 0.49 22 1.00 (ref) 1.25 ± 0.51 12 1.00 (ref) 0.96 ± 0.44 10 1.00 (ref) 
     Q2 2.20 ± 0.34 15 0.70 
(0.36—1.35) 
2.40 ± 0.30 11 0.92 
(0.40—2.08) 
2.05 ± 0.29 4 0.45 
(0.14—1.43) 
     Q3 3.28 ± 0.43 18 0.85 
(0.45—1.59) 
3.52 ± 0.38 15 1.26 
(0.58—2.70) 
3.08 ± 0.36 3 0.37 
(0.10—1.34) 
     Q4 5.08 ± 1.58 18 0.85 
(0.45—1.61) 
5.40 ± 1.63 12 0.96 
(0.42—2.19) 
4.81 ± 1.47 6 0.79 
(0.28—2.24) 
     p for trend   0.76   0.85   0.34 
Total plant fat          
     Q1 11.65 ± 2.02 22 1.00 (ref) 10.74 ± 
1.76 
17 1.00 (ref) 12.61 ± 
1.85 
5 1.00 (ref) 
     Q2 15.06 ± 1.23 18 0.84 
(0.45—1.56) 
14.03 ± 
0.80 
7 0.41 
(0.17—0.99) 
15.92 ± 
0.79 
11 2.47 
(0.85—7.12) 
     Q3 17.80 ± 1.28 15 0.72 
(0.37—1.39) 
16.71 ± 
0.83 
10 0.59 
(0.27—1.29) 
18.63 ± 
0.86 
5 1.24 
(0.36—4.35) 
     Q4 21.74 ± 2.92 18 0.88 
(0.47—1.66) 
20.48 ± 
2.72 
16 0.94 
(0.46—1.88) 
22.52 ± 
2.76 
2 0.53 
(0.10—2.77) 
     p for trend   0.80   0.15   0.12 
Total cholesterol   ! ! ! ! ! ! !
     Q1 62.53 ± 15.42 22 1.00 (ref) 62.88 ± 
15.37 
15 1.00 (ref) 62.30 ± 
15.45 
7 1.00 (ref) 
     Q2 92.04 ± 7.33 13 0.63 93.16 ± 9 0.61 90.98 ± 4 0.69 
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 Overall Men Women 
Median 
intake 
(g/kcal, ±  SD) Cases, n 
HR 
(95% CI) * 
Median 
intake 
(g/kcal, ±  
SD) Cases, n 
HR 
(95% CI) * 
Median 
intake 
(g/kcal, ±  
SD) Cases, n 
HR 
(95% CI) * 
(0.32—1.26) 7.37 (0.27—1.41) 7.16 (0.20—2.38) 
     Q3 116.95 ± 8.35 20 1.01 
(0.55—1.86) 
118.83 ± 
8.56 
12 0.83 
(0.39—1.79) 
115.49 ± 
7.85 
8 1.56 
(0.56—4.39) 
     Q4 156.29 ± 
42.14 
16 0.93 
(0.49—1.76) 
161.28 ± 
47.29 
14 0.98 
(0.47—2.07) 
152.25 ± 
36.47 
4 0.82 
(0.23—2.87) 
     p for trend   0.54   0.65   0.53 
* adjusted for age (years), gender (male/female, in overall model only), interview year (1993-1995/1996-1998), dialect (Hokkien/Cantonese), education (less than 
secondary/secondary or greater), tobacco smoking (never/ever), alcohol consumption (never/ever), body mass index (<20, 20-<24, 24-<28, or !28 kg/m2), and 
total energy intake (kcal/day) 
 
 
Table 55.  Hazard ratios (HRs) and 95% confidence intervals (95% CIs) for quartiles of antioxidant intake and the risk of cardia gastric cancer in the Singapore 
Chinese Health Study. 
 Overall Men Women 
Median 
intake ±  
SD Cases, n 
HR 
(95% CI) * 
Median 
intake ±  
SD Cases, n 
HR 
(95% CI) * 
Median 
intake ±  
SD Cases, n 
HR 
(95% CI) * 
Total selenium 
(µg/kcal) 
         
     Q1 53.81 ± 
5.07 
20 1.00 (ref) 53.76 ± 
4.85 
15 1.00 (ref) 53.83 ± 
5.25 
5 1.00 (ref) 
     Q2 61.56 ± 
1.88 
17 0.82 
(0.43—1.57) 
61.09 ± 
1.75 
12 0.76 
(0.36—1.63) 
61.96 ± 
1.90 
5 1.01 
(0.29—3.50) 
     Q3 67.82 ± 
2.11 
17 0.80 
(0.42—1.53) 
67.11 ± 
1.94 
12 0.74 
(0.34—1.58) 
68.37 ± 
2.07 
5 1.00 
(0.29—3.48) 
     Q4 77.31 ± 
8.75 
19 0.86 
(0.46—1.63) 
76.03 ± 
7.95 
11 0.66 
(0.30—1.46) 
78.19 ± 
9.23 
8 1.47 
(0.47—4.54) 
     p for trend   0.90   0.75   0.87 
Total          
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 Overall Men Women 
Median 
intake ±  
SD Cases, n 
HR 
(95% CI) * 
Median 
intake ±  
SD Cases, n 
HR 
(95% CI) * 
Median 
intake ±  
SD Cases, n 
HR 
(95% CI) * 
carotenoids 
(µg/kcal) 
     Q1 1771.00 ± 
499.15 
28 1.00 (ref) 1569.97 ± 
430.42 
20 1.00 (ref) 1980.15 ± 
476.48 
8 1.00 (ref) 
     Q2 2795.98 ± 
376.33 
16 0.60 
(0.33—1.12) 
2524.97 ± 
256.31 
10 0.51 
(0.24—1.09) 
3045.52 ± 
283.47 
6 0.85 
(0.29—2.46) 
     Q3 3844.34 ± 
487.95 
15 0.60 
(0.32—1.13) 
3486.02 ± 
340.25 
11 0.60 
(0.28—1.26) 
4125.13 ± 
385.84 
4 0.60 
(0.18—2.00) 
     Q4 5811.57 ± 
1948.95 
14 0.60 
(0.31—1.16) 
5265.59 ± 
1754.35 
9 0.53 
(0.24—1.18) 
6201.37 ± 
1980.48 
5 0.76 
(0.24—2.40) 
     p for trend   0.23   0.22   0.86 
!-carotene 
(µg/kcal) 
         
     Q1 29.86 ± 
20.52 
22 1.00 (ref) 20.07 ± 
13.44 
15 1.00 (ref) 42.03 ± 
21.37 
7 1.00 (ref) 
     Q2 85.81 ± 
22.09 
19 0.86 
(0.46—1.59) 
68.89 ± 
13.81 
15 0.95 
(0.46—1.95) 
100.43 ± 
16.50 
4 0.61 
(0.18—2.10) 
     Q3 153.81 ± 
36.78 
17 0.78 
(0.41—1.48) 
126.96 ± 
23.53 
10 0.64 
(0.29—1.44) 
176.40 ± 
30.25 
7 1.12 
(0.39—3.20) 
     Q4 332.95 ± 
224.87 
15 0.72 
(0.37—1.40) 
278.20 ± 
187.03 
10 0.69 
(0.31—1.54) 
375.39 ± 
239.39 
5 0.80 
(0.25—2.55) 
     p for trend   0.78   0.62   0.79 
"-carotene 
(µg/kcal) 
         
     Q1 635.74 ± 
201.97 
24 1.00 (ref) 538.81 ± 
160.12 
18 1.00 (ref) 747.12 ± 
186.11 
6 1.00 (ref) 
     Q2 1038.41 ± 
171.11 
20 0.87 
(0.48—1.58) 
898.74 ± 
97.04 
12 0.68 
(0.33—1.42) 
1164.68 ± 
116.11 
8 1.43 
(0.50—4.14) 
     Q3 1465.99 ± 
232.05 
18 0.82 
(0.44—1.51) 
1275.45 ± 
132.95 
13 0.77 
(0.38—1.59) 
1626.14 ± 
164.74 
5 0.91 
(0.28—3.02) 
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 Overall Men Women 
Median 
intake ±  
SD Cases, n 
HR 
(95% CI) * 
Median 
intake ±  
SD Cases, n 
HR 
(95% CI) * 
Median 
intake ±  
SD Cases, n 
HR 
(95% CI) * 
     Q4 2299.51 ± 
880.12 
11 0.53 
(0.26—1.08) 
1975.03 ± 
741.98 
7 0.44 
(0.18—1.07) 
2521.20 ± 
892.44 
4 0.75 
(0.21—2.71) 
     p for trend ! ! 0.37   0.32   0.73 
!-cryptoxanthin 
(µg/kcal) 
         
     Q1 12.06 ± 
14.35 
22 1.00 (ref) 13.28 ± 
14.40 
10 1.00 (ref) 10.73 ± 
14.30 
12 1.00 (ref) 
     Q2 71.46 ± 
17.14 
20 1.01 
(0.55—1.86) 
69.13 ± 
15.88 
15 1.56 
(0.70—3.50) 
73.50 ± 
17.87 
5 0.52 
(0.18—1.51) 
     Q3 142.32 ± 
28.18 
19 1.00 
(0.54—1.87) 
136.38 ± 
26.63 
14 1.50 
(0.66—3.41) 
147.06 ± 
28.41 
5 0.56 
(0.19—1.65) 
     Q4 323.55 ± 
283.03 
12 0.62 
(0.30—1.28) 
309.38 ± 
254.88 
11 1.16 
(0.48—2.48) 
333.47 ± 
302.25 
1 0.11 
(0.01—0.89) 
     p for trend   0.53   0.66   0.15 
Lycopene 
(µg/kcal) 
         
     Q1 90.53 ± 
61.09 
21 1.00 (ref) 105.40 ± 
65.89 
13 1.00 (ref) 80.26 ± 
54.58 
8 1.00 (ref) 
     Q2 312.87 ± 
79.75 
14 0.73 
(0.37—1.43) 
345.30 ± 
78.00 
10 0.79 
(0.34—1.80) 
287.52 ± 
72.27 
4 0.65 
(0.19—2.18) 
     Q3 627.01 ± 
119.05 
23 1.27 
(0.69—2.31) 
657.09 ± 
111.43 
17 1.41 
(0.68—2.93) 
603.63 ± 
119.41 
6 1.10 
(0.37—3.25) 
     Q4 1311.77 ± 
1210.93 
15 0.93 
(0.47—1.83) 
1396.34 ± 
1196.84 
10 0.94 
(0.40—2.18) 
1245.72 ± 
1219.55 
5 0.96 
(0.30—3.05) 
     p for trend   0.42   0.48   0.87 
Lutein (µg/kcal)          
     Q1 597.01 ± 
173.40 
24 1.00 (ref) 520.16 ± 
139.35 
19 1.00 (ref) 688.74 ± 
163.54 
5 1.00 (ref) 
     Q2 939.52 ± 
143.27 
19 0.84 
(0.46—1.54) 
825.32 ± 
81.85 
11 0.61 
(0.29—1.28) 
1045.90 ± 
97.82 
8 1.76 
(0.57—5.39) 
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 Overall Men Women 
Median 
intake ±  
SD Cases, n 
HR 
(95% CI) * 
Median 
intake ±  
SD Cases, n 
HR 
(95% CI) * 
Median 
intake ±  
SD Cases, n 
HR 
(95% CI) * 
     Q3 1296.07 ± 
191.42 
15 0.69 
(0.36—1.32) 
1132.96 ± 
110.31 
11 0.64 
(0.30—1.35) 
1427.47 ± 
134.42 
4 0.87 
(0.23—3.27) 
     Q4 1949.59 ± 
639.28 
15 0.70 
(0.37—1.35) 
1684.55 ± 
518.06 
9 0.54 
(0.24—1.20) 
2128.98 6 1.23 
(0.37—4.11) 
     p for trend   0.63   0.36   0.64 
Total vitamin C 
(mg/kcal) 
         
     Q1 21.66 ± 
6.76 
25 1.00 (ref) 19.99 ± 
6.50 
14 1.00 (ref) 23.02 ± 
6.68 
11 1.00 (ref) 
     Q2 39.63 ± 
5.71 
14 0.61 
(0.31—1.17) 
37.35 ± 
4.99 
11 0.80 
(0.36—1.76) 
41.60 ± 
5.50 
3 0.33 
(0.09—1.20) 
     Q3 60.24 ± 
8.33 
22 1.03 
(0.57—1.85) 
56.55 ± 
6.84 
16 1.25 
(0.60—2.60) 
63.40 ± 
8.09 
6 0.72 
(0.26—2.02) 
     Q4 102.73 ± 
151.60 
12 0.59 
(0.29—1.19) 
94.37 ± 
127.18 
9 0.74 
(0.31—1.76) 
108.74 ± 
167.54 
3 0.37 
(0.10—1.39) 
     p for trend   0.20   0.55   0.25 
Total vitamin E 
(mg !-
tocopherol 
equivalents/kcal) 
         
     Q1 2.59 ± 0.47 25 1.00 (ref) 2.38 ± 0.40 17 1.00 (ref) 2.84 ± 0.43 8 1.00 (ref) 
     Q2 3.41 ± 0.31 16 0.67 
(0.36—1.26) 
3.14 ± 0.19 9 0.54 
(0.24—1.21) 
3.64 ± 0.20 7 1.01 
(0.36—2.81) 
     Q3 4.10 ± 0.34 14 0.62 
(0.32—1.20) 
3.80 ± 0.21 11 0.68 
(0.32—1.46) 
4.33 ± 0.23 3 0.48 
(0.13—1.84) 
     Q4 5.25 ± 
64.00 
18 0.82 
(0.44—1.53) 
4.85 ± 
54.66 
13 0.81 
(0.39—1.69) 
5.49 ± 
70.52 
5 0.86 
(0.27—2.72) 
     p for trend   0.45   0.48   0.72 
Total soy 
isoflavones 
 ! ! ! ! ! ! ! !
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 Overall Men Women 
Median 
intake ±  
SD Cases, n 
HR 
(95% CI) * 
Median 
intake ±  
SD Cases, n 
HR 
(95% CI) * 
Median 
intake ±  
SD Cases, n 
HR 
(95% CI) * 
(mg/kcal) 
     Q1 3.63 ± 1.65 22 1.00 (ref) 3.25 ± 1.45 14 1.00 (ref) 4.00 ± 1.72 8 1.00 (ref) 
     Q2 7.74 ± 1.35 21 0.98 
(0.54—1.78) 
7.02 ± 1.07 13 0.90 
(0.42—1.91) 
8.37 ± 1.24 8 1.19 
(0.44—3.20) 
     Q3 12.24 ± 
1.87 
17 0.80 
(0.42—1.51) 
11.12 ± 
1.46 
15 1.01 
(0.48—2.11) 
13.15 ± 
1.66 
2 0.33 
(0.07—1.56) 
     Q4 20.72 ± 
9.85 
13 0.61 
(0.31—1.22) 
19.12 ± 
8.76 
8 0.53 
(0.22—1.28) 
22.00 ± 
10.39 
5 0.85 
(0.27—2.66) 
     p for trend   0.49   0.47   0.43 
Genistein 
(mg/kcal) 
         
     Q1 1.70 ± 0.76 22 1.00 (ref) 1.52 ± 0.67 15 1.00 (ref) 1.88 ± 0.80 7 1.00 (ref) 
     Q2 3.58 ± 0.62 22 1.03 
(0.57—1.86) 
3.24 ± 0.49 13 0.84 
(0.40—1.77) 
3.87 ± 0.56 9 1.55 
(0.57—4.20) 
     Q3 5.63 ± 0.85 15 0.70 
(0.36—1.36) 
5.10 ± 0.66 13 0.81 
(0.39—1.72) 
6.04 ± 0.75 2 0.38 
(0.08—1.83) 
     Q4 9.46 ± 4.37 14 0.66 
(0.34—1.30) 
8.72 ± 3.90 9 0.56 
(0.24—1.29) 
10.04 ± 
4.59 
5 0.98 
(0.31—3.16) 
     p for trend   0.43   0.60   0.32 
Daidzein 
(mg/kcal) 
         
     Q1 1.69 ± 0.78 20 1.00 (ref) 1.52 ± 0.69 12 1.00 (ref) 1.86 ± 0.81 8 1.00 (ref) 
     Q2 3.65 ± 0.64 23 1.18 
(0.65—2.15) 
3.31 ± 0.52 15 1.21 
(0.57—2.59) 
3.96 ± 0.59 8 1.20 
(0.45—3.22) 
     Q3 5.81 ± 0.90 17 0.89 
(0.46—1.70) 
5.28 ± 0.70 15 1.19 
(0.55—2.57) 
6.24 ± 0.80 2 0.33 
(0.07—1.56) 
     Q4 9.92 ± 4.84 13 0.67 
(0.33—1.34) 
9.14 ± 4.29 8 0.62 
(0.25—1.54) 
10.55 ± 
5.12 
5 0.86 
(0.28—2.67) 
     p for trend   0.44   0.44!   0.43 
Glycitein          
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 Overall Men Women 
Median 
intake ±  
SD Cases, n 
HR 
(95% CI) * 
Median 
intake ±  
SD Cases, n 
HR 
(95% CI) * 
Median 
intake ±  
SD Cases, n 
HR 
(95% CI) * 
(mg/kcal) 
     Q1 0.24 ± 0.11 21 1.00 (ref) 0.21 ± 
0.096 
13 1.00 (ref) 0.26 ± 0.11 8 1.00 (ref) 
     Q2 0.51 ± 
0.087 
21 1.03 
(0.56—1.88) 
0.46 ± 
0.070 
13 0.97 
(0.45—2.10) 
0.55 ± 
0.080 
8 1.19 
(0.44—3.20) 
     Q3 0.80 ± 0.12 18 0.89 
(0.47—1.68) 
0.73 ± 
0.096 
16 1.17 
(0.56—2.45) 
0.86 ± 0.11 2 0.33 
(0.07—1.56) 
     Q4 1.36 ± 0.65 13 0.64 
(0.32—1.29) 
1.25 ± 0.58 8 0.57 
(0.24—1.40) 
1.44 ± 0.69 5 0.85 
(0.27—2.66) 
     p for trend   0.56   0.43   0.43 
Total 
isothiocyanate 
(µmol/kcal) 
         
     Q1 2.39 ± 0.84 21 1.00 (ref) 2.06 ± 0.71 13 1.00 (ref) 2.71 ± 0.83 8 1.00 (ref) 
     Q2 4.26 ± 0.68 15 0.75 
(0.39—1.46) 
3.79 ± 0.48 11 0.88 
(0.39—1.96) 
4.68 ± 0.54 4 0.55 
(0.17—1.85) 
     Q3 6.25 ± 0.92 25 1.31 
(0.73—2.35) 
5.59 ± 0.66 18 1.52 
(0.74—3.11) 
6.77 ± 0.75 7 0.99 
(0.36—2.76) 
     Q4 10.08 ± 
4.36 
12 0.64 
(0.31—1.31) 
9.08 ± 3.79 8 0.69 
(0.28—1.67) 
10.81 ± 
4.58 
4 0.56 
(0.17—1.88) 
     p for trend   0.15   0.23   0.62 
* adjusted for age (years), gender (male/female, in overall model only), interview year (1993-1995/1996-1998), dialect (Hokkien/Cantonese), education (less than 
secondary/secondary or greater), tobacco smoking (never/ever), alcohol consumption (never/ever), body mass index (<20, 20-<24, 24-<28, or !28 kg/m2), and 
total energy intake (kcal/day) 
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Table 56.  Hazard ratios (HRs) and 95% confidence intervals (95% CIs) for tea and coffee intakes and the risk of cardia gastric cancer in the Singapore Chinese 
Health Study. 
 Overall Men Women 
Median 
intake ±  
SD Cases, n 
HR 
(95% CI) * 
Median 
intake ±  
SD Cases, n 
HR 
(95% CI) * 
Median 
intake ±  
SD Cases, n 
HR 
(95% CI) * 
Black tea 
(cups/month) 
         
     Q1 0.00 43 1.00 (ref) 0.00 26 1.00 (ref) 0.00 17 1.00 (ref) 
     Q2 2.00 ± 1.14 13 1.52 
(0.82—2.84) 
2.00 ± 1.14 9 1.53 
(0.72—3.28) 
2.00 ± 1.13 4 1.56 
(0.52—4.69) 
     Q3 10.70 ± 
4.48 
7 0.87  
0.39—1.94) 
10.70 ± 
4.61 
6 0.96 
(0.39—2.33) 
10.70 ± 
4.30 
1 0.62 
(0.08—4.72) 
     Q4 30.00 ± 
26.28 
10 1.17 
(0.58—2.36) 
30.00 ± 
27.73 
9 1.27 
(0.59—2.74) 
30.00 ± 
23.36 
1 0.75 
(0.10—5.70) 
     p for trend   0.54   0.68   0.79 
Green tea 
(cups/month) 
         
     Q1 0.00 38 1.00 (ref) 0.00 25 1.00 (ref) 0.00 13 1.00 (ref) 
     Q2 2.00 ± 1.11 20 1.77 
(1.03—3.06) 
2.00 ± 1.11 13 1.68 
(0.86—3.30) 
2.00 ± 1.10 7 2.02 
(0.80—5.09) 
     Q3 10.70 ± 
4.28 
5 0.68 
(0.27—1.75) 
10.70 ± 
4.44 
5 0.87 
(0.33—2.27) 
10.70 ± 
4.09 
0 0.00 (n/a) 
     Q4 30.00 ± 
40.71 
10 1.09 
(0.53—2.21) 
75.00 ± 
42.47!
7! 0.93 
(0.40—2.19)!
30.00 ± 
38.12!
3 1.62 
(0.45—5.82) 
     p for trend   0.12   0.39   0.51 
Any tea 
(cups/month) 
         
     Q1 0.00 29 1.00 (ref) 0.00 17 1.00 (ref) 0.00 12 1.00 (ref) 
     Q2 4.00 ± 1.83 19 1.32 
(0.74—2.37) 
4.00 ± 1.87 12 1.28 
(0.61—2.69) 
4.00 ± 1.79 7 1.43 
(0.56—3.67) 
     Q3 10.70 ± 
4.96 
8 0.64 
(0.29—1.42) 
12.70 ± 
5.09 
7 0.75 
(0.31—1.81) 
10.70 ± 
4.80 
1 0.36 
(0.05—2.76) 
     Q4 40.70 ± 
39.87 
17 0.90 
(0.49—1.67) 
40.70 ± 
41.56 
14 0.91 
(0.45—1.87) 
34.30 ± 
37.07 
3 0.89 
(0.25—3.20) 
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 Overall Men Women 
Median 
intake ±  
SD Cases, n 
HR 
(95% CI) * 
Median 
intake ±  
SD Cases, n 
HR 
(95% CI) * 
Median 
intake ±  
SD Cases, n 
HR 
(95% CI) * 
     p for trend   0.37   0.69   0.58 
Coffee 
(cups/week) 
         
     Never 0.00 15 1.00 (ref) 0.00 8 1.00 (ref) 0.00 7 1.00 (ref) 
     Monthly 0.46 ± 0.15 1 0.64 
(0.08—4.81) 
0.46 ± 0.15 1 1.18 
(0.15—9.49) 
0.46 ± 0.15 0 0.00 (n/a) 
     Weekly 2.50 ± 1.46 10 1.35 
(0.60—3.01) 
2.50 ± 1.45 7 1.74 
(0.63—4.83) 
2.50 ± 1.47 3 0.94 
(0.24—3.63) 
     1 cup/day 7.02 ± 0.79 22 0.77 
(0.40—1.48) 
7.02 ± 0.83 12 0.84 
(0.34—2.05) 
7.02 ± 0.77 10 0.65 
(0.25—1.71) 
     2-3 cups/day 17.56 ± 
1.96 
23 0.83 
(0.43—1.60) 
17.56 ± 
1.97 
20 1.19 
(0.52—2.74) 
17.56 ± 
1.96 
3 0.32 
(0.08—1.26) 
     !4 cups/day 31.60 ± 
5.19 
2 0.47 
(0.11—2.09) 
31.60 ± 
4.68 
2 0.70 
(0.15—3.35) 
31.60 ± 
5.95 
0 0.00 (n/a) 
     p for trend   0.64   0.70   0.70 
* adjusted for age (years), gender (male/female, in overall model only), interview year (1993-1995/1996-1998), dialect (Hokkien/Cantonese), education (less than 
secondary/secondary or greater), tobacco smoking (never/ever), alcohol consumption (never/ever), body mass index (<20, 20-<24, 24-<28, or !28 kg/m2), and 
total energy intake (kcal/day) 
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Table 57.  Hazard ratios (HRs) and 95% confidence intervals (95% CIs) for quartiles of fish intake and the risk of non-cardia gastric cancer in the Singapore 
Chinese Health Study. 
 Overall Men Women 
Median 
intake 
(g/kcal, ±  
SD) 
Cases, 
n 
HR 
(95% CI) * 
Median 
intake 
(g/kcal, ±  
SD) 
Cases, 
n 
HR 
(95% CI) * 
Median 
intake 
(g/kcal, ±  
SD) 
Cases, 
n 
HR 
(95% CI) * 
Total fish and 
shellfish 
         
     Q1 17.60 ± 6.04 94 1.00 (ref) 16.49 ± 
5.49 
59 1.00 (ref) 18.67 ± 
6.34 
35 1.00 (ref) 
     Q2 29.10 ± 3.25 76 0.82 
(0.61—1.11) 
27.61 ± 
2.81 
43 0.71 
(0.48—1.05) 
30.46 ± 
3.02 
33 1.00 
(0.62—1.61) 
     Q3 39.46 ± 3.80 87 0.93 
(0.69—1.25) 
37.46 ± 
3.26 
55 0.90 
(0.63—1.31) 
41.06 ± 
3.43 
32 0.95 
(0.59—1.54) 
     Q4 55.58 ± 13.99 88 0.92 
(0.68—1.23) 
53.05 ± 
13.55 
55 0.88 
(0.61—1.28) 
57.42 ± 
14.01 
33 0.96 
(0.59—1.55) 
     p for trend   0.64   0.39   1.00 
Fresh fish and 
shellfish 
         
     Q1 15.91 ± 5.73 90 1.00 (ref) 14.80 ± 
5.18 
56 1.00 (ref) 17.08 ± 
6.02 
34 1.00 (ref) 
     Q2 27.27 ± 3.24 81 0.91 
(0.67—1.23) 
25.73 ± 
2.76 
47 0.81 
(0.55—1.20) 
28.60 ± 
3.00 
34 1.05 
(0.66—1.70) 
     Q3 37.54 ± 3.81 83 0.92 
(0.68—1.24) 
35.45 ± 
3.23 
51 0.88 
(0.60—1.28) 
39.19 ± 
3.41 
32 0.98 
(0.61—1.60) 
     Q4 53.50 ± 14.01 91 0.99 
(0.74—1.32) 
50.85 ± 
13.55 
58 0.98 
(0.68—1.42) 
55.52 ± 
14.02 
33 0.98 
(0.60—1.59) 
     p for trend   0.90   0.69   0.99 
Preserved fish 
and shellfish 
  ! ! ! ! ! ! !
     Q1 0.16 ± 0.13 89 1.00 (ref) 0.19 ± 0.15 53 1.00 (ref) 0.15 ± 0.12 36 1.00 (ref) 
     Q2 0.80 ± 0.25 77 0.87 
(0.64—1.18) 
0.88 ± 0.24 48 0.91 
(0.62—1.35) 
0.73 ± 0.23 29 0.82 
(0.50—1.34) 
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 Overall Men Women 
Median 
intake 
(g/kcal, ±  
SD) 
Cases, 
n 
HR 
(95% CI) * 
Median 
intake 
(g/kcal, ±  
SD) 
Cases, 
n 
HR 
(95% CI) * 
Median 
intake 
(g/kcal, ±  
SD) 
Cases, 
n 
HR 
(95% CI) * 
     Q3 1.79 ± 0.37 86 0.97 
(0.72—1.31) 
1.85 ± 0.36 48 0.90 
(0.60—1.33) 
1.73 ± 0.36 38 1.10 
(0.69—1.74) 
     Q4 3.75 ± 2.57 93 1.07 
(0.79—1.43) 
3.83 ± 2.59 63 1.19 
(0.82—1.73) 
3.69 ± 2.56 30 0.88 
(0.54—1.44) 
     p for trend   0.61   0.41   0.64 
Fish, fresh and 
preserved 
         
     Q1 15.03 ± 5.50 89 1.00 (ref) 13.95 ± 
4.96 
53 1.00 (ref) 16.11 ± 
5.78 
36 1.00 (ref) 
     Q2 25.93 ± 3.13 87 0.98 
(0.73—1.32) 
24.44 ± 
2.69 
56 1.01 
(0.70—1.48) 
27.21 ± 
2.86 
31 0.90 
(0.56—1.46) 
     Q3 35.90 ± 3.74 72 0.79 
(0.58—1.08) 
33.82 ± 
3.13 
44 0.78 
(0.52—1.17) 
37.57 ± 
3.37 
28 0.80 
(0.49—1.31) 
     Q4 51.73 ± 13.95 97 1.04 
(0.78—1.39) 
53.06 ± 
13.52 
59 1.03 
(0.71—1.49) 
53.69 ± 
13.93 
38 1.04 
(0.66—1.65) 
     p for trend   0.34  ! 0.49   0.72 
Shellfish, fresh 
and preserved 
         
     Q1 0.69 ± 0.41 104 1.00 (ref) 0.81 ± 0.43 54 1.00 (ref) 0.61 ± 0.38 50 1.00 (ref) 
     Q2 1.92 ± 0.36 86 0.92 
(0.69—1.22) 
2.03 ± 0.34 51 1.04 
(0.71—1.52) 
1.82 ± 0.35 35 0.79 
(0.51—1.22) 
     Q3 3.26 ± 0.50 72 0.81 
(0.60—1.10)! 3.34 ± 0.47! 48! 1.03 (0.70—1.53)! 3.19 ± 0.51! 24! 0.57 (0.35—0.93)!
     Q4 6.06 ± 3.19! 83 0.96 
(0.71—1.29) 
6.02 ± 2.87 59! 1.28 
(0.88—1.86)! 6.11 ± 3.42! 24! 0.59 (0.36—0.97)!
     p for trend   0.59   0.56   0.07 
* adjusted for age (years), gender (male/female, in overall model only), interview year (1993-1995/1996-1998), dialect (Hokkien/Cantonese), education (less than 
secondary/secondary or greater), tobacco smoking (never/ever), alcohol consumption (never/ever), body mass index (<20, 20-<24, 24-<28, or !28 kg/m2), and 
total energy intake (kcal/day) 
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Table 58.  Hazard ratios (HRs) and 95% confidence intervals (95% CIs) for quartiles of fat intakes and the risk of non-cardia gastric cancer in the Singapore 
Chinese Health Study. 
 Overall Men Women 
Median 
intake 
(g/kcal, ±  
SD) 
Cases, 
n 
HR 
(95% CI) * 
Median 
intake 
(g/kcal, ±  
SD) 
Cases, 
n 
HR 
(95% CI) * 
Median 
intake 
(g/kcal, ±  
SD) 
Cases, 
n 
HR 
(95% CI) * 
Total Fat          
     Q1 18.57 ± 2.81 91 1.00 (ref) 17.71 ± 
2.71 
56 1.00 (ref) 19.29 ± 
2.71 
35 1.00 (ref) 
     Q2 23.33 ± 1.26 93 1.13 
(0.84—1.51) 
22.62 ± 
1.14 
57 1.09 
(0.75—1.57) 
23.88 ± 
1.07 
36 1.18 
(0.74—1.88) 
     Q3 26.93 ± 1.23 89 1.17 
(0.87—1.57) 
26.27 ± 
1.10 
54 1.10 
(0.75—1.60) 
27.44 ± 
1.09 
35 1.29 
(0.80—2.07) 
     Q4 31.60 ± 2.74 72 1.07 
(0.78—1.47) 
31.05 ± 
2.76 
45 1.02 
(0.68—1.52) 
32.02 ± 
2.65 
27 1.14 
(0.68—1.93) 
     p for trend   0.74   0.95   0.78 
Saturated Fat          
     Q1 5.92 ± 1.01 88 1.00 (ref) 5.76 ± 0.99 56 1.00 (ref) 6.06 ± 1.01 32 1.00 (ref) 
     Q2 7.93 ± 0.51 79 1.01 
(0.74—1.36) 
7.77 ± 0.49 50 1.00 
(0.68—1.46) 
8.16 ± 0.49 29 1.03 
(0.62—1.70) 
     Q3 9.61 ± 0.54 99 1.35 
(1.01—1.81) 
9.41 ± 0.52 57 1.20 
(0.82—1.73) 
9.75 ± 0.52 42 1.64 
(1.03—2.62) 
     Q4 11.85 ± 1.33 79 1.18 
(0.87—1.62) 
11.67 ± 
1.34 
49 1.12 
(0.75—1.66) 
12.01 ± 
1.31 
30 1.31 
(0.78—2.20) 
     p for trend   0.13!   0.74   0.13 
MUFA          
     Q1 6.10 ± 0.96 92 1.00 (ref) 5.87 ± 0.93 57 1.00 (ref) 6.30 ± 0.93 35 1.00 (ref) 
     Q2 7.79 ± 0.43 82 0.98 
(0.73—1.32) 
7.59 ± 0.40 46 0.86 
(0.58—1.26) 
7.94 ± 0.39 36 1.17 
(0.74—1.87) 
     Q3 9.11 ± 0.43 98 1.25 
(0.94—1.67) 
8.94 ± 0.41 61 1.20 
(0.83—1.72) 
9.25 ± 0.40 37 1.33 
(0.83—2.12) 
     Q4 10.88 ± 1.09 73 1.03 
(0.75—1.41) 
10.73 ± 
1.10 
48 1.02 
(0.69—1.51) 
10.99 ± 
1.07 
25 1.00 
(0.59—1.70) 
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 Overall Men Women 
Median 
intake 
(g/kcal, ±  
SD) 
Cases, 
n 
HR 
(95% CI) * 
Median 
intake 
(g/kcal, ±  
SD) 
Cases, 
n 
HR 
(95% CI) * 
Median 
intake 
(g/kcal, ±  
SD) 
Cases, 
n 
HR 
(95% CI) * 
     p for trend   0.30   0.39  ! 0.59 
PUFA          
     Q1 3.24 ± 0.55 109 1.00 (ref) 3.09 ± 0.52 63 1.00 (ref) 3.38 ± 0.54 46 1.00 (ref) 
     Q2 4.26 ± 0.31 71 0.72 
(0.54—0.98) 
4.08 ± 0.25 46 0.78 
(0.54—1.15) 
4.42 ± 0.27 25 0.63 
(0.38—1.02) 
     Q3 5.27 ± 0.43 86 0.93 
(0.70—1.24) 
5.03 ± 0.34 52 0.93 
(0.64—1.36) 
5.45 ± 0.39 34 0.92 
(0.58—1.44) 
     Q4 7.30 ± 1.48 79 0.88 
(0.65—1.18) 
6.90 ± 1.38 51 0.93 
(0.64—1.36) 
7.62 ± 1.49 28 0.76 
(0.47—1.24) 
     p for trend   0.19   0.65   0.26 
Total n-3          
     Q1 0.36 ± 0.055 91 1.00 (ref) 0.34 ± 
0.051 
54 1.00 (ref) 0.38 ± 
0.054 
37 1.00 (ref) 
     Q2 0.45 ± 0.030 77 0.90 
(0.66—1.22) 
0.43 ± 
0.022 
42 0.80 
(0.54—1.20) 
0.47 ± 
0.023 
35 1.04 
(0.65—1.65) 
     Q3 0.53 ± 0.033 93 1.09 
(0.82—1.46) 
0.51 ± 
0.025 
67 1.26 
(0.88—1.80) 
0.55 ± 
0.026 
26 0.81 
(0.49—1.34) 
     Q4 0.67 ± 0.18 84 1.01 
(0.75—1.36) 
0.64 ± 0.16 49 0.93 
(0.63—1.37) 
0.69 ± 0.19 35 1.12 
(0.70—1.79) 
     p for trend   0.66   0.12   0.64 
Marine n-3          
     Q1 0.092 ± 0.032 96 1.00 (ref) 0.087 ± 
0.029 
56 1.00 (ref) 0.097 ± 
0.033 
40 1.00 (ref) 
     Q2 0.15 ± 0.017 72 0.76 
(0.56—1.04) 
0.15 ± 
0.015 
45 0.79 
(0.53—1.17) 
0.16 ± 
0.016 
27 0.71 
(0.44—1.17) 
     Q3 0.21 ± 0.019 91 0.95 
(0.72—1.27) 
0.20 ± 
0.017 
57 0.99 
(0.69—1.44) 
0.21 ± 
0.018 
34 0.89 
(0.56—1.40) 
     Q4 0.29 ± 0.072 86 0.88 
(0.66—1.18) 
0.28 ± 
0.071 
54 0.92 
(0.63—1.34) 
0.30 ± 
0.072 
32 0.82 
(0.51—1.31) 
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 Overall Men Women 
Median 
intake 
(g/kcal, ±  
SD) 
Cases, 
n 
HR 
(95% CI) * 
Median 
intake 
(g/kcal, ±  
SD) 
Cases, 
n 
HR 
(95% CI) * 
Median 
intake 
(g/kcal, ±  
SD) 
Cases, 
n 
HR 
(95% CI) * 
     p for trend   0.34   0.63   0.59 
Non-marine n-3          
     Q1 0.21 ± 0.033 104 1.00 (ref) 0.21 ± 
0.030 
64 1.00 (ref) 0.22 ± 
0.032 
40 1.00 (ref) 
     Q2 0.28 ± 0.019 79 0.83 
(0.62—1.12) 
0.26 ± 
0.015 
52 0.86 
(0.59—1.24) 
0.29 ± 
0.015 
27 0.78 
(0.48—1.28) 
     Q3 0.33 ± 0.021 72 0.79 
(0.58—1.07) 
0.31 ± 
0.017 
44 0.74 
(0.50—1.10) 
0.34 ± 
0.018 
28 0.85 
(0.52—1.39) 
     Q4 0.42 ± 0.18 90 1.00 
(0.75—1.34) 
0.40 ± 0.16 52 0.87 
(0.60—1.26) 
0.44 ± 0.19 38 1.20 
(0.76—1.90) 
     p for trend   0.28   0.52   0.32 
Total n-6          
     Q1 2.82 ± 0.49 108 1.00 (ref) 2.69 ± 0.46 61 1.00 (ref) 2.95 ± 0.48 47 1.00 (ref) 
     Q2 3.75 ± 0.29 72 0.74 
(0.55—1.00) 
3.59 ± 0.23 48 0.85 
(0.58—1.24) 
3.89 ± 0.25 24 0.59 
(0.36—0.97) 
     Q3 4.70 ± 0.41 85 0.93 
(0.70—1.24) 
4.47 ± 0.32 51 0.95 
(0.65—1.39) 
4.87 ± 0.38 34 0.89 
(0.57—1.40) 
     Q4 6.64 ± 1.40 80 0.89 
(0.66—1.20) 
6.26 ± 1.30 52 0.99 
(0.67—1.44) 
6.95 ± 1.40 28 0.74 
(0.46—1.20) 
     p for trend   0.27   0.83   0.18 
Total animal fat     ! ! ! ! !
     Q1 4.57 ± 1.27 98 1.00 (ref) 4.82 ± 1.30 57 1.00 (ref) 4.41 ± 1.21 41 1.00 (ref) 
     Q2 7.14 ± 0.70 82 0.91 
(0.68—1.22) 
7.49 ± 0.64 52 0.98 
(0.67—1.42) 
6.87 ± 0.61 30 0.82 
(0.51—1.32) 
     Q3 9.31 ± 0.78 89 1.06 
(0.80—1.42) 
9.70 ± 0.71 49 0.98 
(0.66—1.44) 
8.99 ± 0.66 40 1.20 
(0.77—1.87) 
     Q4 12.40 ± 2.23 76 0.99 
(0.73—1.35) 
12.93 ± 
2.23 
54 1.18 
(0.80—1.73) 
11.93 ± 
2.12 
22 0.71 
(0.42—1.22) 
     p for trend   0.80   0.74   0.20 
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 Overall Men Women 
Median 
intake 
(g/kcal, ±  
SD) 
Cases, 
n 
HR 
(95% CI) * 
Median 
intake 
(g/kcal, ±  
SD) 
Cases, 
n 
HR 
(95% CI) * 
Median 
intake 
(g/kcal, ±  
SD) 
Cases, 
n 
HR 
(95% CI) * 
Total red meat 
fat 
         
     Q1 1.08 ± 0.49 102 1.00 (ref) 1.25 ± 0.51 49 1.00 (ref) 0.96 ± 0.44 53 1.00 (ref) 
     Q2 2.20 ± 0.34 83 0.86 
(0.64—1.14) 
2.40 ± 0.30 51 1.10 
(0.74—1.63) 
2.05 ± 0.29 32 0.63 
(0.41—0.99) 
     Q3 3.28 ± 0.43 80 0.86 
(0.64—1.15) 
3.52 ± 0.38 50 1.11 
(0.74—1.64) 
3.08 ± 0.36 30 0.63 
(0.40—0.98) 
     Q4 5.08 ± 1.58 80 0.90 
(0.67—1.22) 
5.40 ± 1.63 62 1.44 
(0.98—2.11)!
4.81 ± 1.47! 18! 0.40 
(0.23—0.68)!
     p for trend   0.68   0.26   0.005 
Total plant fat          
     Q1 11.65 ± 2.02 84 1.00 (ref) 10.74 ± 
1.76 
57 1.00 (ref) 12.61 ± 
1.85 
27 1.00 (ref) 
     Q2 15.06 ± 1.23 88 1.12 
(0.83—1.51) 
14.03 ± 
0.80 
52 0.94 
(0.64—1.37) 
15.92 ± 
0.79 
36 1.49 
(0.90—2.45) 
     Q3 17.80 ± 1.28 93 1.26 
(0.94—1.70) 
16.71 ± 
0.83 
53 1.00 
(0.68—1.45) 
18.63 ± 
0.86 
40 1.81 
(1.11—2.96) 
     Q4 21.74 ± 2.92 80 1.16 
(0.85—1.59) 
20.48 ± 
2.72 
50 1.01 
(0.68—1.48) 
22.52 ± 
2.76 
30 1.46 
(0.86—2.48) 
     p for trend   0.49   0.98   0.13 
Total 
cholesterol 
         
     Q1 62.53 ± 15.42 96 1.00 (ref) 62.88 ± 
15.37 
53 1.00 (ref) 62.30 ± 
15.45 
43 1.00 (ref) 
     Q2 92.04 ± 7.33 79 0.92 
(0.68—1.24) 
93.16 ± 
7.37 
43 0.90 
(0.60—1.34) 
90.98 ± 
7.16 
36 0.95 
(0.61—1.48) 
     Q3 116.95 ± 8.35 84 1.04 
(0.78—1.40) 
118.83 ± 
8.56 
56 1.22 
(0.84—1.78) 
115.49 ± 
7.85 
28 0.81 
(0.50—1.31) 
     Q4 156.29 ± 86 1.13 161.28 ± 60 1.36 152.25 ± 26 0.80 
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 Overall Men Women 
Median 
intake 
(g/kcal, ±  
SD) 
Cases, 
n 
HR 
(95% CI) * 
Median 
intake 
(g/kcal, ±  
SD) 
Cases, 
n 
HR 
(95% CI) * 
Median 
intake 
(g/kcal, ±  
SD) 
Cases, 
n 
HR 
(95% CI) * 
42.14 (0.84—1.51) 47.29 (0.93—1.98) 36.47 (0.49—1.32) 
     p for trend   0.63   0.15   0.75 
* adjusted for age (years), gender (male/female, in overall model only), interview year (1993-1995/1996-1998), dialect (Hokkien/Cantonese), education (less than 
secondary/secondary or greater), tobacco smoking (never/ever), alcohol consumption (never/ever), body mass index (<20, 20-<24, 24-<28, or !28 kg/m2), and 
total energy intake (kcal/day) 
 
 
Table 59.  Hazard ratios (HRs) and 95% confidence intervals (95% CIs) for quartiles of antioxidant intake and the risk of non-cardia gastric cancer in the 
Singapore Chinese Health Study. 
 Overall Men Women 
Median 
intake ±  
SD 
Cases, 
n 
HR 
(95% CI) * 
Median 
intake ±  
SD 
Cases, 
n 
HR 
(95% CI) * 
Median 
intake ±  
SD 
Cases, 
n 
HR 
(95% CI) * 
Total selenium 
(µg/kcal) 
         
     Q1 53.81 ± 
5.07 
94 1.00 (ref) 53.76 ± 
4.85 
53 1.00 (ref) 53.83 ± 
5.25 
47 1.00 (ref) 
     Q2 61.56 ± 
1.88 
64 0.67 
(0.48—0.91) 
61.09 ± 
1.75 
36 0.67 
(0.44—1.02) 
61.96 ± 
1.90 
41 0.66 
(0.41—1.07) 
     Q3 67.82 ± 
2.11 
94 0.95 
(0.72—1.27) 
67.11 ± 
1.94 
62 1.11 
(0.77—1.61) 
68.37 ± 
2.07 
28 0.74 
(0.47—1.18) 
     Q4 77.31 ± 
8.75 
93 0.90 
(0.68—1.21) 
76.03 ± 
7.95 
61 1.07 
(0.73—1.55) 
78.19 ± 
9.23 
32 0.70 
(0.44—1.10) 
     p for trend   0.07   0.08   0.29 
Total 
carotenoids 
(µg/kcal) 
         
     Q1 1771.00 ± 
499.15 
107 1.00 (ref) 1569.97 ± 
430.42 
64 1.00 (ref) 1980.15 ± 
476.48 
43 1.00 (ref) 
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 Overall Men Women 
Median 
intake ±  
SD 
Cases, 
n 
HR 
(95% CI) * 
Median 
intake ±  
SD 
Cases, 
n 
HR 
(95% CI) * 
Median 
intake ±  
SD 
Cases, 
n 
HR 
(95% CI) * 
     Q2 2795.98 ± 
376.33 
82 0.86 
(0.64—1.14) 
2524.97 ± 
256.31 
51 0.86 
(0.59—1.25) 
3045.52 ± 
283.47 
31 0.82 
(0.52—1.30) 
     Q3 3844.34 ± 
487.95 
78 0.89 
(0.66—1.19) 
3486.02 ± 
340.25 
53 0.97 
(0.68—1.41) 
4125.13 ± 
385.84 
25 0.73 
(0.44—1.20) 
     Q4 5811.57 ± 
1948.95 
78 0.99 
(0.74—1.34) 
5265.59 ± 
1754.35 
44 0.90 
(0.61—1.33) 
6201.37 ± 
1980.48 
34 1.09 
(0.69—1.74) 
     p for trend   0.66   0.85   0.37 
!-carotene 
(µg/kcal) 
       ! !
     Q1 29.86 ± 
20.52 
96 1.00 (ref) 20.07 ± 
13.44 
62 1.00 (ref) 42.03 ± 
21.37 
34 1.00 (ref) 
     Q2 85.81 ± 
22.09 
84 0.87 
(0.65—1.17) 
68.89 ± 
13.81 
49 0.76 
(0.52—1.11) 
100.43 ± 
16.50 
35 1.06 
(0.66—1.71) 
     Q3 153.81 ± 
36.78 
84 0.90 
(0.67—1.21) 
126.96 ± 
23.53 
56 0.88 
(0.61—1.27) 
176.40 ± 
30.25 
28 0.88 
(0.53—1.46) 
     Q4 332.95 ± 
224.87 
81 0.93 
(0.69—1.25) 
278.20 ± 
187.03 
45 0.75 
(0.51—1.11) 
375.39 ± 
239.39 
36 1.23 
(0.77—1.98) 
     p for trend   0.82   0.40   0.61 
"-carotene 
(µg/kcal) 
         
     Q1 635.74 ± 
201.97 
94 1.00 (ref) 538.81 ± 
160.12 
55 1.00 (ref) 747.12 ± 
186.11 
39 1.00 (ref) 
     Q2 1038.41 ± 
171.11 
97 1.12 
(0.84—1.48 
898.74 ± 
97.04 
65 1.25 
(0.87—1.80) 
1164.68 ± 
116.11 
32 0.90 
(0.56—1.43) 
     Q3 1465.99 ± 
232.05 
69 0.85 
(0.62—1.16) 
1275.45 ± 
132.95 
44 0.89 
(0.60—1.33) 
1626.14 ± 
164.74 
25 0.75 
(0.46—1.25) 
     Q4 2299.51 ± 
880.12 
85 1.13 
(0.84—1.51) 
1975.03 ± 
741.98 
48 1.04 
(0.70—1.53) 
2521.20 ± 
892.44 
37 1.22 
(0.77—1.93) 
     p for trend   0.26   0.35   0.29 
"-cryptoxanthin         !
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 Overall Men Women 
Median 
intake ±  
SD 
Cases, 
n 
HR 
(95% CI) * 
Median 
intake ±  
SD 
Cases, 
n 
HR 
(95% CI) * 
Median 
intake ±  
SD 
Cases, 
n 
HR 
(95% CI) * 
(µg/kcal) 
     Q1 12.06 ± 
14.35 
103 1.00 (ref) 13.28 ± 
14.40 
57 1.00 (ref) 10.73 ± 
14.30 
46 1.00 (ref) 
     Q2 71.46 ± 
17.14 
81 0.92 
(0.69—1.24) 
69.13 ± 
15.88 
52 1.01 
(0.69—1.48) 
73.50 ± 
17.87 
29 0.78 
(0.49—1.25) 
     Q3 142.32 ± 
28.18 
93 1.12 
(0.84—1.50) 
136.38 ± 
26.63 
61 1.23 
(0.85—1.78) 
147.06 ± 
28.41 
32 0.93 
(0.58—1.47) 
     Q4 323.55 ± 
283.03 
68 0.81 
(0.59—1.10) 
309.38 ± 
254.88 
42 0.82 
(0.55—1.24) 
333.47 ± 
302.25 
26 0.74 
(0.45—1.22) 
     p for trend   0.20   0.25   0.59 
Lycopene 
(µg/kcal) 
   ! ! ! ! ! !
     Q1 90.53 ± 
61.09 
123 1.00 (ref) 105.40 ± 
65.89 
72 1.00 (ref) 80.26 ± 
54.58 
51 1.00 (ref) 
     Q2 312.87 ± 
79.75 
74 0.70 
(0.52—0.93) 
345.30 ± 
78.00 
50 0.80 
(0.55—1.15) 
287.52 ± 
72.27 
24 0.55 
(0.34—0.90) 
     Q3 627.01 ± 
119.05 
74 0.77 
(0.57—1.03) 
657.09 ± 
111.43 
44 0.76 
(0.52—1.11) 
603.63 ± 
119.41 
30 0.76 
(0.48—1.21) 
     Q4 1311.77 ± 
1210.93 
74 0.89 
(0.66—1.20) 
1396.34 ± 
1196.84 
46 0.93 
(0.64—1.37) 
1245.72 ± 
1219.55 
28 0.81 
(0.50—1.30) 
     p for trend   0.07   0.43   0.12 
Lutein (µg/kcal)          
     Q1 597.01 ± 
173.40 
88 1.00 (ref) 520.16 ± 
139.35 
53 1.00 (ref) 688.74 ± 
163.54 
35 1.00 (ref) 
     Q2 939.52 ± 
143.27 
90 1.12 
(0.83—1.50) 
825.32 ± 
81.85 
51 1.03 
(0.70—1.52) 
1045.90 ± 
97.82 
39 1.23 
(0.78—1.94) 
     Q3 1296.07 ± 
191.42 
86 1.13 
(0.84—1.52) 
1132.96 ± 
110.31 
58 1.24 
(0.86—1.81) 
1427.47 ± 
134.42 
28 0.93 
(0.56—1.53) 
     Q4 1949.59 ± 
639.28 
81 1.10 
(0.81—1.50) 
1684.55 ± 
518.06 
50 1.10 
(0.75—1.63) 
2128.98 31 1.07 
(0.66—1.75) 
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 Overall Men Women 
Median 
intake ±  
SD 
Cases, 
n 
HR 
(95% CI) * 
Median 
intake ±  
SD 
Cases, 
n 
HR 
(95% CI) * 
Median 
intake ±  
SD 
Cases, 
n 
HR 
(95% CI) * 
     p for trend   0.85   0.67   0.69 
Total vitamin C 
(mg/kcal) 
         
     Q1 21.66 ± 
6.76 
108 1.00 (ref) 19.99 ± 
6.50 
62 1.00 (ref) 23.02 ± 
6.68 
46 1.00 (ref) 
     Q2 39.63 ± 
5.71 
80 0.86 
(0.64—1.15) 
37.35 ± 
4.99 
49 0.87 
(0.59—1.26) 
41.60 ± 
5.50 
31 0.82 
(0.52—1.30) 
     Q3 60.24 ± 
8.33 
82 0.98 
(0.73—1.31) 
56.55 ± 
6.84 
57 1.10 
(0.76—1.58) 
63.40 ± 
8.09 
25 0.75 
(0.45—1.23) 
     Q4 102.73 ± 
151.60 
75 0.94 
(0.69—1.27) 
94.37 ± 
127.18 
44 0.87 
(0.58—1.30) 
108.74 ± 
167.54 
31 0.99 
(0.61—1.59) 
     p for trend   0.76   0.56   0.60 
Total vitamin E 
(mg !-
tocopherol 
equivalents/kcal) 
         
     Q1 2.59 ± 0.47 94 1.00 (ref) 2.38 ± 0.40 56 1.00 (ref) 2.84 ± 0.43 38 1.00 (ref) 
     Q2 3.41 ± 0.31 86 1.02 
(0.76—1.37) 
3.14 ± 0.19 57 1.11 
(0.77—1.61) 
3.64 ± 0.20 29 0.87 
(0.54—1.42) 
     Q3 4.10 ± 0.34 85 1.10 
(0.82—1.47) 
3.80 ± 0.21 47 0.96 
(0.65—1.43) 
4.33 ± 0.23 38 1.28 
(0.81—2.02) 
     Q4 5.25 ± 
64.00 
80 1.10 
(0.81—1.49) 
4.85 ± 
54.66 
52 1.12 
(0.76—1.65) 
5.49 ± 
70.52 
28 1.01 
(0.62—1.67) 
     p for trend   0.90   0.83   0.46 
Total soy 
isoflavones 
(mg/kcal) 
  ! ! ! ! ! ! !
     Q1 3.63 ± 1.65 86 1.00 (ref) 3.25 ± 1.45 56 1.00 (ref) 4.00 ± 1.72 30 1.00 (ref) 
     Q2 7.74 ± 1.35 89 1.08 
(0.81—1.46) 
7.02 ± 1.07 53 0.97 
(0.67—1.41) 
8.37 ± 1.24 36 1.28 
(0.79—2.09) 
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 Overall Men Women 
Median 
intake ±  
SD 
Cases, 
n 
HR 
(95% CI) * 
Median 
intake ±  
SD 
Cases, 
n 
HR 
(95% CI) * 
Median 
intake ±  
SD 
Cases, 
n 
HR 
(95% CI) * 
     Q3 12.24 ± 
1.87 
93 1.18 
(0.88—1.59) 
11.12 ± 
1.46 
53 1.00 
(0.68—1.46) 
13.15 ± 
1.66 
40 1.52 
(0.94—2.45) 
     Q4 20.72 ± 
9.85 
77 0.99 
(0.73—1.36) 
19.12 ± 
8.76 
50 0.94 
(0.64—1.39) 
22.00 ± 
10.39 
27 1.07 
(0.63—1.81) 
     p for trend   0.64   0.99   0.31 
Genistein 
(mg/kcal) 
         
     Q1 1.70 ± 0.76 84 1.00 (ref) 1.52 ± 0.67 55 1.00 (ref) 1.88 ± 0.80 29 1.00 (ref) 
     Q2 3.58 ± 0.62 96 1.20 
(0.90—1.62) 
3.24 ± 0.49 58 1.09 (0.75—
1.58) 
3.87 ± 0.56 38 1.41 
(0.87—2.29) 
     Q3 5.63 ± 0.85 89 1.15 
(0.85—1.55) 
5.10 ± 0.66 50 0.95 
(0.64—1.39) 
6.04 ± 0.75 39 1.53 
(0.94—2.49) 
     Q4 9.46 ± 4.37 76 1.01 
(0.74—1.38) 
8.72 ± 3.90 49 0.94 
(0.64—1.39) 
10.04 ± 
4.59 
27 1.11 
(0.65—1.88) 
     p for trend   0.51   0.87   0.27 
Daidzein 
(mg/kcal) 
         
     Q1 1.69 ± 0.78 88 1.00 (ref) 1.52 ± 0.69 56 1.00 (ref) 1.86 ± 0.81 32 1.00 (ref) 
     Q2 3.65 ± 0.64 88 1.05 
(0.78—1.41) 
3.31 ± 0.52 52 0.96 
(0.65—1.40) 
3.96 ± 0.59 36 1.21 
(0.75—1.95) 
     Q3 5.81 ± 0.90 92 1.14 
(0.85—1.54) 
5.28 ± 0.70 55 1.04 
(0.72—1.52) 
6.24 ± 0.80 37 1.31 
(0.81—2.12) 
     Q4 9.92 ± 4.84 77 0.97 
(0.71—1.32) 
9.14 ± 4.29 49 0.92 
(0.63—1.36) 
10.55 ± 
5.12 
28 1.04 
(0.62—1.73) 
     p for trend   0.72   0.94 ! ! 0.65 
Glycitein 
(mg/kcal) 
         
     Q1 0.24 ± 0.11 89 1.00 (ref) 0.21 ± 
0.096 
57 1.00 (ref) 0.26 ± 0.11 32 1.00 (ref) 
     Q2 0.51 ± 86 1.01 0.46 ± 52 0.94 0.55 ± 34 1.14 
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 Overall Men Women 
Median 
intake ±  
SD 
Cases, 
n 
HR 
(95% CI) * 
Median 
intake ±  
SD 
Cases, 
n 
HR 
(95% CI) * 
Median 
intake ±  
SD 
Cases, 
n 
HR 
(95% CI) * 
0.087 (0.75—1.36) 0.070 (0.64—1.36) 0.080 (0.70—1.85) 
     Q3 0.80 ± 0.12 94 1.15 
(0.86—1.55) 
0.73 ± 
0.096 
55 1.02 
(0.70—1.49) 
0.86 ± 0.11 39 1.38 
(0.86—2.22) 
     Q4 1.36 ± 0.65 76 0.94 
(0.69—1.29) 
1.25 ± 0.58 48 0.89 
(0.60—1.31) 
1.44 ± 0.69 28 1.04 
(0.62—1.73) 
     p for trend   0.60   0.88   0.52 
Total 
isothiocyanate 
(µmol/kcal) 
         
     Q1 2.39 ± 0.84 83 1.00 (ref) 2.06 ± 0.71 54 1.00 (ref) 2.71 ± 0.83 29 1.00 (ref) 
     Q2 4.26 ± 0.68 94 1.22 
(0.91—1.65) 
3.79 ± 0.48 55 1.08 
(0.74—1.58) 
4.68 ± 0.54 39 1.46 
(0.90—2.37) 
     Q3 6.25 ± 0.92 88 1.22 
(0.90—1.65) 
5.59 ± 0.66 56 1.19 
(0.82—1.73) 
6.77 ± 0.75 32 1.26 
(0.76—2.09) 
     Q4 10.08 ± 
4.36 
80 1.16 
(0.85—1.58) 
9.08 ± 3.79 56 1.03 
(0.69—1.53) 
10.81 ± 
4.58 
33 1.36 
(0.83—2.26) 
     p for trend   0.52   0.82   0.46 
* adjusted for age (years), gender (male/female, in overall model only), interview year (1993-1995/1996-1998), dialect (Hokkien/Cantonese), education (less than 
secondary/secondary or greater), tobacco smoking (never/ever), alcohol consumption (never/ever), body mass index (<20, 20-<24, 24-<28, or !28 kg/m2), and 
total energy intake (kcal/day) 
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Table 60.  Hazard ratios (HRs) and 95% confidence intervals (95% CIs) for tea and coffee intakes and the risk of non-cardia gastric cancer in the Singapore 
Chinese Health Study. 
 Overall Men Women 
Median 
intake ±  
SD Cases, n 
HR 
(95% CI) * 
Median 
intake ±  
SD Cases, n 
HR 
(95% CI) * 
Median 
intake ±  
SD Cases, n 
HR 
(95% CI) * 
Black tea 
(cups/month) 
         
     Q1 0.00 225 1.00 (ref) 0.00 130 1.00 (ref) 0.00 95 1.00 (ref) 
     Q2 2.00 ± 1.14 46 1.10 
(0.80—1.51) 
2.00 ± 1.14 24 0.87 
(0.56—1.34) 
2.00 ± 1.13 22 1.50 
(0.94—2.40) 
     Q3 10.70 ± 
4.48 
27 0.71 
(0.47—1.06) 
10.70 ± 
4.61 
19 0.66 
(0.41—1.07) 
10.70 ± 
4.30 
8 0.81 
(0.39—1.67) 
     Q4 30.00 ± 
26.28 
47 1.18 
(0.85—1.62) 
30.00 ± 
27.73 
39 1.21 
(0.84—1.74) 
30.00 ± 
23.36 
8 0.94 
(0.46—1.95) 
     p for trend   0.19   0.16   0.30 
Green tea 
(cups/month) 
         
     Q1 0.00 211 1.00 (ref) 0.00 125 1.00 (ref) 0.00 86 1.00 (ref) 
     Q2 2.00 ± 1.11 48 0.80 
(0.59—1.10) 
2.00 ± 1.11 23 0.60 
(0.39—0.94) 
2.00 ± 1.10 25 1.13 
(0.72—1.77) 
     Q3 10.70 ± 
4.28 
36 0.97 
(0.68—1.39) 
10.70 ± 
4.44 
23 0.83 
(0.53—1.31) 
10.70 ± 
4.09 
13 1.24 
(0.69—2.23) 
     Q4 30.00 ± 
40.71 
50 1.07 
(0.78—1.47) 
75.00 ± 
42.47 
41 1.09 
(0.76—1.56) 
30.00 ± 
38.12 
9 0.79 
(0.40—1.59) 
     p for trend   0.50   0.10   0.72 
Any tea 
(cups/month) 
         
     Q1 0.00 149 1.00 (ref) 0.00 81 1.00 (ref) 0.00 68 1.00 (ref) 
     Q2 4.00 ± 1.83 61 0.89 
(0.66—1.19) 
4.00 ± 1.87 30 0.70 
(0.46—1.06) 
4.00 ± 1.79 31 1.16 
(0.75—1.77) 
     Q3 10.70 ± 
4.96 
48 0.85 
(0.61—1.18) 
12.70 ± 
5.09 
30 0.72 
(0.47—1.09) 
10.70 ± 
4.80 
18 1.10 
(0.65—1.86) 
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 Overall Men Women 
Median 
intake ±  
SD Cases, n 
HR 
(95% CI) * 
Median 
intake ±  
SD Cases, n 
HR 
(95% CI) * 
Median 
intake ±  
SD Cases, n 
HR 
(95% CI) * 
     Q4 40.70 ± 
39.87 
87 1.04 
(0.79—1.36) 
40.70 ± 
41.56 
71 1.03 
(0.74—1.42) 
34.30 ± 
37.07 
16 0.84 
(0.48—1.45) 
     p for trend   0.61   0.13   0.74 
Coffee 
(cups/week) 
         
     Never 0.00 64 1.00 (ref) 0.00 36 1.00 (ref) 0.00 28 1.00 (ref) 
     Monthly 0.46 ± 0.15 6 0.95 
(0.41—2.18) 
0.46 ± 0.15 3 0.84 
(0.26—2.72) 
0.46 ± 0.15 3 1.11 
(0.34—3.64) 
     Weekly 2.50 ± 1.46 27 0.89 
(0.57—1.40) 
2.50 ± 1.45 11 0.62 
(0.32—1.22) 
2.50 ± 1.47 16 1.32 
(0.72—2.45) 
     1 cup/day 7.02 ± 0.79 109 0.89 
(0.65—1.21) 
7.02 ± 0.83 67 1.07 
(0.71—1.60) 
7.02 ± 0.77 42 0.71 
(0.44—1.15) 
     2-3 cups/day 17.56 ± 
1.96 
122 1.11 
(0.81—1.50) 
17.56 ± 
1.97 
84 1.26 
(0.85—1.87) 
17.56 ± 
1.96 
38 0.97 
(0.59—1.59) 
     !4 cups/day 31.60 ± 
5.19 
17 1.09 
(0.63—1.87) 
31.60 ± 
4.68 
11 1.07 
(0.54—2.11) 
31.60 ± 
5.95 
6 1.42 
(0.58—3.48) 
     p for trend   0.68   0.35   0.28 
* adjusted for age (years), gender (male/female, in overall model only), interview year (1993-1995/1996-1998), dialect (Hokkien/Cantonese), education (less than 
secondary/secondary or greater), tobacco smoking (never/ever), alcohol consumption (never/ever), body mass index (<20, 20-<24, 24-<28, or !28 kg/m2), and 
total energy intake (kcal/day) 
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Table 61.  Hazard ratios (HRs) and 95% confidence intervals (95% CIs) for quartiles of fish intake and the risk of unspecified gastric cancer in the Singapore 
Chinese Health Study. 
 Overall Men Women 
Median 
intake 
(g/kcal, ±  
SD) 
Cases, 
n 
HR 
(95% CI) * 
Median 
intake 
(g/kcal, ±  
SD) 
Cases, 
n 
HR 
(95% CI) * 
Median 
intake 
(g/kcal, ±  
SD) 
Cases, 
n 
HR 
(95% CI) * 
Total fish and 
shellfish 
         
     Q1 17.60 ± 6.04 25 1.00 (ref) 16.49 ± 
5.49 
15 1.00 (ref) 18.67 ± 
6.34 
10 1.00 (ref) 
     Q2 29.10 ± 3.25 30 1.24 
(0.73—2.11) 
27.61 ± 
2.81 
13 0.86 
(0.41—1.82) 
30.46 ± 
3.02 
17 1.78 
(0.81—3.89) 
     Q3 39.46 ± 3.80 24 0.97 
(0.55—1.70) 
37.46 ± 
3.26 
13 0.85 
(0.40—1.78) 
41.06 ± 
3.43 
11 1.12 
(0.47—2.64) 
     Q4 55.58 ± 13.99 22 0.84 
(0.47—1.50) 
53.05 ± 
13.55 
14 0.88 
(0.42—1.83) 
57.42 ± 
14.01 
8 0.77 
(0.30—1.95) 
     p for trend   0.57   0.97   0.20 
Fresh fish and 
shellfish 
 ! ! ! ! ! ! ! !
     Q1 15.91 ± 5.73 26 1.00 (ref) 14.80 ± 
5.18 
15 1.00 (ref) 17.08 ± 
6.02 
11 1.00 (ref) 
     Q2 27.27 ± 3.24 27 1.07 
(0.62—1.83) 
25.73 ± 
2.76 
13 0.86 
(0.41—1.81) 
28.60 ± 
3.00 
14 1.32 
(0.60—2.92) 
     Q3 37.54 ± 3.81 26 1.01 
(0.59—1.74) 
35.45 ± 
3.23 
13 0.84 
(0.40—1.77) 
39.19 ± 
3.41 
13 1.20 
(0.54—2.69) 
     Q4 53.50 ± 14.01 22 0.80 
(0.45—1.42) 
50.85 ± 
13.55 
14 0.88 
(0.42—1.83) 
55.52 ± 
14.02 
8 0.69 
(0.27—1.71) 
     p for trend   0.78   0.97   0.49 
Preserved fish 
and shellfish 
         
     Q1 0.16 ± 0.13 25 1.00 (ref) 0.19 ± 0.15 14 1.00 (ref) 0.15 ± 0.12 11 1.00 (ref) 
     Q2 0.80 ± 0.25 27 1.09 
(0.63—1.89) 
0.88 ± 0.24 13 0.95(0.45—
2.03) 
0.73 ± 0.23 14 1.29 
(0.58—2.85) 
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 Overall Men Women 
Median 
intake 
(g/kcal, ±  
SD) 
Cases, 
n 
HR 
(95% CI) * 
Median 
intake 
(g/kcal, ±  
SD) 
Cases, 
n 
HR 
(95% CI) * 
Median 
intake 
(g/kcal, ±  
SD) 
Cases, 
n 
HR 
(95% CI) * 
     Q3 1.79 ± 0.37 24 0.97 
(0.55—1.70) 
1.85 ± 0.36 15 1.07 
(0.52—2.24) 
1.73 ± 0.36 9 0.84 
(0.35—2.04) 
     Q4 3.75 ± 2.57 25 1.03 
(0.59—1.80) 
3.83 ± 2.59 13 0.94 
(0.44—2.02) 
3.69 ± 2.56 12 1.16 
(0.51—2.65) 
     p for trend   0.98   0.98   0.77 
Fish, fresh and 
preserved 
         
     Q1 15.03 ± 5.50 25 1.00 (ref) 13.95 ± 
4.96 
14 1.00 (ref) 16.11 ± 
5.78 
11 1.00 (ref) 
     Q2 25.93 ± 3.13 31 1.27 
(0.75—2.15) 
24.44 ± 
2.69 
15 1.05 
(0.51—2.18) 
27.21 ± 
2.86 
16 1.49 
(0.69—3.22) 
     Q3 35.90 ± 3.74 22 0.87 
(0.49—1.54) 
33.82 ± 
3.13 
13 0.87 
(0.41—1.86) 
37.57 ± 
3.37 
9 0.81 
(0.34—1.96) 
     Q4 51.73 ± 13.95 23 0.85 
(0.48—1.50) 
53.06 ± 
13.52 
13 0.84 
(0.39—1.81) 
53.69 ± 
13.93 
10 0.83 
(0.35—1.98) 
     p for trend   0.43   0.93   0.37 
Shellfish, fresh 
and preserved 
         
     Q1 0.69 ± 0.41 31 1.00 (ref) 0.81 ± 0.43 22 1.00 (ref) 0.61 ± 0.38 9 1.00 (ref) 
     Q2 1.92 ± 0.36 25 0.93 
(0.55—1.57) 
2.03 ± 0.34 9 0.46 
(0.21—1.01) 
1.82 ± 0.35 16 2.10 
(0.92—4.79) 
     Q3 3.26 ± 0.50 22 0.87 
(0.50—1.51) 
3.34 ± 0.47 13 0.71 
(0.35—1.43) 
3.19 ± 0.51 9 1.27 
(0.50—3.23) 
     Q4 6.06 ± 3.19 23 0.93 
(0.54—1.62) 
6.02 ± 2.87 11 0.58 
(0.28—1.22) 
6.11 ± 3.42 12 1.82 
(0.75—4.40) 
     p for trend   0.97   0.21   0.28 
* adjusted for age (years), gender (male/female, in overall model only), interview year (1993-1995/1996-1998), dialect (Hokkien/Cantonese), education (less than 
secondary/secondary or greater), tobacco smoking (never/ever), alcohol consumption (never/ever), body mass index (<20, 20-<24, 24-<28, or !28 kg/m2), and 
total energy intake (kcal/day) 
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Table 62.  Hazard ratios (HRs) and 95% confidence intervals (95% CIs) for quartiles of fat intakes and the risk of unspecified gastric cancer in the Singapore 
Chinese Health Study. 
 Overall Men Women 
Median 
intake 
(g/kcal, ±  
SD) 
Cases, 
n 
HR 
(95% CI) * 
Median 
intake 
(g/kcal, ±  
SD) 
Cases, 
n 
HR 
(95% CI) * 
Median 
intake 
(g/kcal, ±  
SD) 
Cases, 
n 
HR 
(95% CI) * 
Total Fat          
     Q1 18.57 ± 2.81 33 1.00 (ref) 17.71 ± 
2.71 
16 1.00 (ref) 19.29 ± 
2.71 
17 1.00 (ref) 
     Q2 23.33 ± 1.26 24 0.81 
(0.48—1.37) 
22.62 ± 
1.14 
13 0.86 
(0.41—1.79) 
23.88 ± 
1.07 
11 0.74 
(0.34—1.58) 
     Q3 26.93 ± 1.23! 24! 0.89 
(0.52—1.51)! 26.27 ± 1.10! 16! 1.13 (0.56—2.26)! 27.44 ± 1.09! 8! 0.62 (0.26—1.46)!
     Q4 31.60 ± 2.74! 20! 0.85 
(0.48—1.52)! 31.05 ± 2.76! 10! 0.77 (0.34—1.74)! 32.02 ± 2.65! 10! 0.94 (0.42—2.14)!
     p for trend   0.87   0.79   0.67 
Saturated Fat          
     Q1 5.92 ± 1.01 33 1.00 (ref) 5.76 ± 0.99 14 1.00 (ref) 6.06 ± 1.01 19 1.00 (ref) 
     Q2 7.93 ± 0.51 28 0.95 
(0.57—1.57) 
7.77 ± 0.49 15 1.18 
(0.57—2.45) 
8.16 ± 0.49 13 0.78 
(0.38—1.58) 
     Q3 9.61 ± 0.54 21 0.76 
(0.44—1.33) 
9.41 ± 0.52 15 1.24 
(0.60—2.58) 
9.75 ± 0.52 6 0.39 
(0.16—0.99) 
     Q4 11.85 ± 1.33 19 0.75 
(0.42—1.35) 
11.67 ± 
1.34 
11 0.96 
(0.43—2.15) 
12.01 ± 
1.31 
8 0.59 
(0.25—1.40) 
     p for trend   0.68   0.89   0.23 
MUFA     ! ! ! ! !
     Q1 6.10 ± 0.96 32 1.00 (ref) 5.87 ± 0.93 19 1.00 (ref) 6.30 ± 0.93 13 1.00 (ref) 
     Q2 7.79 ± 0.43 24 0.83 
(0.49—1.41) 
7.59 ± 0.40 13 0.71 
(0.35—1.45) 
7.94 ± 0.39 11 0.98 
(0.44—2.20) 
     Q3 9.11 ± 0.43 21 0.79 
(0.45—1.38) 
8.94 ± 0.41 10 0.58 
(0.27—1.26) 
9.25 ± 0.40 11 1.11 
(0.49—2.50) 
     Q4 10.88 ± 1.09 24 1.02 
(0.59—1.76) 
10.73 ± 
1.10 
13 0.82 
(0.40—1.70) 
10.99 ± 
1.07 
11 1.34 
(0.58—3.08) 
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 Overall Men Women 
Median 
intake 
(g/kcal, ±  
SD) 
Cases, 
n 
HR 
(95% CI) * 
Median 
intake 
(g/kcal, ±  
SD) 
Cases, 
n 
HR 
(95% CI) * 
Median 
intake 
(g/kcal, ±  
SD) 
Cases, 
n 
HR 
(95% CI) * 
     p for trend   0.75   0.55   0.89 
PUFA          
     Q1 3.24 ± 0.55 26 1.00 (ref) 3.09 ± 0.52 17 1.00 (ref) 3.38 ± 0.54 9 1.00 (ref) 
     Q2 4.26 ± 0.31 33 1.44 
(0.86—2.42) 
4.08 ± 0.25 17 1.08 
(0.55—2.12) 
4.42 ± 0.27 16 2.12 
(0.93—4.83) 
     Q3 5.27 ± 0.43 20 0.95 
(0.52—1.71) 
5.03 ± 0.34 8 0.53 
(0.23—1.23) 
5.45 ± 0.39 12 1.75 
(0.73—4.21) 
     Q4 7.30 ± 1.48 22 1.07 
(0.60—1.90) 
6.90 ± 1.38 13 0.88 
(0.42—1.86) 
7.62 ± 1.49 9 1.35 
(0.53—3.45) 
     p for trend   0.39   0.39   0.31 
Total n-3          
     Q1 0.36 ± 0.055 27 1.00 (ref) 0.34 ± 
0.051 
14 1.00 (ref) 0.38 ± 
0.054 
13 1.00 (ref) 
     Q2 0.45 ± 0.030 28 1.11 
(0.65—1.88) 
0.43 ± 
0.022 
12 0.87 
(0.40—1.89) 
0.47 ± 
0.023 
16 1.35 
(0.65—2.82) 
     Q3 0.53 ± 0.033 24 0.95 
(0.54—1.64) 
0.51 ± 
0.025 
13 0.89 
(0.42—1.91) 
0.55 ± 
0.026 
11 0.97 
(0.43—2.17) 
     Q4 0.67 ± 0.18 22 0.88 
(0.50—1.56) 
0.64 ± 0.16 16 1.11 
(0.54—2.30) 
0.69 ± 0.19 6 0.55 
(0.21—1.45) 
     p for trend   0.87   0.91   0.30 
Marine n-3          
     Q1 0.092 ± 0.032 27 1.00 (ref) 0.087 ± 
0.029 
16 1.00 (ref) 0.097 ± 
0.033 
11 1.00 (ref) 
     Q2 0.15 ± 0.017 30 1.15 
(0.68—1.94) 
0.15 ± 
0.015 
13 0.82 
(0.39—1.70) 
0.16 ± 
0.016 
17 1.60 
(0.75—3.43) 
     Q3 0.21 ± 0.019 24 0.90 
(0.52—1.56) 
0.20 ± 
0.017 
12 0.73 
(0.35—1.55) 
0.21 ± 
0.018 
12 1.11 
(0.49—2.52) 
     Q4 0.29 ± 0.072 20 0.72 
(0.40—1.28) 
0.28 ± 
0.071 
14 0.83 
(0.40—1.70) 
0.30 ± 
0.072 
6 0.53 
(0.19—1.43) 
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 Overall Men Women 
Median 
intake 
(g/kcal, ±  
SD) 
Cases, 
n 
HR 
(95% CI) * 
Median 
intake 
(g/kcal, ±  
SD) 
Cases, 
n 
HR 
(95% CI) * 
Median 
intake 
(g/kcal, ±  
SD) 
Cases, 
n 
HR 
(95% CI) * 
     p for trend   0.42   0.87   0.13 
Non-marine n-3          
     Q1 0.21 ± 0.033 28 1.00 (ref) 0.21 ± 
0.030 
16 1.00 (ref) 0.22 ± 
0.032 
12 1.00 (ref) 
     Q2 0.28 ± 0.019 23 0.92 
(0.53—1.61) 
0.26 ± 
0.015 
8 0.53 
(0.22—1.24) 
0.29 ± 
0.015 
15 1.48 
(0.69—3.17) 
     Q3 0.33 ± 0.021 24 0.99 
(0.57—1.72) 
0.31 ± 
0.017 
14 0.92 
(0.45—1.91) 
0.34 ± 
0.018 
10 1.05 
(0.45—2.45) 
     Q4 0.42 ± 0.18 26 1.09 
(0.63—1.88)!
0.40 ± 0.16! 17! 1.08 
(0.53—2.17)!
0.44 ± 0.19! 9 1.00 
(0.42—2.41) 
     p for trend   0.95   0.39   0.70 
Total n-6          
     Q1 2.82 ± 0.49 26 1.00 (ref) 2.69 ± 0.46 17 1.00 (ref) 2.95 ± 0.48 9 1.00 (ref) 
     Q2 3.75 ± 0.29 34 1.49 
(0.89—2.49) 
3.59 ± 0.23 18 1.13 
(0.58—2.21) 
3.89 ± 0.25 16 2.14 
(0.94—4.86) 
     Q3 4.70 ± 0.41 18 0.85 
(0.46—1.57) 
4.47 ± 0.32 6 0.40 
(0.16—1.02) 
4.87 ± 0.38 12 1.75 
(0.73—4.19) 
     Q4 6.64 ± 1.40 23 1.11 
(0.63—1.97) 
6.26 ± 1.30 14 0.95 
(0.46—1.97) 
6.95 ± 1.40 9 1.34 
(0.53—3.43) 
     p for trend   0.22   0.16   0.30 
Total animal fat          
     Q1 4.57 ± 1.27 33 1.00 (ref) 4.82 ± 1.30 18 1.00 (ref) 4.41 ± 1.21 15 1.00 (ref) 
     Q2 7.14 ± 0.70 22 0.75 
(0.43—1.28) 
7.49 ± 0.64 9 0.54 
(0.24—1.21) 
6.87 ± 0.61 13 1.00 
(0.47—2.11) 
     Q3 9.31 ± 0.78 19 0.71 
(0.40—1.26) 
9.70 ± 0.71 10 0.65 
(0.30—1.42) 
8.99 ± 0.66 9 0.78 
(0.34—1.81) 
     Q4 12.40 ± 2.23! 27! 1.13 
(0.67—1.91)! 12.93 ± 2.23! 18! 1.30 (0.66—2.55)! 11.93 ± 2.12! 9! 0.90 (0.38—2.13)!
     p for trend   0.31   0.12   0.94 
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 Overall Men Women 
Median 
intake 
(g/kcal, ±  
SD) 
Cases, 
n 
HR 
(95% CI) * 
Median 
intake 
(g/kcal, ±  
SD) 
Cases, 
n 
HR 
(95% CI) * 
Median 
intake 
(g/kcal, ±  
SD) 
Cases, 
n 
HR 
(95% CI) * 
Total red meat 
fat 
         
     Q1 1.08 ± 0.49 29 1.00 (ref) 1.25 ± 0.51 14 1.00 (ref) 0.96 ± 0.44 15 1.00 (ref) 
     Q2 2.20 ± 0.34 25 0.93 
(0.55—1.59) 
2.40 ± 0.30 12 0.94 
(0.44—2.04) 
2.05 ± 0.29 13 0.94 
(0.44—1.97) 
     Q3 3.28 ± 0.43 19 0.75 
(0.42—1.33) 
3.52 ± 0.38 12 0.96 
(0.44—2.09) 
3.08 ± 0.36 7 0.54 
(0.22—1.33) 
     Q4 5.08 ± 1.58 28 1.18 
(0.69—2.01) 
5.40 ± 1.63 17 1.45 
(0.70—3.00)!
4.81 ± 1.47! 11! 0.93 
(0.42—2.07)!
     p for trend   0.49   0.60   0.57 
Total plant fat          
     Q1 11.65 ± 2.02 33 1.00 (ref) 10.74 ± 
1.76 
17 1.00 (ref) 12.61 ± 
1.85 
16 1.00 (ref) 
     Q2 15.06 ± 1.23 20 0.64 
(0.67—1.12) 
14.03 ± 
0.80 
11 0.65 
(0.30—1.39) 
15.92 ± 
0.79 
9 0.62 
(0.27—1.41) 
     Q3 17.80 ± 1.28 26 0.90 
(0.54—1.51) 
16.71 ± 
0.83 
13 0.80 
(0.39—1.66) 
18.63 ± 
0.86 
13 0.99 
(0.47—2.07) 
     Q4 21.74 ± 2.92 22 0.81 
(0.47—1.41) 
20.48 ± 
2.72 
14 0.90 
(0.44—1.85) 
22.52 ± 
2.76 
8 0.66 
(0.28—1.57) 
     p for trend   0.47   0.72   0.56 
Total cholesterol          
     Q1 62.53 ± 15.42 30 1.00 (ref) 62.88 ± 
15.37 
16 1.00 (ref) 62.30 ± 
15.45 
14 1.00 (ref) 
     Q2 92.04 ± 7.33 20 0.77 
(0.44—1.35) 
93.16 ± 
7.37 
11 0.78 
(0.36—1.69) 
90.98 ± 
7.16 
9 0.75 
(0.32—1.74) 
     Q3 116.95 ± 8.35 23 0.96 
(0.55—1.66) 
118.83 ± 
8.56 
13 0.98 
(0.47—2.04) 
115.49 ± 
7.85 
10 0.93 
(0.41—2.13) 
     Q4 156.29 ± 
42.14 
28 1.26 
(0.74—2.13) 
161.28 ± 
47.29 
15 1.15 
(0.56—2.36) 
152.25 ± 
36.47 
13 1.37 
(0.63—2.97) 
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 Overall Men Women 
Median 
intake 
(g/kcal, ±  
SD) 
Cases, 
n 
HR 
(95% CI) * 
Median 
intake 
(g/kcal, ±  
SD) 
Cases, 
n 
HR 
(95% CI) * 
Median 
intake 
(g/kcal, ±  
SD) 
Cases, 
n 
HR 
(95% CI) * 
     p for trend   0.41   0.81   0.57 
* adjusted for age (years), gender (male/female, in overall model only), interview year (1993-1995/1996-1998), dialect (Hokkien/Cantonese), education (less than 
secondary/secondary or greater), tobacco smoking (never/ever), alcohol consumption (never/ever), body mass index (<20, 20-<24, 24-<28, or !28 kg/m2), and 
total energy intake (kcal/day) 
 
 
Table 63.  Hazard ratios (HRs) and 95% confidence intervals (95% CIs) for quartiles of antioxidant intake and the risk of unspecified gastric cancer in the 
Singapore Chinese Health Study. 
 Overall Men Women 
Median 
intake ±  
SD 
Cases, 
n 
HR 
(95% CI) * 
Median 
intake ±  
SD 
Cases, 
n 
HR 
(95% CI) * 
Median 
intake ±  
SD 
Cases, 
n 
HR 
(95% CI) * 
Total selenium 
(µg/kcal) 
         
     Q1 53.81 ± 
5.07 
12 1.00 (ref) 53.76 ± 
4.85 
11 1.00 (ref) 53.83 ± 
5.25 
10 1.00 (ref) 
     Q2 61.56 ± 
1.88 
28 1.31 
(0.74—2.30) 
61.09 ± 
1.75 
15 1.37 
(0.63—2.98) 
61.96 ± 
1.90 
13 1.26 
(0.55—2.87) 
     Q3 67.82 ± 
2.11 
27 1.21 
(0.68—2.15) 
67.11 ± 
1.94 
14 1.21 
(0.55—2.66) 
68.37 ± 
2.07 
13 1.21 
(0.53—2.77) 
     Q4 77.31 ± 
8.75 
25 1.03 
(0.58—1.86) 
76.03 ± 
7.95 
15 1.20 
(0.55—2.65) 
78.19 ± 
9.23 
10 0.84 
(0.35—2.04) 
     p for trend   0.75   0.89   0.77 
Total 
carotenoids 
(µg/kcal) 
         
     Q1 1771.00 ± 
499.15 
38 1.00 (ref) 1569.97 ± 
430.42 
17 1.00 (ref) 1980.15 ± 
476.48 
21 1.00 (ref) 
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 Overall Men Women 
Median 
intake ±  
SD 
Cases, 
n 
HR 
(95% CI) * 
Median 
intake ±  
SD 
Cases, 
n 
HR 
(95% CI) * 
Median 
intake ±  
SD 
Cases, 
n 
HR 
(95% CI) * 
     Q2 2795.98 ± 
376.33 
20 0.60 
(0.35—1.04) 
2524.97 ± 
256.31 
13 0.87 
(0.42—1.81) 
3045.52 ± 
283.47 
7 0.38 
(0.16—0.89) 
     Q3 3844.34 ± 
487.95 
23 0.76 
(0.45—1.29) 
3486.02 ± 
340.25 
13 0.95 
(0.46—1.96) 
4125.13 ± 
385.84 
10 0.59 
(0.28—1.27) 
     Q4 5811.57 ± 
1948.95 
20 0.75 
(0.43—1.31) 
5265.59 ± 
1754.35 
12 1.00 
(0.47—2.12) 
6201.37 ± 
1980.48 
9 0.54 
(0.23—1.23) 
     p for trend   0.32   0.98   0.11 
!-carotene 
(µg/kcal) 
         
     Q1 29.86 ± 
20.52 
30 1.00 (ref) 20.07 ± 
13.44 
18 1.00 (ref) 42.03 ± 
21.37 
12 1.00 (ref) 
     Q2 85.81 ± 
22.09 
28 0.95 
(0.56—1.59) 
68.89 ± 
13.81 
13 0.73 
(0.36—1.50) 
100.43 ± 
16.50 
15 1.25 
(0.59—2.68) 
     Q3 153.81 ± 
36.78 
20 0.69 
(0.39—1.22) 
126.96 ± 
23.53 
9 0.50 
(0.23—1.12) 
176.40 ± 
30.25 
11 0.96 
(0.42—2.18) 
     Q4 332.95 ± 
224.87 
23 0.86 
(0.50—1.48) 
278.20 ± 
187.03 
15 0.88 
(0.44—1.75) 
375.39 ± 
239.39 
8 0.78 
(0.32—1.92) 
     p for trend   0.61   0.39   0.74 
"-carotene 
(µg/kcal) 
     ! ! ! !
     Q1 635.74 ± 
201.97 
33 1.00 (ref) 538.81 ± 
160.12 
17 1.00 (ref) 747.12 ± 
186.11 
16 1.00 (ref) 
     Q2 1038.41 ± 
171.11 
29 0.96 
(0.58—1.59) 
898.74 ± 
97.04 
14 0.90 
(0.44—1.83) 
1164.68 ± 
116.11 
15 1.01 
(0.50—2.04) 
     Q3 1465.99 ± 
232.05 
18 0.64 
(0.36—1.15) 
1275.45 ± 
132.95 
10 0.68 
(0.31—1.48) 
1626.14 ± 
164.74 
8 0.59 
(0.25—1.38) 
     Q4 2299.51 ± 
880.12 
21 0.82 
(0.47—1.42) 
1975.03 ± 
741.98 
14 1.01 
(0.49—2.07) 
2521.20 ± 
892.44 
7 0.57 
(0.23—1.40) 
     p for trend   0.45   0.76   0.39 
"-cryptoxanthin          
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 Overall Men Women 
Median 
intake ±  
SD 
Cases, 
n 
HR 
(95% CI) * 
Median 
intake ±  
SD 
Cases, 
n 
HR 
(95% CI) * 
Median 
intake ±  
SD 
Cases, 
n 
HR 
(95% CI) * 
(µg/kcal) 
     Q1 12.06 ± 
14.35 
35 1.00 (ref) 13.28 ± 
14.40 
19 1.00 (ref) 10.73 ± 
14.30 
16 1.00 (ref) 
     Q2 71.46 ± 
17.14 
19 0.67 
(0.38—1.17) 
69.13 ± 
15.88 
10 0.61 
(0.28—1.33) 
73.50 ± 
17.87 
9 0.70 
(0.31—1.60) 
     Q3 142.32 ± 
28.18 
26 0.98 
(0.58—1.65) 
136.38 ± 
26.63 
19 1.21 
(0.63—2.32) 
147.06 ± 
28.41 
7 0.60 
(0.24—1.47) 
     Q4 323.55 ± 
283.03 
21 0.78 
(0.44—1.36) 
309.38 ± 
254.88 
7 0.43 
(0.18—1.03) 
333.47 ± 
302.25 
14 1.19 
(0.57—2.51) 
     p for trend   0.45   0.07   0.39 
Lycopene 
(µg/kcal) 
         
     Q1 90.53 ± 
61.09 
29 1.00 (ref) 105.40 ± 
65.89 
16 1.00 (ref) 80.26 ± 
54.58 
13 1.00 (ref) 
     Q2 312.87 ± 
79.75 
29 1.23 
(0.73—2.06) 
345.30 ± 
78.00 
14 1.07 
(0.52—2.21) 
287.52 ± 
72.27 
15 1.39 
(0.66—2.95) 
     Q3 627.01 ± 
119.05 
27 1.28 
(0.75—2.18) 
657.09 ± 
111.43 
17 1.45 
(0.72—2.90) 
603.63 ± 
119.41 
10 1.05 
(0.45—2.43) 
     Q4 1311.77 ± 
1210.93 
16 0.89 
(0.48—1.66) 
1396.34 ± 
1196.84 
8 0.81 
(0.34—1.92) 
1245.72 ± 
1219.55 
8 0.97 
(0.39—2.39) 
     p for trend   0.59   0.53   0.78 
Lutein (µg/kcal)          
     Q1 597.01 ± 
173.40 
29 1.00 (ref) 520.16 ± 
139.35 
15 1.00 (ref) 688.74 ± 
163.54 
14 1.00 (ref) 
     Q2 939.52 ± 
143.27 
36 1.37 
(0.84—2.24) 
825.32 ± 
81.85 
20 1.47 
(0.75—2.88) 
1045.90 ± 
97.82 
16 1.25 
(0.61—2.57) 
     Q3 1296.07 ± 
191.42 
15 0.61 
(0.33—1.15) 
1132.96 ± 
110.31 
7 0.56 
(0.23—1.38) 
1427.47 ± 
134.42 
8 0.66 
(0.28—1.58) 
     Q4 1949.59 ± 
639.28 
21 0.89 
(0.51—1.57) 
1684.55 ± 
518.06 
13 1.06 
(0.50—2.24) 
2128.98 8 0.70 
(0.29—1.69) 
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 Overall Men Women 
Median 
intake ±  
SD 
Cases, 
n 
HR 
(95% CI) * 
Median 
intake ±  
SD 
Cases, 
n 
HR 
(95% CI) * 
Median 
intake ±  
SD 
Cases, 
n 
HR 
(95% CI) * 
     p for trend   0.06   0.17   0.39 
Total vitamin C 
(mg/kcal) 
         
     Q1 21.66 ± 
6.76 
36 1.00 (ref) 19.99 ± 
6.50 
17 1.00 (ref) 23.02 ± 
6.68 
19 1.00 (ref) 
     Q2 39.63 ± 
5.71 
20 0.67 
(0.39—1.16) 
37.35 ± 
4.99 
11 0.74 
(0.35—1.60) 
41.60 ± 
5.50 
9 0.57 
(0.26—1.28) 
     Q3 60.24 ± 
8.33 
28 1.07 
(0.64—1.77) 
56.55 ± 
6.84 
18 1.36 
(0.69—2.67) 
63.40 ± 
8.09 
10 0.72 
(0.33—1.59) 
     Q4 102.73 ± 
151.60 
17 0.69 
(0.38—1.24) 
94.37 ± 
127.18 
9 0.68 
(0.30—1.57) 
108.74 ± 
167.54 
8 0.65 
(0.28—1.53) 
     p for trend   0.25   0.27   0.53 
Total vitamin E 
(mg !-
tocopherol 
equivalents/kcal) 
         
     Q1 2.59 ± 0.47 32 1.00 (ref) 2.38 ± 0.40 19 1.00 (ref) 2.84 ± 0.43 13 1.00 (ref) 
     Q2 3.41 ± 0.31 28 0.98 
(0.59—163) 
3.14 ± 0.19 10 0.58 
(0.27—1.24) 
3.64 ± 0.20 18 1.58 
(0.77—3.24) 
     Q3 4.10 ± 0.34 25 0.96 
(0.57—1.63) 
3.80 ± 0.21 14 0.85 
(0.42—1.71) 
4.33 ± 0.23 11 1.08 
(0.48—2.43) 
     Q4 5.25 ± 
64.00 
16 0.66 
(0.36—1.22) 
4.85 ± 
54.66 
12 0.75 
(0.36—1.58) 
5.49 ± 
70.52 
4 0.44 
(0.14—1.38) 
     p for trend   0.56   0.56   0.13 
Total soy 
isoflavones 
(mg/kcal) 
 ! ! ! ! ! ! ! !
     Q1 3.63 ± 1.65 35 1.00 (ref) 3.25 ± 1.45 21 1.00 (ref) 4.00 ± 1.72 14 1.00 (ref) 
     Q2 7.74 ± 1.35 19 0.57 
(0.33—1.00) 
7.02 ± 1.07 6 0.30 
(0.12—0.73) 
8.37 ± 1.24 13 0.98 
(0.46—2.08) 
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 Overall Men Women 
Median 
intake ±  
SD 
Cases, 
n 
HR 
(95% CI) * 
Median 
intake ±  
SD 
Cases, 
n 
HR 
(95% CI) * 
Median 
intake ±  
SD 
Cases, 
n 
HR 
(95% CI) * 
     Q3 12.24 ± 
1.87 
26 0.82 
(0.49—1.37) 
11.12 ± 
1.46 
16 0.81 
(0.42—1.57) 
13.15 ± 
1.66 
10 0.81 
(0.36—1.83) 
     Q4 20.72 ± 
9.85 
21 0.67 
(0.39—1.16) 
19.12 ± 
8.76 
12 0.60 
(0.29—1.24) 
22.00 ± 
10.39 
9 0.76 
(0.32—1.77) 
     p for trend   0.21   0.06   0.89 
Genistein 
(mg/kcal) 
         
     Q1 1.70 ± 0.76 36 1.00 (ref) 1.52 ± 0.67 21 1.00 (ref) 1.88 ± 0.80! 15! 1.00 (ref)!
     Q2 3.58 ± 0.62! 18! 0.53 
(0.30—0.93)!
3.24 ± 0.49! 6! 0.30 
(0.12—0.74)!
3.87 ± 0.56! 12! 0.84 
(0.39—1.80)!
     Q3 5.63 ± 0.85! 25! 0.76 
(0.46—1.28)!
5.10 ± 0.66! 15! 0.76 
(0.39—1.48)!
6.04 ± 0.75 10 0.75 
(0.34—1.68) 
     Q4 9.46 ± 4.37 22 0.69 
(0.40—1.18) 
8.72 ± 3.90 13 0.66 
(0.33—1.33) 
10.04 ± 
4.59 
9 0.71 
(0.31—1.63) 
     p for trend   0.15   0.07   0.84 
Daidzein 
(mg/kcal) 
      ! ! !
     Q1 1.69 ± 0.78 35 1.00 (ref) 1.52 ± 0.69 21 1.00 (ref) 1.86 ± 0.81 14 1.00 (ref) 
     Q2 3.65 ± 0.64 19 0.57 
(0.33—1.00) 
3.31 ± 0.52 6 0.30 
(0.12—0.74) 
3.96 ± 0.59 13 0.98 
(0.46—2.09) 
     Q3 5.81 ± 0.90 26 0.82 
(0.49—1.37) 
5.28 ± 0.70 16 0.82 
(0.43—1.59) 
6.24 ± 0.80 10 0.81 
(0.36—1.83) 
     Q4 9.92 ± 4.84 21 0.67 
(0.39—1.17) 
9.14 ± 4.29 12 0.61 
(0.29—1.25) 
10.55 ± 
5.12 
9 0.76 
(0.33—1.77) 
     p for trend   0.22   0.06   0.89 
Glycitein 
(mg/kcal) 
         
     Q1 0.24 ± 0.11 36 1.00 (ref) 0.21 ± 
0.096 
21 1.00 (ref) 0.26 ± 0.11 15 1.00 (ref) 
     Q2 0.51 ± 20 0.58 0.46 ± 7 0.35 0.55 ± 13 0.91 
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 Overall Men Women 
Median 
intake ±  
SD 
Cases, 
n 
HR 
(95% CI) * 
Median 
intake ±  
SD 
Cases, 
n 
HR 
(95% CI) * 
Median 
intake ±  
SD 
Cases, 
n 
HR 
(95% CI) * 
0.087 (0.34—1.01) 0.070 (0.15—0.81) 0.080 (0.43—1.92) 
     Q3 0.80 ± 0.12 25 0.77 
(0.46—1.28) 
0.73 ± 
0.096 
15 0.77 
(0.39—1.50) 
0.86 ± 0.11 10 0.75 
(0.33—1.68) 
     Q4 1.36 ± 0.65 20 0.62 
(0.36—1.08) 
1.25 ± 0.58 12 0.60 
(0.29—1.24) 
1.44 ± 0.69 8 0.62 
(0.26—1.48) 
     p for trend   0.18   0.09   0.72 
Total 
isothiocyanate 
(µmol/kcal) 
         
     Q1 2.39 ± 0.84 36 1.00 (ref) 2.06 ± 0.71 23 1.00 (ref) 2.71 ± 0.83 13 1.00 (ref) 
     Q2 4.26 ± 0.68 26 0.78 
(0.47—1.30) 
3.79 ± 0.48 6 0.29 
(0.12—0.70) 
4.68 ± 0.54 20 1.66 
(0.82—3.34) 
     Q3 6.25 ± 0.92 21 0.68 
(0.39—1.16) 
5.59 ± 0.66 12 0.62 
(0.31—1.25) 
6.77 ± 0.75 9 0.77 
(0.33—1.82) 
     Q4 10.08 ± 
4.36 
18 0.61 
(0.34—1.08) 
9.08 ± 3.79 14 0.74 
(0.38—1.46) 
10.81 ± 
4.58 
4 0.37 
(0.12—1.13) 
     p for trend   0.30   0.05   0.02 
* adjusted for age (years), gender (male/female, in overall model only), interview year (1993-1995/1996-1998), dialect (Hokkien/Cantonese), education (less than 
secondary/secondary or greater), tobacco smoking (never/ever), alcohol consumption (never/ever), body mass index (<20, 20-<24, 24-<28, or !28 kg/m2), and 
total energy intake (kcal/day) 
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Table 64.  Hazard ratios (HRs) and 95% confidence intervals (95% CIs) for tea and coffee intakes and the risk of unspecified gastric cancer in the Singapore 
Chinese Health Study. 
 Overall Men Women 
Median 
intake ±  
SD Cases, n 
HR 
(95% CI) * 
Median 
intake ±  
SD Cases, n 
HR 
(95% CI) * 
Median 
intake ±  
SD Cases, n 
HR 
(95% CI) * 
Black tea 
(cups/month) 
         
     Q1 0.00 63 1.00 (ref) 0.00 31 1.00 (ref) 0.00 32 1.00 (ref) 
     Q2 2.00 ± 1.14 10 0.90 
(0.46—1.76) 
2.00 ± 1.14 6 0.95 
(0.39—2.28) 
2.00 ± 1.13 4 0.83 
(0.29—2.37) 
     Q3 10.70 ± 
4.48 
13 1.35 
(0.74—2.48) 
10.70 ± 
4.61 
8 1.22 
(0.56—2.67) 
10.70 ± 
4.30 
5 1.57 
(0.61—4.07) 
     Q4 30.00 ± 
26.28 
15 1.53 
(0.86—2.72) 
30.00 ± 
27.73 
10 1.38 
(0.67—2.83) 
30.00 ± 
23.36 
5 1.86 
(0.72—4.83) 
     p for trend   0.40   0.81   0.47 
Green tea 
(cups/month) 
         
     Q1 0.00 56 1.00 (ref) 0.00 29 1.00 (ref) 0.00 27 1.00 (ref) 
     Q2 2.00 ± 1.11 23 1.53 
(0.94—2.50) 
2.00 ± 1.11 11 1.31 
(0.65—2.62) 
2.00 ± 1.10 12 1.79 
(0.91—3.55) 
     Q3 10.70 ± 
4.28 
10 1.12 
(0.57—2.21) 
10.70 ± 
4.44 
8 1.31 
(0.60—2.89) 
10.70 ± 
4.09 
2 0.65 
(0.15—2.75) 
     Q4 30.00 ± 
40.71 
12 1.12 
(0.59—2.12) 
75.00 ± 
42.47 
7 0.87 
(0.38—2.01) 
30.00 ± 
38.12 
5 1.56 
(0.59—4.11) 
     p for trend   0.40   0.76   0.27 
Any tea 
(cups/month) 
         
     Q1 0.00 36 1.00 (ref) 0.00 17 1.00 (ref) 0.00 19 1.00 (ref) 
     Q2 4.00 ± 1.83 23 1.48 
(0.88—2.51) 
4.00 ± 1.87 9 1.04 
(0.46—2.35) 
4.00 ± 1.79 14 1.93 
(0.96—3.86) 
     Q3 10.70 ± 
4.96 
16 1.32 
(0.73—2.41) 
12.70 ± 
5.09 
12 1.44 
(0.69—3.04) 
10.70 ± 
4.80 
4 0.93 
(0.32—2.76) 
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 Overall Men Women 
Median 
intake ±  
SD Cases, n 
HR 
(95% CI) * 
Median 
intake ±  
SD Cases, n 
HR 
(95% CI) * 
Median 
intake ±  
SD Cases, n 
HR 
(95% CI) * 
     Q4 40.70 ± 
39.87 
26 1.53 
(0.91—2.58) 
40.70 ± 
41.56 
17 1.28 
(0.65—2.53) 
34.30 ± 
37.07 
9 1.85 
(0.83—4.15) 
     p for trend   0.34   0.76   0.18 
Coffee 
(cups/week) 
         
     Never 0.00 22 1.00 (ref) 0.00 12 1.00 (ref) 0.00 10 1.00 (ref) 
     Monthly 0.46 ± 0.15 3 1.39 
(0.42—4.64) 
0.46 ± 0.15 2 1.73 
(0.39—7.76) 
0.46 ± 0.15 1 1.06 
(0.14—8.30) 
     Weekly 2.50 ± 1.46 12 1.19 
(0.59—2.41) 
2.50 ± 1.45 6 1.07 
(0.40—2.87) 
2.50 ± 1.47 6 1.40 
(0.51—3.86) 
     1 cup/day 7.02 ± 0.79 29 0.69 
(0.39—1.20) 
7.02 ± 0.83 18 0.88 
(0.42—1.82) 
7.02 ± 0.77 11 0.52 
(0.22—1.23) 
     2-3 cups/day 17.56 ± 
1.96 
31 0.85 
(0.49—1.48) 
17.56 ± 
1.97 
15 0.68 
(0.32—1.47) 
17.56 ± 
1.96 
16 1.17 
(0.53—2.60) 
     !4 cups/day 31.60 ± 
5.19 
4 0.77 
(0.26—2.27) 
31.60 ± 
4.68 
2 0.55 
(0.12—2.48) 
31.60 ± 
5.95 
2 1.47 
(0.32—6.84) 
     p for trend   0.56  ! 0.75   0.31 
* adjusted for age (years), gender (male/female, in overall model only), interview year (1993-1995/1996-1998), dialect (Hokkien/Cantonese), education (less than 
secondary/secondary or greater), tobacco smoking (never/ever), alcohol consumption (never/ever), body mass index (<20, 20-<24, 24-<28, or !28 kg/m2), and 
total energy intake (kcal/day) 
